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Abstract 
Introduction: The predominate issue in transplantation today is the inadequate supply of suitable 
organs for an increasing number of patients on the transplant waiting lists. In efforts to address this 
demand there has been an increasing use of expanded-criteria and donation-after-cardiac death 
donor kidneys and pancreases, however these organs are at higher risk for reperfusion injury. 
Advances in organ preservation thus need to focus on techniques to assess and optimise organ 
viability prior to transplantation.     
 
Methods: This research focuses on organ viability assessment during preservation using rapid 
sampling micro-dialysis (rsMD); preconditioning organs with novel endothelial localising anti-
coagulants to prevent micro-vascular thrombotic complications; development of both novel 
hypothermic machine perfusion (HMP) solutions to minimise reperfusion injury, and HMP strategies 
that offer superior preservation of organ integrity compared to static cold storage (SCS). Using HMP 
and normothermic-reperfusion models of porcine and human kidney and pancreatic grafts, this 
project has investigated strategies addressing these themes. 
 
Results: rsMD can successfully provide detailed real-time information on tissue and organ viability 
during both SCS and HMP. Pre-conditioning grafts with novel localising anticoagulant proteins has 
been successful in ameliorating disturbances in macro and micro-vascular perfusion and graft 
microcvascular thrombosis, processes which play key roles in reperfusion injury and organ 
dysfunction. Separately the application of a novel adenosine/lidocaine based preservation solution 
in renal HMP preservation can potentially ameliorate reperfusion injury seen using conventional 
solutions. Post-ischaemic HMP reconditioning has been investigated in the context of recovering 
organs with an extreme period of SCS which may be a potential option to expand donor organ pools. 
Finally models of pancreatic HMP have been successfully established, opening the potential for 
organ viability assessment and optimization. 
 
Conclusion: This research has been successful in its overall objective to develop novel translational 
strategies that have high potential for clinical implementation. In doing so the goal would be to 
enable an expansion of the pool of acceptable donor organs by improving the methods used to 
determine and optimise their viability, specifically more effective preservation techniques and by 
addressing specific post-operative complications through graft preconditioning.  
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1.1 Kidney and Pancreas  Transplantation – State of the Field 
 
1.1.1 Kidney Transplantation 
Kidney transplantation is the optimal treatment for patients with end-stage renal failure [1]  and 
provides the best clinical outcomes, optimal quality of life and cost savings when compared with 
other modalities of renal replacement therapy [2] .  
In the UK by end 2012 54,824 adults were receiving renal replacement therapy, an absolute increase 
of 3.7% from 2011, and approximately a 75% increase in the number of patients since 2000, with the 
median patient age for the start of replacement therapy at 58 years. Furthermore the percentage of 
these patients aged greater than 70 years increased from 19.2% in 2000 to 24.9% in 2012 [3]. 
In patients on replacement therapy the 1 year survival rate is 79%, with 5 year survival rates 
depending on patient age; 58% if aged 18-34, and 12% if greater than 75 years [4] . Comparatively 
the most recent 1 and 5 year patient survival rates for deceased kidney transplant recipients in the 
UK are over 95% and 88% respectively.  
In parallel with the improvement in transplant results over the years to current levels demand has 
increased, with continuing emergence of new indications and decreasing contra-indications for 
receiving a transplant. 
Despite the demonstrated advantages of transplantation, the full potential of these be nefits to 
patients cannot be obtained due to the severe shortage of donated kidneys [5]. Indeed the largest 
problem facing the transplant community is the critical shortage of donor organs.  
In the UK in 2014 2142 deceased donor, and 1243 living donor kidney transplants were performed. 
With 5881 patients registered on the national kidney transplant waiting list the number of patients 
have declined for the fifth year running (see Figure 1). This is due to patients leaving the transplant 
list, while the number of people joining the list is relatively stable. Despite this decline the number of 
patients registered has risen  approximately 8% since 2005 and 70% since 2000 [6,7]. 
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Figure 1  Dec eas ed donor  (DCD a nd DBD) kidney progra mme i n the UK, April  2004 - March 2014, 
Number  of donors , tra nspla nts a nd pa tients on the a c tive tra nsplant l ist a t 31  Ma rch 2014.  
 
 
Deceased Donor Kidney Transplantation 
To meet this demand the organ supply pool has been expanded by a number of creative strategies. 
The most successful of which is the living donor donation scheme. The number of living donor kidney 
transplants has increased from 338 in 1999 to 1243 in 2014 – a threefold increase, and now accounts 
for 34% of kidneys transplants. This increase however significant does not match the need of 
potential recipients.  
An alternative to living donor kidney transplantation is the use of allografts from deceased donors -  
either donation after brain death (DBD)  or donation after cardiac death (DCD). At present deceased 
donors comprise the largest fraction of donated organs in the UK, with 2142 transplants occurring in 
2013-14. 
DBD describes a donor who has had primary brain death where cardiac circulation and respiration 
are intact or maintained by medical measures. DCD donors are grouped via the Maastricht 
Classification which has 5 categories[8]. These categories are further defined by being controlled or 
uncontrolled. Categories I, II and V are designated uncontrolled and categories III and IV are 
controlled  
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Category 1: Death has occurred outside of the hospital. For these 
individuals to be potential donors, the moment of sudden death needs to 
have been witnessed, the time that it occurred documented, and 
‘resuscitation’ continued after death. 
Category 2: Unsuccessful resuscitation where CPR is started outside of 
hospital following a collapse. Death is confirmed on admission to hospital. 
Category 3: Patients on intensive care units with non-survivable injuries but 
where brain stem death criteria are not fulfilled who have treatment 
withdrawn and are awaiting cardiac arrest.  
Category 4: Cardiac arrest in a brain stem dead individual.  
Category 5: Unexpected cardiac arrest in a hospitalised setting.   
 
Overall the number of DCD donors in the UK has increased the past decade compared to DBD 
donation which has remained relatively stable (see Figure 2).  
 
Figure 2 Number of dec eas ed donors i n the UK, Ja nuary 1 , 2003 to Dec ember 31, 2012. Overall  
the number  of DCD donors  has  i ncreas ed the pas t deca de whil e DBD dona ti on has  remained 
s ta ble [9]. 
 
32 
 
The number of transplants arising from DBD donors has however decreased the past 14 years, with 
1157 transplants performed in 2014 (vs. 1359 in 2001) . Conversely there has been an increase in the 
number of transplants (784 in 2014 vs.  56 in 2001) from DCD donors, led by successful initiatives to 
pursue potential donors more aggressively and accept a broader range of organs for transplantation 
to address the increasing numbers of patients on the waiting list [9]  (see Figure 3). 
 
Figure 3  Number of kidney trans plants i n the UK, Ja nuary 1 , 2003 to Dec ember 31, 2012. The 
l a rgest i nc reasing donor s ub-group i s the DCD c ohort[9].  
 
The pattern of demand for kidney transplants outstripping the suitable supply of organs is repeated, 
with only some specific regional variations, throughout the world. Efforts to expand the various 
donor pools are prevalent in most countries [10], and at present it is realized the largest potential 
growth in recruitment of donors is from the DCD group. Of note a more aggressive pursuit of kidneys 
from DCD donors has the capability to increase the number of organ donors by 2.5-4 times and thus 
potentially eliminate waiting lists completely [11,12] .  
 
1.1.2 Pancreas Transplantation  
The Extent of the Problem 
Diabetes mellitus is one of the fastest growing chronic diseases in the world with an estimated 171 
million people, or 2.8% of the world’s population, suffering from diabetes in 2000[13]. In the United 
Kingdom more than 1.8 million people (or 3.5% of the population) are diabetic, with a projected 
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increase to 2.6 million by 2030. Diabetes is a relentless disease affecting multiple organ systems 
insidiously[14] causing blindness, renal disease, impotence, neuropathy, foot ulcers, amputations, 
and heart disease; which not only shortens life expectancy but adversely affects quality of life in the 
process. 
In the UK diabetes costs the National Health Service (NHS) between an estimated £1.3[15] and £2.7 
billion per year, with a mean expenditure of £1600 on each diagnosed diabetic, and with treatment 
for diabetes and associated complications accounting for approximately 9% of NHS hospital 
budgets[16]. With the expected increased prevalence of diabetes over the next two decades the cost 
of treatment will rise steeply. 
Def ining the Problem 
Diabetes mellitus is a condition that results from the failure of pancreatic beta cells to appropriately 
produce insulin. From a patho-physiological point of view, two predominant types of diabetes 
mellitus exist and must be differentiated[17]. Diabetes mellitus type I or juvenile-onset diabetes 
mellitus results from a total or near total selective T-cell mediated auto-immune destruction of the 
insulin-producing beta cells within the islets of Langerhans in the pancreas. It has a peak onset in 
adolescence, hence the name, but may occur at any age and is believed to result from a combination 
and interaction of both environmental and genetic factors. Autoimmune destruction of beta cells 
has usually been progressing for a number of months or years, with symptoms emerging only once 
less than 20% of the total beta cell mass remains[18]. Patients hence become dependent lifelong on 
exogenously administered insulin immediately at diagnosis. 
The second form known as Type 2 diabetes, or non-insulin dependent diabetes mellitus, involves a 
complex metabolic syndrome characterised by peripheral insulin resistance[18]. In Type II diabetes, 
genetic predisposition for initial systemic resistance to endogenous insulin progresses slowly for a 
period up to 10 years before Beta cell failure supervenes and diabetes is diagnosed. Because the 
pancreatic beta cells retain their ability to produce insulin initial pharmacological treatment includes 
insulin secretagogues and insulin sensitizers, with insulin replacement reserved only for late phases 
of the disease.       
Treatment Strategies for Diabetes 
Under physiological conditions, blood glucose levels are kept within a very narrow range by a 
sensitive feedback mechanism controlling the secretion of insulin [18]. In the case of Type I diabetes 
slight under or over replacement of insulin compared to what is physiologically required will result in 
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a disproportionate change in glucose and fatty acid metabolism in liver and adipose tissues [14]. 
From a theoretical point of view it is clear exogenous insulin therapy cannot mimic the minute by 
minute physiological variations of insulin secretion in vivo necessary to maintain the same degree of 
blood glucose control[19].  
Minimising hyperglycaemia has however been recognised as an important goal in the management 
of both types  of diabetes and tight control of blood glucose levels is beneficial in preventing 
progression of subsequent secondary diabetic complications. The Diabetes Control and 
Complications Trial[20] (DCCT) showed tight blood glucose control depicted by target Glycated 
haemoglobin (HbA1C) levels of less than 7% in Type 1 Diabetics lowered the incidence of diabetic 
retinopathic, neuropathic, and nephropathic lesions by 47%, 60%, and 39% respectively. One 
important issued noted however in the trial was that the cost of achieving such tight control, and 
thus a reduction in secondary complications was a three-fold increase in the number of severe 
hypoglycaemic episodes that occurred. Thus it is apparent that no true physiological control of blood 
glucose levels can be accurately achieved with interval exogenous insulin administration, and even 
welcomed tight control carries additional risks that cannot be ignored.  
In order to artificially control blood glucose levels to a similar physiological degree as performed by 
Beta cells a closed loop system must be used whereby insulin levels are adjusted on a moment-to-
moment basis according to requirement[18]. There are two methods of achieving this continuous 
control. One method would be to utilise an insulin pump attached to a continuously monitoring 
blood glucose sensor[18]. At present external pumps are commonly used with manual control in 
clinical practice. However truly automated devices are troubled by the requirement of an accurate 
and continously monitoring sensor which has not been perfected neither has the ideal target tissue 
for monitoring, e.g. skin, subcutaneous fat. Despite technological progress in these designs over the 
past few decades, concerns of safety and reliability for planned implantable pumps means this truly 
automated approach is still several years away from clinical application. Thus the alternative and 
currently only available strategy to provide an effective closed loop system in Type 1 insulin 
dependent diabetics is beta cell transplantation in the form of a whole vascularised pancreatic 
transplant, or islet cell transplantation (ICT). 
United Kingdom Pancreas Transplantation Trends  
Pancreatic transplantation can broadly be considered in terms of whole pancreas and ICT.  Interest 
in ICT has increased in recent years predominately arising from the development of the Edmonton 
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Protocol, which has given rise to clinical trials involving cadaveric donor pancreata whereby the islets 
are infused via the portal vein. These result in persistent insulin secretion, but have the disadvantage 
that top-up from anti-hyperglycaemic medications is still required [21–23]. ICT has shown both 
reduced frequency of hypoglycaemic episodes [20] and reduced microvascular complications [24–
26]. It also improves quality of life and patient survival  [27–29]. Persistent insulin independence 
however has not been achieved through ICT and this remains a great drawback. Additionally, ICT 
often requires multiple transplants to attain enough beta cell mass unlike whole transplantation 
which only requires one.  Despite a number patients continuing to require exogenous insulin 
hypoglycaemic awareness with fewer hypoglycaemic episodes, thought to be due to  the initial 
restoration of glycaemic control, the glucagon and epinephrine response, and overall resetting of  
anti-hypoglycaemic controls, which then persists after  islet graft failure[30]. 
 
However evidence that ICT is a potentially viable treatment has led to advocates supporting 
introduction of such clinical programs and indeed the NHS now fund ICT particularly for patients 
with reduced hypoglycaemia awareness or those taking immunosuppressive drugs because of a 
previous kidney transplant[31].  
 
Whole pancreas transplant however remains predominate definitive treatment for Type 1 diabetes. 
In the United Kingdom the number of patients registered on the active transplant list for a 
simultaneous-pancreas-kidney (SPK), pancreas-after-kidney (PAK) or pancreas-transplant-alone 
(PTA) has increased by more than 6 fold over the past 14 years, from 45 patients in 1998-99 to 270 
patients in 2013-14 (see Figure 4). The number of pancreatic donors and transplants has also 
increased steadily since 1998-99 from 30 donors, resulting in 24 transplants, to 456 donors and 246 
transplants in 2013-14 [7]. The majority (76%) were SPK transplants, while 11% were pancreas only 
transplants (PTA/PAK) and 13% were islet transplants. Between 2012-13 and 2013-14 the number of 
DBD pancreas donors increased by 1% to 365, while transplants from donors after brain death 
increased by 6% to 203, similarly the number of DCD pancreas donors decreased by 1% to 91, while 
transplants from donors after circulatory death increased by 5% to 43[7].  
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Figure 4  Dec eas ed pancreas a nd isl et progra mme i n the UK, 1 April  2004 - 31  March 2014, 
Number  of donors , tra nspla nts a nd pa tients on the a c tive tra nsplant l ist a t 31  Ma rch. [7]  
 
As can be seen in Figure 4 despite the availability of greater numbers of deceased donors than the 
number of patients awaiting a pancreas transplant fewer transplants are performed than needed. 
This had improved in recent years with demand stabilizing over the past  3 years but one reason for 
the continued disparity is that the proportion of pancreases retrieved but that subsequently cannot 
be used for transplantation is greater than in kidney, liver or heart transplantation, and as such there 
is a vast underutilization of pancreatic donors. Such pancreases however are not completely 
discarded and are generally used in approved national research projects.  
Pancreatic Transplantation Effects on Seco ndary Diabetic Complications  
As mentioned the DCCT[20] study demonstrated the beneficial effects of tight glycaemic control on 
development and progression of secondary diabetic complications. With the success of pancreatic 
transplantation it would be reasonable to assume that similar ameliorations in diabetic lesions 
would be observed in pancreatic transplant recipients. Patients demonstrate almost immediate 
freedom from insulin and a return to normoglycaemia after transplantation, with HbA1c levels 
normalising after several months[32].  
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Diabetic Nephropathy  
In SPK and PKA the goal of the procedure is to treat uraemia with the renal allograft, and prevent 
recurrence of diabetic lesions by achieving euglycaemic control. In PTA the aim is stabilization or 
regression of established diabetic lesions, specifically nephropathy[33]. Diabetic lesions in recently 
transplanted kidneys in SPK at 1 year are absent compared to kidney transplant alone (KTA), and at 
10 years there is regression of characteristic diabetic lesions in autologous kidneys in PTA  [34]. 
However pancreas transplantation can have deleterious effects on renal function – with chronic 
dehydration (bladder drainage) and calcineurin-inhibitor exposure (immune suppression) implicated 
in most cases[33]. Thus overall though the damage from continuous hyperglycaemia is removed post 
pancreatic transplantation, the added requirement for immune suppression may lead to progressive 
long term renal insufficiency. 
Diabetic Retinopathy and Neuropathy  
Most patients who undergo pancreatic transplantation have a plethora of secondary diabetic 
complications already, and most have active retinopathic lesions, or have been treated for such 
lesions with photo-laser therapy. Studies are inconclusive but resolution of hyperglycaemic states in 
SPK and PTA recipients may limit the progression of already established lesions, and reduce the need 
for laser therapy [35]. Most benefit may however only be observable in patients with early lesions, 
as damage may be irreparable in more advanced stages of retinopathy [33].  In addition after SPK 
patients experience improvement in symptoms of autonomic dysfunction (gastric emptying)[36], 
and improved sensory and motor neuropathies as measured by conduction studies  [37].  
 
Qual i ty of Li fe after Pancreatic Transplantation  
While regulation of glycaemic control with pancreas transplantation can provide some amelioration 
of secondary diabetic complications, the procedure’s effect on patient quality of life may be the 
most important and beneficial outcome[33]. Recipients of pancreas transplants enjoyed 
improvements in their quality of life when compared to patients that received a kidney allograft 
alone [18]. Consistent findings in quality of life assessments in pancreas transplantation is improved 
perception of diabetes specific issues such as satisfaction with diet flexibility, health management 
with the patient relieved  to be free from dietary restrictions, frequent blood glucose monitoring, 
and insulin therapy [18]. In addition to feeling better about their lives, pancreas transplantation 
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recipients (specifically SPK) can expect to live an addition 10 to 15 years longer compared to 
diabetics on a transplant waiting list and recipients of KTA respectively [38].  
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1.2 The Impact of DCD and ECD Organ Transplantation  
The most prevalent deceased donor cohort is the DBD group. DBD describes a donor with primary 
brain death where circulation and respiration are intact or maintained by medical intervention. 
Conversely a DCD donor refers to the situation where the criteria from brain death is not met, but 
where survival is unexpected, and where cardiac death occurs before organ procurement. Cardiac 
death can be either unexpected and uncontrolled (uncontrolled DCD) or deliberate and controlled 
(controlled DCD) whereby supportive intervention is systematically withdrawn after consent from 
the family [8].  
Use of DCD donors is not without limitations. Unlike DBD donors, DCD donors are subject to 
lengthier warm ischaemic injury (10-45mins) during the time between cardiac arrest and initiation of 
cold preservation flush and organ retrieval[39]. Despite this, outcomes for DBD and DCD kidney 
transplants are similar in terms of both allograft and recipient survival, but with DCD kidneys at 
higher risk of primary non-function (PNF), DGF 20-80% vs. 20-30% for DBD [40], necessitating further 
dialysis, with reports also suggesting an increased risk of acute rejection and poorer long term 
function [41].  
To add to these differences a DBD or DCD donor can also be a standard criteria donor (SCD) or an 
expanded criteria donor (ECD) depending on whether the appropriate standard or expanded criteria 
are met, potentially increasing the risk of complications, specifically with older DCD donor organs 
negatively impacted by DGF [42]. 
Thus one of the major consequences of expansion of donor pools with DCD/ECD cohorts is the 
increased risk of PNF and prolonged DGF due to donor organ damage, and their associations on 
immediate and long-term outcomes. It is the immediate and longer term complications associated 
with PNF and DGF in these organs that have tempered the acceptance and widespread use of 
kidneys from these donor pools.  
1.2.1 Expanded Criteria Donors 
In addition parallel to the expansion of certain donor pools, the demographic and health profiles of 
the majority of donors has changed, with steadily older donors with co-morbidities increasingly 
common place [43], so called marginal, expanded (or extended) criteria donors (see Figure 5). In 
2001 approximately 38% of cadaveric kidney donors and recipients in the UK were older than 50 
years of age, 14 years later this number has risen dramatically to 60% [9].   
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Strategies to expand the donor pools have thus been limited by the comparative outcomes of grafts 
from these older ECD and DCD donors to SCD and DBD groups respectively. 
SCD refers to donors <50 years of age with no history of hypertension (HTN) or diabetes and where 
donation occurs after brain death (DBD). While ECD donors are those who are >60 years of age or 
aged 50-59years with two of either 1) Cause of death cerebrovascular accident (CVA); 2) a history of 
HTN; or 3) terminal serum creatinine >133 micromoles/litre.[44]  
ECD kidneys through their inherent description are associated with declining renal function, a 
reduced nephron reserve and decreased graft viability, with their transplant predisposing to a 77% 
increased risk of graft failure [45] and an average graft survival expectancy of 5.1 years, compared to 
10 years for a younger non-ECD kidney [46]. In addition ECD kidneys are more susceptible to 
ischaemic injury and display higher rates of DGF (33%) compared to an SCD kidney (21%), as well as 
primary non-function and acute rejection.  
Transplant however of such inherently higher risk kidneys is not without benefit, with multiple 
studies demonstrating a definitive survival advantage to receipt of an ECD kidney vs. remaining on 
dialysis and waiting for an SCD kidney[47].  
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Figure 5  Donor  trends April  1 , 1999 to Ma rc h 31, 2009. (A) Total number  of de c eas ed organ 
donors  a nd (D) Expanded c riteria  donors , hi ghlighting the i ncreas e in both DCD and in par tic ular 
ECD/DCD donors  in the UK . From Summers  et a l .[48]. 
 
1.2.2 Delayed Graft Function 
DGF itself is can be defined as the need for more than one episode of dialysis in the immediate post-
operative period [49] indicating a temporary failure of the transplanted kidney to resume adequate 
function. Approximately 20%-80 of kidney transplant recipients experience some degree of DGF in 
the first week depending on a number of variables, with type of donor allograft a predominant 
factor. This is supported by the acceptance that DGF is rarely experienced in living donor 
transplantation suggesting that donor factors themselves significantly influence DGF. The five key 
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contributing variables are related to donor tissue quality, donor brain death and related stress, 
preservation characteristics, immune factors and recipient variables [50].  
Damage sustained by the organ during the transplantation process causes an acute halting of organ 
function in the postoperative period and this DGF deleteriously leads to a more complex post-
operative period for the patient. The presence of DGF increases the likelihood of acute rejection 
(probably by unmasking hidden donor foreign antigens to the recipient) in the early period post-
transplant [50]. It is this increased immunogenicity that is likely to contribute to instances of 
interstitial nephritis and tubular atrophy, and negatively affect long-term graft and patient survival. 
DGF increases the risk of graft loss by 41%, and acute rejection by 38%, with worse graft function at 
3.5years compared to patients without DGF [41]. Deservedly DGF is associated with prolonged 
periods of hospitalization, higher treatment costs and adverse effects on transplant patients’ general 
rehabilitation [51,52].  
DGF is thus the clinical end result of predominantly ischaemic stress and injury sustained during 
organ retrieval and preservation, with the damage caused by this insult then accentuated during the 
reperfusion period, so called ischaemia-reperfusion (IR) injury [41], leading to a spectrum of 
irreversible damage the effect of which causes impaired long term organ function.  
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1.3 Ischaemia Reperfus ion Injury  
 
Ischaemia is defined as the cessation of arterial blood flow that subsequently deprives tissue of 
oxygen. There are various stages of the transplantation process where kidneys are exposed to 
ischaemic stress and these can be classified according to the temperature of the local environment –
warm or cold.  During retrieval warm ischaemic injury is sustained in the time between donor 
cardiac arrest and cold perfusion of preservation solution in-situ. This period is known as the primary 
warm ischaemia time or WIT. This is followed by further cold ischaemic damage (also known as cold 
ischaemia time or CIT) that ensues after flushing and storage of the allograft with cold preservation 
solution, and then transport to the recipient centre.  
In DBD donors warm ischaemia can be minimised where access to abdominal vasculature can be 
achieved prior to withdrawal of support, allowing quicker institution of cold perfusion after cardiac 
arrest has occurred. While in DCD donation time between cardiac arrest and the start of cold 
perfusion is variable but demonstrated to be significantly longer.  
The main goal of organ preservation is the maintenance of the functional, biochemical and 
morphological integrity of the graft during retrieval from the donor and transport to recipient: from 
harvest to revascularisation[53] .  
During the period of implantation between removal of the organ from cold preservation and 
reperfusion there is a second period of warm ischaemia (known as secondary warm ischaemia). 
Upon revascularisation there is a further period of unavoidable damage due to the sudden influx of 
oxygenated warm blood into an organ that has undergone cold ischaemic and then warm ischaemic 
stress for a number of hours – known as reperfusion injury (see Figure 6). This was first 
demonstrated experimentally in a canine model of IR injury by Jenning et al. in the 1960, when they 
reported an unexpected acceleration of cellular necrosis and tissue damage after inducing  transie nt 
ischemia and subsequent reperfusion, compared to permanent ischaemia[54].   
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Figure 6 Cell dea th during I R inj ury - s peci fically ei ther isc hemia  and s ubs equent reper fusion or 
prolonged ischemia , highlighti ng the probl em a nd da m age endured duri ng reper fusi on. 
Repr i nted from Va nden Hoek et a l . [55]. 
 
The theoretical premise of IR injury is that in any given tissue exposed to ischaemic stress a number 
of cells will suffer irreparable damage, that ultimately leads to cell death. A larger percentage of cells 
in this tissue will sustain damage but still remain viable, with the potential for self-repair and return 
to normal function (see Figure 7). As the former sub-group of cells will definitively undergo cell 
death, the degree and severity of IR injury remains with the number of cells in the 2nd subgroup that 
are salvageable and can actually remain viable after reperfusion [56]. Thus the aim of preservation 
strategies is to optimise the potential for these cells to be rescued, and improve function of the 
organ after transplantation. The cellular damage that occurs is based directly on the lack and then 
return of oxygen, the development of cellular oedema and intracellular acidosis, calcium overload, 
and the generation of reactive free radicals [57].  
The following sections will describe and discuss the pathological entities involved in IR injury. The 
dominant discussion will relate to renal IR injury however the same mechanisms are involved in IR 
injury to all organs.  
45 
 
 
Figure 7  The c onc ept of ischemia-reper fusion inj ury, where the fa te of c ells a t risk (grey) 
determina tes  the full  extent of tissue i njury wi th ei ther  a  compl ete recovery (a ), a  pa rtial 
rec overy (b) or  full  reperfusion induced i njury (c ). From Dorweiler et a l  [58]. 
 
1.3.1 Types of Ischaemic and Reperfusion Injury 
In kidneys the susceptible target of the initial warm ischemic insult are the proximal tubular cells. 
These morphologically and functionally specialised cells have high metabolic requirements to 
facilitate transport of ions, water, and macromolecules across several cell membrane layers by highly 
selective transport systems[59]. These cells however can tolerate short exposures to warm 
ischaemia, but not without exhibiting alterations in trans-epithelial potentials, cell-cell junctions, 
with increased leakage and slowing of the active transport mechanisms[60] . Longer periods of cold 
ischaemia can be similarly tolerated [57]. It is the combined insult of warm, then cold ischaemia and 
finally reperfusion upon transplantation that causes damage and functional deficits  (see Figure 8).  
Cold ischaemic injury starts during the retrieval procedure when the kidney is flushed with cold 
preservation solution. Cold preservation is based on the principle of suppression of cellular 
metabolism through hypothermia. According to van’t Hoff’s rule tissue cooling from normothermic 
temperatures to 0°C decreases the rate of metabolic activity 12 times, with 10-12% of metabolism 
remaining at 4°C [61,62] .  Metabolism is slowed but not halted and hypothermia itself is detrimental 
to tissue, and mitochondrial swelling and rounding, extra- and intra-cellular oedema, and 
margination of chromatin in the nucleus has been seen in kidney proximal tubules [63]. Thus though 
cellular damage occurs during cold ischaemia, warm ischaemic stress is more detrimental.  
With warm revascularisation and the return of oxygen, reperfusion injury as the effecter phase of 
ischaemic injury ensues [59]. This is the final event that can cause profound injury with marked cell 
death in the transplanted organ. Thus while ischaemic injury is associated with the lack of  oxygen, 
reperfusion injury is initiated by the return of oxygen.  
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Tubular cells are the key cell type whose dysfunction is predominately related to the functional delay 
in a kidney after transplant. It is endothelial cells (ECs) lining the lumen of blood vessels that are the 
first cells to sustain warm reperfusion damage [64].  Hypothermia followed by re-warming (37˚C) 
induces a pronounced apoptosis in ECs and renal interstitial cells, the extent of which depends on 
the duration of the cold incubation [65]. The damage that occurs is facilitated by several of the 
processes that started during cold preservation. Once normothermic blood flow is re-established 
cellular metabolism is re-initiated and cell repair mechanisms occur in parallel with apoptosis, 
autophagy, and necrosis; the final degree of damage sustained dependent on the balance between 
cell death and regeneration[57]. These processes involve elements of direct cell damage mediated 
through activation of innate immune processes that target both endothelial and renal interstitial and 
tubular cells. However IR injury to endothelial cells also results in microvascular dysfunction which is 
widely described in key organs systems[57] and is a serious problem as it potentiates tissue damage 
and limits recovery of function.       
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Figure 8  A s chema tic  repres enta ti on of i l lustra ting the connec ti on between mec hanis ms 
preval ent duri ng isc ha emi a a nd reper fusion injury. Cold SCS induc es  ATP depl etion res ul ting in 
the loss  of c ell ular el ec trol yte balanc e wi th increas es   in a na erobic meta bolism. T his promotes 
the ac cumula ti on of c ellular  c alcium ca using l ysos omal  ins ta bility. There is  a n i nhibi tion of 
mi toc hondrial  oxida ti ve phosphoryla ti on decreasing ATP s ynthesis  a nd inc reasing a c tiva ti on of 
c ell ular proteas es .  El ec trolyte dis turba nc es resul ts  i n c ell ular oedema of both i ntri nsic c ells of 
the tiss ue and endothelial c ells . Endothelial c ells undergo 'ac ti va ti on' wi th induc tion of c ellular 
a dhesion mol ecul es , produc ti on of infla mma tory modula tors  (cytokines  a nd c hemokines), a nd 
a n i ncreas ed vascular  permea bility all  of which c ontribute to neutrophilic ac cumula ti on a nd 
trans endothelial mi gra tion into the tissue upon reper fusion. I nfi ltra ting neutrophils a nd 
l euc oc ytes  c aus e pa renc hymal  da ma ge by l ocal  produc tion of reac ti ve oxygen s peci es  (ROS), 
whil e ac ti va ted endothelial c ells a nd organ specific  c ells produc e ROS through disrupted 
mi toc hondrial oxi da ti ve phos phoryla ti on a nd xanthine oxi das e. The degree of ac cumula ted of 
c ell ular da ma ge res ul ts in ei ther rec overy, or  c ell  des truc ti on through necrosis or  a poptosis 
dependi ng on a vailability of ATP. Ada pted from Za ouali et a l . [66].  
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1.3.2 Cellular Pathogenesis of IR Injury 
Apoptosis vs. Necrosis 
In necrosis cell integrity is loss, with release of cytosolic contents into the extracellular environment 
evoking an inflammatory response. The degree of necrosis is dependent on the severity and duration 
of ischaemia. Apoptosis however is a highly coordinated and programmed process, results in cellular 
degradation and confinement in a series of contained apoptotic cell bodies, without arousing an 
inflammatory reaction, but that requires adenosine tri-phosphate (ATP) to take place [58]. The 
contribution of each to tissue damage during IR is based on the phase of IR - during ischaemia with a 
lack of oxygen and thus minimal ATP generation, necrosis prevails. Upon reperfusion and the influx 
of oxygen cells that had started apoptotic cascade, triggered by ischaemic insult, are able to 
proceed. Reperfusion thus paradoxically produces damage through the provision of oxygen and ATP 
generation enabling apoptotic processes to complete. Experimental comparisons of IR and ichaemia 
has shown that cell death during prolonged ischaemia was 17% compared to 73% in reperfused 
tissue [67]. Reperfusion itself also triggers an local inflammatory cell reaction and this phase of injury 
is characterised by micro-vascular dysfunction and poor tissue perfusion – aptly named the capillary 
‘no re-flow’ phenomenon [68].  
Deprivation of  oxygen 
It is generally accepted that within minutes of the deprivation of oxygen there is switch from aerobic 
to anaerobic glycolytic metabolism through the activation of anaerobic genes as oxygen debt rises; 
the rate of change dependent on the basal metabolic demands of the tissue. Anaerobic metabolism 
of glucose however, produces an insufficient supply of ATP, 2 molecules vs. 38 molecules under 
normal conditions. To compensate for this discrepancy glucose consumption is increased (by up to 
12 fold in some estimates) [69], resulting in a progressive net depletion of energy substrates, and 
subsequent starvation of cells, reflected by lower glycogen granules observed in ischaemic tissue 
[57].   
Normally nicotinamide adenine dinucleotide (NADH) is generated from the reduction of NAD+ 
through the metabolism of glucose to pyruvate and processes within the  Kreb’s cycle. In anaerobic 
conditions NAD+ can only be regenerated by pyruvate’s fermentation to lactic acid. As ischaemia 
progresses acid build up causes a progressive excess of free hydrogen ions, lowering cytoplasmic pH, 
a uniform observation in ischaemic tissues [70] [71]  , which correlates well with the degree of tissue 
injury [72] [73] . Moreover hydrogen ion expulsion from the cell via H+ATPase pump and Na/H+ 
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exchanger is lost as the intracellular ionic disturbance worsens [53] .  The excess acid inhibits key 
glycolytic enzymes to stem further acid production. In adequately perfused tissue lactate acid is 
washed out into the circulation, and glucose metabolism continues, but in an ischaemic setting a 
lack of blood flow brings glycolysis to a halt. As glycolysis slows ATP production ceases. After 40 
minutes of warm ischaemia all ATP is lost [74]. Any ATP available is metabolised to adenosine di-
phosphate (ADP) and degraded to osmostically active inorganic phosphates, adenosine, inosine,  and 
hydrogen ion depriving cells of substrates essential to generate further ATP, and exacerbating both 
osmotic flows and cytoplasmic acidity. It is these small molecules in parallel with the accumulation 
of toxic glycolytic products and intermediaries, including lactate, creatine, NADH, and free radicals, 
that cause the patho-histological sequelae characteristic of ischaemic injury.  
Cel lular Oedema 
ATP is the required energy unit for the majority of cell functions. A lack of ATP causes inhibition of 
ATP dependent Na+/K+ ATPase and impairs a cell’s ability to maintain membrane polarity and cell 
excitability, due to unchallenged trafficking of Na and K ions into and out of the cell. As Na 
accumulates it draws with it excess water causing cellular swelling. Furthermore, accumulation of 
glycolytic intermediaries as anaerobic metabolism slows acts to accelerate the increase in the 
osmotic load within the cell, attracting more water through simple diffusion, and exacerbating the 
ischaemic oedema [57] .   
Cellular oedema results in disruption to cell membranes including those of the endoplasmic 
reticulum (ER), mitochondrion, and golgi apparatus [75]. An increase in cell volume results in 
activation of membrane stretch receptors, with a dissipation of membrane semi -conductance, both 
of outer cell membranes and those of the ER, mitochondrion, and golgi apparatus. A key use of 
preservation solutions is to limit cellular oedema and these biochemical and intracellular sequale 
(see Section  1.7.1.3 Formulation of Organ Preservation Solutions). 
 
ER and Mitochondrial Stress 
The ER is responsible for synthesis, maturation, and trafficking of a wide range of proteins, the 
biochemical reactions for which require a delicate environment that is based on pH, ionic 
concentrations, and re-dox potentials, and if disturbed causes ER functionality to be lost [76]. 
Several factors can cause ER associated stress and dysfunction in ischaemic tissue – namely hypoxia, 
energy substrate depletion, and an imbalance in ER calcium distribution [77]. The key response by 
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the ER to external stress is the unfolded protein response (UPR) the primary purpose of which is to 
enable adaptation to the changing environment and several pathways have been elucidated to be 
active in this protective process and involve ER localised transmembrane proteins specifically: 
Insitol-requiring enzyme-1, double-stranded RNA-activated protein kinase-like ER kinase (PERK), and 
activating transcription factor 6 (ATF6) [78]. These proteins are core adaptive UPR signal transducers 
and when activated promote expression of genes encoding for ER chaperones molecules, induction 
of mis-folded ER degradation, and anti-oxidant enzymes. If  however experience excessive or 
prolong stress the UPR may fail to resolve the environmental changes and restore ER functionality. 
At this point the UPR proceeds to activate apoptosis – designated as the maladaptive UPR. The same 
pathways initially promoting the adapative response switch and mediate apoptosis. The 
transcription factor CHOP is activated downstream of PERK and ATF6 and induces pro-apoptopic 
proteins, while down regulating anti-apoptotic Bcl-2 family protein members. Insitol-requiring 
enzyme-1 through interaction with adaptor factor tumour necrosis factor receptor-associated factor-
2 activates ER membrane associated caspases, key cellular initiators of programmed cell death. 
Finally dysfunction in calcium homeostasis with a cellular re-distribution and build up within the 
mitochondrial matrix causes a disruption of inner membrane polarity and generation of free radicals, 
which augment pro-apoptotic pathways.[78]    
Mitochondrial dysfunction alone however is one of the critical events in ischaemic stress as it is the 
initiator of both apoptotic and necrotic cascades leading to cell death. Mitochondrion membranes 
facilitate oxidative pathways and stretching and unfolding causes changes in distances between 
membrane components resulting in a loss of coordination of oxidative phosphorylation.  Once 
mitochondrial damage ensues if ATP is available, as is the case upon revascularisation with newly 
available oxygen, cytochrome c amongst other proapoptopic mediators [79] is released from the 
mitochondrial membrane causing the activation of initiator pro-caspases 8 and 9 [80,81]. This starts 
a cascade that in turn activates downstream caspase 3 [82] initiating programmed cell death [83]. ER 
associated calcium redistribution to the mitochondria augments pro-apoptopic mediatior activation. 
Caspase 3 is considered to be the key apoptotic molecule responsible for cleaving various proteins, 
disabling cell structure, and inhibiting repair processes [84,85]. The caspase family of proteins have 
substrates in plasma membranes, lysosomes, mitochondria, and nuclei [57] . When ATP is 
unavailable necrosis ensues. Histologically mitochondrial densities and the loss of cristae integrity 
heralds an irreversible phase of cellular injury [86] . 
Calcium Re-distribution  
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During ischaemia there is an intracellular build-up of calcium ions, a result of both redistribution 
from the ischaemically stressed ER due to the UPR [79] , and reverse action of the Na/Ca exchanger 
[87–89] . Calcium pyrophosphate and uric acid is formed as a result and these ‘danger signal’ 
molecules bind intracellular proteins to form inflammasome complexes which stimulate the 
production of both pro-inflammatory mediators known collectively as cytokines [90,91]. Calcium 
also activates cytoplasmic proteases and phosphoplipases namely the caspases and calpains [92], 
which in severe intracellular acidosis augment the action of pro-apoptotic proteins released from the 
damaged mitochondria [93] . 
Calcium ions are sequestered in the mitochondrial matrix to offset the ionic potential of excess 
intracellular sodium and maintain mitochondrial membrane potential [94]. Mitochondrial uptake is 
regulated by phospholipase C-delta-1, whose expression is up-regulated in cold ischaemia [95]. 
Calcium overload causes damage to the organelle and as key phosphorylative enzymes (complexes 
I,III,IV) are inhibited ATP depletion accelerates [96] . The influx of extracellular calcium that occurs 
during reperfusion facilitates pro-apoptotic protein (cytochrome c) release via the mitochondria 
permeability transition pore, which is normally closed, but which opens under high calcium loads 
[57]. Prolonged opening of the mitochondria permeability transition pore differentiates between 
reversible and irreversible cellular injury [96,97] . The unregulated calcium entry in the cell also 
activates cell membrane bound enzymes specifically phospholipase A2 which leads to formation and 
extracellular release of arachidonic acid metabolites (leukotriene B4, thromboxane A2) starting a 
pro-inflammatory cascade which perpetuates by recruitment and activation of neighbouring 
parenchymal, endothelial, and immune cells. 
 
Free Radicals and Reactive oxygen species 
Reactive oxygen species (ROS) play an important role in ischaemia induced cell damage [98,99]. ROS 
are generated from the metabolism of oxygen and biologically important species include the 
superoxide (O2-), hydroxyl (OH-) and peroxynitrite (ONOO-) anions [100]. Under physiological 
conditions 95% of cellular oxygen is metabolised in the mitochondria at the end of the electron 
transport chain by tetravalent reduction with the direct formation of water (H2O), and generation of 
ATP[101]; the remaining 5% are reduced in a series of univalent pathways with the formation of free 
radical intermediaries, such as O2- and hydrogen peroxide which forms OH- anions [102]. These 
species play a role in normal intra- and inter-cellular communication, and are quickly reduced by the 
anti-oxidant enzymes superoxide dimustase, catalase, and glutathione peroxidise to water.  
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In ischaemia oxidative phosphorylation for the purpose of ATP generation is halted, however 
molecular oxygen can still be present within the mitochondria, and dysfunction of respiratory chain 
cytochromes during this period causes excess formation of O2- anions from this residual 
oxygen[103]. Additional O2-, hydrogen peroxide and OH- anions are formed via the still active 
alternative univalent pathways. These free radicals are highly reactive due to the free and unpaired 
valence electrons and mediate mitochondrial injury, as well as causing damage to intracellular lipids, 
nucleic acids and proteins[104] - so called ‘oxidative stress’. It has been shown that the 
mitochondrial permeability transition is induced by ROS and in turn triggers mitochondrial ROS 
generation[105]. 
Furthermore under these conditions physiologically non-ROS producing enzymes (xanthine 
dehydrogenase, XO) can undergo conformational changes (induced by high calcium levels [106]) to 
isoenzymes capable of forming ROS[107].   
 
1.3.3 Ischaemic Reperfusion Injury and the Kidney 
1.3.3.1 Tubular Dysfunction  
Ischaemic injury to proximal tubular epithelial cells leads to both structural and functional changes in 
their cell membranes. During IR activation of cytoplasmic calpains by increasing calcium levels leads 
to digestion and severing of cytoskeletal actin filaments which disrupts the structure and stability of 
epithelial cell membranes[108,109]   and leads to functional changes in and obstruction of the 
tubular apparatus.  
This instability and in concert with local cytokine effects disrupts apical tight junction integrity. ZO-1, 
ZO-2[110] and cingulin tight junction proteins are dephosphorylated, forming insoluble complexes 
with cytoskeletal proteins such as fodrin[111]. These new complexes alter the permeability and 
polarity of the epithelial membranes and result in back leak of glomerular filtrate into the 
interstitium with ensuing oedema[112]. At the same time Na+/K+ ATPase membrane channel 
proteins re-localise to the apical plasma membrane. This reduces Na transport out of the proximal 
tubules, increasing Na+ delivery to the distal tubular region. This delivery can activate 
tubuloglomerular feedback at the macula densa and induce afferent arteriolar constriction (through 
Renin and Angiotensin) which further negatively impacts glomerular filtration. These membrane 
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disturbances can help explain the observed increase in fractional Na excretion in transplant patients 
during the initial post operative period.[113] 
Zona adheren junctions are also affected during IR injury. A lack of ATP results in a breakdown of the 
cadheren-actin cytoskeleton interface that makes up zona adheren junction[109] . E-cadherin, and 
alpha/beta catenin (proteins linking cadherin and actin) become phosphorylated by activated 
cytoplasmic kinases and dissociate from the plasma membrane[114–116]. Inflammatory cytokines 
may induce similar junctional changes acting on B-catenin through a wnt/wingless signal 
transcriptional pathway which regulates proliferative, and apoptotic gene expression[117], 
suggesting that disruption in adheren junctional complexes may start during ischaemia but are 
perpetuated during reperfusion by inflammatory mediators. 
At the point of reperfusion depending on the degree of ischaemic injury epithelial cells can be shed 
into the tubular lumen. Epithelial cell exfoliation is mediated by disruption in cell-matrix adhesion 
specifically and primarily by B1 integrin proteins which anchor cells to the basement membrane. In a 
similar mechanism to protein re-localisation seen in zona adheren junctions integrins re-distribute to 
apical membranes which has two effects: 1)  mediating detachment of the epithelial cell into the 
tubule lumen, and 2) facilitating through the new apical integrins interaction and possible adhesion 
with other shed cells - potentially worsening tubular obstruction[117]. Despite convincing 
experimental evidence in-vivo analysis has not yet confirmed these findings[113], and the true 
mechanism may be a complex interaction between other proteins of the integrin family, and the 
local effect of pro-inflammatory cytokines such as tumour necrosis factor (TNF), interleukin (IL)-1 
and interferon gamma (IFN-γ). 
1.3.3.2 Inf lammatory Role of Tubule Cells 
Tubular epithelial cells contribute to the inflammatory process by secreting both cytokines (TNF-α, 
IL-6, IL-1), chemokines (monocyte chemoattractant protein 1 [MCP-1], IL-8, CCL5 [chemokine ligand 
5], fractalkines), and transforming growth factor beta (TGF-β) in response to IR injury [113]. Tubule 
cells then interact with infiltrative immune cells that perpetuate the initial inflammatory response 
provoked by reperfusion and endothelial activation[118].  
Furthermore chemokines induce migration and adhesion of leucocytes to epithelial membranes 
facilitating direct macrophage induced tubular injury.  
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Proximal tubular epithelial cells also express the CD40 receptor for CD154 a ligand expressly found 
on T-cells. Tubular interaction with T-cells and binding of this ligand-receptor complex activates c-
Jun N-terminal kinases and mitogen activated protein kinase (MAPK) pathways which stimulate IL-9 
and MCP-1 production by these cells[119]. In parallel CD40 induces CCL5 production by epithelial 
cells, actions of which are amplified by T-cell (Th2 subset) secretion of IL-4 and IL-13[120]. 
The expression of toll-like receptor (TLR) 2 and 4 on epithelial cells after ischaemic injury[121] serves 
as another potential activator in the interstitium of both the innate immune response and 
specifically complement - exacerbating pro-inflammatory cascades and identifying tubular cells as a 
target for direct cell mediated damage. Tubule cell expression of C5a complement receptors 
increases after IR injury[122]. C5a is a key immunomodulator and chemoattractant recruiting and 
activating macrophages, neutrophils and T-cells, and binding of C5a generated during IR exacerbates 
the inflammatory infiltrate into the interstium. Blockade with anti-C5a monoclonal antibody (mAB) 
limits neutrophil and macrophage invasion and affords protection from renal dysfunction in 
mice[122].  
1.3.3.3 Inf lammatory Cells in Ischaemia Reperfusion Injury 
Macrophages 
Macrophages are active in both innate and adaptive immunity and are actively involved in the 
pathogenesis of IR injury. During IR macrophages become activated (through stimulation by 
chemokines such as MCP-1) exhibiting potent phagocytic activity and secreting key cytokines (IL-1, 
IL-6, IL-8, IL-12 and TNF-α) [123]. Within hours of reperfusion macrophages are adherent to renal 
endothelial of the vasa recta in the post capillary venules of the outer medulla[124]. This influx and 
infiltration enhances inflammatory cascades with subsequent recruitment of more macrophages and 
neutrophils and induction of apoptosis in the allograft. Macrophage activity has been implicated in 
the progressive development of renal fibrosis post IR injury[125] - illustrating a further potentially 
chronic role of these cell types rather than just in an acute phase of IR. In contrast phenotypic 
switching of macrophages from the M1 (pro-inflammatory) to M2 (anti-inflammatory) cell type may 
promote renal repair after ischaemia[126,127] . Macrophages have a key role in IR pathogenesis and 
subsequent tissue repair the nature of which however is still being  investigated and is undoubtedly  
a complex interplay with other inflammatory cells and species.  
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Neutrophils 
Neutrophils are key players in the innate immune response and active in phagocytosis, producing 
reactive oxygen and nitrogenous species, and antimicrobial peptides. The role of neutropils in IR 
injury has been widely established but their involvement in IR mediated renal damage is considered 
to be less than in other tissue types such as cardiac and skeletal muscle[128]. The exact role of 
neutrophils in IR mediated renal damage is still ill-defined, and despite discrepancies in the extent of 
their involvement in the IR process it is likely that one mechanism of injury is through direct damage 
by plugging renal microvasculature with release of reactive species and proteases[129].  
Lymphocytes 
CD4 T cells have been implicated as important mediators in the initial phase of injury during renal IR. 
CD4 knockout mice were protected from IR injury, and this damage was restored by adoptive CD4 
transfers, while in contrast CD8 knockouts showed no effect on IR injury[130]. More recently distinct 
CD4 cell subsets  including: CD4+, ygT, and Tregs, have been explicitly linked to IR pathogenesis with 
Th1 (IFN-γ) and Th17 cells (IL-17) promoting immune activation and damage, and Tregs limiting 
inflammation and contributing to tissue repair[131]. The functional variants of T-cell subpopulations 
reflect their differences in tissue-specific T cell/innate immune cell infiltrates and kinetics in IR injury, 
meaning that different T-cells will promote or inhibit damage at different temporal stages of IR 
mediated injury[132].  
Natural Ki ller ce lls 
Natural Killer (NK) cells are cytotoxic lymphocytes that lack T-cell or B-cell membrane receptors. 
They are potent components of the innate immune response and can target and kill infected cells 
directly as well as produce cytokines including IFN-γ and TNF-α. The known role of NK cells in acute 
kidney IR injury is still limited but due to their important cytotoxic, secretory, and stimulatory roles 
NK cells are predicted to be important in inducing IR renal injury. The exact contribution of NK cells 
to renal IR injury is still not well defined. NK cells can directly kill tubular epithelial cells after IR, and 
NK cell depletion in wild-type C57BL/6 mice has a protective effect, with the adoptive transfer of NK 
cells to Rag2−/− c −/− mice, which naturally lack NK, natural killer T , T, and B cells, worsening injury 
[133].  
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1.3.3.4 Inf lammatory Mediators in Ischaemia Reperfusion Injury 
Cytokines 
Cytokines are low-molecular-weight regulatory glycoproteins released from various cell types and 
are key inflammatory mediators [134] involved in every aspect of immunity and inflammation, 
including: innate immunity, antigen presentation, haemopoetic cell differentiation, cellular 
recruitment and inflammation, and adhesion molecule expression [135]. IR injury is an inflammatory 
reaction that is potentiated by cytokines secreted by endothelial and tubular cells of the renal 
allograft as well as infiltrating immune cells of the recipient.  
These cytokines act within the allograft to increase 1) expression of cellular adhesion molecules, 2) 
vascular permeability in the allograft, 3) recruitment and activation of endothelial and inflammatory 
cells into pro-inflammatory states, 4) activation of the complement system as well as expression of 
TLRs, 5) generation of ROS, and 6) activation of aracadonic acid derivatives (prostaglandins and 
leukotrienes) which serve to amplify cytokine release [135]. Key cytokines identified in IR injury 
include  tumour necrosis factor, interleukin-1, and interleukin-6.  
Tumour necrosis factor 
TNF exists as several specific proteins - TNF-α and β -  produced by immune cells (mononuclear 
phagocytes, neutrophils, activated lymphocytes, natural killer cells) and also endothelial and mast 
cells[136]. During IR injury TNF stimulates endothelial cells to express a variety of cell adhesion 
molecules; intracellular adhesion molecule 1 (ICAM-1), vascular adhesion molecule 1 (VCAM-1) and 
E-selectin, while also inducing vascular and endothelial permeability which enables  egress of 
inflammatory cells into the renal parenchyma[137]. TNF is a potent neutrophil activator as well as a 
chemotactic agent, mediating cell adherence but also infiltration, degranulation, and development 
of the respiratory burst and formation of ROS.[135] 
Interleukin 1 ( IL-1) 
IL-1 is primarily produced by mononuclear phagocytes, however during periods of cellular stress 
such as IR injury endothelial cells have been shown to secrete IL-1. IL-1 is a key activator of T-
lymphocytes and up-regulates IL-2 and IL-2 Receptor production and expression (which induces 
clonal T-cell proliferation) [138]. It is also a stimulator of hepatic acute phase protein production (C-
reactive protein [CRP], complement) and shares similar effects as TNF - promoting endothelial 
expression of ICAM-1, VCAM-1 and E-selectin [136]. 
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Interleukin 6 ( IL-6) 
IL-6 is the key inducer of hepatic acute phase proteins, and mediates T-cell activation, growth, and 
differentiation, as well as B-cell differentiation into plasma cells [135]. Its synthesis, capable from 
mononuclear phagocytes as well as T- and B-cells, endothelial cells, fibroblasts, hypatocytes and 
haemopoetic  cells, is induced by both TNF and IL-1 [138]. 
Chemokines 
Chemokines are a subgroup of cytokines whose primary effect is chemotaxis and leukocyte 
activation [134]. Chemokines activity have been documented in a number of reperfusion injury 
models in brain, heart, liver and kidney injury [139] . During IR injury chemokine induction is 
stimulated via a variety of mechanisms including ROS stress [140] [141] , allied pro-inflammatory 
cytokines (TNF-α, IL-1) [142], complement activation [143], TLR receptor activation and the NFƙ-B 
transcription pathway  [139] .  
A key chemokine is IL-8 which plays a predominate role in neutrophil recruitment, has been shown 
to be upregulated in clinical kidney transplantation of cadaveric allografts, with concentrations 
correlated to the degree of cold ischaemic injury [144] , and inhibition of the IL-8 receptor mitigating 
IR injury in murine renal transplant models [145]. 
Another chemokine of note is MCP-1. MCP-1 is a potent chemotactic protein acting on monocytes, T 
cells, and NK cells. It is implicated in monocytic infiltrative diseases, including IR injury in cardiac 
[146], cerebral ischaemia [147] , and in particular in renal ischaemia where mice deficient in the 
MCP-1 receptor demonstrated decreased tubular injury and monocytic infiltrates during acute 
kidney injury (AKI) [148] .  
Other prominent chemokines include CCL5 (regulation upon activation, normal T cell expressed and 
secreted) and Fractalkine/CX3CL1 [149]. These are key players in general IR inflammation, and are 
likely active in renal IR injury. Fractalkin/CX3CL1 in particular is expressed on injured endothelial cells 
and is a potent chemotactic and adhesion molecule for macrophages with their expression up-
regulated in post-ischaemic kidneys, and receptor inhibition shown to confer a degree of protection 
from macrophage infiltration [150] . Despite recent suggestions the exact role of these molecules 
have yet to be elucidated in renal IR.   
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1.3.4 Transcription Factor NFƙ-B 
NFƙ-B is a family of transcription factors that integrates a complex network of extracellular signalling 
pathways, resulting in the transcriptional regulation of a large number of genes related to 
inflammation, immunity, apoptosis, cell proliferation, and differentiation. 
NFƙ-B by binding to discrete DNA sequences known as B elements in promoter and enhancer 
elements of target genes can induce or repress gene expression. NFƙ-B activation through a number 
of stimuli results in nuclear translocation and can proceed either through a series of classical  or 
alternative, and hybrid pathways. 
The complete repertoire of target genes encompasses key inflammatory molecules; cytokines (Il-
1,2,6 and IL-2 receptors), chemokines (IL-8, IL-10, MCP-1, CCL5), colony stimulating factors, TNF-α/β 
and INF-β; cell membrane surface molecules (T-cell receptor B chains, B2-microglobin, CAMs 
[selectins, ICAM, VCAM, ELAM], and major histocompatibility complex [MHC] Class I and II); 
inflammatory enzymes (iNOS, iCOX, PLA); acute phase proteins (Tissue factor, metalloproteinases); 
and allied transcription factors that act to regulate, mediate, or promote inflammatory gene 
transcription [such as c-rel, c-myc, IFR, IkBa].[151]  
Depending on the pathway involved expression of specific gene subsets may be induced or 
repressed.  Transcription of a number of key inflammatory mediators is guaranteed by short 
stimulations of NF-B regardless of stimulus concentration. These include negative regulators of NF-B 
activity (IkBa ,IkBe, and A20) and pro-inflammatory cytokines (IL-6, IL-8, MCP-1, and IP10). Some 
genes however are transcribed only with prolonged NF-B activation, such as cell surface receptors, 
adhesion molecules and signal adapters, and key chemokines such as CCL5. 
There are numerous stimuli relevant to NFƙ-B activation in kidneys and include inflammatory 
cytokines (IL-1/2, TNF-α, IFN-γ) and growth factors, pathogen and cellular damage-associated 
molecular patterns, TLRs and nucleotide-binding oligomerization domain receptors (NOD like 
receptors), metabolic (high glucose, advanced glycation end products [AGEs]) or genotoxic stress, 
vasoactive and endothelial related agents (endothelin, angiotensin II, thrombin), cell membrane 
activation proteins (CAMs, fibronectin), immune mediators, proteinuria, and mechanical 
stretch.[152] 
Renal NFƙ-B activation in the setting of reperfusion injury regulates neutrophil, macrophage, 
lymphocyte, and dendritic cell biology, as well as endothelial cell activation, and has been 
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documented in  both in vivo and in vitro models in intrinsic glomerular cells such as podocytes and 
mesangial, tubular, and endothelial cells during renal IR injury. [153] 
 
1.3.5 Complement  
The complement system plays an important part in innate immune response processes. It is 
composed of a group of serum and cell membrane bound proteins whose interplay with each other 
and other molecules of innate and adaptive immune systems means it has di verse roles in 
inflammation, and IR injury [154] . 
Three different complement pathways can be distinguished: the alternative pathway, the classical 
pathway, and the MB-lectin pathway and all three are active in IR injury to variable degrees 
depending on the models and organs involved.  
After activation of any of the three pathways there is a merged formation of a the complement 
component C3 and enzyme C5 convertase and ultimately the formation of the membrane attack 
complex (MAC) formed by a C5b-C9 complement complex [154], with the split products of C3, C4, 
and C5 formed in the pathway capable of immuno-modulating functions [155] [156] . 
The predominate pathways responsible in renal IR injury appear to be the alternative [157] and MB-
lectin pathways [158] with the role of classical pathway in the inflammatory milieu occurring during 
and after renal ischaemia [154] only recently emerging as an important mechanism.  
Select inhibition of the alternative pathway affords protection from ischemic injury in kidney models 
[157]. In murine models of AKI , C3 production from tubular epithelial cells is stimulated and the 
endogenous complement inhibitor Crry expressed on the tubular basolateral surface is depressed 
after IR [159]. While C3a has been demonstrated to play a crucial role in chemokine production by 
tubular epithelial cells after IR, supporting the role of the alternative pathway after IR injury [160], 
with small interfering RNA (siRNA) gene slicing targeting C3 and caspase 3 improving renal function 
and affording structural protection in a murine transplant model [161]. 
The MAC and C5a also contribute to ischemic AKI with C5a receptor antagonists demonstrating 
protective effects against IR injury [162]. In addition MAC deposition on tubular epithelial cells is 
known to stimulate production of key inflammatory cytokines - TNF-α and IL-6 [163]. 
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1.3.6 Toll like receptors 
TLRs are a family of 13 trans-membrane prototype pattern recognition receptors and are key 
components of the innate immune response primarily due to their ability to recognise pathogen 
related molecules. Recognition and engagement of exogenous molecules by TLRs induces generation 
of cytokine and chemokines, upregulating co-stimulatory molecules, enhancing antigen processing 
by antigen presenting cells, and guiding T-cell induction and activation, that altogether  initiate and 
amplify the innate immune response[91].  
Signal transduction and activation of innate responses by TLRs is via several pro-inflammatory 
kinases and the NF-κB pathways, that lead to generation of pro-inflammatory cytokines [134]. TLRs 
have also been shown to recognise endogenous cellular molecules derived during cellular injury 
(damage-associated molecular patterns [DAMPs]) - such as products from degradation of macro-
molecules, proteolytic cascades, and intracellular components of ruptured cells, such as hyaluronan, 
fibronectin, as well as heat shock proteins (HSPs), high-mobility group box protein-1 (HMGB1) and 
host DNA [164]. Though predominately present on immune related antigen presenting cells TLRs are 
now known to be expressed on a variety of non-immune functioning cells. In particular TLR2 and 
TLR4 are constitutively expressed on renal tubular epithelial cell membranes and cells of the 
Bowman capsule [165], which recognise to HSP-60 and HSP-70, and the expression of which is up-
regulated during renal ischaemia and reperfusion injury [121]. 
 More recently transgenic knockout of TLR3 in mice was shown to be protective in renal IR with less 
renal damage biomarker production Neutrophil gelatinase-associated lipocalin, lower cumulative 
kidney damage, and improved renal blood perfusion [166]. 
Experimentally loss of function TLR4 gene mutations are associated with improved kidney graft 
function post operatively, with TLR4 expression upregulated in cadaveric vs. living donor kidneys 
[121], while in clinical liver transplantation the TLR4 genotype enhanced sterile inflammation and 
was linked to poor graft survival [167].   
TLR signally by HMGB1 has been shown to accelerate the inflammatory response to IR injury in a 
positive feedback loop instigated by TLR mediated ROS release [121]. TLR activation and signally thus 
not only impacts immediate damage during IR, but persistent activation through these pathways 
impacts recipient allo-responses, graft rejection, and chronic allograft injury. The role of TLR is acute 
injury has been widely described, and though definitively involved in chronic responses the exact 
mechanism played in chronic injury is less understood.  
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1.3.7 Nitric Oxide 
Nitric Oxide (NO), or endothelium relaxing factor is a labile free radical produced in varying degrees 
through the conversion of the amino acid L-arginine to L-citrulline, catalysed by nitric oxide synthase 
(NOS). It plays a role in both normal and abnormal tissue function and contributes to the 
pathogenesis of IR injury[99] . There are three isoformic variants of NOS - nNOS1 and eNOS are 
constitutive, calcium/calmodulin dependent, and primarily in neuronal and endothelial cells 
respectively, while iNOS is calcium independent, inducible and involved predominately in 
inflammation[99] . All three variants are found in the kidney.  
The extent of NO's role as a protective or deleterious entity in inflammation is dependent on the 
site, cellular origin, quantity and rate of production, and precipitating factor for its generation. 
Constitutive NOS is regarded to be associated with cytoprotective formation of NO, while iNOS 
expressed predominately after hypoxic or cytokine exposure is associated with deleterious 
generation of NO that is actively involved in the progression of IR injury and in kidneys, acute renal 
failure (ARF). Ultimately the degree of damage is dependent on balance and shift between NO and 
ROS formation and their ultimate metabolism during ischaemia and subsequent re -perfusion 
1.3.7.1 Cytotoxic NO 
Cytotoxic properties of NO are related to its interaction with other ROS produced during periods of 
ischaemia and hypoxia, and subsequent reperfusion. NO can react with O2- anions to form ONOO-. 
Depletion of the NOS cofactor BH4 during ichaemia may also trigger changes in NOS function, 
switching from NO to O2- formation. 
1.3.7.2 Cytoprotective NO 
More recently NO has been shown to be a potentially cytoprotective molecule in IR injury, with 
several key properties[168].   
NO acts as an anti-oxidant free radical scavenger capable of reacting with O2- and reducing 
superoxide mediated tissue damage[169] [170]. This reaction produces the highly toxic ONOO-, the 
reactivity of which however is determined by the NO:02 -ratio with excess NO reducing ONOO- 
elicited activity[171]. NO is also able to inhibit mitochondrial respiration, and reduce ROS formation 
during reperfusion by competitively binding to cytochrome-C oxidase[172]. During ichaemia binding 
is more pronounced due to the lack of O2, mitigating a degree of preconditioning, and during 
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reperfusion ischaemia is slowly abated by progressive competition for binding by oxygen, preventing 
sudden resumption in electron transport chain activity, and less ROS formation. 
NO can mediate inflammatory processes specifically preventing inflammatory neutrophilic 
infiltration, and cytokine production[173]. TNF-α is a key cytokine involved in accumulation of 
neutrophils and production of allied cytokines, as well as inducing pro-inflammatory gene expression 
via the NF-KB pathway[174]. Direct NO administration in murine models of renal and pulmonary IR 
injury using NO-donors (molsidomine [170], nitroprusside [175]) has been shown to reduce IR 
damage and apoptosis via a significant reduction in TNF-α. While liver preconditioning through NO 
leads to a reduction in IL-1 release, with protection against IR injury[176]. 
NO also influences the expression of a number of cell adhesion molecules (CAMS) which play a key 
role in the cellular inflammatory aspect of IR injury. During and after IR injury CAM are upregulated 
on vasculature endothelial cells - with selectins mediating the initial tethering of neutropils to 
activated endothelial an important step in IR pathogenesis. L-selectin is constitutively specific for 
leucocytes while P and E- selectin are expressed on endothelial cells in response to stimuli - such as 
ROS, and cytokines (IL-1, TNF-α)[58]. IR injury has been shown to decrease intracellular NO levels 
and increase P-selectin expression[177]. Delivery of NO by molecular donors in both animal and 
human in-vitro models  decreases leukocyte endothelial attachment, rolling, and infiltration, and 
inhibits the expression of P-selectin[177] , E-selectin, VCAM-1 and ICAM-1, achieved possibly by 
inhibition of TNF-α [137] and blockade of NFƙ-B.  
NO can exhibit both pro-apoptotic and anti-apoptotic effects [178]. NO can reduce the amount of 
apoptosis induced by TNF-α, ROS, and glucose deprivation, while conversely high concentrations of 
intracellular NO can induce necrosis and apoptosis [99] . The mechanisms by which NO mediates 
these opposite effects are only slowly being elucidated, and may differ between cell types. Possible 
mechanisms include through a diminished response of the intracellular g-protein messenger enzyme 
guanylyl cyclase to NO [178] , down regulation of the proapoptotic gene p53 [179], direct dose-
dependent inhibition of apoptotic caspases [180], and even the induction of HSP70. 
In parallel to down regulating CAM expression NO has been shown to regulate the chemokine 
response. NO acts by modulating the production[142] of the potent neutrophil chemoattractants 
macrophage inflammatory proteins (MIP-1 and 2) that are expressed during IR injury[181]. The 
mechanisms for many of investigated protective effects of NO likely lie with modulating the effects 
or actions of transcription factors such as NFƙ-B and AP-1, and the MAPKs.  
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MAPKs are signal transducers modulating gene expression and protein production involved in cell 
proliferation, differentiation, survival, and apoptosis. NO has been shown to affect activation of 
several species: extracellular signal-regulated kinases (ERK1/2), c-Jun N-terminal kinases, p38 
kinases, guanylyl cyclase and cGK, and through one of these pathways NO exhibits its beneficial IR 
protective effects . 
Transcription factors are protein complexes that control the transcription of DNA, with NFƙ-B 
involved in cellular responses to stressful stimuli, cytokines, ROS, bacterial or viral pathogens. Genes 
regulated by NFƙ-B include those for iNOS, TNF-α, IL-6 and IL-1 - all key species in the pathogenesis 
of IR injury. NO may inhibit NFƙ-B activity by a number of mechanisms: scavenging of ROS   (O2-), 
interrupting NFƙ-B DNA binding, and stabilising NFƙ-B precursors (IƙBa) .  
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1.4 The Coagulation Cascade and Ischaemia Reperfus ion Injury 
1.4.1 Physiology of Coagulation 
The coagulation system is composed of both cellular and macromolecular protein elements. Cellular 
components include platelets, inflammatory cells, and in few numbers RBCs and vascular micro-
particles), while the proteins are a series of coagulatory and anti-coagulatory enzymes and co-
factors [182].  
Once coagulation is activated - through trauma or other stimuli - cells interact with the macro-
molecular coagulation proteins initiating a series of enzymatic cascades that lead to the formation of 
a fibrin meshwork. Enzymatic proteases exist in two predominant forms - as a pre-cursor form 
known as a zymogen and an activated form. 
Historic models divided the coagulation cascade into 3 components [183] - the intrinsic, extrinsic and 
common pathways. The intrinsic relies on exposed collagen in damaged vessels to activate Factors 
XII, XI, IX and VIII. The extrinsic on stabilisation of endothelial bound Tissue Factor (TF, an 
transmembrane glycoprotein) which then complexes with the zymogen Factor VII to form the 
activated serine protease  TF-FVII complex (TF-FVIIa). In both instances the end products of each 
activated Factor VIII (FVIIIa) and TF-FVII converge on the common pathway by activating Factor X 
which cleaves prothrombin (FII) into thrombin (FIIa). Thrombin in turn acts on fibrinogen to generate 
fibrin which is then cross linked to other fibrin molecules in an insoluble fibrin meshwork.  
The most recent model of coagulation is based on TF being the key trigger of coagulation[183] with 
limited requirement for contact activation of the intrinsic pathway, the TF-VIIa complex able to 
activate Factor IX directly ('the josso pathway'), and thrombin able to activate Factor XI [184]. The TF 
extracellular domain binds and increases the activity of FVII/VIIa. Thus TF initiates the pathway for 
extrinsic coagulation, playing a critical role in thrombin generation, and thrombus formation. 
Because TF-VIIa can also activate FIX directly, to form a complex with FIXa and FX, an essential 
amplification loop re-generating FXa is initiated [185]. This is potentiated in the presence of 
thrombin activated platelets. 
Coagulation reactions do not take place in the liquid plasma phase of the circulation, but in the solid 
phase occurring on cell membranes or the surface of developing thrombi. The primary step in 
endothelial cells acquiring a thombogenic phenotype is upregulation of bound TF.   
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In a normal state there is a constant generation of TF and activation of small quantities of the 
coagulation proteases, with fibrin formation. However to prevent uncontrolled fibrin formation and 
thrombosis a tightly controlled endogenous anti-coagulant system exists, predominant in the 
circulation and at the endothelial surface. During episodes of stimuli endogenous anti-coagulant 
mechanisms are inactivated and overwhelmed by the pro-thrombotic stimulus. 
There are three endogenous anti-coagulant systems: anti-thrombin III (AT), tissue factor pathway 
inhibitor (TFPI), and the protein C system (see Figure 9) . Evidence of their importance in maintaining 
vascular fluidity and preventing unintentional thrombosis is derived from analysis of congenital and 
experimental, deficiencies or functional defects of ATIII [186] , TFPI [187], and Protein C[187] that 
increases thrombotic risk. 
 
 
 
Figure 9  Overvi ew of the c oa gula ti on network and various  endogenous  inhibi tors . The proc ess  
begins  wi th tissue fac tor conta c ting fac tor  VII /VI Ia i n bl ood a fter  I R i njury or  during 
infla mma tion.  Thrombin is genera ted by a s eri es  of feedba ck a nd a mplifica ti on s teps  res ul ting 
in genera tion of fibri n polymers  wi th fibrin deposi tion (not shown). The three main regula tors  of 
c oa gula tion are a nti -thrombi n, tissue- fac tor  pa thway i nhi bi tor , a c tiva ted protei n C / 
thrombomodulin. Fibrinolysis  is facil i ta ted by plas min formed fr om the cl ea va ge of plas mi nogen 
by ti s s ue pl asminogen a ctivator (t -PA). 
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1.4.1.1 Anti -thrombin 
AT is a potent proteinase inhibitor, inactivating the majority of serine proteases in particular 
thrombin and FIVa and FXa. Inhibition is catalysed by heparan and dermatan sulphate which are 
glycoaminoglycans present within the glycocalyx of the endothelial cell membrane. These co-factors 
potentiate by a factor of 100 the activity of ATIII [188,189].  
1.4.1.2 TFPI  
TFPI is produced by endothelial cells. It binds to minute quantities of generated FXa then proceeds 
to inhibit the TF-FVIIa complex on the endothelial surface[190,191].   
1.4.1.3 Protein C System 
Protein C is a vitamin K dependent  protein produced by the liver. It is a circulating molecule 
activated by it binding to the thrombin-thrombomodulin complex on the endothelial surface. 
Thrombomodulin (TM) is a 100-kDa transmembrane protein produced by endothelial cells in either a 
bound or soluble circulating form. Once bound to TM protein C associates with protein S (a 
cofactor), and the endothelial protein C receptor (EPCR) which serve to accelerate protein C 
activation 20-fold[192]. Bound to its cofactors Protein C suppresses FV and FVIII, while 
independently protein C directly inhibits FXa [193]. 
1.4.1.4 Endogenous Anti-fibrinolytic Systems 
Once fibrin is generated by the action of thrombin on fibrinogen there are intrinsic fibrinolytic 
mechanisms in action to prevent widespread coagulation and thrombosis. The primary system is 
through the protease tissue plasminogen activator (t-PA). t-PA is released by endothelial cells and 
transforms plasminogen on the cell surface or the clot itself into plasmin. Plasmin degrades fibrin 
with the release of fibrin degradation products (D-dimers). t-PA itself is solely produced in the micro-
circulation. In the kidney a specific plasminogen activator is evident u-PA - expressed during 
remodelling in tissue repair and angiogenesis, as well limiting vascular homeostasis during localised 
infection [194,195]. Fibrinolysis is controlled by alpha-2 antiplasmin (a plasmin inhibitor) and 
plasminogen activator inhibitor 1-3(PAI 1-3). PAI-1 also mediates inflammatory responses through 
the induction of leucocytes (neutrophils and lymphocytes), activation of neutrophils via TLR-4 and 
clearance of apoptotic cells and debris [196].  
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1.4.2 Coagulatory and Inflammatory  Cross Talk During  
Ischaemia Reperfusion Injury  
There is much cross talk between inflammatory mediators and coagulatory proteases.   Coagulation 
proteases produced as a direct consequence of the inflammation accompanying innate immune 
responses activated during IR injury continuously refuel the coagulation-inflammation cycle 
perpetuating and strengthening the inflammatory reaction. It is evident that unlike during 
coagulation initiated through the intrinsic pathway and direct acute vessel injury inflammation 
induced coagulation is not balanced by natural anti -coagulatory and endogenous fibrinolytic 
systems. However, coagulatory enzymes can also modulate key processes in inflammation including 
leucocyte activation, cytokine release, CAM expression, and NFƙ-B signalling. Mechanisms in this 
relationship have been elucidated in in-vitro and in-vivo models of endotoxic and IR based 
inflammation.   
1.4.2.1 TF and TFPI  
The key initiator of inflammation induced coagulation is TF[185] with TFPI a potent endogenous 
inhibitor. TF is not constitutively expressed on endothelial cells, present on cells not in direct contact 
with blood. Histologically, TF is present in adventitial layers of vessels, creating a 'TF envelope' that 
can be initiate coagulation quickly after disruption to the endothelial[197]. Inflammation induced 
coagulation can be initiated through TF up regulation or theoretically TFPI inhibition. 
During IR injury cytokine activated monocytes and macrophages expressing TF  are recruited into 
allograft. Leucocyte-endothelial adherence enables immune cell derived TF forming complexes with 
FVIIa, as well as transfer of TF at the endothelial surface, activating the coagulation 
cascade[198,199].  
Despite mononuclear cells considered to be responsible for substantive TF expression in the 
vasculature recent findings have demonstrated endothelial expression as potentially key step in IR 
induced activation of coagulation. Endothelial have been shown to express TF through a variety of 
mechanisms. 
In-vitro models have shown TF expression can be induced by a variety of stimuli [182,197,200] 
including  thrombin, inflammatory cytokines and chemokines (IL-6, IL-1, TNF-α, IFN, MCP-1), a result 
of CAM expression and receptor binding (ICAM, P-selectin), soluble and deposited complement 
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(C5a), AGEs, oxidised low density lipoproteins (LDLs) as well as hypoxia and ROS [201,202].  TF 
expression can also be inhibited by enhanced eNOS generation, specifically in endotoxin and 
cytokine induced expression in vitro [203].  Expression is mediated by a number of intracellular 
kinase signalling pathways (e.g. protein kinase C [PKC], and MAPKs) and also NFƙ-B [197].  In-vitro 
TNF-α induces TF expression on cultured endothelial cells, and blockade of thromboxane receptors 
inhibits cytokine induced expression by limiting activity of PKC and NADPH oxidase, with decreased 
ROS generation [204,205]. TLR2 and TLR4 activation can induce TF expression in macrophages and 
endothelial cells respectively via a JAK2-STAT3, and the NFƙ-B signalling pathways [206,207]. The 
complexity of interactions between inflammatory and coagulatory cascades as well as the nature of 
in-vitro experiments has proven difficult in translating in-vitro TF expression profiles using some in-
vivo models [208]. 
In-vivo cardiac IR models demonstrate endothelial TF expression mediated by ROS and reduced by 
treatment with ROS scavengers, and directly by TF mAb [209,210]. However similar models have 
suggested that TF expression may in fact predominate in cardiomyocytes, with endothelial 
expression limited [211,212], pointing to TF solely as an initiator (regardless of localization) and 
thrombin as the dominant effector in infarct size. TF-VIIa inhibition in murine cardiac IR reduces 
activation of NFƙ-B and IL-6 expression with TLR4 down regulation a potential mechanism[213]. 
In contrast renal models have firmly implicated up regulated endothelial TF expression during IR 
injury as key to mediated damaged [214–216]. TFs role in renal IR is abrogated with TF antisense 
oligonucleotides [217], recombinant TFPI[218], direct thrombin inhibitors, and in protease activated 
receptor-1 (PAR-1) or TF deficient mice [215]. Furthermore extended CIT (24 v 6 hours) is associated 
with up regulation of endothelial TF expression in murine renal transplantation, and induces a 
procoagulant state with greater loss of endothelial integrity and tubular necrosis[219]. Early 
inflammation in renal allografts appears not to have an immunogenic source[220] but rather IR 
mediated and activation of coagulation cascades through TF likely plays an important part in this 
process. Similar findings have been shown in hepatic models of IR injury [221–224].  
Studies in clinical transplantation are limited by comparison. Studies available indicate a chronic pro-
coagulant state, with renal transplant recipients demonstrating increased TF plasma activity 
compared to healthy controls [225]. In contrast immunohistology has localised of TF in biopsies from 
normal and transplanted kidneys[226]. In normal kidneys TF localised to glomerular epithelium and 
basements membranes only. Donor kidneys showed TF reactivity in renal capsule, and adventitia of 
large arteries but not on endothelial cells. Some pre-implantation biopsies even demonstrated 
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depleted glomerular TF. Furthermore long-term allografts with progressive dysfunction and those 
with advanced rejection in contrast to plasma activity exhibited diminished TF expression in 
glomerular epithelium and basement membranes.  
CRP is marker of inflammation. It is also an inducer of TF expression in vitro and in vivo and 
promotes a prothrombotic and inflammatory phenotype [227–230]. The kidney allograft is known to 
locally produce CRP in glomeruli and cortical tubules[231] during episodes of acute rejection, and 
increased levels of  CRP perioperatively and on follow up are associated with poorer graft survival 
[232,233]and the development of metabolic syndrome[234]. Experimentally in murine renal IR 
models CRP exacerbates reperfusion injury by upregulating macrophage activation and FcγR 
expression[235] and impairing tubular epithelial regeneration[236]. CRPs role in inflammatory 
reactions in the kidney has multiple dimensions. Studies to date have yet to fully elucidate the acute 
role for CRP in the immediate IR setting but TF involvement is a plausible component.  
Despite TFPI being the main inhibitor of the TF-VIIa complex and thus thrombin formation the 
complete role of TFPI during inflammation related coagulation has not been fully characterised. 
Clinical studies show that TFPI levels are not decreased in inflammatory endotoxaemia[237]. This 
may not be representative however as the majority of TFPI is endothelial bound with only 10-20% in 
the circulation bound to lipoprotein[238]. Recombinant TFPI treatment however blocks 
inflammatory thrombin generation and necrosis [218] as well as reducing microcirculatory 'no-
reflow' dysfunction (capillary malperfusion upon revascularisation) [239] in renal and cardiac IR 
models, and reduces mortality in severe endotoxaemia via IL-6 [185]. Available evidence does not 
point to depletion or dysfunction of TFPI during inflammatory states, such as endotoxaemia. It may 
be that overwhelming inflammatory stimuli overcome the endogenous activity of TFPI, and thus 
pharmacological treatment increasing TFPI levels above physiological  levels may enable activity to 
counter thrombin generation.  
1.4.2.2 APC 
There is a down regulation of APC activity during inflammation. In endotoxaemia APC zymogens 
levels are decreased due to consumption from the amplified generation of thrombin and fibrin, 
impaired synthesis due to the acute phase response, and degradation from neutrophilic elastases 
[185,240]. In IR injury during transplantation the influence from degradation likely predominates, 
related to the activation, adherence and infiltration of neutrophils and macrophages. Release of 
TNF-α, which in turn stimulates IL-6 production, and IL-1 down regulates endothelial TM expression 
70 
 
via NFƙ-B, disrupting a key step in APC functionality [241,242]. Cofactor protein S is found bound in 
plasma to complement C4b (60%) and also in a free soluble form. During IR cytokine release, ROS, 
and TLR activation stimulates the acute phase response with increased complement production and 
activation reducing the free:bound ratio of protein S, rendering a relative deficiency for APC 
[243,244]. Finally the EPCR receptor is downregulated in endotoxaemic stress, and experimental 
receptor blockade in animal endotoxaemia models results in severe thrombosis[245].  
In addition to anti-coagulatory properties  APC exerts anti-inflammatory effects. This functionality is 
mediated in part by  PAR1-4 which are the predominate G-protein receptors mediating cell signalling 
by coagulation proteases, but also by binding to EPCR receptors[246]. The anti-inflammatory 
properties have been demonstrated in endotoxaemic,  renal, and hepatic IR models [247]: APC 
reduces leucocyte-endothelial adhesion and activation through down regulating cytokine (IL-6, TNF-
α) and chemokine (MCP-1) production [248–252]; down regulates ICAM, ECAM and E-selectin 
mobilization from Weible Paladi bodies to the endothelium[253]; and ameliorates mitochondrial 
oxidative stress[254]. The APC-EPCR complex preserves endothelial barrier integrity by inducing 
membrane sphingosine 1-phosphate receptor activation and signalling (S1P)[255], and inhibiting 
endothelial cell apoptosis [256,257]. EPCR, through the similarity of its homology with major 
histocompatibility complex  receptor CD1 may also play a direct role in mediating inflammation, and 
experimental transgenic expression of EPCR in mice enhances APC levels protecting against 
endotoxaemia[257]. 
Loss of TM from the endothelium also contributes to the pro-inflammatory phenotype during IR. TM 
reduces MAPK and NFƙ-B signalling[258]. In addition the TM-thrombin complex inhibits thrombin-
induced endothelial activation[259], activating thrombin-activatable fibrinolysis inhibitor (TAFI), a 
procarboxypeptidase B which is a potent C5a inhibitor contributing to a reduction in microvascular 
dysfunction[260].  
Shear stress stimulates TM transcription and endothelial expression via krupple like factor 2, and in a 
transplant IR setting, SCS where by pulsatile and pressure stimulation of the vasculature is absent, 
upon reperfusion the endothelium is compromised and less able to tolerate the inflammatory influx 
[261–263].  
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1.4.3 Thrombin - The Key Coagulatory Protease 
Thrombin has a central role in the coagulation cascade whose generation once started is accelerated 
by a series of feedback amplification loops resulting in fibrin deposition at the site of endothelial 
injury. The haemostatic actions of thrombin are depicted in Figure 9. Thrombin is a multifunctional 
molecule also possesses non-haemostatic properties and in particular is involved in 
inflammation[264–266].  Thrombin induces cytokine (e.g. IL-6 and IL-8) and chemokine (MCP-1) 
production in a number of cell types including endothelial cells [267,268] , mural cells, epithelial 
cells, adipocytes, and leucocytes[269]. Thrombin can induce endothelial expression of adhesion 
molecules (P-selectin, E-selectin and ICAM)[270], promotes release of growth factors (such as 
platelet derived growth factor [PDGF]) and chemokines (PAF)[271] promoting endothelial-leucocyte-
platelet interactions and adhesion[272], as well as production of platelet-activating factor [273], 
endothelin [274], von Willebrand factor [275], and plasminogen activator and inhibitor [276]. 
Thrombin directly activates complement  (C3 and C5) and modulates innate immune responses by 
altering secretion and expression of cytokines and receptors in antigen-presenting cells[277–279]. 
Thrombin also increases endothelial permeability, a feature of inflammation, indirectly by 
stimulating histamine and prostacycline[280] release from platelets and endothelial cells, and 
directly through the S1P signalling pathway, that in contrast when stimulated by APC/EPCR actually 
reduces barrier failure [279,281,282]. Thrombin influences tissue repair and potentiates the effects 
of VEGF, and clot-bound thrombin, which is protected from AT inactivation, contributing to 
angiogenesis [265]. The PAR receptors form the crucial molecular link between coagulation and 
inflammation and the majority of extra-haematostatic effects of thrombin are mediated by PARs.  
1.4.3.1 Protease Activated Receptors  
The extra-haemostatic pro-inflammatory cellular effects of coagulation proteases, such as thrombin 
and FX, as well as the anti-inflammatory effects of the APC pathway are mediated by PAR 
signalling[283].   
Four types of PAR (PAR 1–4) have been described as part of the G-protein-coupled family of 
receptors each with a transmembrane domain [284].  PAR receptors are found on various cell types 
including mononuclear cells, endothelial cells, platelets, fibroblasts, and smooth muscle cells[285] 
and are illustrated in Figure 10.  
PAR activation by coagulation proteases is a unique 'self' mechanism the extracellular PAR receptor 
domain is cleaved by the protease, revealing a previously cryptic neo-aminoterminus and ligand for 
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the same receptor, initiating signal via the transmembrane domain. The proteolytic cleavage of 
extracellular PAR domains by thrombin or factor Xa activates of a canonical G-protein mediated 
pathway with downstream signalling that triggers multiple transcription-regulated, and cell-specific 
events[286].  
The specific effect of PAR activation is dependent on the tissue in question, and there is a difference 
in expression between humans and mice[287] rendering direct translation of potential interventions 
complicated. 
PAR-1, PAR-3 and PAR-4 are thrombin receptors, PAR-2 is activated by TF/FVIIa, TF/FVIIa/Xa, while 
FXa and the APC/EPCR complex can also induce signalling via both PAR-1 and PAR-2 [288]. PAR 2 can 
also be activated by alternative proteases such as trypsin and mast cell tryptase[284]. Thrombin-
activated PAR-1 has also been shown to transactivate PAR-2 by donating the tethered ligand forming 
a heterodimer and inducing signalling [289]. 
Stimulation of PARs on endothelial cells leads to induction of pro-inflammatory mediators - IL-6, IL-8, 
TGF-β, MCP-1, PDGF, and CAM (ICAM-1, P-selectin). PAR-1 on monocytes and macrophages activates 
cells and enhances leucocyte-endothelial-platelet adhesion with production of IL-1, TNF-α, IL-6, 
MCP-1 and IL-10, downregulating IL-12 release; while PAR-2 enhances IL-1, IL-6, and IL-8 
release[290]. 
PAR-1 has an interesting dual role being the primary thrombin receptor but also a receptor for the 
anti-coagulant (and anti-inflammatory) APC/EPCR complex. Thrombin however is a 100 fold more 
potent PAR-1 activator than APC/EPCR, with levels of APC required to match thrombin activation 
higher than those found endogenously in-vivo. Thrombin is the primary PAR-1 agonist on endothelial 
cells thus the predominant effects of PAR activation are pro-inflammatory[291].  
However while PAR-1 thrombin activation induces a pro-inflammatory enhancing response, 
activation by APC/EPCR results in an anti-inflammatory response that preserves endothelial 
integrity. These contrasting effects are mediated by differential coupling of activated PAR-1 to 
different S1P proteins. APC/EPCR activation results in a PAR-1/S1P-R1 association preserving 
endothelial integrity, while thrombin activation in PAR-1/S1P-R3 causing barrier disruption and 
endothelial permeability[282].  
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PAR-2 shares use of intracellular adaptor proteins with TLR4 in activating NFƙ-B during inflammation 
potentially modulating responses[292]. Transactivation of PAR-2 by PAR-1 ligands is also implicated 
in the anti-inflammatory effects of PAR-1 (via APC) [289].  
PAR-3 acts as co-factor for PAR-1, with receptor dimerization regulating intracellular signalling in 
endothelial barrier failure[293]. Both PAR-3 and PAR-4 may accelerate TF induced thrombin 
generation on vascular smooth muscle surfaces[294], while PAR-4 is implicated directly in cardiac IR 
injury [295]and endothelial activation[296], and in platelet aggregation [297,298]. 
Despite animal models demonstrating benefit of APC, TM, and TFPI, in reducing inflammatory 
responses in endotoxaemic and IR models [237,299–307], this has not been translated into clinical 
practice. The most recent randomised control trial (RCT) for APC use in severe sepsis (PROWESS-
SHOCK Trial) demonstrated no survival benefit in patients, with data supported by a Cochrane 
systemic review [308]; neither have trials involving recombinant TFPI [300], or TM [309]. PAR 
signalling in endotoxaemic murine models has demonstrated that single PAR deficiency does not 
protect against inflammation, but that multiple simultaneous inhibition is required to down regulate 
inflammatory responses [310]. 
There maintains an inherent difficulty in translating animal model based IR treatments to clinical 
practice due to differences between murine and human expression and function of coagulation 
proteases and receptors, as well as the complex interaction between coagulation and 
inflammation[311]. In clinical practice these interactions are further confounded by multiple 
interlacing patient co-morbidities and pathologies, as well as differing geno- and pheno-types, and 
concurrent pharmacological treatments and medications. The temporal differences in PAR 
activation, differences in expression and dose-related responses of the wide range of proteases, and 
interaction between PARs themselves serves to highlight the complexities in these pathways and is 
one further reason why beneficial interventions in experimental models targeting PARs (e.g. APC) 
may have not been successful in clinical practice[312].   
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Figure 10 Dia gra mma tic  repres enta tion of PAR rec eptors, their vari ous ac ti va tors , a nd the 
predomina nt c ell  type of their  expression. I n par tic ular  thrombin is a  key ac tiva tor of PAR 1 ,3 , 
a nd 4 , whic h are all  express ed on endothelial  c ells , demons tra ti ng thrombin wide non -
c oa gulatory potential. Ada pted from Es mon et a l . [313]. 
 
1.4.3.2 Anti -thrombin  
AT is the primary inhibitor of thrombin and functions as a general protease inhibitor. Heparan 
sulfates are endogenous glycosaminoglycans that promote AT function at the endothelium. When 
heparan sulphates binds to AT it induces a conformational change that increases the rate of 
thrombin inactivation by a 100 fold. Thrombin has several functional binding regions for binding 
sodium, an active site, and 2 exosites (exosite I and II). Sodium binding modulates thrombin function 
in a prothrombotic or anti-coagulant fashion - with absence of sodium favouring thrombin binding to 
Protein C. The active site is highly negatively charged and substrate access to it is restricted by 
presence of 'insertion loops' of thrombin peptides. Exosite I is an important electropositive binding 
site responsible for binding fibrinogen, TM and involved in recognising thrombin substrates directly 
(fibrinogen, PAR1, FV and FVIII) or indirectly APC and FXIII) [314]. Exosite II is located on the opposite 
to site I and binds highly sulphated polysacchardes such as heparan sulphate, as well as for TM, and 
is the principle site for thrombin-AT and thrombin-protein C interactions [264]. 
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During inflammation AT levels are reduced by similar mechanisms as for APC. However inflammatory 
cytokines also reduce synthesis of glycosaminoglycans within the glycocalyx - heparan sulphate 
being one of them, resulting in less effective natural inhibition of thrombin by AT [283,315].  
In a small animal translational model of liver IR injury AT administration lowered plasma 
myeloperoxidase and leucocyte infiltration, with less organ damage and liberation of hepatic 
enzymes[316]. AT treatment improved the hepatic blood flow and capillary perfusion - which is 
disrupted during IR due to leucocyte-endothelial interactions, the generation of thrombin and 
fibrin(ogen) which potentiates inflammatory responses, and obstruction of microvessels through 
endothelial barrier failure and oedema.   As well as inhibiting thrombin, and thus potentially 
reducing thrombin induced PAR signalling, AT induces prostacyclin release from endothelial cells 
[317]; a potent vasodilator and inhibitor of leucocyte migration and endothelial permeability. 
Intravital microscopy has shown AT treatment to reduce rolling and adherence to the endothelial 
during experimental mesenteric IR[318], while also limiting systemic coagulatory and inflammatory 
responses[301].    
AT has also been used with success in transplantation models of IR injury. In experimental murine 
cardiac transplantation using an allogenic rejection model AT induced indefinite graft survival[319]; 
while in xenogenic rejection (which is extremely proinflammatory, prothrombotic and prone to 
hyperacute rejection) AT prolonged graft survival albeit in-conjunction with a complement receptor 
inhibitor[319]. Furthermore in a pig-to-primate xenogenic renal transplant model AT treatment 
increased graft survival and doubled time to graft failure[320].  Early results with AT treatment in 
combined human kidney-pancreas transplantation, and pancreas re-transplantation are promising 
with less renal and pancreatic IR injury, decreased rates of pancreas allograft thrombosis and 
pancreatitis, and better graft function [321][322]. Despite these early successes AT use in clinical 
trials for severe sepsis, as a modulator of systemic inflammation, proved less beneficial in terms of 
patient survival[323].    
1.4.3.3 Fibrin and Fibrinogen  
Fibrinogen is a 340kDa glycoprotein produced in the liver and is an acute phase protein. In normal 
physiology plasma concentrations range from 2-4 g/L. During inflammatory conditions this level can 
increase several fold [324]. It is composed of two sets of 3 polypeptide chains (Aa, Bb, and g). 
Coagulation occurs when thrombin acts on fibrinogen to form fibrin where thrombin cleaves at the 
N-terminals of Aa and Bb chains releasing fibrinopeptides A and B. This cleavage exposes 
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polymerization sites on the activated fibrin molecule. Fibrin monomers polymerize at these site by 
bind to complementary sites on other molecules forming larger 'protofibrils'. Thrombin activated 
FXIIIa stabilises the fibrin clot formation catalysing isopeptide bonds between g chains in adjacent 
molecules.  
Fibrinolysis of fibrin clots is dependent on plasmin. Its zymogen plasminogen is activated by t -PA or 
uPA and the activated plasmin cleaves fibrin at various sites releasing X and Y fragments,  D-Dimers, 
D and E fragments, Bβ15-42, and smaller a chain remanents [325–327].  
Various experimental models have been used to investigate the role of fibrin(ogen) during 
inflammatory responses - including endotoxaemia, IR, and chronic inflammatory diseases. 
Fibrinogen and/or fibrin [fibrin(ogen)] were first demonstrated to have a pro-inflammatory potential 
in more than five decades ago. In-vivo and in-vitro studies showed fibrin(ogen) inducing leucocyte 
migration  [328–330] and modulating inflammatory actions of both leucocytes, ECs, and platlets by 
increasing cytokine and chemokine responses [331].  
In-vitro exposure to fibrin activates ECs with upregulation IL-8 mRNA transcription and cytokine 
release, a potent chemotactic and inducer of leucocyte activation and migration. Similarly exposing 
mononuclear cells to fibrinogen induces an inflammatory phenotype[332] with increased formation 
of ROS[333], as well as cytokine (TNFa, Il-1, IL-6) [334,335], chemokine (MCP-1, MIP-1 and 2), and 
matrix metalloproteinase-9 expression [332,336].  
Inflammatory effects of fibrin(ogen) are mediated by a variety of receptors, but intra cellular 
signalling is propagated by key inflammatory kinases (MAPK, PKC) and transcription factors 
(NFκB)[332]. In-vitro TLR signalling (TLR-2 and 4) is associated with fibrin(ogen) induced cytokine 
[337] and chemokine expression [336] in murine models. This supports the concept of fibrin(ogen) as 
an acute phase protein acting as a DAMP mediating pro-inflammatory responses through innate 
immune signalling mechanisms. 
Fibrin(ogen) binds the leucocyte CD11b/CD18 integrin receptor (also known as Mac-1 or 
complement receptor 3) [338,339] inducing and mediating ROS production, cytokine expression, and 
leucocyte migration. CD11b/CD18 was previously identified as a complement receptor further 
demonstrating the close interaction and complex interplay between coagulation proteases and 
mediators of inflammation. Fibrinogen binding to CD11b/CD18 has also been shown to be important 
in the pathogenesis of chronic inflammatory conditions such as skeletal muscle injury, multiple 
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sclerosis, rheumatoid arthritis , colitis, and colitis associated cancers[324], further highlighting the 
spectrum of involvement of coagulation proteins in inflammatory states.  
Fibrin(ogen) also mediates ligand–receptor interactions with leukocytes via by acting on endothelial 
membrane receptors. Fibrin(ogen) binds ICAM-1 on endothelial cells, augmented by VE-cadherin, 
acting as a leucocyte bridge enhancing endothelial-leucocyte adhesion [340,341]. Through ICAM-1 
fibrinogen also induces local vasoconstriction with increased production of endothelin -1[342], 
though this may be balanced by signalling through other membrane integrins [324]. Fibrin(ogen) 
signalling through both receptors affects endothelial barrier integrity and permeability by altering 
tight junction protein occludin and ZO-1 and 2 expression bound to cellular actin[343–345].  
Most recently the VLDL receptor has been identified as a novel receptor for fibrin modulating trans-
endothelial leucocyte migration[346]. 
Fibrinogen can also mediate platelet activation and aggregation by binding to aIIBb3 integrin on 
platlets while P-selectin the key endothelial-platelet CAM requires the presence of fibrinogen to 
maintain continued platelet expression [324].  
Fibrinogen like protein 2 (fgl2) is a membrane bound protein that exhibits prothrombinase activity 
(directly converting prothrombin into thrombin), resulting in fibrin deposition, microvascular 
thrombosis and tissue inflammation. Fgl2 expression on endothelial cells has been shown to be 
upregulated by TNF-α in murine cardiac IR models, and mediates formation of fibrin rich 
microvascular thrombi, contributing to ischaemic tissue injury and the no-reflow phenomenon 
[347,348]. Thus fgl2 provides a further potential mechanism of microvascular dysfunction relating to 
coagulation activation in I/R conditions. 
Despite evidence supporting fibrin(ogen)'s role in endothelial leucocyte adhesion and infiltration in-
vivo studies have shown that leucocytes and platelets do not accumulate in fibrin clots [312,341]. 
This however alludes more that fibrin(ogen)ic inflammatory effects may not predominate during an 
overwhelming stimulus for coagulation, but during inflammation may have a key underappreciated 
non-haemostatic role to act and augment inflammatory responses. On the other hand an 
overwhelming inflammatory response, such as during IR injury, can activate the coagulation system, 
with the deposition of fibrin, and in the inflammatory milieu propagate obstruction of microvascular 
vessels. 
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Inhibition at specific points of the coagulation cascade has been shown to ameliorate IR injury a 
number of small animal models [237,299–307] , and this can be in part related to less activation of 
PAR receptors and potentially less generation of fibrin(ogen) and related degradation products 
which have inflammatory effects.  
In murine crescentic glomerulonephritis direct thrombin inhibitors protected kidneys better against 
inflammation than did PAR-1 deficiency, and though thrombin inhibition also decreases PAR-4 
activation these findings suggest involvement of fibrin(ogen) or its derived products[349]. 
Furthermore TF induced inflammation was abrogated by fibrinogen depletion with ancrod, with 
similar effects to use of a direct thrombin inhibitor[350].  Fibrinogen deficient  murine models of 
myocardial and cerebral ischaemia demonstrated smaller sized infarcts and reduced mortality 
[351,352]. However only recently it was suggested an absolute lack of fibrinogen may be as 
detrimental as the increased levels seen during IR.  A partial reduction of fibrinogen, seen in 
heterozygous mice models  though can improve renal function and overall outcome in a murine 
model of renal IR injury [353]. 
1.4.3.4 Fibrin(ogen) Fragments in Experimental Models 
During fibrin formation, and then fibrin clot breakdown by the action of plasmin various degradation 
products are produced - designated fibrinogen degradation products (FDP). Thrombin cleaves 
fibrinogen into fibrin releasing fibrinopeptides A and B. Conflicting evidence exists as to the 
inflammatory potential of these fragments. Determination of any isolated effect however is further 
complicated by co-existent thrombin activity. While both have been suggested to function as 
chemoattractants [354–356], recently it was shown that proinflammatory effects may differ 
between the two peptides, with B identified to be the primary inflammatory agent [327,357]. In 
complete contrast a different study determined both to have anti -inflammatory effects capable of 
reducing extravascular induced inflammation[358]. In both studies thrombin impact was abolished.  
The full role of these fibrinogen fragments remains controversial.  
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1.4.3.5 D-Dimers 
After formation of activated fibrin monomers a stable clot forms by cross-linking between 
protofobrils. Through the action of plasmin fibrin clots are degraded releasing D-dimers and other 
FDPs. Studies have demonstrated a variety of pro-inflammatory properties for D-dimers. In-vitro 
exposure of human promomocytic leukemic cells, and peripheral monocytes to D-dimers induces 
expression of IL-1 (a and b), uPA, TF, PAI-2 [359]; and IL-1, IL6 and PAI respectively [360,361]. Some 
reports have suggested that the inflammatory potential for D-dimers on monocytic cells is minimal 
[362] or even anti-inflammatory [363].  
Levels of D-dimers in plasma however are used as a marker of stabilized cross-linked fibrin 
formation, indicating the activation of coagulation and subsequent fibrinolysis. Determination of the 
D-dimers levels as a diagnostic parameter is useful in the detection of thromboembolic 
complications, where elevated levels are used in the diagnosis of deep vein thrombosis and 
pulmonary embolism, and higher levels of D-dimer are associated with increased rates of multi-
organ dysfunction and patient mortality in severe sepsis and with disseminated intravascular 
coagulopathy [364,365]. Higher rates of D-dimers point to not only greater coagulation activity but 
also a co-existing inflammatory response mediated by the FDPs, fibrinogen, thrombin and other key 
proteases.   
Various other fragments are generated during fibrin(ogen) cleavage and fibrinolysis - such as fibrin 
fragment E (FnE), fibrinogen fragment E (FgnE), Bβ15–42, and Bβ43–63.  
FnE and FgnE have been shown to differentially influence angiogenesis (Fne promoting angiogenic 
and FgnE as an anti-angiogeneic), as well promote IL-6 release from macrophages through binding 
CD11c. FnE in particular is associated with N-terminal disulfide knot II (NDSKII) binding of VE-
cadherin and this interaction is thought to be involved in mediating monocytic and neutrophilic 
migration[341]. Little in all is known on the full inflammatory potential of these fragments. 
The Bβ43–63 peptide was only recently identified as a cleavage fragment of fibrin(ogen) but has 
been shown to exhibit anti-angiogenic and anti-tumour effects in-vitro. 
Bβ15–42 is fragment of the N-terminal of the β chain generated during fibrinolysis by the cleavage of 
cross linked fibrin by plasmin, and whose sequence is independent from fibrinopeptide B.  Its role in 
inflammation has been investigated by various groups worldwide. Early studies suggested the 
isolated Bβ15–42 fragment is a chemoattractant for neutrophils and fibroblasts [354,357], and 
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capable of inducing IL-8 expression in-vitro in a human oral squamous carcinoma cell line, 
determined using mAb against Bβ15–42 and a synthetic peptide sequence mimicking fibrin exposure 
[366]. More recently however Bβ15–42 has been demonstrated to be protective against 
inflammation especially in IR based injury. 
Bβ15–42 protects against IR in-vivo in both murine and porcine myocardial ischaemia[367–369] and 
murine cardiac transplant  models[370].  Bβ15–42 reduced infarct size and necrosis, NDSKII induced 
leucocyte recruitment  competing for binding to VE-cadherin[367], as well as improved cardiac 
function[370].  A follow up phase IIa clinical trial investigating Bβ15–42 treatment for myocardial 
infarction at reperfusion reported smaller necrotic core zones on MRI early after cardiac events, but 
with similar longer term outcomes [371].  
Functionally Bβ15–42 is also able to ameliorate single [372]  and polymicrobial  [373] endotoxaemia 
and lung transplant[374] induced endothelial barrier failure in murine models, by signalling through 
the Rho-kinase, inhibiting activation, and preserving VE-cadherin stability, maintaining endothelial 
integrity. 
In a large animal porcine model  of haemorrhagic shock Bβ15–42 protected animals against 
myocardial, pulmonary hepatic, and intestinal IR injury; with higher pulmonary and cardiac 
functional indices, better tissue perfusion and oxygenation, lower levels of cytokine (IL-6) production 
and neutrophil infiltration [375].   
In mouse models of hepatic[376] and renal[377] IR injury Bβ15–42 treatment preserved histological 
integrity, reduced cytokine expression, maintained endothelial barrier function, and improved blood 
velocity and organ perfusion. 
Bβ15–42 fragment's protective effects however require the presence of fibrinogen, with protection 
abrogated  by fibrinogen depletion[367], suggesting that Bβ15–42 may be part of an endogenous 
feedback mechanism to regulate the pro-inflammatory effects of coagulatory molecules at both 
specific sites of inflammation and systemically. This study supports similar findings in renal IR that 
suggest complete fibrinogen depletion may be harmful[353]. Evidence proves Bβ15–42 is a 
promising therapeutic agent, however the complete mechanism of action, and in what clinical 
pathologies it would be most beneficial still requires investigation. 
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1.4.4 Exogenous Anti-coagulants in Ischaemia Reperfusion Injury 
A number of exogenous anticoagulants have demonstrated promising results in the reduction of IR 
injury and inflammatory states. These include heparin and heparin like compounds, direct thrombin 
inhibitors (DTI), and FXa inhibitors (see Figure 11). 
 
Figure 11  Overvi ew of the coagula ti on network vari ous  endogenous inhibi tors  and exogenous 
inhibi tors . Repri nt of Fi gure 11 demons tra ti ng the mec hanis m a nd loca tion of ac ti on of 
hepa r i ns, DTI s a nd FXa i nhibitors.  
 
1.4.4.1 Heparin 
Exogenous heparin is similar in structure and nature to endogenous heparan sulphate and is part of 
the same glycosaminoglycan family[378]. Heparin also termed unfractionated heparin (UFH) has a 
mean molecular weight of 15,000 Da with the structure determined by repeating sequences of 
uronic acid and amino sugar containing disaccharides. It is a highly sulphated polysaccharide 
composed of and D-glucose-amine and hexuronic acid residues bound by glycosidic linkages[265].  
Similar to endogenous highly sulphated polysaccharides heparin binds AT via a unique 
pentasaccharide sequence[379].  Binding to AT induces a conformational change that increases 
thrombin inactivation by a factor of a 100 fold. The circulating thrombin complex  is irreversibly 
composed of a ternary with AT bound to the thrombin active site while heparin (bound to AT) and 
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the exosite II[264]. Heparin clearance is predominately through binding of endothelial and 
macrophage heparin receptors with a smaller percentage cleared by the kidneys [265]. 
Low molecular weight heparin (LMWH) has a mean molecular weight of 5000 Da and is composed of 
less than 18 saccharide units in length, it is formed from by partial hydrolysis or enzymatic 
degradation of UFH[379]. Due to its smaller size then standard UFH LMWH is less able to bind both 
thrombin exosite II and AT (requiring a molecule > 18 saccharide units), and is thus a greater 
inhibitor for FXa[380]. Advantages over UFH are a longer half-life and predictable dose responses 
reducing the need for frequent monitoring. 
Because it can be synthetically produced It is one of the most important anti-coagulants in clinical 
practice today and is used in prevention and treatment of arterial and venous thrombosis , including 
limb, pulmonary and associated with myocardial infarction [381]. In addition it is used in 
extracorporeal circuits and haemodialysis to prevent thrombosis.  
Despite being used clinically for its anticoagulant properties evidence has suggested that heparin 
possesses anti-inflammatory properties. The close interaction between coagulation and 
inflammation, its effects on endogenous anti-coagulants that also exhibit anti-inflammatory 
properties logically support this. Various exogenous anticoagulants have been analysed in I/R injury 
models to reveal their protective properties.  
In particular the use of heparin in myocardial IR has been extensively studied[382].  
In a canine model heparin and an N-acetylheparin analogue administrated prior to reperfusion both 
reduced the size of infarcts and improved coronary endothelial vasodilatory function[383,384].  In 
isolated cardiac organ reperfusion experiment heparin and N-acetylheparin reduced the infarct size 
and improved myocardial function[385].   
While low molecular weight heparin infusion in an isolated reperfusion rabbit heart model with 
damage mediated by complement (human plasma) reduced tissue injury and preserved discordant 
organ function[386], and in a related murine model reduced occurrence of arrhythmias.   
Heparin and a non-anticoagulant heparin derivative (O-desulfated heparin) both equally preserved 
coronary endothelial vasodilatory function, reduced inflammatory cell infiltration, and reduced 
infarct size in a canine IR model[387]. The anti-inflammatory properties of both agents were 
attributed to inhibition of NFƙ-B transcription factor activation.  
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The anti-inflammatory potential of heparin have also been demonstrated in clinical settings [388–
390]. Use of heparin-bonded circuits reduced incidence of myocardial infarction, with less 
requirements for ionotropic support, and less post-operative complications after cardiopulmonary 
bypass. While use of a higher dose of systemic heparin demonstrated a non-significant but 
observable trend of lower systemic cytokines (IL-6 and TNF-α) compared to standard doses. 
The anti-coagulatory mechanisms of heparin are well established. There are several potential 
mechanisms for anti-inflammatory effects however that have been investigated. 
Heparinoids (UFH, LWMH, and some derivatives) exhibit non-specific protein binding and more than 
100 different heparin binding proteins (HBP) have been identified[391]. HBPs are diverse in origin 
and function and can be involved in coagulation and fibrinolysis, a variety of growth factors, involved 
in lipid metabolism, be extracellular matrix proteins, and in mediation of immune responses 
[392](including acute phase proteins[393] and complement[394]). Heparin binding of HBPs can 
modulate the structure and function of the HBP in question and thus heparin has a wide spectrum of 
potential effects based on the heterogeneity of HBPs. 
Endogenous heparinoids such as heparan sulphate in the glycocalyx of endothelial cells bind 
cytokines and chemokines (e.g. INF-γ) stabilising them, protecting them from proteolytic 
degradation, and localising them to sites of inflammation within the vasculature, where in the 
proximity of their receptors binding is enhanced during inflammation[395]. Because heparinoids can 
bind inflammatory cytokines/chemokines , exogenously administered soluble heparin (UHF or 
LMWH) can attenuate inflammatory responses by binding these mediators, and neutralising them by 
preventing binding to their receptors. 
Heparinoids can also interfere with endothelial-platelet-leucocyte interactions, and inhibit leucocyte 
infiltration in tissues. In vitro UFH and LMWH inhibited P- and L- selectin binding of their receptor 
ligands, as well as inhibiting thrombin and PAF induced leucocyte-endothelial P-selectin 
adhesion[396,397], by directly binding to P-selecting on activated endothelial cells[398]. UFH and 
LMWH can also bind CD11b/CD18 receptors on neutrophils, inhibiting the receptor binding with 
fibrinogen, complement or FX and limiting inflammation and neutrophil migration[399].  
Once bound at the glycocalyx and cell membrane heparin can be internalised into the cytosolic 
compartment of endothelial cells[398], vascular smooth muscle cells [400], hepatocytes[401], and 
cardiac myocytes[402]. Based on its  electro-chemical structure,  heparin once within the cell can 
bind and interfere with NFƙ-B transcription factor translocation in activated endothelial cells, 
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lymphocytes, and monocytes, limiting inflammatory gene activation and transcription of pro-
inflammatory mediators[387]. In a murine cardiac IR model heparin directly inhibited TNF-α 
expression, and by inhibiting P-selectin mediated leucocyte-endothelial adhesion limited 
inflammatory cell infiltration and further generation of inflammatory cytokines[403]. Finally in-vitro 
heparin modulated cytochrome c (a key component of the mitochondrial electron transfer chain), 
limiting its reactivity by 200 fold, potentially inhibiting cytochrome c activation of the caspase 
cascade and thus inflammatory apoptosis[404].  
UFH has traditionally been used because of its relatively low cost, ability for simple monitoring and 
effective reversibility with the antidote protamine. Despite experiment evidence for potential 
benefit the use of heparin as an anti-inflammatory agent been largely limited by the its anti-
coagulant effects and the risk of haemorrhage, as well as the persistent risk of heparin resistance 
and heparin-induced thrombocytopenia (HIT).  
Heparin like molecules, and associated glycoaminoglycans, like pentosan poly sulphate have also 
been investigated in animal models with a limited degree of success to reduce reperfusion injury and 
expression of  genes associated with IR injury[405,406]. These effects however have not been 
translated into clinical trials, though pentosan with limited anticoagulant ability may have benefit as 
risk of bleeding complications in post-operative patients would be less than with conventional 
heparins.  
 
1.4.4.2 Direct Thrombin Inhibitors  
The most widely studied and clinical exploited DTI is hirudin extracted from the parapharyngeal 
glands of the medicinal leech Hirudo medicinalis, and was the first anticoagulant used in humans in 
1905. Hirudin is a polypeptide of 65 amino acids, stabilised by three disulphide bridges, with a 
molecular mass of 7000 Da and is one of the most potent and natural DTI[314]. In current medicine 
hirudins today are produced as recombinant proteins by genetically modified yeasts.  
Effective thrombin inhibition by AT requires the catalytic effect of heparin bound to the AT-
Thrombin complex. In contrast hirudin inhibits thrombin directly and independently of any other co-
factors. Hirudin forms non-covalent and irreversible 1:1 complexes with thrombin, binding to 
exosites I and II [264]. Unlike heparin, hirudin inhibits both free and clot-bound thrombin molecules, 
as  well as thrombin bound to fibrin(ogen) degradation products[407,408]. Heparin-AT complexes on 
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the other hand are relatively ineffective in accessing bound thrombin. Hirudin also exhibits no 
interaction with circulating plasma proteins, and so shows a more stable and predictable dose-
response compared to heparin[409]. The lack of plasma protein binding also renders the potential 
for immunologic resistance and HIT like syndromes low[410]. Renal clearance accounts for 90% of 
the systemic clearance of hirudins, and t1/2 lengthens with renal dysfunction. 
The recombinant hirudin lepirudin was the first DTI approved for clinical use in Europe (European 
Medical Evaluation Agency) in 1997, and the US (U.S Food and Drug Administration) in 1998 as a 
treatment of HIT that is complicated by co-existing thrombosis[410]. Since another recombinant 
hirudin, desirudin gained approval for use in thrombosis prophylaxis after major surgery.  There are a 
number of recombinant hirudins and hirudin analogues in clinical and experimental use. 
Hirudins such as lepirudin, bivalirudin (Hirulog) and desirudin have been used in various trials for 
acute coronary syndrome in myocardial infarction and subsequent angioplasty [411–414]  and 
unstable angina [415]; for the prophylaxis and treatment of DVT in high risk patients[416,417]; and 
in lower extremity bypass [418]. Hirudins have also been assessed for anticoagulation in scenarios 
involving artificial surfaces, such as haemodialysis circuits[419] and complicated high risk cardiac 
bypass surgery[420,421], and extracorporeal membrane oxygenation[422].  
Because DTIs are able to mitigate thrombin in nonbound and clot-bound forms hirudins have been 
found to be promising in various animal IR models (e.g. lung, heart or brain) [423–425] by reducing 
the proinflammatory effects of thrombin [426–428]. 
 
Bivalirudin attenuated the inflammatory effects of thrombin in a carrageenan-induced rat paw 
oedema model [429]. Since bivalirudin binds to both the catalytic site and the anion-binding exosites 
(I and II) of thrombin [430,431], it blocks thrombin effects mediated both by PAR cleavage and 
activation as well as by the non-catalytic activities of the mitogenic and chemotactic peptide 
domains[196,432].  
By binding to the thrombin active and  preventing PAR-1 from cleavage [426][332], hirudins thereby 
diminished thrombin signalling [433] of CAM expression[434], and secretion of cytokines and 
chemokines; VEGF[435], IL-6 [436], IL-8 and MCP-1 [437].  
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In in-vitro endotoxaemia models hirudin analogs (lepirudin) effectively ameliorated endotoxin 
induced platelet activation [310,438,439].  While melagatran a hirudin analogue and a thrombin 
active site inhibitor diminished platelet P- selectin expression [426,440]. 
 
1.4.4.3 Direct FXa Inhibition 
FXa can induce expression of pro-inflammatory chemokines and cytokines  (TNF-α, IL-6, IL-8 and 
MCP-1) as well as CAM (P-selectin) through PAR-1 and PAR-2 signalling [200,441]. Several known 
endogenous and exogenous synthetic anti-coagulants can inhibit FXa, such as LMWH or APC. Direct 
FXa inhibitors, e.g. rivaroxban, have been investigated in treatment of acute coronary syndrome, 
with experimental data suggesting a non-anticoagulant anti-inflammatory profile, with rivaroxban 
associated with a significant increase in endothelial TM. In-vitro rivaroxban down regulated 
expression of IL-6, TNF-α and MCP-1 in thrombin activated endothelial cells, to the same extent as 
select PAR-1 inhibition[428].  
The upstream position of FX in the coagulation cascade means that FXa inhibition prevents thrombin 
generation, but could also allow functions of existing thrombin to continue, such as activating 
protein C, thus maintaining an endogenous anti-coagulant and anti-inflammatory mechanism active. 
Combined with recent preliminary data supporting FXa inhibition as both potentially inflammation 
modulating as well anti-coagulant has led to suggestions that direct FXa inhibitors may be superior 
than DTIs[313]. However FXa inhibition in context of alternative inflammatory conditions (such as 
endotoxaemia, or transplantation IR injury) and interactions with other pathological processes need 
to elucidated before any further translational use is feasible.    
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1.5 The Microcirculation in Organ Transplantation 
In transplantation the endothelium is the first site where inflammatory cells in the recipients' oxygen 
rich warm blood encounter and interact with the donor tissue - and is thus the site of the first 
challenge with the initiation of IR related cascade of inflammatory and coagulatory events. It is now 
recognised that microvascular dysfunction is an early and rate-determining effect of the IR injury to 
endothelial cells and then their interaction with and promotion of the inflammatory responses.  In 
the immediate peri-transplantation setting the endothelium is where the post-operative function of 
the allograft is determined. 
1.5.1 Physiology of  the Endothelium 
The endothelium is composed of a single layer of cells that line the entire vascular system. 
Approximately 10 trillion (10-13) endothelial cells form a 0.2 um think haemo-compatible barrier 
with a surface area estimated to be between 3000-6000m2[442], forming an almost 1 kg organ[443]. 
They are flat shaped cells juxtaposed in a mosaic fashion so their long axis is orientated to the 
direction of blood flow. They are attached to the basal membrane which is high in content of 
collagen and glycoproteins and thus acts as a barrier between blood and the extra-cellular matrix. 
The endothelial itself is not a passive component of the vasculature, it is dynamic and able to 
respond to stimuli and stress emanating from the circulation. Microscopically cultured ECs have a 
cobblestone appearance, but if exposed to shear stress in a perfusion chamber similar to that in the 
circulation cells re-orient and align themselves along the axis of stress [444,445] and this is seen in-
vivo in cardiopulmonary bypass patients where endothelial of saphenous grafts elongate and re-
organise themselves to the new direction of the arterial flow [446,447]. The actual concept of the 
endothelium as an organ stems from these observations and recognition of the various 
consequences and diseases that are secondary to endothelial injury and dysfunction - including 
diabetes, atherosclerosis, HTN, sepsis and inflammatory syndromes. 
Endothelial cells are the gatekeeper and primary interface between blood and tissues, and in 
addition to a general role relevant to controlling extravasation of fluid, solutes, hormones, 
macromolecules, haemostatic and inflammatory cells, have a specific role in the maintenance of 
blood fluidity by regulating thrombosis, thrombolysis, platelet adherence, vascular tone and blood 
flow[448]. They are dynamic with both metabolic and synthetic functions, exerting autocrine, 
paracrine, and endocrine influence on smooth muscle, platelets, and peripheral inflammatory cells.  
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Endothelial cells are phenotypically variant in different vascular trees relating to the specific tissue 
and organ and related to the perfusion dynamics and shear stresses that predominate in and 
differentiate between the larger arteries and veins, and micro-circulatory arterioles, venules and 
capillaries. Arterioles are the thinner, smaller branches of arteries, and are the principal controllers 
of resistance in the microcirculation. Venules act as larger lower pressure reservoirs through which 
the circulation is directed back to the heart. In conjunction with smooth muscle cells the 
endothelium controls microcirculatory perfusion through local vasoregulation mediated by direct 
action and through the response to locally generated and systemic vasoactive agents - such as NO, 
endothelin, prostacyclin, and adrenaline. 
Capillary beds lie between arterioles and venules and are the smallest of vessels. With luminal walls 
consisting of only a single layer of endothelial cells, thus shortening the distance for diffusion 
between blood and tissue they are the site of exchange of molecules between the circulation and 
tissue - making an effective capillary circulation a necessary prerequisite of tissue perfusion and 
organ function[315]. In fact the majority of endothelial cells - 600g of the 1kg organ - are micro-
vascular capillary endothelial cells[443] - where the exchange of nutrients, hormones, and immune 
cells between tissues and the circulation is dominant.     
1.5.2 The Endothelium in Ischaemia Reperfusion Injury 
1.5.2.1 Endothelial Injury  
Endothelial dysfunction is a pathogenic early consequence of IR injury. ECs are the first cells of the 
allograft to experience the effects of reperfusion with warmed oxygenated blood after ischaemia. 
The dysfunction seen is caused by the multiple pathological sequelae started during ischaemia and 
then accentuated during reperfusion - specifically: ROS mediated damage, ion homeostasis and 
osmotic stress leading to cellular swelling, and membrane dysregulation and activation, production 
of pro-inflammatory mediators, and apoptosis [449]. 
Prolonged hypoxia has deleterious effects on cellular metabolism as described in Section 1.32. These 
cellular changes occur in endothelial cells and at the same time to adjacent renal interstitial tubular 
causing both cell types to enter an activated state. There is an upregulated Secretion of pro-
inflammatory cytokines is induced and up-regulated by induction of pro-inflammatory transcription 
factors (such as NFƙ-B), while there is an increased expression of endothelial cell adhesion 
molecules. This promotes recruitment, activation and infiltration into the renal parenchyma of 
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recipient immune cells (macrophages, lymphocytes, neutropils). This inflammatory infiltrate serves 
to complement the local inflammatory processes by allied secretion of cytokines, destruction of 
apoptotic cells, and further recruitment of inflammatory cells. In parallel activation of the 
complement system and generation of ROS by tubule, endothelial and recruited inflammatory cells 
promotes the sustained activation of these inflammatory cascades. 
IR related endothelial injury is associated with a multitude of features: altered cell membrane 
potentials, changes in cell membrane fluidity, disturbances of ionic intra- and intercellular flux, 
cellular swelling, altered cytoskeletal organization, concerted loss of energy stores, diminished 
production of important bioactive constitutive anti-inflammatory species (NO, prostacyclin), and 
production of inducible pro-inflammatory agents (endothelin, thromboxane A2) [449,450]. During 
ischaemia inflammatory genes for CAMs and cytokines are induced, while genes for cNOS and TM 
are inhibited[451]. These plethora of cellular responses to the initial ischaemic injury are then 
amplified during reperfusion. 
Morphologically cells are swollen, with loss of pinocytitic vesicles, detachment from the basement 
membrane (BM) with adherence of activated leucocytes to endothelial surfaces [449]. The 
reperfusion phase is characterised by specific micro vascular events. Lymphocytes, macrophages, 
and granulocytes migrate to the allograft and through increased expression of adhesion molecules – 
in particular ICAM-1, VCAM-1, P-selectin and various other integrins– producing an infiltrate that 
results in dissolution of the endothelial cell lining, worsening interstitial oedema, and causing deeper 
parenchymal injury from ROS and infiltrating cells [91].  
There is an increase in cytokine and chemokine production – locally form ECs and from the 
infiltrating macrophages and leukocytes. Complement, leukotrienes, platelet activating factors, 
thromboxane A2, TNF-A, IL-1, and endothelins are central to potentiating the inflammatory infiltrate 
by up-regulating endothelial cell and leukocyte adhesion molecules[220,452] .  
In the initial stages of reperfusion hyperaemia prevails, this gives way to a progressive and longer 
phase of diminishing flow, characterised by aggregation of leukocytes and platelets and activation of 
coagulation cascades – the no reflow phenomenon[453]. There are two distinct types of no-reflow: 
“structural no-reflow", characterized by an irreversible damage to endothelial and supporting cells; 
and where there is a disturbance of the microcirculation caused by vasoconstriction and micro-
thrombi and -emboli - “functional no-reflow"[315]. 
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Figure 12   Microvascula r  inj ury and tubular  da ma ge before (A) and a fter  (B) renal  I R i njury. 
Hi ghli ghti ng inter fac e between c oa gula tion, infla mma ti on, and devel opment of mic rovasc ular 
dys func tion wi th microcircula tory failure a nd 'no reflow'.  Thes e proc ess es  a re a mplifi ed by 
c ontinued ac ti va tion of coagula tion  c ascades  and genera tion of thrombin a nd fibri n, which 
potentia te i nfla mma tory res pons es , fur ther res tric ti ng per fusion, wi th ongoing rela tive hypoxia 
a nd ROS genera tion. The fi nal clinic al enti ty encountered is dela yed organ func ti on.  Ada pted 
from Legra nd  et a l . [454]. 
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Figure 13  Overvi ew of c ell ular  and infla mma tory casca de invol vement i n I R i njury. (a ) IR i njury 
resul ts i n ac ti va ti on of  the i nna te i mmune s ys tem, wi th hypoxia during the isc hemia 
precipi ta ting TLR-dependent s ta biliza ti on of tra nsc ripti on fa c tor  NF -kB. NF-kB ac ti va ti on 
s ti mula tes expressi on of pro-i nfla mma tory genes  for i nfla mma tory media tors a nd c ell  adhesi on 
mol ec ul es . TLR-4 expression is i ncreas ed by ROS genera ted from inters ti tial as well as 
endothelial c ells, a nd is  ac ti va ted by endogenous  liga nds a nd da ma ge associa ted mol ec ular 
pa ttern mol ec ul es  such as  HMGB1. TLR -3  is si milarl y a c tiva ted. During reper fusi on, increas ed 
c ell  adhesi on mol ec ul e expression and pla tel et -l euc oc yte-endothelial  interac ti ons  facil ita tes an 
infla mma tory i nfi l tra ti on i nto the tissue. Pla tel ets  fur ther  ac ti va te c oa gula tion fa c tors  l eadi ng to 
genera tion of thrombin a nd s ubs equent fibri n forma tion c ontributi ng to the development of not 
j us t a  proi nfla mma tory and but also procoagula nt  micro-environment wi thin the vasc ular  bed of 
orga n. Thrombin fur ther  potentia tes  pro -infla mma tory res pons es  via  PAR r ec eptors . Dia gra m 
a da pted from El tzschig et a l.  [455]. 
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1.5.2.2 Endothelial Activation 
An important feature of endothelial cells is that they can enter an 'activated' state that results in the 
transcription of new genes and affording cells a new range of cell membrane receptors and 
paracrine abilities. Activation allows the endothelium to modulate local inflammatory cascades, 
interact with and direct action of peripheral leucocytes, and shift the local interstitial and 
endovascular environment into a pro-coagulant state. Stimulus to activation ranges from local 
trauma to vessels and endothelium directly, inflammatory cytokines (TNF-α, INF-γ) and triggers of 
the innate and acquired immune responses, stressful metabolic disturbances such as hypoxia and 
ROS. In particular hypoxia induced molecular changes (via NFƙ-B pathways) in endothelial cells 
include up regulation of pro-inflammatory genes, and signally pathways that potentiate the IR 
inflammatory response[456]. Following activation endothelial cells assume an inflammatory 
phenotype that is characterised by accelerated ROS production, further release of cytokines (e.g. IL-
8) and allied inflammatory mediators (platelet activating factor [PAF-1]), increase expression of 
CAMs binding leucocytes and platelets, as well as promoting complement activation and inactivation 
of protective eNOS and NO[457,458]  . 
1.5.2.3 Leucocyte-Platelet-Endothelial Interactions During Ischaemia Reperfusion 
Leukocyte infiltration into post-ischemic tissue involves the well-established process of margination, 
rolling, adherence and migration of leukocytes through the endothelial barrier.  
Leucocyte-endothelial interactions are mediated by increased CAM expression - predominately P- 
and L-selectin [459] (which are rapidly increased soon after the start of IR injury), ICAM [460], and E-
selectin [461]. P-selectin is responsible for the initial tethering of polymorphonuclear cells to 
endothelial walls [462], while L-selectin expressed on leucocytes mediates rolling [463]. ICAM-1 and 
2 on endothelial cells binding to leucocyte function associated antigen-1 (or CD11/18) secures 
leucocyte endothelial attachment and activates the inflammatory cells before migration [464].  
ROS generation via XO in both endothelial cells and activated leucocytes perpetuates the 
inflammatory process by stimulating the expression of further CAM[465] (via transcription factor 
activation such as NFƙ-B), continued production of cytokines and chemokines [466], and increased 
venular permeability. In addition diminished expression of cNOS and production of NO, has been 
implicated facilitating these inflammatory processes [467,468] with experimental evidence to 
support this through NO inhibitor and NO donor administration in animal models reproducing IR 
microvasculature features, and reducing IR damage respectively [469,470]. With the adherence and 
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activation of leucocytes on endothelial membranes further cytokines are generated including 
platelet activating factor 1 (PAF-1), and there is an increased generation of ROS in particular by 
XO[471] and NADPH oxidase [458].  
The recruitment of leucocytes into the post ischaemic microcirculation is accompanied by the 
activation and accumulation of platelets, in particularly the venular microcirculation. In the kidney 
[472] (as well as the brain [473] and liver [474]) platelets can be seen to accumulate early by 30-
45mins after reperfusion. The temporal relationship between leucocytes and platelets adherence in 
IR has lead to proposals of an interdependence for recruitment in inflammatory tissues. During IR 
injury 25% of platelets adhere directly to the endothelium, with the remaining binding to leucocytes, 
in particular neutrophils attached to the endothelium[475].  
1.5.2.4 Endothelial Permeability  
During renal ischaemic injury increases in peri-tubular capillary permeability have been documented 
[476]by two distinct mechanisms; increased 1) para-cellular or 2) transcellular movement of 
molecules and fluid. While paracellular transport has been the widely described the role of 
transcellular transport during IR injury has only recently been thought to be an important element.  
Cellular junctions evident in endothelial cells are similar in nature to tubular epithelial cells but are 
less spatially and structurally organised. Cadherin adheren junctions are present between 
endothelial cells throughout the vasculature, while tight-junctions are can be prominent such as in 
the blood brain barrier or sparse and simple enabling a more leaky barrier interface such as in 
venules or capillaries of the renal vascular [448]. The disparity in cell-junctions in endothelial cells in 
different vascular beds, and from other barrier formations (e.g. tubular epithelial cells) suggests an 
important functional role in mediating permeability [477,478]  . 
Unfortunately the majority of evidence for endothelial-endothelial cell interactions during IR injury 
has come from in-vitro models. It is important to realise that in-vitro responses of cultured 
immortalised endothelial cell lines may not reflect those actually present in-vivo, in particularly as 
there is altered expression of key cell markers compared to cells studied in-vivo [479]. 
During and after ischaemia ATP depletion and free radical ROS damage are suggested to be the 
primary causes of increased paracellular permeability. Studies in mouse models have attributed 
increased permeability to re-distribution of occludin proteins from the ZO-1 antigen in tight 
junctions, along with internalization of vascular endothelium cadherin [480]. In parallel lack of ATP 
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and ROS can alter normal actin cytoskeletal structure in endothelial cells in particular F-actin, with 
surface breakdown, aggregation and dispersal of F-actin within the cytoplasm [481]. This break down 
renders the already leaky 'barrier' less resistant to fluid and macromolecular shifts from the 
circulation. Finally ROS can also increase basal actin stress fibres in endothelial cells and trigger 
endothelial contraction increasing paracellular permeability, which is thought to be mediated by a 
complex interaction of Rho family GTPases, tyrosine kinases, PKC, and cAMP dependent protein 
kinases[482] suggesting numerous other stimuli to these changes still to be deciphered.   
1.5.2.5 Contribution of  Leucocytes and Platelets to IR Endothelial Injury 
The contribution of ROS to increases in endothelial barrier permeability are important. However the 
source of these ROS must be  distinguished. The barrier dysfunction caused by IR is the effect of both 
ischaemic damage to endothelial cells as well as damage during reperfusion with the influx of 
oxygen, inflammatory cells, and production of cytokines. The major sources of ROS (superoxide and 
hydrogen peroxide) during reperfusion is activated leucocytes, followed by endothelial and 
interstitial renal cells via NADPH oxidase, uncoupled eNOS, and XO.  
Despite the acceptance that leucocyte adherence and accumulation is linked to increased in 
endothelial barrier dysfunction during IR recent studies have pointed to complex interactions 
between leucocytes, platelets, endothelial derived cytokines, and ROS at various spatial and 
temporal points during reperfusion to be responsible as opposed to a simple single event of 
leucocyte/endothelial interaction and adherence[483].  
None the less neutrophil accumulation has been shown to be a direct cause of IR induced barrier 
failure rather than a consequence. A strong correlation exists between the degree of IR induced 
permeability and the extent of the neutrophil adherence and infiltration through the venular 
endothelium into tissues[484] [470], with experimental neutropaenia[485] and immune blockage of 
CAM's[486] (P-selectin, ICAM-1, CD11/CD18) diminishing barrier failure during IR.    
Despite the interdependence between platelet  and neutrophil endothelial adherence the exact role 
of platelets in mediating endothelial barrier permeability is still not defined, with studies describing a 
range of involvement from no effect of platelets in inducing barrier failure[487] to even a potentially 
protective effect[488].   
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1.5.2.6 Histological Findings of  Renal Specific Vascular and Tubular Damage During 
Ischaemia Reperfusion Injury 
Despite the biochemical and cellular effects of IR on endothelial cells, the histopathological changes 
seen in IR injury (in human and animal models) and more specifically renal IR are subtle and limited 
to the arteriolar smooth muscle [489] [490]. Definitive evidence of endothelium injury and changes 
are not routinely seen in renal biopsies in transplant recipients, and when present abnormalities are 
mild [40,449,491,492]. There are potential sampling biases in human kidneys (cortex sampled vs. 
medulla) and difficulties in detecting endothelia injury in animal models that may explain this 
phenomena. 
Evidence of ischaemic endothelial failure in other vascular beds however demonstrates that renal 
endothelial injury has a plausible and potentially important role in renal dysfunction. Coronary and 
cerebral IR reveals separation of endothelial tight junctions, endothelial cell detachment from the 
basement membrane and blebbing, and even endothelial necrosis [493,494]  .  
In contrast examining IR renal tubular injury studies have definitively found higher levels of brush 
border injury, tubular necrosis, cell shedding, tubular dilation, and interstitial inflammation in 
kidneys with delayed graft function compared to immediate functioning allografts [40,492,495]  ,  
while other groups have found no distinct differences in these kidneys [496,497] .    
Considering the evidence the histological findings of both tubular and even endothelial injury do not 
correlate with the degree of dysfunction seen in kidneys with delayed graft function. Thus the 
effects of IR may not be easily detectable on histology as they are functional rather than persistent 
morphological effects, especially early in the post operative period.  
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1.5.3 Cardiovascular Risk Factors for Endothelial Dysfunction 
Cardiovascular disease risk factors (HTN, hypercholesterolaemia [HChole] & obesity, and diabetes) 
are an interrelated group of diseases whose pathogeneses are manifested in the systemic 
vasculature,  with the major cellular target the endothelium. These diseases are known to negatively 
influence outcomes in affected transplant recipients. The emergence of the expanded donor criteria 
defining a potentially viable, but with higher risk of graft dysfunction, subset of the donor pool has 
meant the impact of these co-morbidities amongst donors is gaining precedence. Separately and in-
concert they affect oxidative stress and ROS production, impaired vasomotor function, leucocyte-
endothelial interaction, endothelial barrier dysfunction, as well as the recruitment of platelets and 
potentiate a pro-thrombotic environment[498], see Figure 14.  
 
Figure 14  The rol e cardiovasc ular  dis eas e risk fac tors  in I R i nduc ed endothelial  inj ury a nd ba rri er 
failure. Hypertensi on, diabetes mellitus , hyperc hol es terola emia , a nd obesi ty all  induc e a  pro -
oxi da tive, pro-infla mma tory, a nd pro-thrombotic  environment. Thes e effec ts  a re exa c erba ted by 
intera c tions of infla mma tory  c ells a nd c oa gula tion proteas es  wi th the endothelia , resul ting in 
ba rr ier  failure a nd poor per fusion during I R injury [499]. 
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1.5.3.1 Hypertension 
Animal models of HTN (such as spontaneously HTN rats, chronic angiotensin II infusion, and salt 
retaining models) demonstrate an increase in ROS production and oxidative stress. Endothelial and 
leucocyte NADPH oxidase is implicated in the production of superoxide in HTN enhanced ROS. 
Despite HTN affecting only the arterial system in terms of pressure, increased ROS is seen in both 
arterioles and venules. Superoxide as an inhibitor of dilating NO, or a promoter of endothelin 
production, as well as links to activation of angiotensin II receptors, and TNF-α from leucocytes are 
potential patho-mechanisms [500–503]. 
The majority of complications associated with HTN are related to endothelial activation or 
vasomotor dysfunction. Vasomotor dysfunction has been primarily attributed to reduced NO 
bioactivity; with endothelin and angiotensin II receptor activation (possibly from increased ROS) and 
angiotensin 1 receptor mediated T-cell activation with release of TNF-α (which induces a pro-oxidant 
and inflammatory state) as suggested causes. [501,504]. Endothelin alone stimulates cell 
proliferation, upregulating gene expression of collagenases, prostaglandin endperoxidase synthase 
and PDGF, and these is cross talk between endothelin, NO and prostacyclin in the control of 
vasomotor processes [505]. These same mechanisms are also associated with increases in 
endothelial permeability, through angiotensin II receptor activation, ROS generation, and activation 
of stress transcription factors (NFƙ-B and hypoxia inducible factor 1) and production of vascular 
endothelial growth factor and prostaglandins [506–508] 
HTN also enhances leucocyte endothelial cell adhesion - via increased expression of CAMs. 
Angiotensin 1 receptor activation with ROS formation via NFƙ-B and induction of VCAM and P-
selectin are key to these observations [509–511] . 
The combined effects of HTN mediated cellular changes on endothelial integrity and function means 
that HTN itself is associated with degenerative and rarefactive remodelling with a loss of up to 50% 
of the micro-vasculature in some tissue beds [498].  
 Finally HTN in patients is associated with abnormalities in clotting factors, platelet activation, and 
fibrinolysis posing an increased risk of thrombosis. This may be related to endothelial production of 
platelet stimulants (endothelin) as well as reduced generation of inhibitors (prostacyclin, NO), with 
implications of an angiotensin II mediated pathway. [512–514]  
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1.5.3.2 Hypercholesterolaemia 
HChole is also associated with accelerated ROS generation [500]  - the primary source being NADPH 
oxidase and xanthine oxidase from endothelial and leucocyte cells, mediated by T-cell derived INF-γ.  
[515]. HChole induced ROS is further implicated in dysfunctional endothelium dependent 
vasodilatation (NO inactivation) [515–517], and barrier function [518,519] (through endothelin VEGF 
and ROS). In both cases lipid lower statins normalises endothelium permeability and vasodilatation 
[516,518] though the effects may be mediated by anti-inflammatory properties rather than lipid 
lowering actions (such as NFƙ-B inhibition)[152]. HChole is also associated with an impaired 
angiogenic response to VEGF and related growth mediators - thought to be partly mediated through 
ROS inactivation of NO, and increased expression of endostatin [520,521]. Finally HChole and 
oxidised LDL appears to enhance platelet responsiveness and thrombosis, and promote 
leucocyte/endothelial adhesion. There are 2 proposed mechanisms: T-cell derived INF-γ and ROS 
upregulate CAM expression (CD40/40L) for leucocytes, with adherent leucocytes forming leucocyte-
platelet (P-selectin CAM expression) and leucocyte-platelet endothelial aggregates that can activate 
coagulation cascades via tissue factor induction on the endothelium; and reduced NO bioavailability 
(possibly through inactivation by ROS or oxidised LDL) [517,522,523]. Obesity with a high body mass 
index (BMI) is usually associated with HTN, HChole and diabetes. The effect of a large quantity of 
adipose tissue on endothelial function is likely mediated by circulating adipose derived hormones 
(adipokine, adiponectin, leptin). Obesity is associated with increased sensitivity to activation of 
endothelial cells from further stimuli, as well as platelet hyper-reactivity, and increased 
thrombogenesis [524,525] . 
1.5.3.3 Diabetes 
Hyperglycaemia is a major stimulus for ROS generation, with impairment of intrinsic anti-oxidant 
defences. ROS formation is primarily mitochondrial and enhanced through glucose and NADPH 
oxidase, which are linked to AGEs and PKC C activation [526]. NADPH oxidase and angiotensin I 
receptor activation is upregulated  [527]. Oxidative stress in diabetes is implicated in impaired 
endothelial vasomotor function via several mechanisms including: endothelin, AGEs, leukotriene and 
prostaglandin synthesis, and NO inactivation [528].  
Together hyperglycaemia and diabetes induced ROS have been linked to increases in 
leucocyte/endothelial adhesion and endothelial permeability - clinically evident as retinopathy and 
nephropathy of diabetes. P-selectin and receptors for AGE (RAGE) on endothelial cells bind leucocyte 
B2 integrins[529]. Reduction of circulating glucose (insulin), anti-oxidant scavengers or a direct PKC 
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inhibitor have all been shown to blunt these hyperglycaemia induced responses. [530,531]. 
Leucocyte interactions with the endothelial, the generation of inflammatory cytokines and growth 
factors (VEGF), the excess ROS and hyperglycaemia evident in diabetes, and signalling pathways 
involving peroxisome proliferator-activated receptor g [PPARg] and PKC are all implicated in the 
hyperpermeability seen in diabetics [532,533]. These same process are also responsible for the anti-
angiogenic effects of diabetes in retinopathy[520] and may be active in wound healing and repair in 
other tissues. 
Finally diabetes is associated with a hypercoaguable and pro-thrombotic state[534]. Systemically this 
is seen by elevated levels of clotting factors (VII, VIII, XII)  [535], increased numbers of activated 
circulating platelets, and a down regulation of intrinsic fibrinolytic processes [536]. There is an 
increased expression of P-selectin, with enhanced thromboxane production[537]. In parallel AGE 
activation of endothelial and monocytic tissue factor increases the production of thrombin [538], the 
key molecule needed for the formation of fibrin .  
 
1.5.3.4 Effect of  Ischaemia Reperfusion on At Risk Endothelial in Transplantation  
Cardiovascular risk factors render tissue more vulnerable and more at risk in IR injury. These risk 
factors induce a low grade inflammatory response - both systemically and in specific vascular beds - 
which induces endothelial cells into an activated state and more sensitive to secondary stresses. In 
both cases CV risk factors and IR injury promote a pro-oxidative, pro-inflammatory, and pro-
thrombotic phenotype - which manifests as more deleterious injury and organ dysfunction (see 
Figure 15). In transplantation this is further complicated by the potential immune response provoked 
by the transplant itself, and trauma during surgery. These CV factors have been likened to a 'double 
edged sword' where by an organ from an ECD donor is initially compromised, and then more liable 
to yield more damage during IR and transplantation, with organ dysfunction. This is somewhat 
confirmed in renal transplants with glomerular, tubular, parenchymal and vascular abnormalities 
seen on pre-implantation biopsies predictive for delayed graft function and graft failure[40].  
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Figure 15 Ca rdi ovascular  dis eas e ris k fac tors induc e a prothromboti c phenotype i n the 
vasc ula ture. During I R inj ury this  alrea dy 'infla med' a t risk endotheli um predispos es  to a  more 
potentia ted i nfla mma tory res pons e.  AngII  = angi otensin II , oxLDL = oxidi zed low de nsi ty 
l ipoprotein, AGE = a dva nc ed gl yca tion end-produc ts , ROS = rea c tive oxygen s peci es , NO = ni tric 
ox i de, PGI 2  = prostacyclin . Adapted from Granger et a l .  [498]. 
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1.5.4 Role of Tissue Perfusion in IR Injury and Transplantation 
1.5.4.1 Physiology of Renal Microcirculation 
The primary subunit of the kidney is the nephron whose function is to facilitate filtration and 
resorption of solutes and metabolites from the circulation, with the formation of concentration 
urine for excretion[539]. Each human kidney has approximately 1.3 million nephrons. The kidneys 
accounts for 2% of total body weight but receive 25% of total cardiac output, this high blood flow i s 
needed for effective filtration[540].  
A single nephron is composed of a glomerulus where filtration occurs through the bowman's capsu le 
(fed by an afferent and drained by an efferent arteriole), the proximal and distal tubules (primary 
resorption of solutes), the loop of henle (resorption of water), and the collecting duct.  Resorption of 
solutes and water from the filtrate into peri-tubular capillaries and vasa recta is achieved using 
active and passive transport. The components of nephrons are spread across the kidney 
parenchyma, with the cortex consisting primarily of glomeruli, tubules and proximal aspects of the 
collecting duct; and the medulla S3 segments of the proximal tubule, look of Henle and distal 
collecting duct. The medulla has a high metabolic activity from reabsorption of sodium by the think 
ascending limb of the loop of Henle. Due to the requirements of a strict osmotic gradient to facilitate 
water reabsorption blood flow is significantly lower in the medulla compared to the cortical regions, 
with the medulla receiving only 10% of renal blood flow [541]. This regional difference will play a 
major role in ischaemic insults and recovery of kidney function in clinical practice.  
 
1.5.4.2 Al terations of Tissue Perfusion 
Decreased renal blood flow is of critical importance in initiating and then potentiating ischaemic 
kidney injury and ARF. After acute ischaemic kidney injury a substantially reduced total blood flow of 
between 40-50% is evident upon reperfusion in both animal and human models, with regional 
deficits in tissue flow likely playing an important role in extending ischaemic injury into the 
reperfusion phase [542–545]. Following ischaemic injury the reduced blood flow significantly 
contributes to a deteriorating GFR. Animal models of ARF have pointed to persistent perfusion 
deficits in the outer medulla, rather than the cortex or inner medulla, as the prominent regions 
affected [546–548]. As oxygen tension under normal physiological conditions decreases between the 
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outer cortex to the inner medulla[549], combined with the high regional metabolic activity the 
impact of reduced blood flow to this cortico-medullary region is potentially magnified.  
In the majority of animal ARF models, the S3 proximal tubule segment (outer medulla) and not the 
thick ascending limb of the loop of Henle that is most susceptible to ischemic injury [550–552]. This 
is likely due to the IR related reductions in medullary blood flow and oxygen delivery while at the 
same time cortical blood flow is restored to near physiological levels. Furthermore S3 segments have 
a limited capacity to undergo anaerobic metabolism compared to the thick ascending limb of the 
loop of Henle.  Though compared to the proximal tubule, there are fewer histological changes in the 
thick ascending limb, IR upregulates expression of inflammatory genes, inducing cytokine secretion 
[540]. Cytokines from the thick ascending limb and the S3 act as effectors of positive feedback 
enhancing inflammation and potentiating vascular obstruction, via a number of proposed 
mechanisms.  
Rat and canine models of AKI and ARF have demonstrated reduced post-glomerular flow rates and 
perfusion in peritubular capillaries [553] and the outer medulla using morphomotry and carbon 
injections [554], radio nucleotide imaging [543], contrast enhanced MRI [555–558], with an 
increased total renal vascular resistance[559,560] and vascular congestion on histological analysis 
[561,562] during reperfusion. Using laser Doppler flowmetry a mouse model of ARF demonstrated 
reduced total renal blood flow by 45%, and GFR  by 68% during reperfusion, with N -acetyl-cysteine 
pre-treatment ameliorating these deficits - indicating NO and antioxidants as potential modifiers in 
the pathomechanism [563]. In a large animal pre-clinical isolated porcine kidney reperfusion model, 
after 24h CIT organs demonstrated decreased flow rates, GFR, and tubular sodium reabsorptive 
ability [564]. The rat transplant model supports AKI investigations and further shows extended CIT 
correlated to the degree of medullary vascular congestion, most prominent in the outer stripe, with 
red cell trapping and vessel obstruction using radiolabel erythrocytes [544].  
Clinically kidney transplant recipients with DGF demonstrated lower GFR, lower blood flow and 
higher resistance indices (Doppler flow) [565], with higher transcapillary pressure differentials 
compared to functioning allografts [566] - implicating afferent arteriolar constriction as a cause of 
reduced perfusion and dysfunction. Similarly assessing intra-operative renal perfusion using an IR 
camera the rate of re-warming time was correlated with return of renal function post-operatively, 
with greater parenchymal perfusion in LD compared to DCD/DBD donor organs [567].  Recently 
intraoperative spectrometry of DCD donor kidneys 30 minutes into reperfusion revealed allografts 
with DGF exhibited impaired cortical haemoglobin saturations, with capillary congestion and lower 
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microcirculatory perfusion [568] - suggesting that despite macroscopic reperfusion areas of the 
kidney parenchyma may still endure hypoxic stress. Total cortical parenchymal flow is also lower in 
allografts experiencing DGF vs. immediate function [569]. In parallel a high resistance index on 
Doppler US is also predictive of acute tubular necrosis and acute rejection in transplanted renal 
allografts [570,571].   
Examining the cortical kidney microcirculation using orthogonal polarisation spectral (OPS) imaging 
peri-operatively in renal transplant recipients at 5 and 30 minutes demonstrated a 'no reflow' 
pattern with heterogeneous perfusion, oscillating flow and scattered microthrombi in peritubular 
capillaries[572]. The investigators noted a correlation between cortical capillary blood flow and 
creatinine clearance, suggesting microcirculatory perfusion may be useful in predicting IR induced 
draft dysfunction. Similar findings were seen using OPS clinically in pancreas[573,574] and liver 
transplantation[575,576], with poor capillary perfusion and microcirculatory dysfunction correlated 
to graft dysfunction, demonstrating the spectrum  of impact IR microcirculatory dysfunction has in 
the global field of organ transplantation. 
The causes of altered renal perfusion are not completely understood. There may be an imbalance in 
production and activity of endogenous regulators of vasodilatation and vasoconstriction - such as NO 
and endothelin. This is partly supported by studies demonstrating improvement in IR injury with pre-
treatment by vasoconstrictor antagonists [170,577,578].  
Congestion in peri-tubular capillaries and outer medulla may be due to aggregation of leucocytes 
and platelets [129,579] combined with vasoconstrictive elements, and development of pro-
inflammatory and pro-thrombotic cascades. Congestion has been shown to shunt blood flow from 
the outer medulla potentiating hypoxic and ischaemic stress during reperfusion [580–582].  
IR damage to endothelial cells with resultant swelling and vessel permeability with interstitial 
oedema can also contribute to malperfusion through directly compressing peritubular capillaries 
causing vessel obstruction [553]. Interstitial oedema may also contribute to haemoconcentration, 
increasing the potential for platelet/leucocyte/endothelial interactions. This is particularly important 
as these interactions in the IR environment will potentiate further endothelial barrier failure 
[583,584].  
Lastly activation of the clotting cascade by IR effects - ROS, hypoxia, and the subsequent activation 
of complement and inflammatory cells may negatively affect rheological properties of the blood. 
Over all three components of Virchow's triad seem to be met with an activated and damaged 
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endothelium, congestion of flow through the microcirculation, and activation of coagulatory 
proteases. The final factor is likely the inflammatory process that occurs in parallel - and it is now 
widely accepted that there is critical and continuous cross talk between the inflammation and 
coagulation, especially in IR injury[585].  
The mechanisms of altered perfusion may also be divided by the separate units of the vascular bed 
they relate to and specific changes seen in arterioles, capillaries, and venules all contribute to poorer 
tissue perfusion.  
 
Figure 16  The key rol e of the endothelium i n normal  physiol ogical  situa ti ons  a nd in 
infla mma tion during I R inj ury. (A) Normally the endotheli um prevents  c oa gula ti on by: 
expressing thrombomodulin (TM) a nd the endothelial  PC rec eptor  (EPCR) supporting genera ti on 
of ac ti va ted PC by thrombin, expressi ng TF pa thwa y i nhi bi tor (TFPI ) a nd a nti thrombin (AT), a nd 
s ec reti ng tiss ue-type plas minogen ac ti va tor  (t-PA) promoti ng fi brinolysis . (B) During I R there is a 
local  and s ys temic  ac tiva ti on of i nfla mma ti on whic h l ea ds  a  a n increas e i n the rel eas e of pro -
infla mma tory c ytoki nes , wi th ac ti va tion a nd s ubs equent dysfunc ti on of the endotheli um. Wi th 
ac ti va ti on there is  a  rel eas e of metalloproteas e enzymes , a poptosis of s ome endothelial c ells, 
detac hment of others , a nd a general loss of barri er func tion, l ea ding to inter s ti tial tissue 
oedema . Induc ti on of TF on circula ti ng infla mma tory c ells and gra ft endothelial c ells, rel eas e of 
von Will ebra nd fac tor , a nd s ubs equent pla tel et a dhesi on a nd a ggrega ti on, promotes  a  pro -
c oa gulant environment wi thin the gra ft. There is a  dec r eas e in glycosa mi noglyca ns  produc ti on, 
a nd endogenous  a nticoagula nt proteins  (TFPI , AT, EPCR, a nd TM) a re cl ea ved fr om the 
endotheli um s ur fac e trans formi ng  the endothelial into a pro -c oa gula nt phenotype. 
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Furthermore circ ula ting a nd locally produc ed APC a nd AT are c onsumed. Pla tel et ac ti va ting 
inhibi tor  (PAI -1) l evels i ncreas e a nd overwhel m t-PA, l i mi ti ng fi bri nol ysis and s hifti ng to fur ther 
fi bri n forma ti on a nd deposi tion. Thrombin -a c tiva ta bl e fibrinolysis  inhibi tor  (TAFI ) ac ti vi ty is 
reduc ed l ea ding to enha nc ed c ompl ement ac ti va tion and ac ti on of C3a  a nd C5a  a c tivi ty. PAR 
rec eptors  are fur ther  ac ti va ted by thrombi n, TF-FVIIa  c ompl exes a nd FXa , as well  as APC 
modul a ting c ytokine rel ease. Ada pted from Sc houten et a l .  [240] 
 
1.5.4.3 Arterioles 
IR causes a progressive endothelium dependent vasoconstriction of arterioles. During ischaemia 
there is an inducible production of potent vasoconstrictors such as endothelin-1, endothelial 
angiotensin II, sympathetics, adenosine, thromboxane A2, and leukotrienes that act to counter 
constitutive and inducible endogenous vasodilators such as NO, acetylcholine, bradykinin, and 
prostaglandin E2[586]. This effect is then accentuated after reperfusion, by excess ROS production 
from endothelial cells and the recruitment and adherence of leucocytes[449,587] . Whether such 
vasoconstriction arises with certainty due to increased presence of endothelial derived 
vasoconstrictors, or a deficiency in effect of endogenous dilators, such as NO is still being 
investigated[468,588,589]. Evidence for this vasoconstriction is found in spectral Doppler wave 
forms during the initial hours and days after transplantation in kidneys with DGF that show higher 
restrictive indices compared to immediate functioning grafts[571,590,591]. 
1.5.4.4 Capi llaries 
Capillaries are responsible for the exchange of nutrients, hormones, oxygen, CO2, and metabolites 
between the circulation and the organ in question[208]. Key beds in the kidney include the 
glomerulus, and the peri-tubular capillaries. Dysfunction in these beds is likely key to the poor 
functional status of kidneys affects by IR clinically experiencing DGF and reduced glomerular 
filtration rate (GFR).  IR manifests with an increase in fluid infiltration into the interstitium (oedema) 
a result of increased endothelial barrier permeability, rather than higher transcapillary hydraulic 
pressure [92,592] .  Diminished NO levels and leucocyte-endothelial synergy have been implicated in 
this process [587]. This mechanism may also be active in diminishing effective GFR[566]. In parallel 
with increased fluid filtration IR is associated with perfusion deficits and decreased capillary 
perfusion density. This appears to stem from obstruction of capillaries by stiffer, activated 
leukocytes and platelets combined with swollen and partially detached endothelial cells narrowing 
capillary lumens [593].  
 
106 
 
1.5.4.5 Venules 
Venules are the primary site of endothelial dysfunction and the ensuing inflammatory response in IR 
related microvascular injury. The predominate features involve leucocytes: leucocyte -endothelial 
adhesion and transendothelial infiltration, platelet-leucocyte aggregation, with extravasation of 
albumin and fluid into the interstitium due to increased barrier permeability; and increased ROS 
formation[594–596] .   
1.5.5 Derangement of Coagulation in Ischaemia Reperfusion Injury  
The recent developments seen in the understanding of thrombin physiology, and the interlacing 
interactions of coagulation proteases and inflammatory mediators has presented an opportunity for 
pharmacologic intervention using novel anti-coagulants in a variety of processes and conditions that 
have traditionally not been treated by such means in the past. In particular interventions using anti-
coagulants targeting inflammation in IR injury in organ transplantation has the most potential for 
impact because at present IR mediated injury in marginal allografts and the subsequent delayed 
function and complications that arise and impact graft and patient survival represents one of the 
major challenges in transplantation today. 
In transplantation settings of IR injury, activation of coagulation cascades and their interactions with 
recipient (and potentially donor) leucocytes and platelets in the allograft microvasculature leads to 
the generation of and deposition of intravascular fibrin(ogen), propagation of which may cause 
occlusion of the microvasculature and obstruct capillary perfusion [597].   
The localisation of coagulation to areas of infectious inflammation functions to isolate regions within 
in a kidney and contain the pathogenic spread [312]. In a similar manner during IR, on-going 
coagulation reducing perfusion through the micro-circulation would feedback and potentiate the 
progressive thrombosis and ischaemia in the affect regions. Hypoxia during reperfusion will augment 
the pro-inflammatory and pro-coagulant phenotype of endothelial, resulting in amplification of fibrin 
deposition, worsening micro-coagulopathy and inflammation further diminishing microvascular 
perfusion. In parallel the inflammatory processes occurring during IR and the generation of pro-
inflammatory cytokines from endothelial cells, immune cells and cells of the organ amplify and 
ensure continued activation of coagulation proteases. There is also inhibition of intrinsic 
mechanisms of fibrinolysis and natural anticoagulation (which are also anti-inflammatory) ensuring 
continued inflammation. Despite evidence of intravascular fibrin(ogen) deposition during IR this 
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does not lead to overt organ damage, instead it produces a transient inflammatory milieu with-in the 
allograft, affecting normal tissue function [598]. This transient inflammation results clinically as 
delayed graft function which can last from several hours and days to weeks.   
1.5.6 Coagulatory Disturbances in Kidney Transplantation 
IR injury is the exacerbation of ischaemic tissue damage upon reestablishment of the circulation and 
influx of oxygen and cellular blood components. It is an unavoidable process in  organ 
transplantation, and the degree of injury sustained a major contributor to allograft function, and 
both patient and allograft graft survival. 
The patho-physiology of IR injury is complex and not fully understood. Animal and a number of 
human studies have shown that ROS [99], components of the innate immune system  such as 
complement [154], as well as leucocytes and platelets [128] contribute to I/R injury. The interplay 
between components of the inflammatory response and coagulation cascade has been highlighted 
as potential key player, previously underappreciated in IR pathogenesis [599][266]. 
Overt renal allograft thrombosis as an entity is a serious complication in renal transplantation. 
Arterial thrombosis occurs in 0.2-7.5%, and venous thrombosis in 0.1-8.2% of renal allografts[600]. 
There is a heterogeneity in allograft thrombosis rates in the literature, for which there are several 
possible reasons: classification and diagnosis of thrombosis differs between institutions and 
countries (clinical, histological, after allograft removal, radiological), the majority of reports are 
retrospective, and differentiation is frequently not made between arterial or venous thrombosis. A 
brief review of the literature demonstrates this (Table 1).  
None the less it is a detrimental complication that is variably implicated by various analyses in 2-7% 
[601,602], 17-35% [603,604],  and as high as 44% of all cases of early graft loss in adults [605]. 
Furthermore the most recent analysis of paediatric kidney recipients since 1995 (North American 
Paediatric Renal Transplant Cooperative Study [NAPRTC]) suggests despite improved 
immunosuppression in the current era of transplantation 2.7% of all paediatric allografts are lost to 
thrombosis, with thrombosis accounting for 35% of all lost allografts in the 1st year, and 18% of all 
graft losses [606,607]. 
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1.5.6.1 Causes and Risk Factors 
Numerous retrospective analyses of graft outcomes and complications has suggested a number of 
risk factors and donor / recipient pathologies associated with allograft thrombosis[600,602,604,608–
616]. Donor factors include: age(<6 or >60), cold ischaemia time >24 hours, vessel atheroma, 
deceased donor, history of stroke, use of a right kidney. Recipient factors include: Recipient age <5–
6 or >50, Peritoneal dialysis, diabetes mellitus, atherosclerosis of renal or iliac vessels, previous 
history of thrombosis, technical/surgical problems, use of iliac graft anastomosis in young donors, 
hemodynamic instability, thrombophilia, use of artificial grafts, no use of thromboprophylaxis, acute 
allograft rejection, and delayed graft function. 
An important aspect of these risk associations is that no one study has identified all of them, and 
specific risks are not seen in every study analysis. Thus the interactions between risk factors, in 
terms of cumulative or even exponential risk are not known.  
1.5.6.2 Current management of kidney al lograft thrombosis  
Diagnosis of Post-transplant graft thrombosis is based on a mixture of evidence of failing function, 
clinical findings, and radiological imaging including ultrasound scan (USS), magnetic resonance 
imaging (MRI), and biopsy[600]. Venous thrombosis is usually accompanied by a swollen, tender 
allograft and haematuria, while arterial thrombosis may only present with sudden anuria and by pain 
over the graft region. In an arterial/venous thrombosis picture symptoms may be mixed and sparse. 
Clinically it can be difficult to distinguish graft thrombosis from acute rejection, as thrombosis 
frequently occurs in rejection episodes. Partial thrombosis may also present as delayed graft 
function, until the process progresses to complete thrombosis where the full clinical picture is more 
recognisable[617,618]. However delayed function can also mask graft thrombosis, where thrombotic 
events normally occur within the first 10 post days postoperatively, with 93% of cases occurring by 
day 7[601,619], and DGF may have been evident since transplantation. Doppler USS is reliable 
technique to detect renal artery or vein thrombosis, and can help to distinguish between episodes of 
acute rejection, thrombosis and delayed function [591,620–623]. 
Successful salvage of allografts from thrombosis is reported in the literature using injection of anti-
fibrinolytic agents, endovascular aspiration, and surgical thrombectomy [624–626]. In the majority of 
cases graft rescue is disappointing and generally allograft thrombosis causes irreversible loss of 
function and necessitates surgical graftectomy.  
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Apart from addressing the risk factors associated with allograft thrombosis, by either carefully 
scrutinizing donors or optimising the recipient post transplantation the only available preventative 
measure that is widely available is prophylactic anti-coagulation. There has been no national, or 
international census on suggested practice, neither have there been any high quality trials assessing 
the benefit of such treatment on thrombosis prevention and graft loss[627]. None the less several 
studies and analyses have been made examining the effectiveness and safety of routine anti-
coagulation in kidney transplant recipients, particularly in high risk cohorts such as patients with 
diagnosed thrombophilia. The common repertoire of prophylactic anticoagulants used include both 
oral and intravenous medications; aspirin, unfractionated heparin (UFH), and low molecular weight 
heparin (LMWH). Debate and evidence remains to address whether such anticoagulation is effective 
in preventing thrombosis, which anti-coagulant is most effective in different donor/recipient 
cohorts, and if the risk of bleeding is a permissible and acceptable risk. A summary of the studies 
addressing the issue of anti-coagulation in kidney transplantation is presented in Table 2. 
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Author Nationality Year n 
Recipient 
age 
Donor (% 
DBD/ DCD) 
% RAT + RVT % RAT % RVT Study design 
Jordan [628] Canada, Toronto 1970-1980 341 13-67 84 4.4% (15) 3.5% (12) 0.9% (3) Consecutive c.s. 
Penny [601] Australia, ANZDATA 1980-1992 6153 N/A N/A 2.2% (134) 1.1% (70) 1.0% (64) Case-control 
Murphy [629] Ireland, Belfast 1989-1992 202 adults N/A 4.5% (9) 1.0% (2) 3.5% (7) Retrospective c.r. 
Benedetti [630] USA, Minnesota 1985-1993 998 16-74 51 1.4% (14) 0.4% (4) 1.0% (10) Retrospective c.r. 
Bakir [631] Holland, Groningen 1986-1994 558 14-71 100 6.1% (34) 2.0% (11) 3.4% (19) Consecutive c.s. 
Ojo [604] USA, UNOS 1990-1996 84513 >18 N/A 0.9% (751) N/A N/A Case-control 
Perez [619] Spain, A Coruña 1988-1997 827 44 100 5.7% (47) 2.3% (19) 3.4% (28) Retrospective c.r. 
Englesbe [632] USA, Michigan 1993-1997 714 all  43 1.82% (13) 0.8% (6) 1.0% (7) Consecutive c.s. 
Samhan [633] Kuwait, Hawaly 1993-1998 151 all  24 3.3% (5) 2.6% (4) 0.7% (1) N/A 
Osman [615] Egypt, Mansoura 1976-1999 1200 all  0 0.5% (12) 0.4% (5) 0.1% (1) Consecutive c.s. 
Mazzucchi [634] Brazil, Sao Paulo 1995-1999 356 18-70 64 1.4% (5) 0.3% (1) 1.12% (4) Retrospective c.r. 
Parada [635] Portugal, Coimbra 1980-2001 1000 41 98 0.9% (9) 0.6% (6) 0.3% (3) Prospective 
Orlic [636] Croatia, Rijka 1971-2002 725 N/A 53 1.1% (8) 0.6% (4) 0.6% (4) N/A 
Stechman [637] UK, Oxford 1997-2002 401 27-75 78 1.0% (4) 0.75% (3) 0.25% (1) Prospective 
Hernández [617]  Spain, Tenerife 1996-2004 870 18-76 100 4.8% (42) 3% (26) 1.8% (16) Retrospective c.r. 
Sanni [614] UK, Newcastle 1990-2005 1308 N/A 93 2.8% (36) N/A N/A Retrospective c.r. 
Dimitroulis [638] Greece, Athens 1980-2005 1367 N/A 44 2.3% (31) 2% (27) 0.3% (7) Consecutive 
Salehipour [639] Iran, Shiraz 1988-2006 1500 Apr-70 20 1.1% (16) 0.6% (9) 0.5% (7) Retrospective c.r. 
Głyda [640] Poland, Juraszów 1995-2005 327 46.5 100 0 0 0 Retrospective c.s 
Ta bl e 1 Summary of s tudi es  of kidney trans plant outcomes detail ing ra tes of kidney allograft thrombosis . RAT: renal a r tery thrombosis , RVT: renal vein 
thrombos is. c .s: c ase s eries . c .r: c ase review. N/A: not a ddres sed.  
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Author Nationality Year n 
Recipient 
age 
Donor 
(%DBD/ 
DCD) 
% RAT + RVT % RAT % RVT Study design 
Amézquita [613] Spain, Madrid 1990-2006 772 N/A 100 5.5% (42) N/A N/A Case-control 
Sharma [610] USA, Richmond VA 2000-2006 401 adults 72 0.49% (2) N/A N/A Retrospective c.r. 
Kamali [641] Iran, Tehran 1998-2007 718 21-58 0 N/A 3.1% (22) N/A Retrospective c.r. 
Haddiya [642] Rabat, Morocco 1998-2008 67 38-50 0 4.5% (3) N/A N/A Retrospective c.r. 
Phelan [605] Ireland, Dublin 1990-2009 2381 >18 100 0.2% (7) 0.75% (11) 1.2% (30) Retrospective c.r. 
Luna [612] Badajoz, Spain 1992-2009 577 adults 100 6% (35) N/A N/A Retrospective c.r. 
Zil inska [643] Slovakia, Bratislava 2008-2009 103 adults N/A N/A 3.9% (4) 2.9% (3) Retrospective c.r. 
Bessede [644] France, Paris 1971-2010 3129 adults 93 N/A 1.9% (61) 1% (31) Retrospective c.r. 
Eufrásio [645] Portugal, Coimbra 1980-2010 2000 43 +/- 13 96 0.1% (2) 1% (20) 0.4% (8) Retrospective c.r. 
Srivastava [646] India, Uttar Pradesh 1989-2010 1945 6-56 0 0 0.46% (9) 0.15% (2) Retrospective c.r. 
Ghadiani [647] Iran, Tehran 1994-2010 385 35 +/- 14 2 N/A 9% (35) 3% (12) Retrospective c.r. 
Aktas [648] Turkey, Ankara 1975-2011 1843 3-66 24 N/A 0.2% (5) 0.1% (2) Retrospective c.r. 
Sagban [649] Dusseldorf, Germany 1997-2012 338 44 +/- 13 0 0 1.2% (4) 1.2% (4) Retrospective c.r. 
Ta bl e 1  c ontinued.  Summary of s tudi es  of ki dney trans plant outc omes  detail ing ra tes of ki dney all ogra ft thrombosis . RAT: renal a r tery thrombosis , RVT: 
rena l  vein thrombosis. c .s: c ase s eries. c .r : c ase review. N/A: not a ddres sed.  
 
112 
 
Author Nationality Year Study 
 Design 
Cohort Details Group Type of Treatment  n 
Esfand-
iar 
[650] 
Iran, Tehran 
2007-
2008 
Prospectiv
e RCT 
Paediatric 
kidney 
transplantation 
Control  No anticoagulation 63 
Anti-coag 
Group 
Heparin /Aspirin 24 
        
Osman 
[651] 
Egypt, 
Mansoura 
2003-
2005 
Prospectiv
e RCT 
Living donor 
kidney 
transplantation 
Control  No anticoagulation 25 
Anti-coag 
Group 1 
LMWH (Post Op 
1/52) 
25 
Anti-coag 
Group 2 
UFH (Post Op 1/52) 25 
        
Eng 
[652] 
Kentucky, 
USA 
2005-
2009 
Retrospect
ive c.s 
Adult kidney 
transplantation 
Control  No anticoagulation 213 
Anti-coag 
Group 
Aspirin / UFH / 
LMWH / 
LMWH+Warfarin; 
Post Op 
28 
        
Pawlicki 
[611] 
Poland, 
Katowice 
2006-
2008 
Retrospect
ive c.s 
Adult kidney 
transplantation 
Control  No anticoagulation 48 
Anti-coag 
Group 
Heparin (2/7) + 
LMWH (5/7); Post 
Op 
11 
        
Murashi-
ma [653] 
USA, 
Philadelphia 
2003-
2007 
Retrospect
ive c.s 
Adult kidney 
transplantation 
in recipients at 
high risk for VTE 
(e.g. 
Thrombophilia) 
Control No anticoagulation 32 
Anti-coag 
Group 
Anti-coagulation 
(50% 
Thrombophilia) 
16 
        
Kusyk 
[654] 
Australia, 
Camperdow
n 
1998-
2003 
Retrospect
ive c.s 
Adult kidney 
transplantation 
Control  No anticoagulation 310 
Anti-coag 
Group 
UFH  ± LMWH; Post 
Op 
16 
        
Mathis 
[655] 
USA, New 
Jersey 
1998-
2002 
Retrospect
ive c.s 
Adult kidney 
transplantation 
Control  No anticoagulation 697 
Anti-coag 
Group 
Heparin; Post Op 28 
Ta bl e 2 . Summa ry of s tudi es  inves ti ga ting the meri ts  of a nti -c oa gula ti on i n ki dney 
trans planta ti on. Ages  a re repres ented as  ei ther  mea n ± SD, a  ra nge, or  a  des cripti on of the 
c ohort a ge.  ASA: as pirin. RCT: randomis ed  c ontrolled trial. c .s : cas e s eri es . UFH: unfra c tiona ted 
hepa r i n. LMWH: l ow mol ec ular wei ght hepar in. VTE: venous  thrombo embolism.  
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Author Group 
Recipient 
Age 
Donor 
Age 
Donor 
DD % 
RAT + 
RVT % 
RAT 
% 
RVT 
% 
Bleeding  
% Conservative 
Management 
% Requiring 
Reoperation 
Esfandi-
ar 
[650] 
Control  10.4 18.2 0 7.90 0 0 0 0 
Anti -coag 
Group 
9.6 16 0 0 0 0 0 0 
  
        
Osman 
[651] 
Control  29.4 ±8 35.3±10 0 0 0 0 32 0 
Anti -coag 
Group 1 
28.3±8 35.9±11 0 0 0 0 44 4 
Anti -coag 
Group 2 
26+/-6 33±9 0 0 0 0 48 0 
  
        
Eng 
[652] 
Control  Adults  N/A N/A 0 0 0 27 1.7 
Anti -coag 
Group 
31-53 N/A N/A 0 0 0 
32 (21.1% of 
ASA, 71.4% of 
UFH/LMWH) 
14 ( 5.2% of 
ASA, 42.9% of 
UFH/ LMWH) 
  
        
Pawl iki  
[611] 
Control  46 ±11 45 ±12 100 0 0 0 12.5 4.1 
Anti -coag 
Group 
46 ±11 45 ±12 100 0 0 2 
57.9 (63% of 
UFH, 50% of 
LMWH) 
9 
  
        
Murash
ima 
[653] 
Control  N/A N/A N/A 18.8 NA NA 6.3 NA 
Anti -coag 
Group 
N/A N/A N/A 6.3 NA NA 31.3 NA 
  
        
Kusyk 
[654] 
Control  Adult N/A N/A 0 0 0.97 1.3 2.2 
Anti -coag 
Group 
Adult N/A N/A 0 0 0 25 37 
  
        
Mathis  
[655] 
Control  Adult N/A N/A 0 0 0 0 0 
Anti -coag 
Group 
Adult N/A N/A 7.1 0 0 14 50 
Ta bl e 2  c ontinued. Summary of s tudi es  i nves ti ga ti ng the meri ts  of a nti -c oa gula ti on i n ki dney 
trans planta ti on. Cons erva tive ma na gement i ncluded tra ns fusi on of blood produc ts . Bl eeding 
ra tes  are des cri bed as : the perc enta ge of pa ti ents  bl eedi ng requiring i nterventi on wi th 
perc enta ge of thos e bl eeding on s pecific anti -c oa gulants i n bra ckets . DD: dec eas ed donor , RVT: 
renal  vei n thrombosis , RAT: renal  ar tery thrombosis. N/A: not address ed. UFH: unfra c tiona ted 
hepa r i n. LMWH: l ow mol ec ular wei ght hepar in. VTE: venous  thrombo embolism.  
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The lack of sufficient controlled and randomised trials of suitable power limits any attempt at 
producing a protocol based on high quality evidence. Most protocols in use by transplant centres is 
based on anecdotal evidence and individual unit experience.  
Recently a survey of anticoagulation practices of 35 transplant centres in France revealed a high 
degree of variability in patient management[627]. The survey addressed the management of 4 
hypothetical situations necessitating decisions on patient anticoagulation in the peri-operative 
period based on the units standard practice, dealing with issues of thrombophilia, history of 
thrombosis, concurrent anti-coagulation, atrial fibrillation, diabetes, and advancing age. Overall 
there was a large diversity in anti-coagulation practice, with no common management strategy, and 
this likely reflects the complexity of anti-coagulation in renal transplant recipients in the absence of 
good evidence from the literature, and national/regional guidance.  
Bleeding complications in patients cannot be overlooked and in what studies are available  (Table 2) 
document bleeding rates ranging from as low as 1% to as high as 57% in patients on post-operative 
anti-coagulation and higher in those on UFH, with similar high rates requiring reoperation[611,650–
655].  
Use of heparins, especially LMWH, in chronic renal impairment is problematic due to the variability 
and unpredictability in dose response due to insufficient renal clearance. Renal transplant patients in 
general are also susceptible to such problems, with a greater risk of bleeding with UFH, than non 
transplant recipients[656]. Thus use of UFH in the peri-operative period may be cautioned as ideal 
target coagulation parameters to prevent thrombosis but limit bleeding still need be determined. 
Furthermore despite heparin possessing anti-inflammatory properties, which may be beneficial in 
during transplantation these effects are only observable at higher doses than those deems clinically 
safe[657]. 
Emerging acceptance of the complex overlap and interface between coagulation cascades and 
inflammatory responses during IR injury means that the episodes of thrombosis clinically detectable 
are possibly the result of a progressive and exaggerated IR response.  The initial IR injury that 
initiates coagulation and intravascular fibrin deposition in the microvasculature, could overwhelm 
the recipient innate anti-coagulatory and fibrinolytic processes. This process through interactions 
with platelets and leukocytes, and potentiated by cytokines and activation of the graft endothelial 
into an inflamed and pro-coagulant phenotype, can lead to extension and acceleration of thrombosis 
into the larger vessels  -arterial, venous or both -  with subsequent allograft thrombosis.  
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Eventual graft thrombosis does not frequently occur - as evidence by the relatively low  incidence of 
thrombosis in the literature, instead it is likely that the clinical entity encountered is DGF.   
During human transplantation there is a demonstrated malperfusion of the renal micro-circulation 
(cortical and medullary regions)[658] with subsequent effect on renal function, highlighted by 
greater and discontinuous perfusion deficits in kidneys with DGF[568,569,659,660] and also 
subsequent graft failure. Furthermore damage to peritubular endothelial cells is associated with 
DGF, and though damage is initiated by IR responses, it may be potentiated in areas with poor 
perfusion[661].  
Renal transplant recipients demonstrate higher activity of AT, Protein C, and Protein S, with higher 
levels of D-Dimers in the post-operative period suggesting increased thrombotic processes in these 
patients[662,663]. These finding correlate with other studies that show significant release of 
inflammatory cytokines  (IL-6 and IL-8), as well as prothrombin fragment 1+2 (marker of coagulation 
activation) in cadaveric kidney recipients within 30 minutes of implantation demonstrating the 
overlap between inflammatory processes and coagulation events in mediating IR injury[664].  
A similar study demonstrated that higher levels of D-Dimers are released within several minutes into 
the recipient circulation in kidneys that subsequently exhibit DGF compared to immediate 
functioning kidneys[618]. Release however of pro-thrombin fragment 1+2 did not follow this trend, 
suggesting to the authors that resident fibrin deposits in the graft (from retrieval and preservation) 
may have been the cause of the D-Dimer release.  Prevalence of remnant micro-thrombi and fibrin in 
static cold stored kidneys is documented. However this does not negate the key role rapid activation 
of coagulation by the transplanted kidney may have, leading to the generation of fibrin and clot 
formation damaging the allograft and resulting in delayed function[665]. Ex-vivo flush, for example 
with streptokinase (a plasminogen activator) of kidney allografts with biopsy proven intraglomerular 
micro-vascular thrombosis prior to transplantation salvaged kidneys and allowed 
transplantation[666]. Despite this intervention 25% of salvaged kidneys demonstrated DGF.  
Renal transplant recipients have higher levels of t-PA and lower PAI activity compared to healthy 
controls, suggesting ongoing activation of coagulation proteases necessitating continued and up 
regulated activation of the fibrinolytic system[667]. Furthermore PAI activity was higher in recipients 
with chronic allograft rejection compared to those with stable renal function - indicating that 
increased activation of coagulation (and in these patients less fibrinolysis) - is not limited to the early 
IR insult but can persist within chronic inflammatory reactions in these patients. Peritubular 
capillaritis, as well as peritubular thrombosis are both seen in renal transplant allograft biopsies of 
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kidneys with chronic rejection, again indicating the wider spectrum and involvement of activation of 
coagulation cascades and thrombosis in transplant pathology, from perioperative IR injury to 
ongoing inflammation[668,669].  
Stasis of blood within an allograft during the WIT induces coagulation activation with thrombin 
generation, and the activation of platlets with leukocyte-platelet-endothelial complexes formed in 
the glomerular and peritubular microcirculation [670,671]. These processes converge on reperfusion 
with fibrin deposition, the development of microthrombi, occlusion of allograft microvasculature. 
Impaired perfusion, and further hypoxia enhances endothelial and leukocyte activation, which 
amplifies activation of coagulation cascades (via TF expression) with more thrombin generation, 
fibrin(ogen) deposition, and allograft invasion by leucocytes, which is independent of allogenicity 
[220]. In summary effects of IR induced inflammation on haemostasis are mediated by increased 
production of pro-inflammatory cytokines, which potently activate coagulatory cascades while 
seriously inhibiting both fibrinolysis and natural anticoagulatory mechanisms. 
Recently DTIs have been trialled in experimental porcine kidney auto-transplant models with 
successful outcomes. Melagatran is a low molecular weight specific thrombin inhibitor with action 
on free and bound thrombin (half-life of 1.7 to 2.5 hr). Melagatran administration (to the 
preservation solution) during SCS preservation, as well as after transplantation to the recipient 
animal reduced the pro-inflammatory activity of circulating immune cells, as well as renal injury 
(reduced P-selectin and MCP-1), and inflammatory infiltrates.  Animal and graft survival, with good 
function and no DGF, was doubled from 4 to 9 days with melagatran treatment compared to 
controls[672]. In a similar porcine DCD auto transplant model melagatran also improved short and 
longer term graft survival, with reduced DGF peri-operatively, with less interstitial fibrosis and good 
function at 3 months [673,674].  
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1.6 Ischaemia Reperfus ion Injury and the Pancreas  
The cellular mechanisms of renal IR injury, in particular those related to endothelial cell stress and 
damage also play a dominant role in pancreatic reperfusion induced damage during transplantation. 
Pancreatitis and graft thrombosis  are the two primary entities that arise from such IR mediated 
injury. 
1.6.1 The Aetiology of Early Pancreatic Graft Thrombosis 
Though reports indicate that recruitment of marginal donors may be of benefit to expanding certain 
donor pools, with patient and graft survival rates comparable to ideal donors in some cases; older 
age, higher BMIs, and increased organ ischaemia time (as in DCD) are identified risk factors for post-
operative graft thrombosis [675].  
Furthermore procurement and preservation injury, reperfusion injury upon implantation, and 
inherent hypercoagulability of recipients are increasing seen to play a dominant role in graft 
thrombogenesis [676]. Considering the possible factors it would seem that Virchow’s triad  is met in 
most pancreatic transplantation operations; with endothelial damage and activation secondary to 
haemodynamic instability prior to retrieval, the stasis of residual blood within the pancreatic graft 
during procurement and preservation (even with through washout), and the recipient’s 
hypercoagulable diabetic state [677]. It is to this effect that vascular thrombosis has been coined 
‘the Achilles heel’ of pancreatic transplantation [676,678]. 
Rates of pancreatic graft thrombosis are variable but venous vs. arterial thrombosis predominates, 
and reports in the literature suggest an occurrence in 3.1-17% of grafts [679–683]. It is the leading 
non-immunological cause of pancreatic graft failure [678,684,685]. Thrombosis can be classified as 
either completely or partially occlusive. Complete occlusion, with-out sufficient collateral vessels 
would result in a swollen, painful, and failing graft that would require removal if interventions to 
salvage the allograft proved unsuccessful. Partially occlusive thrombosis can be harder to detect, as 
clinical signs may not be as obvious, with the only indicator DGF. Thus partially occlusive thrombosis 
is likely underreported and occurs more frequently than complete occlusion [684]. It is unknown 
what percentage of pancreatic DGF involves or is due to partial thrombosis of large or even smaller 
vessels.    
The pathogenesis of graft thrombosis is inherently related to the degree of IR  injury each organ 
sustains in retrieval and transplantation [321], and pancreatic tissue is extremely vulnerable to 
118 
 
ischaemic stress. IR by definition describes damage sustained during the period of ischaemia after 
retrieval and then the further damage that is inflicted once perfusion is re-established when the 
organ is transplanted to the recipient. A key finding in pancreatic IR related deterioration in graft 
microcirculation is decreased capillary perfusion, with increased macromolecular permeability and 
leucocyte adhesiveness in post-capillary venules [686]. Orthogonal polarisation spectral imaging 
analysis of the pancreatic microcirculation during clinical pancreatic transplantation demonstrated 
that poor post-operative endocrine and exocrine function correlated with microcirculatory 
dysfunction and  impairment of microvascular perfusion in the acute phase post 
transplantation[573].  
This leucocyte-endothelial interaction and inflammatory process heralds platelet activation and 
aggregation with generation of subsequent ROS, and the release of further pro-inflammatory 
cytokines, growth factors, and cytotoxic proteases, which further disrupts graft perfusion through 
platelet stagnation in non-perfused vessels and possibly accumulation in pancreatic venules [687]. 
Histologically pancreatic IR injury is characterised by interstitial and interlobular oedema, 
vacuolization, granulocyte infiltration, scattered necrosis[688] and apoptotic cell death[689]. 
The degree of parenchymal micro-circulation disruption and ischaemic tissue injury caused by re-
perfusion in IR has been correlated with the severity of post operative oedematous and necrotisi ng 
graft pancreatitis [686,690]. Pancreatitis itself is thus one manifestation of graft micro-circulatory 
disruption, and the subsequent hypoxic tissue damage and inflammatory process that prevails in the 
reperfusion setting. Inherent interactions between pro-inflammatory and pro-coagulant cells, 
cytokines, chemokines, and adhesion molecules, and key components of the coagulation  cascade 
(e.g. fibrin) thus play a decisive role in post-ischaemic pancreatic injury [687].   
The interface between inflammation and coagulation has been described in previous sections, and is 
understandably complex[290]. Venous thrombosis for instance is now understood to be an early 
consistent and sensitive marker of anti-body mediated humoral rejection in heart transplants, and 
several small animal studies of acute humoral xenograft rejection illustrate the point by 
demonstrating a complete inhibition of rejection with the use of anti-thrombin agents[691]. 
Coagulatory proteases are thus thought to be an early inflammatory stimulus in anti-graft responses, 
and parallels results from sepsis animal studies that show coagulatory proteases actually  amplify LPS 
induced inflammatory responses [692].  
Thus the inflammatory process evident in pancreatic grafts after IR injury is likely one stimulatory 
factor for the activation of coagulation cascades, with down regulation of fibrinolysis and a decrease 
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in anti-thrombin III (a potent endogenous anti-coagulant) that has been demonstrated in pancreatic 
grafts during reperfusion. This points what appears to be to the development of a local 
hypercoaguable state in the pancreatic vascular bed, and is probably a contributing aspect to the 
development of graft thrombosis[693].  
In addition to both IR injury and early humoral rejection several other possible patho-physiological 
causes and risk factors for graft thrombosis have been identified. Post operative analysis of pancreas 
recipients has revealed consistently higher platelet counts than diabetic controls[694]. In situations 
where endothelial damage is prevalent (such as IR injury in pancreatic grafts) a concurrent 
thrombocytocis may potentiate micro-circulatory dysfunction – so called ‘sticky platelet syndrome’ – 
through increased production of regulatory chemokines and adhesion  molecules – such as von 
Willebrand factor and fibronectin, inducing vasoconstriction (thromboxane A2), and in conjunction 
with tissue factor activate the coagulation system and promote thrombosis and vascular occlusion 
within the graft[695]. 
Inherited thrombophilia in transplant organ recipients is an important factor in the post-operative 
graft thrombosis. Major inherited thrombophilic disorders include factor V leiden, protein C 
deficiency, protein S deficiency, prothrombin gene mutations, and anti -thrombin deficiency. 
Retrospective reports state that up to 18% of patients with pancreatic graft thrombosis are 
thrombophilic[696]. Considering the inflammatory and possible pro-coagulant local process 
occurring in the pancreatic vasculature, an inherited pro-coagulant disorder in the recipient would 
most likely exacerbate the thrombotic tendency in the post-operative period.  
Peritoneal dialysis has been identified as an independent risk factor for renal graft thrombosis – 
though the patho-physiological cause is still elusive. This risk could also be conferred to diabetic 
patients on dialysis who receive a pancreatic graft as well as a renal allograft[697]. 
Furthermore the identified cardiovascular risk factors discussed in Section 1.53 affect both donor 
allograft endothelial as well as the recipient inflammatory and coagulatory profiles, rendering the 
pancreas more prone to microvascular dysfunction, thrombosis, and graft failure after 
transplantation. 
1.6.2 Current Management of Early Pancreatic Graft Thrombosis 
Various surgical and endovascular procedures have been described to salvage pancreatic grafts 
suspected of developing thrombosis[698–700]. Such developments are necessary to reduce graft 
120 
 
loss and morbidity in affected patients, however preventative measures that would reduce the 
incidence of thrombosis are important considerations.  
The lack of evidence in the form of clinical trials, as well as the increasing difficulties in designing 
such trials to determine best management have led Units in the UK in Oxford [676], Newcastle and 
Manchester, as well as Europe [678] to incorporate locally devised systemic anti-coagulation 
protocols post-operatively in efforts to reduce the incidence of early graft thrombosis, but with no 
consensus on the therapeutics employed.  
Despite the widespread, albeit heterogeneous use of systemic anticoagulation, rates of thrombosis 
are still high[684]. Furthermore systemic anticoagulation introduces the additional risk of bleeding 
into a post operative patient [700,701] with  recent reports quoting a 4-8% incidence of major 
bleeding[679,702]. 
Similar to the observed benefits in other models of tissue IR injury and transplantation various 
systemic anti-coagulants have been shown to confer a protective benefit in IR pancreatitis such as 
Anti-thrombin III, and potentially IR related microvascular dysfunction and thrombosis [690].  
The beneficial mechanism of action of heparin in pancreatitis however may only partly be due to its 
anti-coagulatory actions, but also due to its innate ability to inactivate plasma and tissue proteases, 
as well as slowing leucocyte recruitment and endothelial adhesion. Thus it may provide a two-prong 
anti-coagulatory and also anti-inflammatory benefit[703].  
Effective prevention of microvascular graft thrombosis would subdue one of the most troublesome 
complication in the early period post-transplantation, and ultimately improve graft survival of 
pancreases retrieved from ‘ideal’ as well as marginal donors, and allow substantive expansion of the 
donor pool. 
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1.7 Organ Preservation in Transplantation 
 
Organ transplantation is one of the key advances that has been made in the field of medicine in the 
last 50 years and for thousands of patients around the world with end-stage organ failure it remains 
the only effective therapy available. The supply of organs has always been an important issue in 
transplantation, in particular regarding moral & ethical, societal, logistical, and medical dimensions 
to the use of living and cadaveric donors. The impact of these issues on the quality and efficacy of 
treatments is of extreme importance to the overall multi-disciplinary approach in use by countries 
with successful organ transplant systems in place. 
 
The key to ensuring optimal quality of organs lies in the period between retrieval and implantation 
namely organ preservation where efforts are made to preserve the organ ex-vivo against mounting 
ischaemic, and then reperfusion, damage initiated upon re-vascularisation.   
 
As described in Section 1.3 the theoretical premise of IR injury is that in any given tissue exposed to 
ischaemic stress a number of cells will suffer irreparable damage, that ultimately leads to cell death. 
A larger percentage of cells in this tissue will sustain damage but still remain viable, with the 
potential for self-repair and return to normal function. As the former sub-group of cells will 
definitively undergo cell death, the degree and severity of IR injury remains with the number of cells 
in the 2nd subgroup that are salvageable and can actually remain viable after reperfusion [56]. Thus 
the aim of preservation strategies is to optimise the potential for these cells to be rescued, and 
improve function of the organ after transplantation. The cellular damage that occurs is based 
directly on the lack and then return of oxygen, the development of cellular oedema and intracellular 
acidosis, calcium overload, and the generation of reactive free radicals [57].  
 
The key to effective organ preservation is addressing the various pathological processes occurring 
during IR with the aim to minimise the effects of these process on cells and tissues in the organ so it 
may function as effectively as possible after transplantation[704]. 
 
Organ preservation solutions are designed to minimise this damage and attempt to address the 
various biochemical and histological processes that occur during this ischaemic interval. Currently 
there are two predominate methods of cold preservation: Static cold storage (SCS) and hypothermic 
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machine perfusion (HMP). HMP generates a controlled continuous or pulsatile re-circulating flow of 
preservation solution through the vasculature of kidney at 0–4°C.   
 
1.7.1 Static Cold Storage 
Current techniques for ‘static cold storage’ incorporate the use of cold preservative solutions to 
minimize cellular injury and decrease metabolism until the allograft is implanted in the intended 
recipient.  
 
At transplantation reperfusion with the recipient’s blood initiates further cellular damage termed IR 
injury [96]. SCS  starts with a rapid vascular washout to facilitate cooling, removal of blood 
components, and equilibration of the preservative solution with the surrounding tissue. SCS relies on 
the effects of hypothermia alone, supplemented special preservation soluti ons aimed at modulating 
the progressive cellular and molecular changes evident during ischaemia and then reperfusion [705]. 
 
There are limits to the beneficial effects of hypothermic preservation on organ damage. Metabolism 
can only be slowed by a factor of 1.5-2 for every 10oC drop in temperature [704,706]. Metabolism is 
not arrested fully however, and recent evidence indicates that during retrieval cooling is not 
sufficiently quick and inevitable ischaemic injury occurs[96]. Once cooled to hypothermic 
temperatures cold ischemia damage supervenes. Briefly disruption of cytoskeletal structure and 
mitochondrial integrity reduces the formation of ATP, and ATP dependent ion pumps fail, resulting in 
cellular oedema and tissue damage from sodium and calcium influx. The continuing low levels of 
metabolism result in accumulation of toxic metabolites, with formation of ROS and free radicals 
once reperfusion is re-established at transplantation. With reperfusion of the allograft follows influx 
and activation of leucocytes, alterations in endothelial cell structure, with endothelial entering a pro-
inflammatory phenotype, cytokine release from interstitial, endothelial, and immune cells, 
potentiates inflammatory processes with subsequent activation of innate immune responses and the 
coagulation cascade leading to microvasculature injury, perfusion failure, and prolongation of IR 
damage leading clinically to delayed function [96].  
 
Endeavours to produce preservative solutions that intervene in as many of the changes as possible 
to effectively limit the cellular and metabolic derangements identified in cold ischaemia and 
reperfusion, have led to the development of various solutions over the years.  
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1.7.1.2 Cold storage preservation solutions in re lation to the development of cl inical organ 
transplantation worldwide 
With the arrival of clinical transplantation by the 1960s, there was a resurgent interest in the 
knowledge gleamed from anatomists and physiologists concerning the techniques and theories for 
keeping organs viable and functioning whilst outside the body[707–712].  
 
Artificial perfusion circuits were developed with then novel automated pumps to study the 
physiology and function of organs[710,713,714]. These experiments attempted to use whole blood 
as well as synthetic blood substitutes that were predominately crystalloid based, to both 
demonstrate organ function and determine the potential for preservation. It was at this time that 
hypothermia emerged as a potential tool in these experiments for optimising preservation through 
its ability to alter metabolic activity[712], with the potential benefit for clinical transplantation 
increasingly realised[715]. 
 
Sir Roy Calne's team at Westminster Hospital in London led one of the first investigations into the 
merits of cooling kidneys prior to transplantation. Using cooled heparinised blood vascular flushing 
was shown to render more effective mass cooling of tissue than simple surface cooling[716]. Though 
this novel yet practical method of cold preservation would emerge superior within a few decad es, 
the use of blood as the perfusate would not, instead acellular flush and preservation solutions would 
predominate the field of organ preservation.   
 
One of the first preservation solutions developed was in 1969 by GM Collins and co-workers at UCLA 
in the US. This pioneering solution was acellular and designed to replicate the intracellular 
electrolyte balance of mammalian cells, attempting to prevent the cellular consequences of 
ischaemia (warm and cold) as they were understood at the time[717]. A number of versions of these 
solutions were developed aptly named Collins solutions, with the most widely used a version 
modified for use in the Euro-Transplant network in Europe in 1976[718]. This solution termed 'Euro-
collins' solution was subsequently used in transplant centres worldwide for nearly two decades.  
 
The advent of the Collins solutions allowed renal preservation to be extended to 24-36 hours; long 
enough for tissue matching and sharing/transport of organs between centres. This allowed the rapid 
expansion of transplantation as a clinical therapy, in particular for kidney transplantation, but also 
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for other organs such as the liver, pancreas, heart, and lung. Flexible techniques for organ 
procurement were designed which allowed all donor organs to be safely procured with minimal 
damage by being cooled in situ all the while quickly and simultaneously removed in a bloodless field, 
and further dissected and packaged ('benching') on a back table[719]. 
 
The initial achievements made in clinical transplantation through the use of Collins solutions were 
sufficient for clinical needs at the time. However despite the success with Collins solutions in the 
kidney, preserving the heart, lung, liver, and pancreas were not as successful. At the time in 1970s 
however preservation of these organs was not a priority. The biggest problems facing 
transplantation were related to immunogenic rejection, and it was not until the introduction of 
cyclosporine for immunosuppression that extrarenal organ transplantation became an effective 
treatment of patients with cardiac, lung, hepatic failure, or diabetes.  At this time there was a 
renewed interest in the field of organ preservation, in particular for extra-renal organs and research 
into improving solutions for preservation dominated. [720] 
 
These efforts culminated with development of the University of Wisconsin (UW) solution by Belzer 
and colleagues[721].  UW solution then dominated clinical abdominal organ preservation for almost 
two decades before a series of novel solutions emerged as viable and accepted alternatives. Desp ite 
other solutions available UW remains as the gold standard solution for abdominal organ 
transplantation today[722]. 
 
Tolerated periods of cold ischaemia vary depending on the organ in question; as little as 6h-8h for 
the heart and lung respectively, 12-15 hours for the liver, and 24 hours for the kidney, with extended 
CIT a risk factor for DGF post transplantation. Since the fixture of UW as the dominant preservation 
solution in abdominal organ preservation a number of alternatives emerged for SCS organ 
preservation including: Marshall's citrate, Bretschneider’s (Custodiol) Solution, Celsior, Kyoto 
University Solution, and Institute George Lopez-1 solution. 
 
1.7.1.3 Formulation of  Organ Preservation Solutions  
Loss of  Energy Substrates 
Because hypothermia does not abolish metabolic activity the solution should contain substrates 
necessary for ATP production. High-energy amino acids (e.g. glutamic acid) are able to restore ATP 
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dependent enzyme processes. By augmenting solutions with the ATP precursor adenosine, ATP 
synthesis can resume after reperfusion and replenish the pool of high-energy phosphates[705]. 
Cel l  Swelling 
Preservations solution must limit transmembrane osmotic flows that arise due to inhibition of Na/K+ 
ATPase, and K+ / Na+ flux in and out of the cell. By mimicking the intracellular environment (high K+, 
lower Na+) this flux gradient can theoretically be abolished. However high K+ concentration 
solutions (so called 'intracellular solutions') also cause vasoconstriction. The specific effect of such 
vasoconstriction is not known but may alter microvasculature perfusion dynamics during 
preservation if dynamic machine perfusion is utilized, and even in the initial period during 
reperfusion further potentially exacerbating reperfusion injury and 'no-reflow'. Alternatively 
extracellular solutions can be used, with a low K+ and high Na+ content, that generates external 
osmotic pressure counterbalancing the cytoplasmic colloidal pressure[723]. A low potassium 
solution would be suggested to cause potassium efflux from cells preservation solutions have been 
described utilising either of these principles with no benefit of one over the other 
demonstrated[705]. 
 
To further limit transmembrane flux impermeants can be used such as mannitol (182 Da), raffinose 
(504 Da), glucose (180 Da), lactobionic acid (357 Da),  and gluconate (195 Da)]. These molecules are 
large enough to leave capillary vessels and enter the interstitial spaces but either too large or too 
charged to enter the cell. They exert sufficient osmotic pressure within the extracellular space such 
as to counter the physiological intracellular driving force and limit cellular oedema. However the 
impermeant content must be close to the intracellular concentration of osmotically active molecules 
in the 110 – 140 mM range[53].   
 
During flushing and washout at retrieval there is a rapid equilibration between the solution and the 
interstitium with diffusion of solution contents into the extravascular space. A colloidal agent must 
thus also be used to limit interstitial oedema, and a number have been extensively investigated e.g. 
albumin (70 KDa), hydroxyethyl starch (HES, 250 KDa), polyethylene glycol (PEG, 20 – 35 KDa), and 
dextran 40 (40 KDa)[53].  
  
Finally Ca2+ homeostasis should be maintained in several ways[724]. The ideal preservation solution 
should thus theoretically have a low Ca2+, can have a variable Na+ content with carefully adjusted 
K+ and magnesium (Mg2+) concentrations. 
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Intracellular Acidosis 
During the hypoxia of warm and cold ischaemia anaerobic glycolysis prevails with formation of lactic 
acid and H+ ions. Furthermore hydrolysis of ATP yields further H+. A lack of ATP renders extrusion by 
the H+/ATPase and Na+/H+ exchanger inadequate and there is a progressive build up of H+ and 
development of intracellular acidosis[725]. Intracellular acidosis causes damage to cytoplasmic 
contents including mitochondrial membranes, cytochromic enzymes of the electron transfer chain, 
and components of the ER. Sufficient damage will result in necrosis or apoptosis once reperfusion is 
established. Buffers within the preservation solution can help to minimise the variations in pH that 
develop during ischaemia. Theoretically during reperfusion and availability of oxygen excess 
intracellular H+ can then be removed by endogenous mechanisms. Various buffers can be used 
including bicarbonates, phosphate, citrate, hydroxyethyl- piperazine-ethane sulphonic acid (HEPES), 
histidine, and tryptophan, but must be able to diffuse into the intracellular compartment, and 
function at low temperatures during hypothermic preservation[726,727]. 
Oxidative Stress 
Finally the generation of ROS during ischaemia and on subsequent reperfusion is a key initiator and 
cause of cell damage during IR. During reperfusion cells endogenous anti-oxidant mechanisms are 
enabled in efforts to limit ROS mediated damage - such as  superoxide dismutase, catalase, 
glutathione peroxidase and heme oxygenase-1 [728]. Extracellular availability of anti-oxidant species 
is limited by contrast and ROS scavengers in the preservation solution, such as allopurinol and 
reduced glutathione are theoretically beneficial[729].  
 
1.7.1.4 Static cold storage preservation solutions used in cl inical p ractice 
There are several common themes to the various preservation solutions developed [730] in 
particular related to ameliorating sequelae that occur during IR injury (Table 3).  
Col l ins 
Collins was one of the first preservation solutions developed and was modelled on intracellular 
electrolyte levels with a high potassium and glucose as the impermeant[731]. Though this novel 
solution enabling successful preservation of the kidney, heart, liver and lung, the associated maximal 
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storage time was shortened.  This was attributed to glucose aggravating anaerobic glycolysis. 
Modifications to Collins solution emerged - replacing glucose with mannitol or sucrose, which enable 
longer CIT. The final most widely used variant was the Euro-Collins modification in Europe and was in 
large scale use up until the late 1980s[732,733].   
Marshal l's citrate  
Marshall's citrate solution was designed as an alternative to Collins solution with modifications to 
improve buffering and cellular oedema. It is a hyperkalaemic crystaloid solution with high levels of 
Na+ and Mg2+, and offered improved intracellular buffering with citrate. A variation using HEPES 
instead of citrate exists[734], but citrate theoretically also chelates calcium, preventing intracellular 
build-up. Mannitol is used as the impermeant to limit cellular swelling, and with Marshall citrate 
preservation of kidneys for 24-40h can be safely achieved[735]. Unfortunately this protection could 
not be afforded to the liver and so limited its application with multi -organ abdominal retrieval. 
University of Wisconsin solution  
Developed by Belzer and Southard UW solution is the gold standard for abdominal organ 
transplantation today. The primary strategy employed by UW can be summarized as: 1) Prevention 
of oedema (raffinose, lactobionate); 2) Supplementation with ATP precursors (adenosine); and 3) 
antioxidants and ROS defence (allopurinol and reduced glutathione)[720].  
 
Inclusion of HES in UW is contentious. It was added to improve oncotic and colloidal support. 
However studies have shown HES can form red blood cell (RBC) aggregates during flushing, and at 
hypothermic temperatures the viscosity limiting effective washout[736]. 
 
Despite these potential flaws transplantation centres in the 1990s in the US and Europe 
demonstrated improved DGF rates in kidney transplants with UW. This was followed suit by 
improvements in liver transplantation, with safe preservation times extended up to 24h. Since then 
numerous comparative studies have shown UW to be superior over other solutions for pancreas, 
heart, kidney and lung preservation[736].  
Bretschneider’s (Custodiol) Solution  
Histidine-tryptophane-ketoglutarate (HTK) otherwise known as Custodiol or Bretschneider’s solution 
was first developed as a cardioplegia for use during cardiac bypass surgery in 1970s by H.J. 
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Bretschneider at the University of Gottingham in Germany[737]. The solution had three main 
components - histidine (as a buffering agent), and the amino acids tryptophane (a membrane 
stabilizer) and ketoglutarate (a substrate for anaerobic glycolysis), with mannitol as an osmotic 
agent. The potential benefits linked to development and use of HTK lies in the extracellular 
electrolyte composition wit low concentrations of Na+ , K+ , and Mg2+, with hypokalaemia perhaps 
limited vasospasm during flush and retrieval; furthermore because HTK had a low viscosity it was 
considered to be more effective than UW during organ flushing, which contained HES and which 
causes RBC aggregates[738]. However due to the low viscosity larger volumes at lower flow rates 
through the organ of HTK were needed to achieve complete tissue equilibration. Early studies 
demonstrated HTK to be equally effective as UW solution in kidney and liver preservation[739,740]. 
However later studies suggested that HTK was inferior in DCD liver preservation when extreme CITs 
of longer than 8> were encountered[741]. Despite critical papers HTK use with standard CITs in 
kidney and liver transplantation is considered safe and as effective as UW solution. Furthermore 
lower preservation costs per donor case with HTK meant it has  become increasingl y popular over 
last 20 years[742].  
 
Recently modifications to HTK have been reported in efforts to enhance the protective capacity of 
the solution, newly named Custodiol-N [743]. Changes include addition of the amino acids glycine 
and alanine (to inhibit hypoxic cell injury), the iron chelator deferoxamine, and  a new membrane-
permeable hydroxamic acid derivative LK 614 to inhibit ROS injury. Furthermore  histidine has been 
substituted with the derivative  N-acetyl-L-histidine (due to the theoretical risk of toxic side effects in 
combination with oxygen), L-arginine to aid NO production, and aspartate for resumption of the TCA 
Kreb's cycle during reperfusion.  
Celsior Solution  
Celsior is recently developed solution extracellular type solution with a high Na+ concentration. It 
was initially developed for cardiac allograft preservation and sought to combine benefits of various 
components of UW solution (lactobionate and mannitol - osmotic agents) and from HTK (histidine - 
buffering agent). Glutathione is added before use as ROS scavenger. The use of solution has been 
extended from cardiac preservation and has demonstrated successful preservation in the lungs, 
pancreas, and kidney [744–746].  
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Kyoto University Solution  
A new preservation solution has recently been developed at the Kyoto University in Japan. The 
theoretical basis of this solution  is the importance of saccharides and electrolyte balance during 
hypothermic preservation in limiting cellular oedema and the solution contains trehalose, an alpha 
linked disaccharide[747]. The osmotic strength of the solution is further augmented by gluconate 
and HES. There are two primary variants with an intracellular (low Na+, high K+) and extracellular 
(high Na+, low K+) electrolytic composition. 
 
Further improvements to Kyoto solution can be made by addition of ROS scavengers (N-
acetylcysteine), secondary messenger compounds dibutyryl cAMP and even a NO donor 
(nitroglycerin) and such modified Kyoto solutions have demonstrated superior preservation in 
experimental lung and liver transplantation compared to UW solution[748,749].  
IGL-1  
The Institute Georges Lopez (IGL) in France has developed IGL-1, a preservation solution in 
composition identical to UW solution with exception to the substitution of the colloid HES for PEG-
35 [750], which alleviates potential stimulus of RBC aggregation and adds potential benefits of PEG.  
 
In large animal porcine renal transplantation models IGL-1 preserved kidneys demonstrated reduced 
MHC type II, cellular apoptosis and interstitial fibrosis, and superior GFR and renal function at 15 
days post op compared to UW solution[751,752].  In a non-randomised prospective multicentre trial 
IGL-1 preservation of deceased donor kidneys (20% DCD) compared to UW solution showed a trend 
of better renal function in the initial 2 weeks with similar rates of DGF, and patient survival at 12 
months follow-up, demonstrating equality to UW solution[753].  
 
A series of pilot studies successful in liver preservation for orthotropic liver transplantation, with 
better survival, and histology demonstrating less necrosis and better hepatic microcirculation after 
reperfusion[754,755]. Most recently a porcine pancreas transplant model demonstrated equal 
outcomes and effectives of IGL-1 for preservation as compared to UW solution[756]. 
 
The use of PEG as substitute colloid for organ preservation is based on a number of observations 
that suggest PEGs (with low molecular masses) may confer a protective benefit in transplantation 
settings [757]. Firstly, unlike HES it does not form aggregates with RBCs during flush and washout 
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within the allograft. However the exact mechanism of the protective actions of PEG have not yet 
been fully elucidated but PEG is thought to act by stabilisation of the lipid monolayer in cell 
membranes. In part by 1) dehydrating action to reduce lipid molecular motion and cause denser 
packing of membrane lipids, decreasing fluidity; 2) at higher surface pressures PEG induces 
compression of glycerophospholipids. Temperature and pH of the local environment both influence 
PEG binding and it may be that at hypothermic temperatures that most beneficial effects on 
membrane stabilisation can be seen. However the act of binding to cell membranes and conferring 
relative stability may also have an indirect effect coined 'immunocamouflage' [757]. Binding of PEG 
to cell membranes creates organised layers of 'structured water' which act as a 'bumper' preventing 
approach, interaction, and fixation of immune leucocytes during reperfusion[758]. Limiting 
leucocyte endothelial interactions is beneficial, and can limit subsequent proliferation of the IR 
inflammatory response in the allograft and ameliorate subsequent IR damage, as such injury has a 
negative impact on graft outcome. 
Aqix  RS-I 
Aqix RS-1 (Aqix Ltd, UK) is a recently developed SCS preservation solution that is undergoing 
experimental studies[759]. It based on a non-phosphate-buffered solution, with organic buffers, 
amino acids and metabolic substrates and possesses the characteristics of normal physiological 
interstitial fluid. Aligning Aqix composition to interstitial fluid theoretically enables the solution to 
maintain the ionised status of cell membranes, as well as function of enzymatic and receptor 
components. At 286mOsmol/L the osmolarity is similar to serum, the ionic content equal to that of 
can isotonic solution, and ionic conductivity comparable to human serum at 12.6 mS cm–1. The 
combination of bicarbonate and Good's BES asits buffer allows pH to be maintained between 7.2 
and 7.46, over a large temperature range of 4-37˚C, demonstrating the flexibility of the solution and 
the potential use in transplantation in moving from hypothermia to normothermia.  
 
Initially designed for neurophysiological studies, its ability to preserve tissue in hypothermic, and 
normothermic conditions has lead to interest in its use in organ preservation. Preclinical porcine 
studies in kidney and liver preservation demonstrate improvements in organ function compared to 
conventional solutions at both hypothermic[760] and normothermic [759,761] preservation 
temperatures. 
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  Preservation Solutions 
 Collins Euro 
Collins 
Belzer 
UW 
HTK Cels ior PBS HOC 
Custodiol-
N 
IGL-
1 
Belzer-
MPS 
Polysol 
Sodium 10 9.3 25.0 15.0 100 120 80 16.0 120 100 136.0 
Potassium 115 115.1 125.0 10.0 15 - 80 10.0 30 25.0 5.0 
Calcium - - - 0.015 0.25 - - 0.02 - 0.5 9.0 
Magnesium  30 4.7 5.0 4.0 13.0 - 35 8.0 5 5.0 14.0 
Chloride 15 15.0 - 51.03 41.5 - - 30.04 20 1.0 - 
Phosphate 50 57.6 25 - - 60  - 25 25 0.8 
Sulfate 30 4.7 5.0 - - - 40 - 5 - 4.0 
Bicarbonate  9.3  - - - - - - - 25.0 
Glucose 25 1.9  - - - - - - 10.0 16.0 
Gluconate - - - - - - - -  85 95 
Glutamic acid - - -  20.0 - - - - - - 
Raffinose - - 30.0 - - - - - 30 - - 
Lactobionate - - 100 - 80 - - - 100 - - 
HES (g/L) - - 50 - - - - - - 50 - 
Citrate - - - - - - 55 - - - - 
Histidine - - - 180.0 30.0 - - 124.0 - - - 
Adenosine - - 5.0 - - - - - 5  5.0 
a-ketoglutarate - - - 1.0 - - - 2.0 - - - 
Adenine - - - - - - - - - 5.0 5 
Pyruvate  - - - - - - - - - - 0.2 
Allopurinol - - 1.0 - - - - - 1 1.0 1.0 
Glutathione - - 3.0 - 3.0 - - - 3 3 3.0 
Mannitol - 32 - 30.0 60.0 - 185 30.0 - 30 - 
Tryptophane - - - 2.0 - - - 2.0 - - - 
Ribose - - - - - - - - - 0.5 - 
HEPES - - - - - - - - - 10.0 - 
PEG-35 - - - - - - - - 0.03 - 8 
Amino acids  - - - - - - - - - - 11.0 
Phenol red - - - - - - - - - - 0.07 
N-Acetylhistidine - - - - - - - 57.0 - - - 
Sucrose - - - - - 140 - 33.0 - - - 
Aspartate  - - - - - - - 5.0 - - - 
Glycine  - - - - - - - 10.0 - - - 
Alanine - - - - - - - 5.0 - - - 
Arginine - - - - - - - 3.0 - - - 
Deferoxamine  - - - - - - - 25.0 - - - 
LK 614 - - - - - - - 7.5 - - - 
pH - 7 7.4 7.2 7.3 7.1 7.1 - 7.4 7.4 7.4 
Osmolality 
(mOsm/kg) 
- 375 320 310 320 310 400 - 320 - 320 
Relative price (US$) - 275 200 181 228 - - - 184 200 - 
Ta bl e 3  Compositi on of c ommon pres erva ti on sol utions .  PBS: Phos pha te Buffered Suc ros e.  Uni ts 
of s olutes a re in mmol /L unl ess  s ta ted otherwis e. Da ta  is  c ollated fr om s everal 
s ourc es[62,751,762–767]. 
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1.7.1.5 Comparison of Solutions for Cold Storage in Kidney and Pancreas Transplantation  
Kidney  
UW solution remains the most widely used preservation solution for kidney transplantation 
worldwide (See Figure 17). In the UK 2012 Guidance to the National Organ Retrieval Service 
recommended UW solution use for all in-situ perfusion during DCD organ retrieval, especially in 
multi-abdominal organ retrieval (liver, kidney, pancreas or liver and kidney), while for kidney alone 
Marshall's solution is an alternative to UW. In DBD donors apart from multi-organ kidney, pancreas, 
and liver retrieval where UW is preferred, Marshall's Citrate or UW solution is recommended. For 
back table perfusion and SCS packing UW is preferred for the liver and pancreas, while Marshall's or 
UW solution can be used for the kidney [768]. In the UK Marshall's citrate is the most commonly 
used preservation solution, largely on account of its relatively low cost [769]. 
 
Despite the widespread use of UW solution worldwide in organ and especially kidney preservation 
from DCD donors, there is conflicting evidence for on benefits of UW compared to other SCS 
preservations solutions.  
 
Recently a meta-analysis of 15 prospective trials including 3584 kidney transplants systematically 
examined effects of various preservation solutions on DCD kidney outcome - specifically DGF[770].  
Euro-collins was associated with a higher risk of DGF than UW and HTK in two RCTs each 
respectively. There was an equal risk of DGF when using UW compared with Celsior (3 RCTs) and HTK 
(2 RCTs). Only two RCTS compared UW to HTK (no meta-analysis possible) both reported similar 
rates of DGF. Unfortunately there was limited data regarding other comparisons and outcomes to 
form any further conclusions but the data does suggest there is no difference in the incidence of 
DGF with the use of the three dominant solutions Celsior, HTK and UW.   
 
A number of retrospective trials have also examined outcomes with UW preserved kidneys 
compared to HTK. A recent single centre retrospective review reported that equivalent patient 
survival, allograft function, rejection , and graft survival at 2 years compared to UW. HTK use 
however conferred a higher risk of early (<6 months) allograft loss, attributed to PNF, and exclusively 
in ECD allografts. Suggesting HTK may not be suitable for use with ECD donors[771]. Similarly 
analysis of the UNOS database for DBD/DCD kidney transplants showed no increased risk for DGF, 
but an increased risk of death-censored graft survival for allografts preserved with HTK (n=5728) 
133 
 
versus UW (n=15898)[741]. Based on this recent data the routine use of HTK in abdominal organ 
retrieval, especially from ECD donors, has come into question. 
 
A recent single centre retrospective review of DBD/DCD kidney transplants from France comparing 
UW (n=610) to Celsior (n=201) preservation found similar allograft function at 1 month and at 1 
year, without a difference in 5y survival[772]. With similar results from another retrospective 
analysis, with no difference in DGF or rejection, nor graft and patient survival at 3 years[746]. 
 
 
 
Figure 17 Cold s tora ge s oluti ons  in us e in the Eurotra ns plant Regi on a nd the US. (A) Cold 
s tora ge s oluti ons  i n Eurotrans plant region in dec eas ed donors fr om 1985 –2005. (B) Cold s tora ge 
s oluti on i n the Uni ted Sta tes  i n dec eas ed donors  from 1995 –2005. Ada pted fr om Maa thuis et al . 
[736]. 
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Pancreas 
Belzer UW is the most commonly used SCS preservation solution in the world for pancreas 
preservation[682]. It is also the only  solution recommended for pancreas retrieval in the UK[768]. 
Potential alternatives to UW are Celsior and HTK, and several investigators have examined their 
potential use in clinical preservation.  
 
The largest published retrospective review comparison of HTK (n=258) vs. UW (n=50) use for 
pancreas preservation from the University of Indiana reported equivalent outcomes in terms of graft 
function, survival, and patient survival with each solution[773]. Similarly the only RCT comparing UW 
(n=27) to HTK (n=41) for pancreas preservation recently reported similar graft and patient 
outcomes[774].  
 
Analysis of registry data however from UNOS of all pancreas transplants performed in the US 
between  2004 and 2008, of allografts preserved with HTK (n = 5728) vs. UW (n = 15 898) indicated 
that despite no effect on DGF, there was an increased risk of death-censored graft loss, 
predominately for loss after 12 months[741]. This registry data is supported by a recent 
retrospective analysis that highlighted an increased risk of pancreas allograft DGF, and post-
operative complications (e.g. graft thrombosis) in HTK preserved allografts compared to UW, but 
with no impact on graft or patient survival[775]. This registry data must however be considered with 
caution regarding thrombotic complications because as mentioned anti-coagulation is not uniform in 
practice. A further retrospective comparison in 2 centres in Michigan reported similar graft and 
patient survival, with similar allograft function at 90 days, but with more acute rejection within the 
first 180 days with HTK use(25% vs. 9.8%) vs. UW. [776] .  The worrisome reports from these 
analyses, despite other evidence indicating an equivalency of HTK to UW are likely to prompt 
surgeons to remain cautious of HTK and prefer UW. 
 
Equivalent outcomes for UW and Celsior in pancreas transplantation have been reported by two 
RCTs[777,778]. Both were small studies however and a power calculation was not conducted to 
determine if patient numbers were sufficient. A further comparative trial demonstrated similar 
equivalency, however the where significant differences in characteristics between groups such as 
recipient age and BMI, and surgical technique employed that could have confounded and biased 
results[779]. With more use of DCD donor organs with lengthier WITs, and ECD donors of increasing 
age, the effect of co-morbidities and ischaemic damage on these organs is increased with the 
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potential for inferior function and survival after transplantation.  Considering the dominance of SCS 
preservation methods the past 4 decades, and the many transplant programmes facilitated by this 
effective form of preservation, the challenge of maintaining allograft viability in the face of these 
increasing numbers of ECD and DCD organs that are being used worldwide to expand donor pools 
has most likely reached the limits of basic SCS preservation. 
 
Despite the emergence of numerous new SCS preservation solutions designed to address 
mechanisms of this injury, SCS at the most effective level only slows the extent of ischaemic damage. 
To improve organ viability a more dynamic and active form of preservation is needed to both fulfil 
the metabolic needs of the organs, as well as intervene and prevent damage during reperfusion. 
HMP of organs is a preservation modality that can potentially address the needs of such as strategy, 
and many groups have moved towards machine perfusion revisiting its possibilities in clinical 
practice. 
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1.7.2 Machine Perfusion Organ Preservation 
 
The growing need for kidney transplantation stems from it being the optimal treatment for patients 
with end-stage renal failure[780] and providing the best clinical outcomes, optimal quality of life and 
cost savings when compared with other modalities of renal replacement therapy[2]. In the UK in 
2005 approximately 40000 adults were receiving renal replacement therapy – a 28% increase in the 
number of patients since 2000, with median patient age for the start of replacement therapy 65 
years. In patients on replacement therapy the 1 year survival rate was 79%, with 5 year survival rates 
depending on patient age; 58% if aged 18-34, and 12% if greater than 75 years[4]. Comparatively the 
most recent 1 and 5 year patient survival rates for kidney transplant recipients in the UK stood at 
96% and 83% respectively. Despite the demonstrated advantages of transplantation, the full 
potential of these benefits cannot be obtained due to the severe shortage of donated kidneys [781]. 
Recent strategies to improve access to organs suitable for transplantation include increasing 
utilization of kidneys from deceased donor cohorts previously considered unsuitable for 
transplantation, and development of newer methods of preservation superior to SCS, specifically 
HMP as a tool for organ viability assessment and optimization.    
 
1.7.2.1 The Need for Improved Preservation 
Efforts underway to expand the potential donor pool have included use of ‘Expanded Criteria’ (ECD) 
or ‘marginal’ kidney donors, as well as increasing use of kidneys from non -heart beating donors 
(NHBD – now donation after cardiac death, DCD). According to the United Network for Organ 
Sharing (UNOS) marginal or ECD kidneys are from donors aged above 60 years of age, or above 50 
years of age with two or more of: HTN, history of CVA, or terminal creatinine levels greater than 133 
micromoles/litre. NHBD or DCD donors are classified by the Maastricht criteria. The majority of 
kidneys from DCD donors are from Type II (cardiac arrest with unsuccessful resuscitation) and III 
(expected cardiac arrest / withdrawal of treatment) Maastricht categories. DCD kidneys thus may 
experience prolonged periods of warm ischaemia, and this manifests as higher rates of post-
operative graft dysfunction[782], specifically delayed (DGF) >80%, and primary (PNF) >9%, non-
function in transplant recipients of Type II category kidneys; compared to 23% DGF in cadaveric 
heart beating donors[783]. Similarly kidneys from marginal and ECD donors are presumed to be of 
compromised quality and more susceptible to ischaemic injury, and when used in clinical 
transplantation are also associated with increased rates of both DGF and PNF when compared to 
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non-marginal donor kidneys[784]. DGF itself necessitates continued dialysis, and is associated with a 
then increased risk of acute rejection and poorer long term outcome [736]. 
  
Almost 100,000 patients are registered on the United States organ transplant waiting list awaiting a 
suitable kidney[785]. In the UK the number of patients awaiting a kidney transplant has risen by 16% 
since 2001 with 5881 patients currently on the national kidney transplant waiting list [6], with 2804 
new registrations, and 2142 deceased donor kidney transplant performed in 2013-2014. The 
majority of patients wait approximately 3 years to receive a kidney. Of a total of 1243  deceased 
kidney donors, 521 were DCD donors, and 821 transplants resulted from such donors; an annual 
increase of 10%, and an increase of 558% over the last decade. The DCD donor cohort is the largest 
growing group of donors. In comparison the number of DBD kidney transplants is stable having risen 
only 2% to 1321 transplants in 2013 since 2004. Overall only 83% of DCD kidneys retrieved were 
transplanted, compared to 87% of DBD kidneys.  
 
Furthermore deceased donors profiles are changing with more donors trending to be classified as 
ECD being older (37% >60 years of age vs. 14% in 2003), with higher a BMI (24% > 30 BMI, vs. 16% in 
2003), and subsequent more co-morbidities that will affect transplant outcome[9].    
 
With the use of ECD and DCD donors to meet the transplant demand, strategies are needed to 
optimize the viability of donated kidneys and ensure they function to the best of their abili ty. 
Optimising organ viability begins with choice of preservation method. Currently there are two 
dominant methods for preservation – SCS and HMP. 
 
As discussed in previous sections SCS involves flushing the retrieved organ with a preservative 
solution  - commonly Marshall’s hypertonic citrate (Soltran, Baxter Healthcare) or Belzer UW 
solution (Viaspan, Bristol Myers Squibb), and then packing on ice for transport. SCS preservation 
relies on the suppression of cellular metabolism via hypothermia as the organ is flushed free of 
blood, and replaced by the infused cold preservative solution. Most centres in the UK use SCS to 
preserve kidneys for transplantation. This method of preservation however was developed in an era 
of younger donors with higher quality organs[736] and with the recent trend of diminishing 
availability of heart beating donors, and increasing reliance on marginal and DCD organs, the 
limitations of using SCS for effective preservation is thought by many in the field to have been 
reached. 
 
138 
 
At present a kidney allograft may be preserved with SCS and retain viability up to 24 hours in clinical 
scenarios and theoretically 120 hours for research purposes (see Table 4).  
 
 Cl i nical  (hours)  Experi mental  
(hours )  
Opti ma l SCS Solution  
Ki dney 24  120  <24  h: UW, HTK, PBS 
>24 h: UW 
Pa nc reas 12  96  UW, HTK 
Li ver  12  48  UW, HTK 
 
Ta bl e 4  Current s ta tus  of clinic al a nd experi mental col d s tora ge pres erva ti on  of abdominal 
gra fts . Ada pted from 'tHa rt et a l . [786]. 
 
Increasing cold ischaemia time is associated with delayed graft function, and post operative 
complications in liver, cardiac, pancreatic, and renal allografts[787] at transplantation. As mentioned 
with current initiatives to expand donor pools, marginal organs will be increasingly more prone to 
ischaemic injury, and preservation techniques developed for use with ‘ideal’ grafts may be 
inadequate for these more susceptible organs. This is invariable with the case of recipients of kidney 
grafts preserved with conventional cold storage from DCD donors who experienced rates of primary 
non-function, and delayed graft function 2-4x as high as recipients from DBD donors[788]. HMP as a 
method of preservation that may provide additional benefit in such marginal allografts [789]. 
 
1.7.2.2 Historical Development of  Machine Perfusion  
One of the first attempts at isolated organ perfusion was by Langendorf in 1895 when he devised a 
simple non-circulating organ perfusion apparatus consisting of a medium reservoir and a siphon tube 
connected to the organ, with the perfusate driven by gravity.  
Development of perfusion techniques as a method to preserve organs outside the body to make 
organ transplantation a potential reality really only began after the introduction of the first 
successful technique for vascular anastomosis by Alexis Carrel in the early 1900s. By the 1930s Carrel 
in collaboration with famed aviator and innovator Lindbergh after 10 years of work successfully 
designed one of the first ever sterile all glass pulsating perfusion apparatus [790] to extracorporeally 
perfuse a whole organ (Figure 18). This innovation gained both Carrel and Lindbergh international 
fame and paved the way for Carrel being awarded  the Nobel prize for Physiology and Medicine  in 
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1912. Research into organ perfusion and preservation techniques was halted with the advent of 
world war II and it was only in the 1960's that interest in organ perfusion resumed.  
 
Figure 18  Model  of a Li ndbergh glass perfusion pump (l eft) a nd sc hema tic of Li ndbergh's 
per fus ion apparatus dated 1966.  Ada pted from Cowa n et a l . [791] 
 
In the early 1960s a group at the Naval Medical Research Institute were able to recreate the 
perfusion apparatus Carrel had developed 30 years previously, and successfully publish notable 
articles on mammalian ex-vivo perfusion[790]. Finally Carrel and Lindburgh’s original work gained 
widespread recognition at the Tissue Culture Association meeting in Miami in 1964.  That same year 
Lillehei and his associates published they had successfully preserved in-vitro for 24hours a canine 
kidney which functioned normally on re-implantation in the original animal[790].  
By 1965 Belzer and Najarian had started a kidney transplant program for living and decreased 
donors in San Francisco. It was here that Belzer began what would be the most important 
development in research into machine organ perfusion. In contrast to the glass Lindbergh perfusion 
apparatus which incorporated a gas-driven and gravity based pump system for perfusion, the Belzer 
apparatus incorporated two mechanical pumps. Use of this relatively novel technology made the 
apparatus much larger than Lindbergh’s pump, at the size of motorcycle, but which still remained 
relatively transportable, with use of a specially modified truck (Figure 19). Canine experiments of 
renal transplantation using HMP preservation for 72 hours showed promising results and two years 
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later the first human cadaveric kidney transplant preserved by HMP for 17 hours was performed. 
The graft functioned immediately and HMP became a distinct reality. Several more successful 
transplants followed in the next few years and by the early 1970s Belzer unsuccessfully applied HMP  
to livers and hearts.[790].  
 
Fi gure 19  Photograph of the Bel zer  Per fusion Ma chine. Ada pted from Bel zer  et a l .  [792]. 
 
By the mid 1970s the development of an effective SCS solution by Collins that successfully met the 
clinical requirements for renal transplantation saw SCS, rather than HMP, rapidly adopted by most 
clinical transplant centres around the world [18,790].   
With the development of improvement of liver and pancreas transplantation in the 1980s after 
introduction of newer immunosuppressive agents Belzer once more attempted to expand HMPs use 
in clinical transplantation. Initial forays into pancreatic perfusion were promising but technical 
difficulties left further work abandoned, and HMP remained a clinical entity only for renal 
transplantation for the next  20 years [18,790].  
1.7.2.3 Machine Perfusion in the UK  
Though HMP continued to be used in isolated centres in the UK, US and Europe, over the past two 
decades, due to technical, logistical, and economics costs of instituting and running HMP systems 
SCS – which seemed to be the cost effective method to provide sufficient preservation – was the 
dominate method of organ preservation the world over [789]. The potential benefits of HMP over 
SCS have however led to a recent resurgence of interest in machine organ preservation and its use in 
clinical practice (Figure 20). The most recent data suggests that 25-35% of all kidneys in the US 
undergo HMP[793], with and up to 67% of DCD donor kidneys [10].  
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Figure 20  Us e of HMP and SCS in the Uni ted Sta tes between 1988 a nd 2005 . Chart is  bas ed on 
the Orga n Proc urement a nd Trans planta ti on Network da ta ; Oc tober  2006 . Rec ent da ta fr om 
2009 s uggests HMP us e has i nc reased to 36%.  Ada pted from Ma a thuis  et a l . [736] 
 
 
Currently in the UK out of 21 kidney transplant centres in England and Wales 8 centres report use of 
machine perfusion for kidney preservation in clinical practice, and according to the BTS between 
2000-2007 2% of all kidneys from deceased donors underwent HMP, rising to 20% of kidneys from 
the DCD subset[4]. Comparatively in the US the use of HMP increased substantially and by 2008 data 
from the Organ Procurement and Transplantation Network showed 20% of all kidneys in the US 
underwent HMP, including 65% of DCD (non-ECD) kidneys, and 50% of all ECD kidneys[794]. The 
renewed interest in HMP lies in the merit for the potential ‘rescuing’ of marginal, and DCD kidneys 
that are increasingly being used in clinical practice[795]. HMP provides a viable conduit for organ 
viability assessment and modulation, in a subset of the donor pool (DCD and ECD donors) that is 
likely to increase in size over the ensuing years as the waiting li st demand for organs increases. The 
ability to evaluate these organs, and select organs for transplantation based on viability could 
significantly increase the number of available organs in the donor pool.  
 
In clinical practice a kidney would be retrieved, flushed with cold storage solution, and either 
immediately attached to and perfused on a portable perfusion device, or transported using SCS back 
to the base hospital for perfusion on bench-top perfusion machine. In both settings multiple 
parameters related to perfusate flow through the kidney can be measured. These perfusion 
dynamics include – 1) pulse pump rate, 2) perfusate temperature, 3) perfusion pressure (systolic, 
diastolic and mean pressures), 4) real-time flow and 5) vascular resistance.  In addition to the 
SCS
HMP
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capability of monitoring perfusion dynamics, the circulating perfusate can be sampled for levels of 
damage and injury biomarkers. In both instances perfusion dynamics and biochemical perfusate 
analysis have been described in the assessment of organ viability and suitability for organ 
transplantation. 
 
1.7.2.4 Theoretical Basis of  Hypothermic Machine Perfusion and Graft Re -conditioning 
HMP of an organ generates a controlled re-circulating flow of preservative solution at hypothermic 
temperatures in the 0–4°C range[796]. This continuous flow permits perfusion of the organ 
promoting a washout of blood and equilibration with the perfusate medium; delivering oxygen and 
nutrients and removing toxic metabolites. In addition it allows for the possibility of real -time viability 
assessment, provision of metabolic support during perfusion, and the potential for addition of 
pharmacologic agents to the circulating perfusate that can potentially improve perfusion parameters 
and organ viability[797]. The benefits of HMP are summarised schematically in Figure 21. 
Importantly retrospective reports and evidence of lower rates of DGF in machine pumped kidneys, 
have been augmented by the recent publication of an large international prospective RCT, 
confirming a definitive and significant benefit on DGF and both 1 year and 3 year survival rates in 
machine perfused kidneys, especially so in ECD kidneys, compared to SCS [798].   
 
HMP is based on the concept of preserving the organ in a ‘better environment’[799]. Similar to SCS 
HMP slows down metabolism, reducing oxygen requirements and  ATP depletion, by circulating a 
cold preservative solution through the organ via pulsatile or non-pulsatile flow, theoretically 
providing nutrients, and facilitating washout out of toxic metabolites and free radicals.  
 
The mechanisms of HMP improving allograft viability are based on the concepts of hypothermic 
reconditioning[800]. Evidence suggests that HMP acts by preserving allograft energy metabolites, 
acting to suppress programmed cell death and instead promote autophagy, and limiting endothelial 
activation that upon reperfusion would potentiate a greater inflammatory response. [801]  
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Figure 21   Sc hema tic  summary of the i mporta nt ben efi ts of ex -vivo HMP for  renal pres erva ti on 
prior to tra nspla nta tion. Benefi ts  ca n be di vided into physi ological a nd theoreti cal  vs . clinical 
[802]. 
 
HMP and Oxygen 
An important aspect of HMP is perfusate oxygenation[803,804]. The 1st generation of commercially 
available renal perfusion machines (RM3 from Waters Medical Systems, Lifeport from Organ 
Recovery System) do not have an inbuilt hollow-fibre in-line oxygenator within the perfusion circuit. 
Hollow-fibre in-line oxygenators are used in cardiopulmonary bypass machines and are an effective 
method of perfusate oxygenation. Both machines depend on atmospheric pressure to oxygenate the 
perfusate, the RM3 unit by passively sweeping room air (21% O2) over the semi-permeable 
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membrane within the cassette at about 2–4 L/min, while the LifePort has no active or passive 
method of perfusate oxygenation and instead relies directly on atmospheric pressure.  
 
From commercial literature the 2nd generation of renal perfusion machines by these companies 
have been designed with the ability to oxygenate the perfusate. These apparatuses have only 
recently gained FDA and CE approval, and as of yet no reports have been published on their use 
clinically or in research settings.  
 
In a recent study comparing the two 1st generation machines, the RM3 and Lifeport, re searchers 
performed fluid gas analysis on the perfusate during 24 hours HMP of canine kidneys[805]. 
Oxygenation was by atmospheric pressure with both machines, and in both cases such application 
provided a perfusate PO2 between 22-24 kPa (175-180 mmHg). At hypothermic temperatures (4-7°C) 
metabolism is sufficiently suppressed that such oxygenation would theoretically be suitable for the 
remaining active energetic processes [722,730].  
 
Oxygenation during HMP is not a new idea when three decades ago oxygenated perfusate during 48 
hours of HMP was shown to have restored 50% of the ATP:ADP ratio in ischaemically damaged 
rabbit kidneys[806,807]. Furthermore a number of studies have reported that with non-oxygenated 
HMP ROS mediated damage (measured by lipid peroxidation) is elevated despite better graft 
function compared to SCS preservation, suggesting hypoxic injury during HMP may be 
implicated[808–810].  
 
Several studies using porcine auto-transplantation models have demonstrated approximately 20 
hours of actively oxygenated HMP to be superior to SCS, with improved cortical microcirculatory 
perfusion, less proximal tubular damage, less ROS mediated damage, less cytokine expression, and 
better allograft function after transplantation[811,812].  Buchs et al.[813] demonstrated using 
magnetic resonance imaging that oxygenated HMP restored ATP levels in ischaemically damaged 
porcine DCD kidneys (30 minutes WIT), but with no benefit in non-damaged kidneys. There are 
conflicting reports however where 21 hours of oxygenated vs. non-oxygenated HMP in a porcine 
kidney autotransplantation model demonstrated no benefit to active oxygenation, with equity of 
functional outcomes[814].  
 
Further evidence of the benefit of hypothermic oxygenation however is found from liver studies 
where spectroscopy demonstrated re-oxygenation of cytochrome oxidases in SCS preserved rat 
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livers after 2 hours of oxygenated HMP[815]. In these livers mitochondrial dysfunction upon 
reperfusion was avoided, which is central to restoring normal physiological tissue function, and 
maintaining tissue homeostasis. 
Hypothermic oxygenation after SCS also preserved mitochondrial and cytosolic HSP70 during 
isolated rat liver perfusion, with early resumption of aerobic metabolism and exocrine function[816]. 
Because mitochondrial damage is critically linked to mechanisms of programmed cell death, 
ameliorating mitochondrial injury through hypothermic oxygenation can avoid progression to 
cellular apoptosis and potentially necrosis, and instead initiate  autophagy and tissue 
repair[817,818].  
 
Promoting effective autophagy, permitting apoptosis, and limiting cell necrosis through hypothermic 
oxygenation may also limit activation of innate immune responses upon reperfusion. Release of 
DAMPs by necrotic cells provides ligands for innate response receptors. The high mobility group box 
B1 (HMGB-1) protein once released during reperfusion is recognised by toll like receptors (TLR-4) 
both on immune cells and also on the vascular endothelium, promoting a pro-inflammatory and pro-
thrombotic phenotype within the allograft during reperfusion. In a porcine autotransplant model 
hypothermic oxygenation reduced levels of such DAMPs (HMGB-1), as well as TLR-4 expression, and 
improved allograft performance[812].  In a similar model active oxygenation during HMP improved 
both short term and long term (3 months) allograft function, with less fibrosis and chronic 
inflammation compared to non-oxygenated HMP pumped kidneys[819] 
 
Notwithstanding it must be remembered data from the large multi-centre Eurotransplant RCT has 
also established the limited but significant superiority of non-oxygenated HMP over SCS in clinical 
kidney transplantation[820]. At present no trials have been performed investigating the efficacy of 
oxygenated HMP in clinical practice. 
 
The Endothelium 
The endothelium has a key role in IR injury. Newer research points to a vasoprotective and 
endothelial mediated effect of HMP. HMP of porcine livers reduced endothelial von Willebrand 
factor (which is upregulated in endothelial activation and IR injury), and platelet aggregation after 
transplantation. Analysis of perfusate from kidney HMP compared to the 'flush' solution from SCS 
stored kidneys demonstrated that after HMP there was Providing a potential mechanism for HMP to 
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permit a reduction in leukocyte activation and a  decrease in IR activated inflammation during 
reperfusion[821]. 
 
It is now known that endothelial gene expression is strongly influenced by vascular shear stress[822]. 
During organ retrieval and SCS the cessation of vasculature flow promotes a pro-inflammatory and 
pro-coagulatory phenotype, which could worsen IR responses after transplantation[263]. Flow 
mediated endothelial dysfunction is linked to decreased expression of the mechanosensitive 
transcription factor Kruppel-like-factor 2 (KLF-2), which normally suppresses inflammatory signals 
and cytokine production[261].  HMP has been shown to restore levels of KLF-2 compared to SCS 
during reperfusion[823]. 
 
1.7.2.5 Cl inical Benefits of  Hypothermic Machine Perfusion vs. Static Cold Storage 
The benefits of HMP compared to SCS in kidney preservation can be seen in both experimental and 
clinical studies and include improved rates of delayed graft function and patient survival. Not all 
studies however link HMP use with decreases in rates of DGF and improved patient survival. Several 
recent studies examining this comparison deserve to be mentioned.  
 
In 2003 a meta-analysis by Wight et al.  of published literature comparing SCS to HMP between 1971 
and 2001, the paper confidently concluded that use of HMP is associated with a 20% risk reduction 
for DGF compared to standard SCS (even though the studies included were small and heterogenic). 
 
In 2005 Schold et al. examined the use of HMP on ~85000 kidney transplant recipients between 
1994 and 2003 through the Scientific Registry of Transplant Recipients in the US, and reported that 
HMP use led to a significantly decreased incidence of DGF compared to SCS (19.6% vs. 26.6%), but 
without a significant effect on long term survival[824].  
 
In 2006 Matsuoka et al reported analysis on 4618 ECD kidneys registered with the United Network 
for Organ Sharing in the US between 2000-2003. Use of HMP in management of 912 ECD kidneys 
reduced the incidence of DGF (26%) compared to 3706 ECD kidneys (37%) managed with standard 
SCS. Despite kidneys allocated to the HMP group having a greater number of risk factors negatively 
affecting viability a similar 3 year patient survival rate to was evident between HMP and SCS kidneys. 
The group also concluded that the decrease in DGF may have a cost-effective benefit to offset the 
increased cost of a HMP program by decreasing need for dialysis post-operatively. 
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Not all retrospective studies however linked HMP with improvements in DGF and patient outcomes. 
In 2007 Opelz et al. in their retrospective analysis of 91674 deceased donors transplants from the 
Collaborative Transplant Study database looked at the effects of kidney preservation methods and 
times. They concluded that deceased donor kidneys should be transplanted in less than 18h, but that 
less cold ischaemia times had no effect on graft function, and suggested that HMP was not superior 
to SCS in terms of graft survival. In sharp contrast Stratta et al. published their retrospective analysis 
of 141 ECD kidney transplantation comparing HMP to SCS, and reported that despite longer cold 
ischaemia times (~24hrs for HMP vs. ~19hrs for SCS), recipients of ECD kidneys managed with HMP 
had similar survival and functional outcomes as recipients of ECD kidneys undergoing SCS – but that 
rates of DGF were markedly less in the HMP group (11% vs. 37% for SCS kidneys )[825].  
 
Also in 2007, the Oxford Transplant Unit published a retrospective record review[826] of 36 
Maastricht category III and IV DCD donor kidneys comparing HMP preservation to conventional SCS. 
With a cold ischaemia time of ~15hrs they noted immediate renal function in 72% of HMP pumped 
kidneys, compared to 11.8% of kidneys undergoing SCS, and a significantly shorter period of  
hospitalization (8 days in the HMP group vs. 14 days for the SCS group) for the machine perfused 
kidney recipients, supporting other reports on the potential cost-effectiveness of HMP. A more 
specific retrospective study published by the same group in 2008 compared clinical outcomes of 30 
recipients receiving controlled DCD kidneys (Maastricht III only) managed with HMP compared to 30 
recipients of  controlled DCD kidneys preserved by SCS. Results re-enforce their previous findings, 
demonstrating a significantly reduced rate of DGF (53.3% vs. 86.6%), shorter hospital stays (10 days 
vs. 14 days), and better short term graft function at 1, 6, and 12 months post-operatively in the 
controlled DCD HMP group than in the SCS group[827].   
 
More recently the first international multi-centre RCT in the Euro-transplant region comparing HMP 
vs. SCS in kidney transplantation was published by Moers et al. in 2009[828]. This RCT randomly 
assigned a kidney from 336 consecutive deceased (DBD and DCD) kidney donors to either SCS or 
HMP. Recipients were followed up for 1 year and showed a significant risk reduction for DGF in the 
HMP group (20.8% HMP vs. 26.5% SCS), with an improvement in 1 year patient survival for HMP 
preserved kidneys (94% vs. 90%), and 3 year (91% vs. 87%) vs. SCS kidneys. The graft survival 
advantage at 3 years in HMP kidneys was most pronounced for kidneys re-covered from ECD donors 
(86% vs. 76%), with DGF having a profound effect on graft survival in DBD kidneys, but which was 
improved by HMP preservation compared to SCS[798]. 
148 
 
 
Further subgroup analysis examining kidneys from only DCD donors (n=164) demonstrate d further 
benefit with reduced incidence of DGF (and of 4 days shorter duration) at 53.7% vs. 69.5% in HMP 
kidneys vs. SCS, and improved 1 year survival in recipients of HMP DCD kidneys[820]. HMP kidneys 
also had greater eGFR up to 1 month after transplantation, while 1-year graft and patient survival 
was similar (93.9% vs. 95.1%) compared to SCS preserved DCD kidneys, but superior in HMP kidneys 
at 3 years (91% vs. 86%)[798]. [829]  
 
Machine perfusion reduced the incidence of DGF (adjusted odds ratio: 0.43; 95% confidence interval 
0.20–0.89; P = 0.025). DGF was 4 days shorter in recipients of machine-perfused kidneys 53.7% 
(adjusted odds ratio: 0.43; 95% confidence interval 0.20–0.89; P = 0.025). DGF was 4 days shorter in 
recipients of machine-perfused kidneys (P = 0.082). Machine-perfused kidneys had a higher 
creatinine clearance up to 1 month after transplantation (P = 0.027). One-year graft and patient (P = 
0.082). Machine-perfused kidneys had a higher creatinine clearance up to 1 month after 
transplantation (P = 0.027). One-year graft and patient survival was similar in both groups (93.9% vs. 
95.1%). up to 1 month after transplantation (P = 0.027). One-year graft and patient survival was 
similar in both groups (93.9% vs. 95.1%). 
 
In the Euro-Transplant Senior Programme of kidneys from donors >65 years are preferentially 
transplanted into patients >65 years of age[830]. HMP significantly reduced the incidence of PNF 
(3.5% HMP vs. 12.9% SCS), and improved 1-year graft survival (89% HMP vs. 81% SCS), but did not 
influence DGF which (29.4% HMP vs. 34.1% SCS). Incidentally CIT was short averaging 10.75 hours 
between both groups, and HMP benefits on DGF may require longer ischaemic exposure to be 
realised. None the less when DGF had occurred, 1-year graft survival was significantly better after 
HMP compared with SCS (84% vs. 48%) 
 
In contrast to the results from Euro-Transplant a RCT conducted by surgeons at Cambridge 
University, UK in DCD kidney transplantation demonstrated no benefit to HMP, with similar rates of 
DGF (57.8% HMP vs. 55.6% SCS), and 12 month graft function between SCS and HMP cohorts[831].  
There were several fundamental differences between these two studies. In the UK study 
immunosuppression and use of UW for SCS / flushing was standardized, while in the Eurotransplant 
study participants had a choice of immunosuppression and between UW or HTK for flush and SCS 
(this reflects the nature of the Eurotransplant study which included cross border collaborations 
between a number of European countries and centres). A further key difference is timing of HMP, 
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where kidneys were only perfused once transported back (by SCS) to the central transplant centre 
from a local/regional hospital where the retrieval occurred. In the Euro-Transplant study kidneys 
were placed immediately on a machine perfusion device after retrieval, and it use of HMP 
throughout cold preservation may be necessary to achieve benefit. However several large animal 
studies have reported conflicting results for HMP re-conditioning after SCS, and the exact nature and 
mechanism of HMP benefit after a period of SCS as compared to HMP immediately after retrieval 
still need to be elucidated[823,832]. 
 
A retrospective review of high risk uncontrolled DCD (Maastricht categories 1 and 2) donor kidney 
transplantation (n=27) in Lyon, France reported superior 3 year graft survival in HMP preserved 
uncontrolled DCD recipients compared to ECD (n=30) donor kidney recipients (100% vs. 82% 
respectively), without PNF in either cohort[492]. DGF however was more prevalent in DCD vs. ECD 
kidneys (81% vs. 28% respectively).  Other outcomes (GFR and histology on protocol biopsy) were 
similar between the DCD and ECD groups at 3 years. Despite higher DGF rates with uncontrolled DCD 
allografts, 3 year function and survival was similar to ECD allografts suggesting that DGF does not 
have the same impact in DCD compared to ECD organs. These results could also be explained by the 
careful selection of the DCD donors - without past medical history (non-ECD DCD), and use of HMP, 
but suggestions that the cytokine surge in DBD may in fact contribute to outcomes after DGF have 
made[833]. 
 
Jochmans et al. reviewed the outcomes of DCD kidney transplantation (n=287, 94% controlled DCD) 
in Belgium over the 10 year period 2000-2009 [834]. Fifty-three percent of kidneys underwent HMP. 
PNF occurred in 1% and DGF in 31% of recipients. Multivariate analysis revealed SCS (vs. HMP), CIT, 
and use of HTK solution (vs. UW) were independent risk factors for the development of DGF. 
Interestingly analysis of delayed vs. immediate HMP revealed no univariate risk for DGF. Five-year 
patient and death-censored graft survival were 93% and 95% for Belgium vs. DCD kidney transplant 
recipients in the Netherlands.  
 
Recently O'Callaghan et al conducted a meta-analysis examining outcome benefits of HMP vs. 
SCS[835] in kidney transplantation. The analysis included 7 RCTs (1475 kidneys) and 11 non-RCTS 
(728 kidneys) and determined the risk of DGF was less with HMP use vs. SCS, with no effect on PNF, 
and no detectable impact on longer term graft or patient survival. Bathini et al. and colleagues 
performed a systematic review on the effect of HMP preservation vs. SCS specifically in DCD kidney 
transplantation[836]. They included 9 studies with overlap of 5 prospective studies with O'Callaghan 
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et al. and the remaining retrospective (including an analysis of UNOS registry data) or cohort based 
studies. HMP pumped kidneys from DCD donors experienced decreased DGF compared to SCS 
preserved DCD kidneys, with a trend toward improved allograft survival at 1-year in HMP kidneys. 
Both groups contest that due to the poor heterogeneity in studies (e.g. definition of DGF, 
immunosuppression regimes) and a general lack of sufficient power in available studies, and 
relatively short follow-up to-date means further study is required to assess the overall impact of 
HMP on graft function and outcome. 
 
A more recent analysis of data from the Scientific Registry of Transplant Recipients in the US 
included outcome data from all SCD (n=71,192), ECD (n=15,122), and DCD (n=8,395) donor kidney 
recipients between 2000 and 2011[837]. The risk of DGF was found to be lower with HMP. Stratified 
by the type of donor and CIT, the adjusted odds of DGF was lower with HMP across all CITs in SCD, 
for CIT>6 hours in ECD, and for 6>CIT<24 hours in DCD kidney allografts. Length of CIT is known to be 
a risk factor for DGF, irrespective of storage modality, however HMP has been shown to reduce this 
effect. A recent RCT from University of Miami group exploring effect of differing HMP durations in 66 
pairs of donor kidneys reported that longer HMP associated CIT time with HMP was beneficial vs. 
shorter HMP CIT time [838]. Longer HMP time kidneys had reduced rates of biopsy proven acute 
rejection at 12 months, with no effect on organ function (DGF, PNF), nor on graft and patient 
survival compared to short HMP time. This supports the premise that preservation strategies should 
target reducing exposure to CIT but also utilise HMP to limit the impact of any CIT on graft function.  
 
A single centre observational, retrospective review of 88 ECD kidney transplants from Barcelona 
analysed the influence of HMP (n=37) vs. SCS (n=51) on graft outcomes[839]. Univariate analysis 
revealed improved eGFR  at 48 hours post operation  (11±8 vs.16±14 ml/min/ m²; P=0.021) and at 
discharge (29±13 vs. 42±19 ml/min/m²; P=<0.0001), with reduced DGF (7±7.6 vs. 3.2±2.7; P=0.036), 
as indicated by requirement for dialysis, and shorter hospital stay (2.43±1.2 vs. 1.76±1days; P=0.006)  
in HMP preserved kidneys. While multivariate analysis confirmed a reduced rate of DGF (35.1% vs. 
47.1%; P=0.03, OR=0.34) and need for dialysis (P=0.005, OR=0.65) and also revealed a higher 1-year 
graft survival (95% vs. 84%; P=0.025, HR=1.915) in HMP vs. SCS preserved kidneys. 
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1.7.2.6 Hypothermic Machine Perfusion  and Allograft V iability Assessment  
Machine Perfusion Dynamics 
Machine perfusion improves immediate graft function, mediates improved survival rates, and 
enhances preservation of the microcirculatory integrity of the preserved organ. It allows for 
extended preservation, reversal of damage sustained through warm ischae mia time, and the 
potential for graft viability assessment through monitoring of perfusion dynamics and biochemical 
perfusate analysis. At present renal flow rate and vascular resistance are the only two accepted 
parameters used as indicators of kidney viability. Approximately 15% of all HMP preserved kidneys in 
the USA are discarded, predominately because of a high renal resistance [840], however relatively 
little information is definitively known about the true predictive value of RI and other perfusion 
characteristics on transplantation outcome or their use for selecting or discarding kidneys for 
transplantation.  
 
Several groups have published extensively on the topic of viability assessment using HMP – notably 
the Newcastle group by Talbot et al., in Japan by Matsuno et al., Guarrera et al. in the US, Kosieraszki 
et al in Poland, and Ploeig et al. in the Netherlands, however many additional centres have published 
their experiences with HMP viability assessment.  
 
The Newcastle clinical viability protocol has evolved  over  the past decade and sets criteria for HMP 
preservation and assessment of DCD donor kidneys using a unique perfusion apparatus with 
hypothermic Belzer Machine Preservation Solution (MPS) as the perfusate.  Perfusion time is 
approximately 4 hours, with perfusion pressure set at 50-55mm Hg. Viable organs are required to 
exhibit a Perfusion Flow Index (PFI – an index relating flow to pressure) of 0.4/ml/min/100g/mmHg 
or greater, with flow rates >25ml/min/100g of tissue, and a graft weight increase less than 25% post 
machine perfusion[841]. In addition levels of glutathione-S-transferase (GST, an indicator of tubular 
damage and propensity for re-perfusion injury) in perfusate are required to be less than 200IU/100g 
of kidney.  
 
In their experience use of HMP for DCD kidneys and these viability criteria increased utilization of 
DCD kidneys, and over a 24 month period increased graft survival rates from 45.5% (graft survival of 
Type II Maastricht donor kidneys using SCS, n=10) to 88.4% (n=28), and though DGF rates were still 
high[842], renal function and long term graft (and patient) survival was comparable to recipients of 
heart beating donor kidneys[782] . A modified protocol (desired perfusate GST levels changed to be 
152 
 
<100IU/100g of tissue) successfully identified poorly functioning kidneys unsuitable for single 
transplantation, but were instead utilized for dual kidney transplantation[843], and early functional 
outcomes in dual transplant recipients (n=23) at 3 and 12 months were similar to patients receiving 
a single kidney (n=115). This study demonstrates the potential use of HMP viability assessment in 
identifying kidneys suited for dual rather than single transplantation, minimizing non-use of DCD 
kidney allografts. 
 
In Japan a perfusion system known as LPS-II is used for cadaveric kidney preservation using 
cryoprecipitated AB positive plasma. Perfusion pressures are set to between 30-50mmHg, with 
perfusate circulated at 8-10oC, and pH maintained between7.4-7.6. Kidneys are selected for 
transplantation based on a minimum flow rate of 0.4 ml/min/g (40/ml/min/100g), and a concurrent 
decrease in perfusion pressure. Though subject to similar cold ischaemia times (~10hrs), kidneys 
with higher flow rates >90/ml/min/100g equated to increased rates of immediate function, and a 
decreased duration of ATN post-operatively, no incidence of PNF, compared to kidneys with flow 
rates of 40-65ml/min/100g which exhibited 25.7% PNF, and only 8.6% immediate function[844]. In 
another study using the LPS II apparatus kidneys perfusing with flow rates of 110ml/min/100g and 
an equivalent resistance index of 0.55 were successfully transplanted without incidence of DGF post-
operatively[845]. Recently Matsuno et al. used the LPS-II perfusion apparatus and these perfusion 
criteria to successfully transplant 17 uncontrolled DCD kidneys with high initial donor creatinine 
levels (>3.0mg/dl), without incidence of PNF but with instances of severe DGF[846].  
 
In Poland, Kosieraszki et al. performed a retrospective analysis of their 6-year experience with HMP 
for kidney preservation (n=234) to determine the value of each measured perfusion and perfusate 
parameter in predicting DGF. Kidneys were perfused for ~30hrs. No single parameter successfully 
predicted DGF, but flow <45/ml/min and RI of >0.44, and perfusate lactate and LDH levels (indicators 
of cell death) >1/75mmol/L and > 709U/L respectively were associated with a higher incidence of 
delayed function[847]. Kwiatkowski et al. presented long term results of renal transplant patients 
who had received a HMP managed kidney (n=227) vs. patients with kidneys preserved with SCS 
(n=188). In this non-randomised  analysis kidneys stored by HMP had improved 5y graft survival, and 
less incidence of returning to dialysis, despite longer CITs[848].  
 
In the US Polyak et al. reviewed their experience with 650 preserved kidneys in their institution 
between 1993 and 1999 (402 HMP vs. 248 SCS)[849]. HMP time was ~25hrs, systolic HMP pressure 
was ~ 60mmHg, kidneys with flow rates < 50ml/min/100g and RIs > 0.85 mmHg/ml/min/100g were 
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discarded, with idea flow rates >100ml/min/100g and RI <0.4 mmHg/ml/min/100g. They showed 
that HMP reduces rates of DGF compared to SCS (9% HMP vs. 24% SCS), especially so in ECD donor 
kidneys (14% HMP-ECD vs. 37% SCS-ECD). In addition HMP mediated a 10% increase in 1 year graft 
survival in ECD donor kidney recipients compared to SCS. Guarrera et al. from the same institution 
published data that suggested even kidneys with poor HMP characteristics (flow <80 ml/min/100g 
and RI >0.4 mmHg/ml/min/100g) can still be transplanted with adequate outcomes, but that such 
perfusion data should take into account other donor variables[850]. This supports material from 
Mozes et al. who reviewed perfusion dynamics of discarded kidneys. HMP perfusion criteria at 4 
hours are most frequently used at his institution with decisions regarding acceptance for transplant. 
He concluded that kidneys perfusing with RI <0.6 mmHg/ml should not be discarded based solely on 
suboptimal perfusion parameters. Kidneys with RI of 0.4-0.6 demonstrated similar outcomes as 
transplanted kidneys with RI <0.4. Refining perfusion criteria they decreased the discard rate of HMP 
kidneys in their region from 20% in 2002 to 12% and 3% in 2003 and 2004 respectively[851].  
 
Sellers et al. also in US, compared outcomes of 568 HMP vs. 268 SCS managed kidneys between 
1990 and 1995. HMP time was ~20-24 hrs. Overall graft survival was similar for both groups – 
despite worse donor and recipient characteristics in the HMP group. Kidneys with >40 minutes of 
WIT undergoing HMP had higher survival rates vs. SCS kidneys with >40mins WIT. DGF rates were 
higher after SCS (20.2%) vs. HMP (8.8%)[852].   
 
In Spain, Suarez et al. use a Waters RM3 Perfusion Device to pump ECD donor kidneys using a 
modified Belzer MPS solution at 4oC – with added mannitol, bicarbonate, and vasodilators – at a 
perfusion pressure of 40-45mmHg, for ~17hrs[853]. RI, in conjunction with renal biopsy, was the 
criteria to determine transplant suitability, and kidneys with RI > 0.4 were not used for 
transplantation. In a small study use of these criteria increased utilization of ECD kidneys otherwise 
considered unsuitable for transplantation, with no incidence of PNF post-operatively. Continuing 
their work Peri et al. from the same institution in Spain recently published a report detailing their 
experience with ECD donor kidneys and HMP between 2004 and 2007[854]. From 292 ECD donors 
(206 brain death, 86 DCD / Maastricht 2) one kidney underwent SCS and one HMP. Kidneys were 
discarded if RI > 0.4 mmHg/ml/min. Discarded kidneys had lower flow rates compared to 
transplanted kidneys (56 vs. 78.8 ml/min). Length of hospital stay was lower in the DCD HMP group 
(13 days) vs. DCD CD group (35 days) and though HMP kidneys experienced longer CIT than SCS 
controls they showed no significant differences in renal function. 
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Similarly in Russia, Reznik et al. describe a decreasing RI, with an increasing renal flow rate, as a 
reliable predictor of viability in uncontrolled DCD kidneys (in conjunction with adequate biopsy 
histology). In a small study comparing SCS (n=17) with HMP (n=21) DCD kidneys displaying 
immediate function post-transplantation reached a suitable RI after 1-3hrs of HMP, while kidneys 
that experienced DGF required 6-12hrs of HMP to reach acceptable levels, prompting the conclusion 
that up to 10hrs of HMP may be required for ischaemically damaged DCD kidneys to be recovered 
for transplant[855]. 
 
Patel et al. performed several retrospective reviews of approximately 268 kidneys that underwent 
HMP and transplantation at the University at Buffalo (SUNY), New York.  HMP kidneys demonstrated 
improved perfusion dynamics over time, with average flow reached by 2 hours[856]. Kidneys with 
initial poor HMP dynamics but with early improvement by 2 hours were less likely to be discarded, 
but demonstrated higher incidence of DGF compared to kidney exhibiting ideal perfusion from start 
of HMP. Further analysis from the same group observed higher rates of DGF (75%) with HMP kidneys  
perfused at higher pressures (> 23mmHg, n=24) vs. lower pressures (<23 mmHg, n=49), with overall 
higher resistances in high pressure perfused kidneys, but comparable flow rates[857]. Graft survival 
at 1 year was similar. Perfusion pressures can be increased to support lower flow rates but may not 
be beneficial, use of the PFI calculation as advocated by Talbot et al. may minimize perfusion at 
higher pressures which may be detrimental to organ function[858]. They also correlated perfusion 
dynamics during HMP with results of pre-implantation biopsies - classified as Normal (n=60) or 
Abnormal Histology (n=57, glomerulosclerosis or arteriosclerosis >10% in sampled glomeruli or 
arterial lumens/intrarenal arteries respectively) [859]. Allografts with abnormal pre-implantation 
biopsies showed significantly lower flow and higher resistances. Pathology did not predi ct DGF, but 
1-year graft survival (96.2% vs. 80%) and eGFR (58 vs. 48 mL/min) was lower in kidneys with 
abnormal histology, though these metrics did not reach significance. Despite abnormal pathological 
findings kidneys improving flow parameters may allow transplantation of allografts previously 
considered for discard with acceptable results. 
 
Analysis from the Euro-Transplant HMP RCT of 336  DCD and DBD kidneys high RI at the end of HMP 
was an independent risk factor of DGF (odds ratio [OR] 38.1; 95% CI 1.56–934; P=0.026) however the 
predictive value of RI on DGF was poor (AURoC 0.58)[860]. RI was also found to be an independent 
risk factor for 1-year graft failure (hazard ratio 12.33 [1.11–136.85]; p=0.004). 
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A retrospective analysis of 440 transplanted DCD kidneys preserved by HMP was conducted at the 
University Medical Centre in Maastricht, Netherlands[861]. RI at the start of machine perfusion was 
significantly and independently associated with both PNF (OR 2.040, 95% CI 1.362–3.056; p = 0.001), 
and DGF (OR 2.345, 95% CI 1.110–4.955; p = 0.025). However the predictive quality was moderate 
(0.609, 95% CI 0.538–0.681), and there as not association between RI and  graft nor patient survival.  
 
A retrospective analysis of 115 deceased donor kidney transplants (85% DBD) from Romania 
correlated using linear regression HMP Resistive index to Doppler US assessment of renal vascular 
resistance at 1 day post transplantation(R=0.813, R²=0 .661, adjusted R²=0.657, F(1.80)=156.34, 
p<0.0001, Std. Error of estimate: 0.04166)[862]. This important study demonstrates the prognostic 
use of the HMP resistance in predicting allograft perfusion post transplantation. Poor renal vascular 
resistance post transplantation is associated with DGF and poor graft survival, possibly due to 
detrimental effects of IR injury on renal microvascular perfusion. Thus HMP may confer benefits on 
post implantation function by better preserving the microvasculature during cold preservation and 
facilitating better vascular perfusion once transplanted. 
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Renal  Machine Perfusion Perfusate biomarkers 
Research has focused on the use of machine perfusate biomarkers for pretransplant in vitro 
assessment of kidney viability[863–868] . Evidence remains controversial and based largely on 
animal models. Biomarkers most likely will be incorporated in clinical viability scores, rather than be 
used in isolation. Some of the more-established  work has focused on GST, lactate dehydrogenase  
(LDH), N-acetyl-β-D-glucosaminidase (NAG), alanine aminopeptidase,  aspartate aminotransferase, 
and heart-type fatty acid binding protein[869]. 
Glutathione S-transferase 
GST is found in the kidneys and is involved in detoxifying metabolites and conjugating glutathione 
[863–865].  The 2 subtypes, α-GST and π-GST, found in proximal and distal tubules are released 
during ischemia. Proximal tubules, being metabolically more active, are more vulnerable to hypoxia, 
making α-GST a more-sensitive  marker[864], and a potential tool for pretransplant assessment of 
DCD kidney viability. Quantification of total GST is technically easier and often is used as a surrogate 
marker of α-GST levels[870,871] . 
Initial reports on GST use in organ viability assessment were promising. During HMP, α-GST levels 
correlate with warm ischemia time; with prolonged ischemia being associated with higher 
levels[866,867]. Similarly, levels are lower in functioning, compared to non-functioning, grafts from 
DCD donors[866,867]. Further research into functioning DCD kidneys demonstrated that GST levels 
are significantly higher at the end of HMP in kidneys with DGF compared with kidneys with 
immediate function[870].  Moers et al., were the first to show from Eurotransplant data that GST 
levels, although related to warm ischemia time  also represent an independent risk factor, but with 
poor predictive value for DGF [870,872]. A systematic review of 23 studies from the US reported that 
GST, among other biomarkers is significantly associated with DGF[873]. However recently it was 
suggested that only the  π-GST subtype is independently associated with DGF[874]. 
Other research has shown isolated cases of high GST levels occurring in functioning DCD grafts, 
showing that GST levels cannot necessarily be considered in isolation [869]. Similarly, based on their 
experience with a case of immediate graft non-function in a kidney with normal GST but low flow 
rates, Balupuri et al also suggested other factors should be considered in addition to GST levels 
[875]. They postulated that GST may originate from capillary beds, and that low levels of GST may be 
related to small capillary mal-perfusion, not necessarily reflecting ischemic damage, and 
recommended that a flow rate of at least 50 mL/min/100 g kidney is required for GST levels to be 
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clinically relevant. The Newcastle clinical viability protocol recommends a GST content at 4 hours of 
less than 200 IU/L/100 g of renal mass[876]. 
Lactate  dehydrogenase 
LDH  is a nonspecific marker of cellular injury. It was hoped that its level in kidneys undergoing HMP 
would reflect the extent of ischemic injury [869]. However, research by Daemen et al did not confirm 
a significant correlation between LDH and warm ischemia time or graft outcome[867]. In a group of 
DCD functioning grafts, this biomarker was found to be a good discriminator of immediate versus 
DGF, but not independently predictive of graft failure within the first year post-transplant[870]. LDH 
use as a biomarker may be of value in the context of other determinants of graft function, but it is 
unlikely to have independent predictive value[872].  
N-acetyl-β-D-glucosaminidase 
NAG is a lysosomal enzyme. There is limited work looking at NAG levels in renal perfusate of HMP 
grafts and their correlation with ischemic damage [869]. Research by Moers et al. showed that like 
LDH, NAG levels constituted a risk factor for DGF but have no independent predictive value  of graft 
failure in the first year post-transplant[870]. 
Alanine aminopeptidase 
Alanine aminopeptidase  is a peptidase located in renal cells and involved in cell regulation. Like GST, 
it is excreted in the urine secondary to renal tubular damage and has been investigated as a 
pretransplant marker of posttransplant renal viability [869]. In DCD kidneys alanine did demonstrate 
a correlation of alanine aminopeptidase  with DGF, but not PNF, and but with a poor predicative 
value [870,877]. 
Aspartate aminotransferase 
Aspartate aminotransferase  is an enzyme seen in hepatic and renal parenchymal cells that has been 
studied in the context of HMP. Most research has focused on its use in liver transplant, but there is 
also evidence for its applicability in renal transplants [869]. Higher levels are associated with an 
increased risk of delayed, as opposed to immediate, graft function after transplantation but with a 
poor predictive value[870]. 
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Heart-type fatty acid binding protein 
Heart-type fatty acid binding protein (h-FABP) is found mainly in the heart, and in smaller amounts, 
in the small intestine, the skeletal muscle, and the distal tubules of the kidneys[868] and is involved 
in the uptake of fatty acid from the cytosol into the mitochondria. It is an independent risk factor for 
DGF, but  with poor predictive value[870]. 
  
159 
 
1.7.2.7 Machine Preservation solutions 
University of Wisconsin Solution  
The most widely used perfusate for HMP is a formulation of the SCS Belzer UW solution, where 
lactobionate is replaced by gluconate, a suggestion from Dr. F. O. Belzer and Dr. J. H. Southard who 
first developed UW solution at University of Wisconsin[878]. This HMP variant of UW solution is 
known as Belzer MPS. 
There are several further differences between SCS UW solution and Belzer MPS the predominant 
being an inversion of the sodium/potassium electrolyte content - with Belzer MPS representing a 
more extracellular environment  electrolytes. Furthermore Belzer MPS contains glucose as a 
substrate for gluconeogenesis, the addition of mannitol as a further osmotic agent, and omission of 
adenosine.    
Despite Belzer MPS being used as the dominant HMP perfusate Belzer UW was initially designed as a 
HMP perfusate by Belzer and colleagues[722]. Experimental evidence suggests however that Belzer 
UW is superior to Belzer MPS when used for HMP of kidneys from ECD donors, whereas Belzer MPS 
is better for HMP of kidneys from uninjured SC donors[879]. 
Belzer MPS is marketed and distributed with the two most commercially available organ perfusion 
systems by Organ Recovery Systems (ORS, Des Plaines, Illinois, Model LifePort) and Waters Medical 
Systems (WMS, Rochester, Minnesota, Model RM3). 
Belzer-MPS thus continues to be the predominant HMP perfusion solution, and despite numerous 
studies having attempted to alter the composition of MPS to improve its preservation performance, 
it has to-date remained commercially unchanged. Together Belzer UW used for SCS preservation of 
abdominal organs, and Belzer MPS used for clinical HMP of kidneys are considered the gold standard 
for organ preservation today and used by most centres worldwide. 
However with increased understanding of the base molecular changes and mechanisms underlying 
IR injury in transplantation several groups have attempted to develop new solutions to address the 
increasing use of ECD and DCD donor organs which are more susceptible to IR injury, and which may 
not be effectively addressed by the components of the traditional UW based preservation solutions.  
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Polysol 
Polysol is a preservation solution developed in the Netherlands at the Academic Medical Centre in 
Amsterdam, for use in both SCS and HMP preservation [767]. It is based on tissue culture media, is 
both a low viscosity and extracellular type solution, with an iso-osmolar osmolality (320mOsm/L), 
and polyethylstarch as the main colloid. Raffinose, trehalose and gluconic acid are the saccharides 
impermeants used to resist cellular oedema, while glutathione, ascorbic acid, selenium and alpha-
tocopherol are added as free radical scavengers. 
Polysol has been assessed in a porcine kidney auto-transplantation model, and was used for 20 
hours of both SCS or HMP of kidneys, with favourable outcomes (improved initial flushing of 
allografts, and both better microcirculatory perfusion and renal function after transplant) compared 
to controls undergoing SCS with HTK or UW solution alone[880–882]. 
Polysol has also been evaluated in experimental porcine and murine liver HMP and transplantation, 
with limited success compared to SCS[766,883,884]. 
Vasosol 
Guarrera and colleagues at Columbia University in New York have developed a novel solution based 
on Belzer MPS with additional components targeted to ameliorate specific mechanisms of IR injury. 
This solution was designated Vasosol. Rationale of addition of α -ketoglutarate, L-arginine, N-
acetylcysteine, nitroglycerin, and prostanglandin E1  was to provide a supply of energy substrates, 
improve microcirculation, and support endogenous antioxidant systems. Initial experiments utilizing 
a canine kidney auto-transplant model with Vasosol for SCS preservation demonstrated better graft 
function compared to kidneys preserved with UW solution[885]. In the US a randomised prospective 
clinical trial of 162 machine perfused kidneys compared Vasosol HMP with conventional HMP using 
Belzer MPS demonstrated improved early graft and shorter hospital stay in recipients of Vasosol 
perfused kidneys[886]. This paper was retracted shortly after publication due to concerns regarding 
logistical conduct of the study between the multiple centres, however the data and conclusions 
drawn are still of worthy note. Vasosol has also been used in liver HMP preservation in particular the 
first clinical study of liver HMP that was published in 2010 by Guarrera et al where HMP with Vasosol 
improved patient recovery and lower incidences of biliary complications [887]. Allografts were from 
DBD donors, and HMP via dual perfusion of hepatic artery and portal vein.  
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Li for 
Lifor was developed as a normothermic machine perfusion solution. It contains cellular nutrients and 
a non-protein oxygen carrier that works at temperatures higher than 4°C. It has been used to 
machine perfuse porcine kidneys nomorthermically vs. HMP with Belzer MPS, with improved HMP 
flow dynamics using Lifor suggestive of better preservation [888,889]. Lifor has also been evaluated 
in porcine liver machine perfusion investigating differing perfusion temperatures between 4-21°C 
[890]. 
Custodiol-N  
Recently Custodiol-N (the modified HTK solution) has been supplemented with dextran to allow 
kidney HMP. Using a ex-vivo porcine kidney machine perfusion and isolated reperfusion model 
modified Custodiol-N was compared to Belzer MPS [743]. Kidneys undergoing 20 hours of HMP with 
the modified Custodiol-N demonstrated higher renal blood flows, oxygen consumption and 
creatinine clearances compared to Belzer MPS perfused kidneys during isolated haemoreperfusion. 
This preliminary work suggests that there is further potential for the expansion of newer 
preservation solutions that may provide superior preservation and function after reperfusion 
compared to the current gold standard Belzer MPS. 
 1.7.2.8 Economic Benefits of Machine Perfusion  
Improved outcomes in recipients of kidneys managed by HMP compared to SCS has been shown to 
result in a decreased length of hospitalization and need for dialysis. Any cost additional cost of HMP 
compared to SCS could potentially be absorbed by savings as a result of the improved outcomes.  
 
Two cost-effectiveness studies have been conducted by UK groups comparing HMP and SCS, one by 
NICE[4]  and one by the National Institute for Health Research[891]. Both analyses however used 
only preliminary data from two ongoing RCT comparing HMP to SCS, one still on-going[847]  and one 
now complete[892] . Both were largely inconclusive with comparable data supporting both SCS and 
HMP. The NICE technology appraisal guidance is due for review August 2010.  
 
In an analysis by Wszola et al. from Poland comparing HMP to SCS they concluded that as well as of 
clinical benefit – increased long term graft survival (mean F/U at ~7 years) and decreased need for 
post-operative dialysis and incidence of return to dialysis – HMP costs were equalized to SCS costs by 
16 months post transplantation[893]. 
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In the recent RCT by Moers et al. cost-effectiveness analysis suggested that any additional costs of 
HMP are compensated for by the improved clinical outcomes, especially as the reduced incidence of 
DGF, PNF, and graft failure means a  subsequent reduced need for dialysis[894]. This new data 
supports historical 1997 data from Johns Hopkins in Baltimore, US that demonstrated the likelihood 
of requiring dialysis after renal transplantation is 2.33 times higher if SCS is used compared to HMP 
in kidneys from donors >50 years of age, with a potential net saving of $14700 realized through use 
of the paradoxically more expensive HMP preservation method [852] .  
 
More recent economical analysis from the Euro-Transplant RCT combined the short-term data from 
the study with a Markov model with a 10-year time horizon[895]. They included cost of hospital stay, 
dialysis, and complications in their analysis and concluded that HMP reduced the risk of DGF and 
graft failure at lower costs than conventional SCS preservation. The analysis revealed cost savings of 
$86 750 per life-year gained in favour of HMP, with an incremental cost-utility ratio of minus $496 
223 per quality-adjusted life-year (QALY) gained after transplantation, demonstrating gain to life-
years and QALYs while at the same time reducing costs.  
HMP in Practice 
There are several commercially available machine perfusion devices – and these are in use in various 
centres worldwide, however many institutions have developed custom perfusion apparatuses. The 
perfusate is commonly Belzer MPS, a modified UW solution specific for HMP, with some units 
preferring to add specific pharmacological agents to the perfusate to improve kidney perfusion 
dynamics. Initial perfusion pressures in HMP are variable – with advocates for both higher (>55 
mmHg systolic) and lower (<40 mmHg systolic) settings[896]. Most units that utilize HMP as a 
method of assessment of organ viability in kidney transplantation utilize a parameter which is a 
derivative of flow through the renal allograft – whether it be PFI, RI, or actual flow rates. The 
duration of HMP is heterogenic amongst centres – varying from several hours to over 24 hours. 
Biomarkers of cellular damage in the perfusate are measured by some groups – e.g. GST, LDH, 
Lactate – to provide additional viability information. Parameters based on HMP are considered in 
conjunction with other screening tools for selection of suitable organs for transplantation – WIT, CIT, 
donor age and medical history, biopsy result, and macroscopic appearance of the organ – in deciding 
to use or discard a retrieved organ.  
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1.7.2.9 Machine Perfusion Devices 
There are currently two commercially widely available perfusion devices designed for kidney 
perfusion. They are the Waters Medical System ‘RM3 Renal Perfusion System’, and the Organ 
Recovery System ‘Lifeport’ (See Figure 22). 2nd generation machines from both manufacturers are 
also being rolled out into the commercial arena. The Lifeport is portable compact perfusion 
apparatus, while the 1st generation RM3 is a bench-top based perfusion system, and the 2nd 
generation device is transportable. The most recent large RCT comparing SCS to HMP in the 
Eurotransplant region utilized the Lifeport device[892] . This device provided HMP in transit from the 
site of organ retrieval to the base hospital where the potential operation would occur. In the UK of 
21 kidney transplant centres 8 are reported to use the Lifeport for HMP preservation.     
 
 
 
Figure 22  Organ Per fusion Ma chi nes . 1s t genera ti on Wa ters  Medical RM3 Renal  Per fusi on 
Sys tem wi th dual  orga n cass ette for  per fusion of two ki dneys  ( top l eft)  and 2nd genera ti on 
wa ves  ma chi ne (top ri ght) , Organ Recovery Sys tems  1s t genera tion Lifeport devic e (bottom 
r i ght), a nd 2nd generation Lifpor t device ( bottom r ight). 
 
 
Several studies have been conducted to compare the effects of both these machines in HMP of 
kidney allografts. In a retrospective report  of 5 years of kidney transplantation (n=774, ECD and DCD 
donors) at their institution Guarrera et al. [897] found that for similar periods of CIT DGF rates were 
lower in kidneys pumped by the RM3 (31%, 90/378) vs. the Lifeport (41%, 162/396). In addition 
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kidneys managed with the RM3 had better graft function at 1 year, and better 1 year graft and 
patient survival, compared to recipients of kidneys managed with the Lifeport. In a second smaller 
study by Kazimi et al. 89 kidney transplant records (2% DCD) were retrospectively analysed[898]. 
Their main finding was hospitalization was significantly longer for recipients of kidneys managed 
with HMP on a Lifeport (15 days) vs. RM3 unit (9 days). 
 
Recently an RCT reported on comparison of the Waters Medical RM3 vs. the ORS Lifeport for HMP 
preservation of 50 deceased donor kidneys (48% ECD) prior to transplantation[899]. DGF was similar 
using both HMP devices (32%). However patients with DGF required an average of 4.66 
haemodialysis sessions when using the RM3 vs. 2.65 with the Lifeport(P = 0.005). Overall 1-year graft 
survival was 80% vs. 96% in the RM3 and Lifeport groups, and 66% vs. 94% for ECD kidneys 
respectively. Finally interstitial fibrosis and tubular atrophy on biopsy was more common in the RM3 
preserved allografts 45% vs. 0% (P = 0.03) in Lifeport pumped kidneys, but creatinine levels were 
similar between the groups. An important note in this study is that pressures were maintained at 
45mmHg in the RM3 perfused kidneys vs. 30mmHg with the Lifeport. Lower pressures have been 
reported to be superior to higher pressures during HMP and thus this small but key difference 
introduces a large potential bias and confounding factor in interpreting these results[900]. Despite 
the reasons stated for choosing a higher pressure in the RM3 group being that sufficiently higher 
pressures were required to achieve equal flows compared to perfusion with the Lifeport, the data 
presented shows that flow rates were not equal between groups (higher in the RM3 kidneys) as 
were RI indices. In such as comparison between two modalities it would have been more useful to 
maintain one target perfusion variable similar between the two modalities (flow rate or pressure). In 
this case this study not only compares two preservation devices but also two perfusion pressures 
and so in both cases neither group would act as a good control for each other.  
 
Results from this recent RCT are in stark contrast to those from an experimental canine animal 
model of DCD kidney allograft preservation and autotransplantation where the RM3 and the Lifeport 
were compared[805]. Kidneys underwent 45mins of WIT then 24 hours of HMP using the RM3 (n=8) 
and the Lifeport (n=8), followed by auto-transplantation and observation for 7 days. RM3 kidneys 
were perfused at a systolic pressure of 45mmHg, Lifeport at 30mmHg. RI in kidneys on both devices 
was similar for the 24 hours of perfusion, and histology indicated equivalency of preservation injury.  
Serial creatinine over 7 days was similar between RM3 and Lifeport preserved kidneys, however a 
separate subgroup with 8 additional animal demonstrated pulsatile flow is superior to non-pulsatile 
flow with lower creatinine levels after transplantation. Despite RM3 perfusion operating at a higher 
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temperature (2 vs. 5 ˚C) renal function and preservation injury was similar. This study utilized similar 
perfusion targets as the Wszola et al. RCT, but did not report any differences in early renal function. 
It may be that differences would have been evident after 7 days in this study and on longer 
assessment of allograft survival but this was not the remit of the protocol. There have been no 
experimental or clinical reports to date of results with use of the 2nd generation Waters Medical 
Systems or Organ Recovery Systems devices. Furthermore the debate between pulsatile vs non-
pulsatile or continuous perfusion has not been resolved and with further studies needed to 
determine the optimal parameters for effective HMP.  
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1.8 Novel Innovations  In Organ Viabil ity Assessment and Optimization 
1.8.1 Rapid Sampling Microdialysis 
Currently, besides flow rate and vascular resistance during HMP, there are no other entirely 
accepted indicators of kidney viability [841,842,846–848,850,851,853–855,901–903] and 12-18% 
percent of kidneys are discarded due to concerns about their suitability for transplantation [6]. 
Attempts have been made to determine renal biochemical profiles through the analysis of renal 
artery effluent, however, its use is limited and there is no reported consensus on its role in 
predicting graft outcome [873]. An assessment of both renal tissue viability and ex vivo function 
during preservation would facilitate a greater level of discrimination in identifying those organs 
which are at higher risk of delayed function and potentially non-function and would enable a more 
accurate selection of kidneys which are suitable for transplantation.  
Microdialysis is a minimally invasive technique that allows the interstitial composition of a target 
tissue to be sampled, followed by ex vivo analysis, providing an accurate method of monitoring 
tissue biochemistry and metabolism over time. A fine tubular dual lumen microdialysis probe, with a 
semi-permeable bio-compatible membrane tip is introduced into the target tissue of interest. A 
physiological isotonic solution is pumped through the inlet port of the probe at a low, constant, and 
controlled rate and past the semi-permeable membrane tip where it equilibrates with the 
surrounding extracellular tissue fluid. Relatively low molecular weight compounds easily diffuse into 
or out of the lumen of the catheter down their concentration gradients while larger molecules such 
as proteins or those bound to proteins are excluded by the inherent pore size of the membrane. The 
dialysate is sampled at the outlet port and analysed for the molecule of interest.  A schematic 
representation of this process is demonstrated in Figure 23. 
Tissue ischaemia occurs when local oxygen delivery fails to meet cellular metabolic needs. As oxygen 
deficiency progresses, through flow-dependent oxygen consumption, anaerobic metabolism ensues. 
This causes subsequent changes in the concentration of metabolites involved in the glycolytic 
pathway. Microdialysis techniques are capable of sampling and measuring these glycolytic 
substrates specifically lactate, as a potential marker of tissue ischaemia. 
The use of conventional off-line microdialysis for in vivo tissue viability assessment has been 
validated in a variety of research and clinical scenarios [904], including monitoring of cerebral 
ischaemia [905–909], bowel ischaemia [910–912], free flap surgery [913–915], and post-operatively 
in kidney [916,917] and liver [918–921] transplantation. Microdialysis techniques can be translated 
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easily from an experimental to a clinical setting due to the availability of FDA-approved and CE 
marked probes [904]. There are limited reports of the use of microdialysis as a tool for organ viability 
assessment during SCS [916,922,923] or HMP [924] and may be due to the theoretically limited 
metabolism occurring in this period compared to normothermic temperatures. However, the clear 
need for greater tissue assessment compels us to propose that microdialysis could be used to 
effectively quantify and investigate the development of ischaemic injury and stress during this 
period.  
The Department of Bioengineering at Imperial College London has developed a novel online rapid 
sampling microdialysis (rsMD) analyser capable of measuring the concentration of markers of tissue 
ischaemia at 30 second intervals. To date no such system has been used to directly characterise and 
compare the effects of SCS and HMP on renal biochemical activity and the ischaemic injury sustained 
during preservation in real time. If capable of accurately monitoring tissue ischaemia during organ 
preservation, rsMD may have a promising future role in graft viability assessment during the 
preservation period. 
 
 
Figure 23  Sc hema tic repres enta ti on of a mi crodial ysis ca theter . Flui d is otonic  to the target 
tissue extra c ellular  fl uid is pumped through the microdialysis ca theter  a t a  kn own ra te. 
Mol ec ul es a t hi gh c onc entra ti on in the tiss ue equilibra te ac ross the s emi -permeabl e 
mic rodialysis  membrane a nd ca n be a nalys ed i n the coll ec ted perfusa te (the microdiasyla te). 
Courtes y of CMA Mi c rodialysis AB from http://www.mi c rodialysis.com/.  
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1.8.2 Addressive Therapeutics 
1.8.2.1 Theory of  Targeting 
Therapeutic targeting simplistically describes selectively delivering a pharmacological agent to the 
site of disease, and increasing the therapeutic ratio of that agent at that specific site relative to non 
diseased areas.  
The holy grail of targeted therapeutics is the smart ‘Magic  Bullet’ concept, where by an exogenous  
molecular agent  selectively seeks out, finds and binds exclusively and irreversibly to specific 
'targeted' entity in a biological system producing a therapeutic effect [925]. The actual desired effect 
need not be mediated by this interaction directly but potentially indirectly through associated 
molecules at the target site.  In practice though without unrestricted access to the target molecule, 
knowledge of the amount of molecule to be targeted, and considering an infinite association 
constant for the components, designing a 'Magic Bullet' is not feasible.  
The closest practical intervention is distributive-retention targeting - exemplified by clinical use of 
mAB. But this is an en-mass targeted approach with the actual proportion of antibodies that bind the 
target agent usually low, with little useful effect; as they are distributed to all extracellular locations 
in the biological system and catabolised by processes distant to the target site - leaving a low 
proportion of the agent to bind the target.  
Addressive targeting is an interesting approach that can likened to that employed by leucocytes. 
Here differential and temporal expression of CAMs guides and directs inflammatory cell trafficking to 
sites of vascular or tissue damage and mediates a local rather than a systemic response[925]. It is 
characterised by several molecular interactions (acting in sequence or simultaneously) with low 
affinity to identify a site where an agent will aggregate and concentrate mediating a localised effect.  
Addressive targeting has recently been applied in organ transplantation, with the design and clinical 
testing of a complement inhibitor molecule designed with endothelial binding 
functionality[926,927]. Based on the highly effective human complement receptor 1 (CR1) the 
construct designated as APT070 (or Mirococept) consists of the first 3 consensus domains of CR1 and 
a membrane-targeting synthetic peptide, which facilitates binding of the molecule to the 
phospholipid bi-layer of the endothelial cell surface and protection against complement activation. 
Activation of the complement system has been shown to be involved in pathogenesis of tissue 
damage in IR injury and a potential therapeutic target[928]. Mirococept has been evaluated in 
animal models of limb-ischaemia, and renal and cardiac transplantation to ameliorate both IR injury 
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and IR injury and rejection [929], and is currently undergoing MRC funded Phase 2 trials (EMPIRIKAL) 
in the UK in kidney transplantation with DGF the primary end-point.  
The use of membrane-targeting synthetic peptides in organ transplantation introduces the concept 
of 'organ painting'. Organ painting simply put is organ pre-conditioning or pre-treatment prior to 
transplantation with therapeutic agents that (through membrane-targeting peptides) are able to 
localise to the membranes of endothelial cells of the organ vasculature, 'painting' the organ from the 
'inside'. Such compounds can be termed 'cytotopic' (From the Greek: kytos + topos)[930]. 
1.8.2.2 Membrane-targeting synthetic peptides 
Natural Mechanisms 
Approaches to design therapeutic agents for addressive therapies have utilised several aspects of 
natural mechanisms of protein and cell membrane interactions. Several intracellular proteins have 
been shown to undergo reversible binding to inner leaflets of cell membranes, such as ras and 
Src[925]. The mechanism of reversible binding is based on a two site interaction between the 
protein and the cell membrane. 
Such a protein would have undergone post-translational modification, with the attachment of 
hydrophobic group (normally myristoyl or  palmitoyl) to the effector amino acid sequence of the 
protein. The hydrophobic group inserts in the hydrophobic interior of the lipid membrane bi -layer, 
and is then anchored by an electrostatic interaction between positively charged  amino or guanidino 
side-chains in the effector amino acid, and the negatively charged phospholipid heads of the 
membrane. This anchoring provides sufficient energy to enable stable binding and attachment. 
Dissociation is through phosphorylation of series residues near to, or contained within, the main 
effector amino acid sequence, which reduces the overall positive charge of the protein, weakening 
the electrostatic attraction component of the interaction that enabled stable binding, with 
subsequent de-attachment. Once released intracellular phosphatases dephosphorylate the serine 
sequences, resetting the mechanism. [931] 
Theoretical Approach to Designing Therapeutic Addressives  
Smith et al. at theorised that the additive binding concept could be retained, with the switch 
elements discarded, in a system of addressive targeting coined a 'sequential membrane addressin' 
(SMA) to design a moiety that could be produced for attachment to an 'effector' protein and allow 
targeting of that protein to specific biological sites[925].  
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Simplistically each SMA could be regarded as a molecular post code and several SMAs could be 
combined to produce a targeted address, where each consecutive element in the moiety specifies 
for a more specific sequence. e.g. SMA-1 acts as postal are code (all cell membranes), SMA2 as the 
region within the a town (acidic phospholipid membranes) etc. (1).  
SMAs have been designed using the myristoyl- electrostatic switch (MES) concept, but other 
mechanisms that interact with outer cell membrane components are feasible e.g. using sLex 
carbohydrates to target sites on P- and E- selectin CAM receptors, or antibody fragments to bind 
cells modified by dansyl hapten[932]. The CR1 inhibitor Mirococept was designed using the MES 
concept for the SMA.  
Mirococept (APT070) 
Mirococept is a derivative of the anti-complement molecule CR1 (or CD35) conjugated to a MES 
based membrane localising peptide[925,933]. The CR1 component comprises the 'head' of the 
molecule, and the three sequences of CR1 are based on the findings that these initial 3 sequences of 
SCR at the N-terminal effect the relevant biologic activities of CR1[934]. The membrane localising 
'tail' component is myristoyl (SMA1) and the SMA2 is a positive peptide (Gly-Ser-Ser-Lys-Ser-Pro-Ser-
Lys-Lys-Lys-Lys-Lys-Lys-Pro-Gly-Asp). The tail is conjugated to the CR1 head via an activated 
disulphide thiol bridge ([S-2thiopyri- dyl]-Cys-carboxamide). The structure of Mirococept is shown in 
Figure 24. 
The membrane localising tail sequence has been demonstrated to successfully adhe re to both 
murine and porcine endothelial cells in the vasculature of murine and porcine kidneys (see Figure 
25), and porcine hearts, in models of transplantation and IR injury [933,935,936], as well as 
endothelial cells in human kidneys[936] (see Figure 26). 
Localization of Mirococept is rapidly complete within several minutes and the dissociation half -life 
averages several hours, with experiments using radiolabelled tails suggesting that modified 
(localising) CR1 is retained 5–10 times longer than the unmodified CR1 form [935].  
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Fi gure 24  Outline s truc ture of Mi rococept [925]. 
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Figure 25  Demons tra tion of non-tra nsgenic  addressi ve ta rgeting of  myris toyl  tethering a gents 
using whol e-orga n  a utora diogra phy using 
35
S  or  
14
C  labell ed a nti -c ompl ement protei ns. Top: 
porcine ki dney perfus ed wi th the ra dio la bell ed CR3 a nti -c ompl ement c omponent of Miroc oc ept 
(wi thout a  c onj uga ted tail)  demons tra ting only 10% retention. Bottom: porcine ki dney per fus ed 
wi th ra di olabell ed Miroc oc ept (i ntac t protein) wi th 90% retention. Provided by Dr  Ric ha rd 
Smi th, Ki ng's College London . 
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Figure 26  Photomi crogra ph demons tra ting binding of Miroc oc ept wi thin a  huma n ki dney. Left: 
I mmuno-his toc hemis try  of huma n kidneys  per fus ed wi th pres erva ti on s oluti on c ontai ning 
Miroc oc ept s howed tha t the a gent bound to glomeruli  a nd tubul es . Right: huma n ki dney 
per fus ed wi thout Mi rococep t s howed no s taining [936]. 
 
1.8.2.3 Use of  Targeted Anti-coagulants in Organ Transplantation 
The interplay between coagulation cascades and inflammatory responses during IR injury and 
especially during organ transplantation has been demonstrated in numerous experimental and 
clinical models. TF expression [214–216], thrombin generation [264–266], and fibrin deposition [331] 
is known to be actively up regulated during IR responses, and exogenous treatment wi th TFPI[239], 
APC [247], TM [937], AT [307,690], and direct (and indirect) thrombin inhibitors[672–674], have all 
shown variable degrees of benefit in reducing injury and organ function during IR injury.  
Several of these anti-coagulant (and potentially anti-inflammatory) proteins contain heparin-binding 
domains, which lead to the interactions with glycosaminoglycans like heparan sulfate. The 
concentrating presence of these proteins on the glycocalyx ensures maintenance of a quiescent 
rather than an activated state of the endothelium. During IR however the endothelial surface and 
glycocalyx is injured with loss of endogenous anti-coagulant proteins, and activation of endothelial 
cells that promotes both a pro-coagulant and a pro-inflammatory phenotype and response.  
Despite efficacy in experimental models TFPI, APC[938], and TM[309] have not shown clinical 
correlates. DTIs have shown benefit in IR during experimental organ transplantation [672–674], and 
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clinically use of DTIs during cardiopulmonary bypass and acute coronary syndrome [411–414] 
ameliorates cardiac injury.  
Use in transplantation is less certain. Heparin has been used extensively in prevention of thrombosis 
in kidney and pancreas allografts [627,684,939], and is known to possess anti-inflammatory 
properties, but at clinically safe doses only anti-coagulant rather than anti-inflammatory effects 
dominate. Even at clinical doses in the prevention of allograft thrombosis (which maybe evidence of 
progression of IR related coagulation with extension from the micro-circulation into the macro-
vasculature) risk of bleeding is high, and prevention of thrombosis not guaranteed.  
An ideal approach would be an addressive anti-coagulant which localises to within the allograft 
exerting an anti-coagulatory (and thus potentially anti-inflammatory) effect locally at the site of the 
IR response rather than systemically. This would be potentially more effective and omit the need for 
systemic anti-coagulation which confers a serious risk of bleeding to patients.  
Thrombalexin (TLN; PTL004) is one such novel cytotopic agent. It is a sister molecule to Mirococept, 
where the anti-complement CR1 head has been replaced with a Hirudo medicinalis based anti-
coagulant moiety. The anti-coagulant head is a derivative of the DTI bivalirudin (Hirulog), designated 
HLL. Similar to the relationship between CR1 and SCR, HLL is a shorter peptide than Hirulog and 
comprised of the active peptide sequences mediating anti-thrombin activity. The overall structure 
and potential function of TLN is illustrated in Figure 27   
 
Figure 27 The c ytotopic  anti -thrombin mol ecul e: Thrombal exi n. TLN has direc t inhi bitor  of 
thrombin enzyme ac ti vi ty via the a nti-c oa gulant HLL pepti de tha t is rela ted to Hirulog 
(Bi valirudi n). The c ell  membrane tetheri ng tail  is bis -myris toyl  bas ed . Provided by Dr  Ric ha rd 
Smi th, Ki ng's College London.  
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Figure 28  Sc hema tic  of the three pri mary a ddressive c omponents  of the Thrombal exi n: 1) Bas ed 
on the MES c omprising a  bis -myris toyla ted peptide tail ; 2 ) wi th a  posi ti ve peptide s tabili zer 
c onjuga ted to the HLL pepti de by; 3 ) a  dis ulphide bridge (Gl y-Ser -Ser -Lys-Ser-Pro-Ser -Lys -Lys-
Lys -Lys-Lys -Lys-Pro-Gly-As p-S-2thiopyridyl -Cys-carboxa mi de) . Provided by Dr Ric hard Smi th, 
Ki ng's College London.  
 
The membrane localising tail is similar to Mirococept and based on the MES comprising a bis-
myristoylated peptide; with a positive peptide stabilizer conjugated to the HLL peptide by a 
disulphide bridge. TLN has demonstrated the ability to incorporate into outer cell membranes of 
endothelial cells and thus confer a cell-associated anti-coagulant activity that is stable to cell 
washing cycles.  The three main components of TLN are illustrated in Figure 28. 
Due to the nature and size of the hydrophobic anchor internalization of the TLN conjugate is 
discouraged once it is membrane bound, and is thus able to maintain presentation of the functional 
anti-coagulant moiety within the intravascular space. Despite structural differences TLN has similar 
localising characteristics as Mirococept, with demonstrated affinity for porcine endothelial in-vitro, 
and murine endothelial in-vivo [940].  
In the development of TLN several variants of the HLL localising compound were designed. One such 
early variant designated PTL006, comprises the HLL peptide head with the localising tail based on a 
pegylated phospholipid (glycophosphatidyl inositol [GPI]) anchor. PTL006 has been shown to localise 
to glomeruli in rat kidneys (see Figure 29) but comparative analysis has determined that TLN 
- - -
- - -
- -
-
-
-
-
-
- - -
---
---
--
-
-
-
-
-
---
Activated 
Thiol
Cationic Peptide
Hydrocarbon Tail (Myristoyl)
S SPy
O
CH3(CH2)12 GSSKSPSKKKKKKPGD
N
H
NH2
O
S
S N
Cell membrane
Linker to 
therapeutic 
agent
Hydrophobic 
bilayer
2-site interaction with 
outer cell surface
176 
 
(PTL004) binds more strongly once attached to cell membranes with slower cell -cell transfer than 
PTL006 [941]. 
 
Figure 29 Fluoresc ent (FAM) la bell ed PTL006 perfus ed through a ra t ki dney demons tra ting 
localisati on to glomeruli and peri tubular  vess els . Provided by Dr Ric hard Smi th, King's Coll ege 
London. [941]. 
 
The anti-coagulant HLL moiety has been shown to possess similar functional anti-thrombin 
properties as unmodified Hirulog. Expression of HLL in-vitro on porcine endothelial cells by 
transfection of these cells with DNA constructs encoding for the Hirulog-like molecule demonstrated 
an inhibition of clotting on exposure of these cells to human plasma compared to control group cells 
[942,943]. Though the model in this study is xenogenic, and immunogenic factors are an important 
consideration, the demonstration that the hirudin proteins inhibited thrombus formation is evidence 
of effective in-vitro functionality in context of pro-thrombotic stimuli.  
In a murine model of lipopolysaccharide (LPS) induced sepsis, transgenic expression of this hirudin 
based anti-coagulant protein on endothelial cell walls inhibited the widespread intravascular 
thrombosis and consumptive coagulopathy commonly associated with severe endotoxaemia [944].  
More recently in a skin graft presensitized recipient rat renal allograft transplant model (SRAT) TLN 
pre-treatment (via flushing) of allografts during cold storage and prior to transplantation improves 
graft function and extends graft survival to 9 days vs. 2 days for untreated controls[940]. In the same 
model PTL006 demonstrated similar survival benefits[945]. Thus considering the original description 
of the anti-coagulant fusion proteins to be used in this study – the hirudin element has been proven 
to inhibit thrombosis in two different animal models. 
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1.8.3 Organ Preservation Solutions 
The increasing use of ECD and DCD organs to expand donor pools and meet the requirements of the 
growing list of patients awaiting a kidney allograft has led to a resurgence of novel methods to 
optimise marginal organ viability. HMP has been shown to confer benefit in kidney allograft 
preservation compared to SCS [946]. Developments in the understanding of the base molecular 
changes and mechanisms underlying IR injury in transplantation has prompted interest in developing 
new preservation solutions that may more effectively ameliorate IR injury in marginal allografts.  
Adenocaine (AL) solution (Hibernation Therapeutics Global Ltd, Kilquade, Ireland) is a novel 
normokalemic non-depolarising preservation solution initially developed for use as a cardioplegia 
and for adult cardiac allograft preservation.  
AL solution is based on the theoretical benefits of using a non-depolarising membrane approach in-
conjunction with the two key constituents adenosine and lidocaine in providing superior allograft 
preservation and ameliorating IR injury. Experimental and early clinical evaluation of AL solution in 
cardiac surgery and transplantation indicates superior organ preservation and function post 
reperfusion. 
Adenocaine has been shown to exert protective and beneficial effects on cardiac function after 
periods 6-8 hours of SCS using a murine ex-vivo cardiac reperfusion model with better functional 
recovery of coronary and aortic flow rates vs. allografts stored in conventional solutions such as 
Celsior [947–949].  AL appeared to afford cardioprotection by preserving myocardial high-energy 
phosphates, with down regulation of the heart balanced by the expense of a high acid-load during 
ischemia, and then recovery of myocardial pH during reperfusion[950], which enable better function 
on reperfusion and during re-animation[951]. 
The polarizing concept of arrest and protection using Adenocaine is currently being used in a number 
of US centres as all blood microplegia[952], but there is only one case reported of AL microplegia 
used in a high-risk adult patient undergoing cardiac surgery[953]. Furthermore Adenocaine exerts an 
anti-inflammatory effects on in-vitro isolated porcine leucocytes, inhibiting ROS generation, CAM 
expression, and leucocyte-endothelial adhesion and cell infiltration[954]. There is potential for 
application of AL preservation solution to other organs, in particular kidney preserv ation prior to 
transplantation. Adenocaine Machine Preservation Solution (AL-MPS) is a variant of Adenocaine 
specifically modified in-house to facilitate HMP of abdominal organs designed to target specific 
elements of renal physiology in an effort to improve organ preservation. AL-MPS is composed of a 
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modified KHB base with 4mM adenosine; 0.5mM lidocaine; 0.26mM calcium; 16mM Magnesium; 
and 4% bovine serum albumin (BSA) and a comparison with other preservation solutions can be seen 
in  
 
1.8.3.1 Adenosine Physiology  
Adenosine is produced by all mammalian cells and regulates a wide  spectrum of physiological 
activities[955]. It regulates renal renin production, the glomerular filtration rate (GFR) and renal 
vascular tone, and is also a key regulator of tubular-glomerular feedback [955,956]. Tissue adenosine 
levels are increased during states of negative energy balance where the hydrolytic rate of ATP is 
greater than that of ATP synthesis, such as in conditions of ischaemia and tissue hypoxia during 
pathological insults to the kidney[955,957].  
Extracellular adenosine arises from enzymatic hydrolysis of ATP or ADP with high levels (>5mmol/L) 
during ischaemic tissue injury[958]. ATP and ADP may be released into the interstitium via granular 
release from platelets, inflammatory cells, and even endothelial cells. ATP and ADP are hydrolysed 
by ectopyrase (or CD39) in AMP, which is the degraded by enzyme ecto-5′-nucleotidase (CD73) into 
adenosine[959–961]. 
Extracellular ATP deficits from breakdown into adenosine are recognised damage signals promoting 
further tissue injury and destruction[962–964]. Thus CD73 may serve as both a remover of 
deleterious ATP and generation of  cytoprotective adenosine during ischaemic tissue injury [965]. 
Conversely adenosine is thus also a precursor and substrate for ATP production.  
Adenosine effects are mediated by a series of G-protein coupled purinergic adenosine receptors (AR) 
that are either high affinity receptors (10-100nM) and include A1AR, A2AAR, and A3AR receptors, or 
low affinity (>1µM) such as A2BAR where such levels are frequently only encountered in pathological 
conditions[955,966,967]. 
Adenosine has an important role in modulating inflammatory injury highlighted by the fact that its 
receptors are highly expressed on the endothelium and immune cells both critically involved in IR 
injury. Renal AR expression however is heterogeneous (see Figure 30), temporal and dependent on 
the type of insult - whether ischaemia, hypoxic, inflammatory or potentially a composite as in 
transplant related IR injury[965].  
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1.8.3.2 Adenosine in the Kidney 
A1 Adenosine Receptors are expressed in most parts of the kidney, especially in distal afferent 
arterioles, proximal tubules, collecting ducts, and papillary epithelia [966], see Figure 30. These 
receptors regulate vascular tone, TGF and renin release - and stimulation with exogenous adenosine 
results via a PKC and ERK/MAPK signalling [968] in renal arteriolar vasoconstriction, with a decline in 
GFR, and an increase in NaCl, HCO3-, phosphate and fluid resorption [956].  
A1AR receptors are believed to be a key player in modulating renal IR injury. However both A1AR 
activation and blockade can be protective depending on the nature of the pathological insult to the 
kidney  e.g. nephrotoxic vs. ischaemic injury [965].  
During ischaemic insults A1AR stimulation reduces GFR and afferent cortical blood flow - suggesting 
in fact that ischaemic effects may be mediated by these same receptors [955]. The decrease in GFR, 
renin release, sympathetic outflow and fluid transport/reabsorption associated with A1AR 
stimulation however would theoretically reduce the filtration work load of the allograft and with it 
renal oxygen demand and thus consumption, which is a potentially beneficial feedback effect in the 
setting of ischemic renal injury [965]. 
Furthermore though adenosine is a renal vasoconstrictor through interaction with afferent arteriolar 
A1AR receptors it is only so when not affecting the bulk of renal A2AR receptors at the same time 
[969,970]. In-vivo activation of the more prevalent A2AR receptors (found predominately in 
glomerular epithelium and adjacent vasculature) produces an overall persistent vasodilatation in 
kidney allografts, with reduced vascular resistance, despite a relative and short lasting 
vasoconstriction in afferent arterioles [971–973].  
The A2AR receptors facilitate increased medullary blood flow and oxygenation, while lowering 
medullar transport activity [955] through NO generation - with A2AAR agonists improving medullary 
flow and oxygenation after IR injury [970,971]. Thus adenosine functions as a link between renal 
energy demand and supply through its endogenous vaso-constricting and -dilatory effects.  
These receptors are also known for their immuno-regulating ability however  renal protection 
against IR injury has been shown to be independent of macrophage activation. [974] 
A2AAR receptor effects are mediated by Gs protein stimulation of adenylate cyclase and protein 
kinase-A  and results in a cAMP Response-Element Binding-mediated cytoprotection [969,975,976]. 
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A2BAR receptors are expressed primarily on the renal vasculature [977,978] and function through 
the same signalling pathway as A2AAR receptors, producing similar effects. The protection afforded 
by A2BAR receptor subset is thus targeted to the endothelial and in a limited extent the tubular 
epithelial, compared to A2AAR receptors that also modulate infiltrating immune cell activity [979]. 
The distribution and mechanism of the A3 Adenosine receptor sub-type in the kidney is still not 
clear. Neither is the role A3AR plays in IR based tissue injury with contrasting reports in the literature 
suggesting activation or suppression differentially modulates cellular damage depending on the 
mechanism of injury [980,981]. 
 
Figure 30  Adenosi ne rec eptors (ARs ) i n the kidney media ti ng cytoprotec tion. A1AR: endothelial 
a nd tubular  ac ti va tion produc es  cytoprotec tion. A2AAR: found on l eukocytes  (e.g., neutrophils 
a nd l ymphoc ytes ) a nd  tubular  c ells  afford I R protec tion by reduci ng i nfla mma ti on. A2BAR: renal 
tubular  and endothelial expression may also fa cil ita te renal  protec ti on. A3AR: express ed on 
ma ny renal  c ell  types  but i mporta ntl y on endothelial c ells , a nd signalling appea rs varia bl e a nd 
dependent on the type of i njury but ma y be detri m ental  to kidney func ti on during isc hemia  
[982]. 
 
1.8.3.3 Lidocaine  
Lidocaine is a local anaesthetic agent that acts through inhibition of voltage sensitive fast opening 
sodium channels. It is also used as an anti-arrhythmic drug, [983] and, prior to the use of 
amiodarone was drug of choice during cardiac resuscitation[984,985]. Its effects on sodium channels 
also means it posses negative chronotropic and inotropic effects, and acts as a vasodilator[986]. 
A1AR
A3AR
A2AAR
A2BAR
Proximal Tubule Cell
Tubule lumen
Endothelial Cell
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Independent of its mechanism of action via sodium channel inhibition lidocaine has also been shown 
to exert anti-histimainic and anti-inflammatory effects. The anti-inflammatory mechanisms of 
lidocaine have yet to be elucidated. Possible mechanisms include inhibition of: 1) leucocyte 
endothelial interaction [987]; 2) the release inflammatory cytokines and chemokines [988]; 3) the 
production of superoxide anion ROS by XO[989,990]; 4) ROS damage by scavenging hydroxyl free 
radical species [991]; and 5) sodium/calcium exchange and thus reducing cellular calcium 
accumulation during ischemia [992–994].   
Studies have shown that continuous infusion of lidocaine protects against myocardial IR injury in the 
in-vitro rat heart [995] and in the in-vivo rabbit [996], cat [997], pig [998], mice  [999] and canine 
heart reducing infarct size[1000], and also against cerebral IR injury limiting the degree of 
apoptosis[1001].  
Mechanisms of action of lidocaine for limiting IR injury may be related to the 5 proposed anti-
inflammatory effects suggested, however recent evidence suggests lidocaine may limit tissue injury 
by alternative uncharacterised anti-apoptotic pathway[999]. 
These mechanisms may not be mutually exclusive but related, for example increased cytosolic Ca 
during IR is a potential co-factor for formation of XO, and thus inhibition of sodium/calcium 
exchange and limiting calcium accumulation by lidocaine may serve to decreased ROS 
production[1002], while the same mechanism may also help to preserve mitochondrial 
bioenergetics, reduce deleterious mitochondrial calcium loading during reperfusion, and exhibit 
better preservation o ATP [1003]. 
Recently lidocaine has been shown to inhibit IL-1, IL-6, and IL-8 production and ICAM-1 expression 
on activated endothelial cells in-vitro [987,1004], and both blocks TNFα production[988] via NFƙ-B, 
and TNFα signalling by attenuating the PI-3K subunit p85's recruitment to TNF receptor, and limiting 
leucocyte-endothelial adhesion, endothelial barrier permeability, and eNOS activity[1005]. Lidocaine 
has also been shown to reduce P-selectin expression on activated platelets in-vitro, and thus 
potentially may produce a similar effect on endothelial cells[1006]. 
In contrast, the effects of lidocaine on renal function are controversial. Lidocaine pre-treatment of 
renal donors has been previously reported in studies to enhance renal excretory function and reduce 
the incidence of delayed graft function in cadaveric transplantation [1007–1009].  While other 
reports suggest worsening of renal function after IR injury with local anaesthetic intervention [1010]. 
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Perhaps one of the most suggestive reports is of an ex-vivo reperfusion model using canine kidneys 
where low dose lidocaine (80.5µmol/L) addition to Euro Collins SCS solution had a significant 
cytoprotective effect on allograft function evident after 48 hours of SCS [1011]. Reperfusion 
dynamics demonstrated superior viability in-terms of higher GFR and renal flow rates, lower urinary 
LDH, with evidence of less lipid peroxidation, and histologically reduced tubular necrosis, dilatation, 
interstitial oedema and cell detachment.  
Parallel to this however lidocaine has been suggested to impair repair of the ureteric epithelial layer 
and increase the risk of urological complications by decreasing urothelial cell viability, with the effect 
concentration (lowest: 9mM, highest 31mM) and time dependant [1012].  
 
1.8.3.4 Electrolytes  
Magnesium is the second most prevalent intracellular cation after potassium and is a co-factor in 
hundreds of enzymatic reactions for energy metabolism and nucleic acid synthesi s. Its actions have 
been likened to a physiological antagonist of endogenous calcium, and is involved in hormone 
receptor binding; gating calcium channels, with effects on transmembrane ion flux; muscle-fibre 
contraction;; the control of vasomotor tone; cardiac excitability; and both neuronal activity and 
neuro- transmitter release[1013]. Only 1% of magnesium is present in blood and approximately one 
fifth of total magnesium bound intracellularly to ATP within soft tissue, with ATP depletion during 
ischaemia releasing bound magnesium, increasing free levels[1014,1015]. Due to its natural calcium 
antagonist, and anti-inflammatory properties it has historically been an adjunct in surgical 
cardioplegia since the 1970s [1016] protecting against I/R related cytoplasmic calcium 
overload[1017], with magnesium treatment during myocardial IR also reducing infarct size by 
augmenting an adenosine mediated pathway[1018]. The inclusion of magnesium in AL is based upon 
its effects on membrane stabilisation, facilitating ATP production, and observed anti-inflammatory 
properties in IR settings. 
From a scientific standpoint, there are at several areas of concern with potassium concentrations of 
10 mmol/L and above in conventional preservation solutions. Such high potassium levels may 
promote ionic imbalances, with cellular sodium and calcium loading leading to interstitial cell and 
endothelial cell dysfunction and microvascular injury [951,1019]. Vascular endothelial cells can 
become depolarised and activated, entering into a pro-inflammatory and thrombotic state with 
increased permeability [1020]. Finally potassium is a potent vasoconstrictor which during 
preservation and subsequent reperfusion can promote a higher vascular resistance and vessel 
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spasm, impairing effective flushing and inducing mal-perfusion [951,1021]. AL seeks to avoid these 
potential effects, with a normokalemic potassium content. 
AL as a composite of adenosine, lidocaine, and magnesium has been demonstrated in cardiac models 
to afford better protection than conventional preservation solutions possessing membrane voltage 
stabilisation, vasodilatory, anti-inflammatory and anti-coagulant properties, as well as been shown to 
preserve high-energy phosphates during ischaemia[950,954,1022–1024]. With the increasing use of 
ECD and DCD donor organs being used to expand donor pools interventions to optimise kidney 
viability are in much clinical need, and the cytoprotective properties of AL may prove beneficial in 
kidney transplantation.  
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  Preservation Solutions 
 Collins EC Belzer 
UW 
HTK Celsi
or 
HOC Custodiol-N IGL-1 Belzer-
MPS 
Polysol Al-MPS 
Sodium 10 9.3 25.0 15.0 100 80 16.0 120 100 136.0 141 
Potassium 115 115.1 125 10.0 15 80 10.0 30 25.0 5.0 5.9 
Calcium - - - 0.015 0.25 - 0.02 - 0.5 9.0 0.224 
Magnesium  30 4.7 5.0 4.0 13.0 35 8.0 5 5.0 14.0 16 
Chloride 15 15.0 - 51 41.5 - 30.04 20 1.0 - 6.3 
Gluconate - - - - - - -  85 10.0 - 
Phosphate 50 57.6 25 - -  - 25 25 0.8 1.2 
Sulfate 30 4.7 5.0 - - 40 - 5 - 4.0 16 
Bicarbonate  9.3  - - - - - - 25.0 25 
Glucose 25 1.9  - - - - - 10.0 16.0 6.7 
Glutamic acid - - -  20.0 - - - - - - 
Raffinose - - 30.0 - - - - 30 - - - 
Lactobionate - - 100 - 80 - - 100 - - - 
HES (g/L) - - 50 - - - - - 50 - - 
Citrate - - - - - 55 - - - - - 
Histidine - - - 180. 30.0 - 124.0 - - - - 
Adenosine - - 5.0 - - - - 5  5.0 4 
a-ketoglutarate - - - 1.0 - - 2.0 - - - - 
Adenine - - - - - - - - 5.0 5 - 
Pyruvate  - - - - - - - - - 0.2 - 
Allopurinol  - - 1.0 - - - - 1 1.0 1.0 - 
Glutathione - - 3.0 - 3.0 - - 3 3 3.0 - 
Mannitol  - 32 - 30.0 60.0 185 30.0 - 30 - - 
Tryptophane - - - 2.0 - - 2.0 - - - - 
Ribose - - - - - - - - 0.5 - - 
HEPES - - - - - - - - 10.0 - - 
PEG-35 - - - - - - - 0.03 - 20 - 
Amino acids  - - - - - - - - - 11.0 - 
Phenol red - - - - - - - - - 0.07 - 
N-A-H - - - - - - 57.0 - - - - 
Sucrose - - - - - - 33.0 - - - - 
Aspartate  - - - - - - 5.0 - - - - 
Glycine  - - - - - - 10.0 - - - - 
Alanine - - - - - - 5.0 - - - - 
Arginine - - - - - - 3.0 - - - - 
Deferoxamine  - - - - - - 25.0 - - - - 
BSA (g/L) - - - - - - - - - - 40 
Lidocaine - - - - - - - - - - 0.58 
LK 614 - - - - - - 7.5 - - - - 
pH - 7 7.4 7.2 7.3 7.1 - 7.4 7.4 - 7.4 
Osmolality 
(mOsm/kg) 
- 375 320 310 320 - - 320 - - NA 
 
Ta bl e 5  Composi tion of AL-MPS compa red to c ommon pres erva ti on s oluti ons . N -A-H: N- 
Ac etylhis tidi ne. Units  of sol utes are in mmol/L unl ess s ta ted otherwis e. Da ta  is c olla ted fr om 
s evera l s ources[62,751,762–767]. 
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1.8.4 Post-Ischaemic Organ Reconditioning 
Despite the growing evidence for benefits of HMP in allograft preservation implementation of HMP 
protocols similar to those described in the Eurotransplant Trial is logistically complex and resource 
intensive. The necessity of this technology being timely available at the site of organ retrieval for 
transport to the recipient centre, as well as continuous monitoring during preservation and 
transport, has limited uptake of HMP for routine organ preservation, where SCS may actually be 
sufficient for the majority of harvested organs. Use of HMP likely lies in preservation of ECD and DCD 
allografts for reconditioning and assessing viability. Interest has focussed on post-ischaemic 
hypothermic reconditioning as a technique that may allow benefits of HMP to be realized in 
allografts after a period of SCS. 
 
Koetting et al. [800] first demonstrated the benefit of 90 min of hypothermic reconditioning, by 
oxygenated HMP compared to non-oxygenated HMP to recover organs after prolonged (18 hours) 
SCS ischemic injury. Oxygenation during HMP produced substantial 3-fold higher clearances of 
creatinine and urea, and less apoptotic caspase-3 activity during organ viability assessment on an 
isolated reperfusion circuit. The authors concluded that continuous oxygenation during HMP 
effectively ameliorated energetic breakdown and deterioration of mitochondrial redox balance. The 
same group in another study using a porcine renal autotransplantation model demonstrated that a 
short period (2 hours) of reconditioning after prolonged (21 hours) SCS proved as effective as 
continuous HMP for the whole storage time [812]. Active oxygenation was provided in both 
continuous HMP and 2 hours of post-ischaemic reconditioning HMP, and equally improved urea and 
creatinine clearance, as well as tubular function, with lower expression of TLR-4, lower HMGB-1 
release. A short period of HMP even after extended SCS can also normalise expression of KLF-2 
reducing the pro-inflammatory endothelial phenotype [823]. Furthermore a period post-ischaemic 
reconditioning of even 1 hour duration is as effective as 4 hours, after 18 hours of SCS, with 
improved creatinine clearance, tubular reabsorption, and renal flow on an isolated reperfusion 
circuit [1025]. Furthermore the use of pulsatile flow in HMP appears to be the important factor in 
HMP vs. non-pulsatile flow to ensure benefits of HMP are realized compared to SCS [801,823].  
 
Other reports offer conflicting evidence. Using isolated porcine DCD kidney reperfusion model a 
short (4 hour) period of HMP after prolonged (18 hours) SCS was found to confer no advantage over 
simple SCS preservation, compared to 18 hours of continuous HMP[810]. In this study the Lifeport 
machine was used which offers no capacity for active or passive oxygenation and relies solely on 
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atmospheric pressure[805]. Furthermore ROS mediated lipid peroxidation damage was higher in 
HMP than SCS kidneys, further implicating a lack of oxygenation during HMP as an important factor 
in these results compared to studies with oxygenation. 
 
Concerns for the use of oxygenation during HMP are predominately related to the potential 
formation of excess ROS from a high concentration of oxygen. This has supported the use of free 
radical scavengers in HMP perfusate, such as superoxide dimutase. Evidence of ROS or other 
damaging effects of oxygenation are lacking in kidney preservation and transplantation models. Liver 
studies have suggested however that high (>95%) concentrations of oxygen increase ROS generation 
during reperfusion, and so lower concentrations (21%) have been advocated[1026]. More recent 
reports however are inconsistent, with one group observing less oxidative injury and better function 
during reperfusion when 100% oxygen was used for rat liver HMP compared to 21% or with non-
oxygenated HMP[1027].  
 
The overwhelming body of evidence points to HMP - oxygenated or non-oxygenated- as superior to 
SCS preservation. The development of HMP is being directed to towards reconditioning and 
optimising viability of less viable DCD and ECD donor allografts with the intent to promote their 
immediate function, and increase longer term survival, allowing an expansion of the donor pool with 
these donor cohorts. At present the full capacity of HMP to recondition an organ is unknown, but 
research investigating the limits to which HMP can be effectively used will allow a better application 
of HMP in clinical practice.     
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1.8.5 Pancreatic Hypothermic Machine Perfusion Preservation 
1.8.5.1 Historical development of pancreatic machine perfusion 
The preservation method of choice for both ICT and whole pancreas transplantation is currently SCS. 
Despite the definite benefits of transplantation, the shortage of organs is a predominant factor in 
limiting ICT and whole pancreas transplantation. This, combined with the increased use of ECD, has 
led several groups to attempt to utilise the success of HMP with kidneys, in the maintenance and 
assessment of the quality of pancreatic islet cell and pancreatic grafts [869].   
 
Use of HMP confers a number of advantages already demonstrated in kidney preservation. In 
particular the potential for viability testing, and more so the possibility to pharmacologically 
intervene and optimise pancreatic tissue viability has been the key driver behind recent research.   
 
Despite this interest pancreatic HMP remains a mostly unexplored option. Historically in the decades 
where Belzer was developing renal HMP  experimental attempts were made to apply HMP to the 
pancreas, with some limited success compared to that enjoyed in the kidney.  
 
There were several notable attempts reported including the Minneapolis group [1028,1029] under 
Najarian and Sutherland, and Brynger et al.[1030] in the 1970s and early 1980s, and Kenmichi [1031] 
in Japan in 1992. Using a canine auto-transplant model Najarian's group demonstrated that using a 
variety of low perfusion pressures (5-25mmHg), 24 hours of hypothermic perfusion of pancreases 
with a plasma perfusate, was successful in preserving pancreases with good function upon 
transplantation[1028]. Brynger et al. [1030] successfully perfused segmental canine pancreas 
allografts for 24 hours on a Gambro machine at high pressures (50mmHg) with an albumin 
containing electrolyte solution, and despite oedematous change of 135-215% 6 of 9 grafts 
functioned after transplantation. Further canine work however comparing pancreatic HMP 
preservation to SCS however demonstrated pancreatic HMP to be a technically complex procedure 
that was inferior to SCS with poor graft survival in those perfused organs, related to post-HMP 
oedema (see Figure 31) [1029]. 
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Figure 31 Early attempts with a segmental canine pancreatic allograft undergoing HMP; initially (left) 
and after 48 hours displaying severe oedema (right) [1029]. 
 
 
The complexity involved in such perfusion meant that pancreatic HMP remained a non-viable clinical 
entity for the next few decades with limited experimental reports exploring various aspects of using 
HMP for preservation or viability assessment. Kenmochi et al. in 1992 for example used perfusion 
dynamics from a short 1 hour period of HMP to predict graft viability upon transplantation of warm 
ischaemically damaged allografts[1031]. They concluded that flow metrics obtained during HMP 
could be a potential predictor of reperfusion injury in compromised allografts. Most recently our 
group at Imperial College London has experimented with HMP of segmental porcine pancreatic 
grafts with a promising results[1032]. 
 
There were several attempts at normothermic pancreatic haemoperfusion both as methods of 
preservation and viability assessment that were trialled in large animal models in the 1970s-90s by 
Eckhauser el al. in Michigan, USA[1033], and Saito in Tottori, Japan[1034] (see Figure 32), Barthel et 
al. in Gottingen, Germany[1035], and Lykoudis et al. in Greece[1036]. 
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Figure 32 Historical attempts at pancreatic perfusion. Left: schematic diagram of the perfusion 
apparatus used by Saito et al. for normothermic perfusion of the rabbit pancreas set in a chamber 
[1034] (A, arterial cannula (the superior mesenteric artery); D, pancreatic duct cannula; P, pancreas; 
R, perfusion fluid reservoir; V, portal vein cannula; W.B, water-bath). Right: Modified perfusion 
apparatus using inline dialysis unit by Eckhauser et al. [1033].  
 
However despite experimental reports application of these strategies to clinical practice were not 
attempted predominately due to technical difficulty in achieving successful perfusion, and because 
of the relative simplify that SCS offered.  
 
With current pressure to expand donor pools and address the growing list of patients awaiti ng a 
pancreas there has been an increasing use of ECD and DCD donor organs. Unfortunately such organs 
carry with them an increased risk of graft delayed function and graft failure. Once again interest has 
rekindled in strategies to apply the merits of HMP in these organs optimising pancreatic preservation 
and potentially allowing viability assessment. 
 
It can be assumed that because renal HMP preceded other forms of dynamic organ preservation 
attempts to apply HMP to other organs have routinely been based on modifying renal protocols. 
There are however a number of reasons why such renal protocols cannot be directly translated to 
the pancreas first identified by the Minnesota Group [1028].  
 
The main physiological difference with the pancreas is its low flow and pressure environment.  This 
means that machine perfusion has the capacity to damage the fragile vascular endothelium leading 
to platelet activation and thrombosis on graft reperfusion[1037–1039].  
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1.8.5.2 HMP in Islet Cell Transplantation 
 
Recently there has also been interest in HMP to facilitate preservation and liberation of pancreatic 
islets for ICT [869]. In several reports Taylor et al. [1040,1041] used a 24 hour HMP porcine model.  
They found the highest insulin content was in islets harvested from machine perfused pancreata.  
Islet yield was 1.6-1.8 times greater than the fresh group and 2-3 times greater than cold storage 
group.   
 
One of the previously reported disadvantages of machine perfusion was organ oedema, thought to 
lead to bleeding and necrosis[795].  This group found that though they observed moderate oedema, 
there was no associated loss of function.  They further suggested that the oedema appeared to aid in 
enzymatic digestion, producing a greater yield and purity of islets compared with pancreas subjected 
to 24 h of SCS [795]. It was noted however that islets were oedematous, suggesting a degree of 
ischaemic injury and thus that HMP for islet isolation may not be solely beneficial.  
 
In a small (n=4) human model, Leeser et al. [1042] used 13 hour low-flow machine perfusion 
compared with two groups of cold storage of <8 and >8 h.  They found that machine perfusion may 
be beneficial in pancreata with prolonged cold ischaemic time, which would normally be less likely to 
meet criteria, by maintaining islet yield, viability and function.  They reported islet yields from 
machine perfused pancreata of 3435 IEQ/g, compared with 5134 IEQ/g and 2640 IEQ/g respectively 
for those cold stored for <8 and >8 h.  Mean islet viability after perfusion was 86% (vs. 74% and 74% 
for the <8 and >8 h groups) and insulin secretion index was 6.4 (vs. 1.9 and 1.8 for the <8 and >8 h 
groups).  
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1.8.5.3 Key i ssues in the development of pancreatic perfusion models  
1)  Animal model  
In development of experimental translational models one of the key considerations for large animal 
models is the species utilized. Historically canine models have been used extensively, however the 
porcine model provides a consistent and reliable source of tissue[1043]. In both instances despite 
similarities to the human pancreases definitive anatomical differences are present. 
2)  Type of  pancreatic graft 
Types of pancreatic graft that can be retrieved can be classified as segmental[1044] or whole[1035] 
for ex-vivo perfusion and include or not include the duodenum. Choice will depend on the degree of 
translational applicability desired, with a whole pancreatic graft including a duodenal segment most 
akin to what would be encountered in a clinical setting. Never the less a whole porcine pancreatic 
graft has a more complex and fragile anatomy compared to the human pancreas, but is one of the 
best approximations available in a non-primate species. 
3)  Perfusion Solution  
Clinically Belzer MPS is the gold standard for HMP. Despite the development of several new 
experimental solutions none have reached clinical practice, have been used primarily in kidney, and 
a lesser extent in liver models. The Minnesota group used a plasma based perfusate supplemented 
with albumin to enhance the osmotic potential of the solution and limit oedema[1028]. Alternatives 
to Belzer MPS include the SCS variant Belzer UW solution. Belzer UW was initially developed as HMP 
solution for kidneys[722], and has proved beneficial in DCD donor allografts experimentally[879]. 
Karcz et al. used Belzer UW in the initial development of pancreatic HMP models at Imperial College 
London. Any solution employed would likely require supplementation with osmotic agents to help 
minimise allograft oedema. 
4)  Perfusion Protocols 
The inherent differences between the kidney and the pancreas necessitates lower perfusion 
pressures, and flow expectations. The kidney as a whole is a high-flow filter, while the pancreas is 
both a glucose sensor and reservoir of potent digestive enzymes. Excessive barotrauma can damage 
the pancreas and result both in oedema and potentially graft pancreatitis upon reperfusion and 
transplantation[1028]. Despite this understanding optimal perfusion pressures in hypothermic, and 
192 
 
even normothermic instances have not been established. However because recent evidence 
suggests that perfusion pressures <40mmHg during renal HMP are optimal [882], it is probable that 
even lower pressures would be needed for pancreatic HMP. 
5)  V iability Assessment 
HMP has been used a tool for viability prediction using perfusion dynamics and perfusate analysis for 
biomarkers. However suitably predictive markers have not been found[873]. Physiological 
differences between the kidney and pancreas suggest that some markers used in renal assessment 
may be useful in the pancreas but that independent and pancreas specific indicators exist.  With 
ideal perfusion pressures lower in the pancreas expected flow dynamics will be less than in renal 
HMP and thus viability criteria for the kidney[876] will not be suitable. Calculated PFI 
(ml/min/100g/mmHg) developed by the Newcastle group in the UK may however provide a useful 
metric as it incorporates both flow rates[1031] and systolic perfusion pressures used but also 
accounts for the weight of the pancreatic allograft. 
 
Assessment of tissue metabolism using rsMD would provide insight into both tissue ischaemic injury, 
and also changes in tissue metabolism during  preservation. Assessing organ viability in an 
experiment addressing the modality of hypothermic preservation can also be done after 
preservation during reperfusion. The gold standard would require an auto-transplant model, 
however an isolated reperfusion model would provide an indication of immediate organ viability and 
function[722]. Microdialysis, if incorporated during normothermic reperfusion can provide 
additional real-time information on reperfusion injury. Furthermore functional pancreatic viability 
can be assessed during reperfusion by glucose stimulation and monitoring insulin release, as well as 
pancreatic exocrine secretions. 
 
Finally an important aspect of any large animal organ preservation and perfusion work is developing 
protocols and a strategy that could be applied to human allografts in clinical practice.  
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Chapter 2: 
Basic Methodology 
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2.1 General Techniques  
2.1.1 Hypothermic Machine Organ Perfusion System 
2.1.1.1 The RM3 Hypothermic Perfusion Machine 
  
The Waters Medical Systems (Rochester, MN, USA) RM3 organ perfusion machine was initially 
designed as a two-part kidney preservation system which includes (1) a control unit (the RM3) for 
the pulsatile perfusion and monitoring of one or two kidneys and (2)  a sterile, disposable, single-use 
cassette designed to circulate the perfusate through the kidney(s). The following details of the RM3 
device and its operation have been extracted and adapted from the RM3 Device Manual [1045].  
 
The RM3 machine provides a simple and efficient method for hypothermic pulsatile preservation for 
one or two organs by maintaining pressure, flow and temperature with the self contained ‘control’ 
or ‘base’ unit monitoring perfusion parameters and controlling cassette function. The cassette is a 
circulation system consisting of a central chamber to house the organ, venous and arterial 
reservoirs, a bubble trap, oxygenator, heat exchanger, and a pulsatile pump head. Pressure, flow and 
perfusate temperature are under control of the RM3 base unit, and free for alteration and 
evaluation by the operator. A schematic diagram of the base unit and cassette can be seen in Figure 
33. 
 
2.1.1.2 The RM3 Control Unit  
The RM3 control unit regulates the pulsatile perfusion of the perfusate, and in real-time monitors 
perfusion pressure, perfusate flow and perfusate temperature .  
 
Readings for monitored parameters are displayed on the central display screen as isolated values or 
in a graphical representation of trend over time. During normal operation the largest section will 
display the real-time analog waveform, the menu or the trend graphs. A second section will display 
the numerical information which includes systolic, mean and diastolic pressures, flow from both the 
right and left kidneys, temperature of the perfusate, renal resistance of the right and left kidneys 
and the pump pulse rate. The third section displays the identification of the menu keys located on 
the front panel overlay. A photograph of the display screen can be seen in Figure 34. 
 
196 
 
The RM3 control unit has variable stroke volume control, allowing the operator to mechanically 
adjust the occlusion of the pulsatile pump arm. By turning the stroke volume knob clockwise, the 
volume of perfusate from the pump head to the kidneys is increasing along with a corresponding 
increase in pressure. 
 
In addition the RM3 contains an alarm system which will signal an audio as well as a visual alarm for 
user selected alarm conditions.  
 
 
Fi gure 33  Sc hematic  of RM3 base unit a nd organ c assette. Ada pted from RM3 Ma nual [1045]. 
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Figure 34  Photograph of the RM3 bas e uni t dis play wi th per fusion readi ngs on the right side of 
the s c reen. 
 
 
2.1.1.3 The Cassette 
The MOX DCM-100 cassette is a gravity flow system circulating perfusate through the attached 
kidneys. The perfusate is pumped from the arterial reservoir, through the heat exchanger to the 
bubble trap where it is delivered to the cannulated kidney(s). The perfusate returns to the arterial 
reservoir by gravity through the right and left venous reservoirs and the membrane oxygenator. The 
cassette is easily mounted on the RM3 by the mounting brackets on the left front and right rear 
connectors on the cassette and allows positioning of the pulsatile pump head into the pump arms of 
the RM3. A photograph of a cassette in operation can be seen in Figure 35. 
 
A pressure transducer line, an inlet tubing to the ambient air pump, temperature probe cable and 
flow transducers are then attached to the RM3 base unit. To complete the installation, the heat 
exchange lines from the ice water bath or the refrigeration unit are attached to the cassette. For the 
most efficient operation, the inlet connection is located on the top and the outflow connection on 
the bottom. A temperature probe located in the bubble trap will control a circulation pump located 
in the ice water bath and thermostatically maintain the temperature of the perfusate.  This 
temperature was correlated with the temperature of the organ being perfused using a separate 
temperature monitor in the tissue to ensure effective cold preservation.  
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The bubble trap separates any trapped air bubbles from the perfusate to prevent air bubbles from 
reaching the kidneys. It also provides mounting positions for the perfusate temperature probe and 
the pressure transducer line. Since the bubble trap is operated at the perfusion pressure, it is critical 
to insure that there are no air leaks in the pressure system. It is recommended by the manufacturers 
that all tubing connectors are tie-strapped for airtight connections. 
 
Sample ports are located on the bubble trap. The syringe access pressure port allows the operator to 
regulate the proper perfusate level at all times. By inserting a needle and syringe into the pressure 
port and either infusing or withdrawing air, the perfusate level can be moved up or down. The 
sample port below the perfusate level indicator line can be used to infuse products or remove a 
sample of the perfusate. A persistently rising fluid level indicates a leak in the pressure system and 
the perfusate level should be at the indicator line at all times for accurate pressure measurements. 
 
Perfusate migrating down the pressure transducer line will damage the transducer and so a 
hydrophobic filter is used during operation of the RM3. 
 
The pulse pump arm of the RM3 control unit and the pump head in the cassette provide pulsatile 
flow. The pump head includes a pair of occlusive valves placed in series and is alternately 
compressed and released by the cam-driven arm of the pump arm. The pump head must be placed 
in the pump arm assembly with the holding brackets positioned directly at the base of each valve in 
the pump head. During initial priming of the cassette, some air may be trapped in the pulsatile pump 
head. To remove this air, the discharge end of the cassette (the nearest the coolant source) should 
be raised from the top of the RM3 and held at an upward angle while manually squeezing the pump 
head. 
 
The RM3 control unit has a variable stroke volume control, allowing the operator to manually adjust 
the occlusion of the pulsatile pump arm. By turning the stroke volume knob on the base unit the 
flow through the pump head is altered; e.g. turned clockwise the volume of perfusate from the 
pump head to the kidneys is increased along with a corresponding increase in pressure.  
 
The flow from each organ is collected in the respective venous reservoirs; the flow from the right 
half of the cassette flows into the left venous reservoir, flow from the left, into the right reservoir. 
These reservoirs are calibrated in 20ml increments. The flow rate is measured by timing the flow 
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from each kidney into the venous reservoir. The graduated marking on the venous reservoirs of the 
cassette are provided to permit direct measurement of the perfusate.  
 
The perfusate in the cassette can be cooled by either the ice water bath in the RM3 or by means of 
an auxiliary refrigeration system.  
  
 
Figure 35  Photograph of orga n cass ette in us e wi th a  porcine kidney. Key components of the 
c a s sette a re l abelled.  
 
 
2.1.1.4 Measuring f low with the RM3 
The RM3 uses two methods of measuring flow. The first method uses real-time flows measured with 
Transonic ultrasonic clamp-on flow probes using the ultrasound signal method to insure precision 
measurements on each inlet tube from the bubble trap into the organ chamber.  In this manner, 
sterile perfusate does not come in contact with the flow probe.  
 
The second method for measuring flow is the Direct Timer method. This method measures the filling 
time on the volume increments on the venous reservoir and automatically places the value in the 
appropriate display area. The direct timer method is utilised if there is a primary malfunction with 
the real-time flow probes during an experiment. 
 
Organ Chamber
Syringe Access – Sample port
Bubble Trap
Syringe Access – Pressure port
Temperature Probe
Pressure Transducer and tubing
Membrane oxygenator
Air inlet
Kidney
Arterial reservoir
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How the Flow probes Work  
The Transonics flow probes in the RM3 use the ultrasound to measure the transit time ultrasound 
between to transducers to accurately measure perfusate flow.  The flow probes are pre-calibrated 
for use with the RM3 and perfusate. The left and right flow probes are attached to the RM3 directly 
to the flowmeter board located inside the battery door. The flow probes are clamped onto outflow 
arterial outflow tubing from the bubble trap (see Figure 36). 
 
 
Fi gure 36  Photograph of rea l -time fl ow probes on a rter ial tubing.  
  
Di rect Timer Method 
‘L Flow Timer’ (left flow timer) and ‘R Flow Timer’ (right flow timer) in the SYSTEM MENU measures 
the rate of flow from each kidney using the cassette’s venous reservoirs. The markings in the venous 
reservoirs are in 20ml increments, ranging from 0 to 80ml. When selecting the manual timer 
method, the RM3 Flow Timer is switched from Auto (using the flow probes and real-time flow) to 
Man (manual). Once the left or right timer is selected, the LEVEL key will determine the volume of 
perfusate measured. The levels that can be selected are 20ml, 40 ml, 60 ml and 80 ml, which 
correspond to the volume of perfusate collected in the venous reservoir. The flow is measured by 
occluding the tube exiting from the respective section of the venous reservoir chamber. The right 
kidney chamber will flow into the left venous reservoir and the left kidney chamber into the right 
venous reservoir. 
 
Real-time Doppler Flow Probes on Arterial Flow Tubing
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For Example ( taken from RM3 Manual): 
To measure the right flow: 
1. From the MAIN MENU select the SYSTEM MENU. 
2. In the SYSTEM MENU select R Flow Timer (right flow timer). 
3. Adjust the timer for level 20ml. 
4. Occlude the tube exiting the left venous reservoir to the oxygenator. 
5. When the perfusate reaches the 0 mark, press the START key. This starts a digital counter on the 
display. 
6. When the perfusate reaches the 40ml mark in the reservoir, press the STOP key.  
The RM3 will compute the flow and display flow readings on the digital display, and calculate flow 
resistance. These values will remain displayed until a new flow volume is calculated, at any time, 
using the Direct Timer method.  
 
2.1.1.5 Pressure Measurements  
A replaceable Honeywell transducer measures pressure. Systolic, mean and diastolic pressures are 
displayed digitally as well as in analog waveform. Pressures are continuously updated for digital 
display and in real-time for the analog display. The fluid level in the bubble trap should be at the 
perfusate level mark to insure accurate pressure measurements. This can be accomplished using a 
30ml syringe with a 22 gauge needle or smaller in the top injection port to adjust the fluid level in 
the bubble trap. Using Pressure and Flow measurements the Resistance to flow is calculated and 
displayed by the RM3 base unit. 
 
2.1.1.6 The Circulation (CIRC)  Pump and Reservoir  
The circulator pump, is a submersible pump located in the 5L coolant reservoir. It circulates 
approximately 3.5 litres per minute through the cassette’s heat exchanger to cool the perfusate. The 
electrical connector is located inside the reservoir in the upper front section. Control of hypothermic 
cooling time depends on the ambient conditions. The use  of a cassette cover will help maintain 
temperature for a longer period of time.  
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2.1.1.7 The Air Pump 
The air pump will circulate approximately 500 ml/min of ambient air (21% O2) over the oxygenator 
membrane in the cassette. It is operated from the SYSTEM MENU with a port connected at the top 
of the RM3 cabinet to the right of the pressure port. The air pump allows more air to circulate across 
the membrane. 
2.1.1.8 The Temperature Sensor  
The RM3 will report temperature readings from 0 to 45°C. For values outside this range the RM3 will 
display - - (for readings less than 0°) and + + (for readings greater than 45°C).  
 
2.1.1.9 RM3 Operational Checklist  
Before each experiment the RM3 machine was primed and made ready for attachment of the 
pancreatic graft to the perfusion circuit. Furthermore after a graft is removed, and subsequently 
reattached to the organ perfusion cassette the flow probes and pressure readings are zeroed before 
continuing perfusion. 
 
1) Attaching the perfusion cassette to the RM3 Machine via the top mounted screw clamps 
2) Adding 1.5L of water and ice to the coolant reservoir. 
3) Connecting the cassette gas inlet tubing to the RM3 machine. 
4) Connecting the temperature probe to the cassette and RM3 machine. 
5) Attaching the Transonic flow probes to the arterial tubing. 
6) Attaching the coolant tubing to the cassette. 
7) Priming the cassette with the desired volume of perfusate (in this case UW solution).  
8) De-bubbling the pump head once the machine is switched on and perfusate flowing through 
 the cassette. 
9) Adjusting the fluid level in the bubble trap to correspond to the centre line.  
10) And once the perfusate is at the desired temperature – (4-8˚C or normothermic), the 
 pressure sensor and flow probes are zeroed. 
 
 
203 
 
 
2.1.2 Normothermic Reperfusion 
2.1.2.1 Modif ication of the RM3 Perfusion Apparatus  
The RM3 unit was modified to facilitate normothermic reperfusion of grafts for viability assessment 
(see Figure 37). To perfuse organs normothermically a water heater (Grant Instruments FH16D Flow 
Heater) was externally attached to the circulation pump and the cassette via the cassette’s heat 
exchanger ports. Where two RM3 units were being used the cassettes were attached in series. The 
external water heater maintained the temperature of the water between 35-41˚C to warm the 
perfusate to a target temperature of between 37±2˚C (human grafts) or 38±2˚C (porcine grafts) 
depending on the experimental protocol.  
 
 
Figure 37  Photograph of ki dney undergoing normothermic  ha emoreper fusion. Provision of 
oxygen via holl ow probe i nto the a r terial res ervoir , a nd normothermia  mai ntained by us e of an 
externa l  hea ted r e-circ ulator. 
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2.1.2.2 Provision of Oxygen  
Oxygen was administered by inserting a thin hollow probe through which an oxygen / carbon dioxide 
mixture (95% O2, 5% CO2) was passed into the arterial reservoir to allow effective oxygenation of the 
perfusate (see Figure 37). Carbon dioxide was included in the mixture to supplement acid buffering 
within the perfusate during reperfusion. 
 
2.1.3 Retrieval of Grafts 
2.1.3.1 Porcine Grafts  
Porcine kidney and pancreas grafts for this project were obtained from pigs at a local slaughterhouse 
Cheale Meats Ltd, Brentwood Essex. Pigs were white crossed large pigs (mixed breed) weighing 
between 70-120kg.  
 
There were two methods used for retrieval of porcine organs targeting a shorter (15 minutes) and 
longer (45 minutes) WIT.  
 
Shorter (15 minutes) i schaemia time 
Pigs were sacrifice by stunning, and then exsanguination. After death the internal thoracic and 
abdominal organs were removed and supplied for dissection and retrieval of the kidneys and/or 
pancreas and associated vasculature. Time between death and flushing was aimed to be maintained 
at 15 minutes. During this time organs were dissected and made ready for flushing and cold storage 
transport to the laboratory. After approximately 15 minutes organs were flushed with 0.5-1L of 
organ preservation solution (UW, Soltran or Adenocaine Solution depending on the project protocol) 
at a pressure of 100cm H2O. The period until flushing in pancreatic retrieval was longer due to the 
time needed to accurately dissect the organ and ligate key vessels, ice was placed near the organs to 
facilitate cooling during dissection in this case until flushing. Organs were flushed until effluent via 
the venous drainage was clear, and then packed in the same flush preservation solution on ice and 
transported back to the laboratory. Transport time was approximately 4 hours.  
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Longer (45 minutes) i schaemia time 
Pigs were sacrifice by stunning, and then exsanguination as part of the commercial processing line at 
the slaughterhouse. The time between death and provision of the organs was approximately 25-30 
minutes, and included a 10 minute period in a 65˚C water bath.  
After this period the internal thoracic and abdominal organs were removed and supplied for 
dissection and retrieval of the kidneys and/or pancreas and associated vasculature. A rapid 
dissection was conducted to minimise further warm ischaemia time (5-10 minutes) and cold flush 
initiated. During flushing dissection and back benching of organs continued and the organs made 
ready for cold storage transport to the laboratory. Organs were flushed with 0.5-1L of organ 
preservation solution (UW, Soltran or Adenocaine depending on the project protocol being used) at 
a pressure of 100cm H2O. Organs were flushed until effluent via the venous drainage was clear. 
Transport time was approximately 4 hours. 
 
Autologous Blood Collection  
If blood was required as part of the project protocol autologous porcine blood (1L) was collected 
from the animal before death in a container with 10,000 IU of heparin (Multiparin®; CP 
Pharmaceuticals, Wrexham, UK) to prevent extracorporeal thrombosis. This blood was then placed 
in a cold storage bag for transport back to the laboratory.  
 
 
2.1.3.2 Graft Anatomy 
Porcine Kidney 
Porcine renal anatomy and size is similar to that of the human kidney. During dissection the renal 
capsule was dissected and partially removed. The renal artery and vein were isolated and benched 
to ensure no leaks were evident, and the ureter preserved. Flushing was via the renal artery and out 
flow via the renal vein (see Figure 38). Once at laboratory further dissection of the graft, and 
preparation for machine perfusion was performed. All bench work was undertaken with the graft 
placed on an ice/UW mixture. Aberrant and earlier missed vessels were located and tied. The kidney 
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graft was weighed using electronic scales. The renal artery was cannulated with a perfusion cannula 
used for attachment to the RM3 arterial tubing. The vein and ureter were left to drain freely.  
 
 
Fi gure 38  Porcine ki dneys. Prior to benc hing (left) and being flushed (right).  
 
Porcine Pancreas  
The porcine pancreas model has historically been used for experimental pancreas transplantation 
due to the anatomical and immunological similarities with humans [18]. The similar size & function 
of the porcine pancreas to the human type make swine amenable for research using equipment 
designed for human sized organs and tissues  – in this case the RM3 Perfusion system. Porcine 
pancreatic anatomy though similar to human pancreatic anatomy has several distinct differences in 
morphology, as well as arterial and venous vasculature [1043].  
 
Lobe structure 
The porcine pancreas is a retroperitoneal structure ventral to the 1st, 2nd, and 3rd lumbar 
vertebrae. It weighs approximately 25-200g (depending on the size of the animal) and is triradiate in 
shape [1043]. It is composed of three lobes, with irregular margins and a nodular surface. The 
splenic lobe (corresponding to the tail and body in the human pancreas) is situated posteriorly and is 
attached to the spleen and the stomach. The duodenal lobe corresponding to the head of the 
pancreas) is located adjacent to the duodenum while the connecting lobe (corresponding to the 
uncinate process) is an extension of the pancreas which is attached to the anterior aspect of the 
portal vein. In addition there is a bridge of pancreatic tissue serving as an anatomical connection 
between the splenic and connecting lobes [1043]. Anatomy of the porcine pancreas can be seen in 
Figure 39. 
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Figure 39 The porcine pancreas . Depic tion of porci ne pa ncrea tic a na tomy i ncluding ar terial a nd 
venous  network (l eft) a da pted fr om Ferrer  et al . [1043]. Photogra ph of benc hed whol e porcine 
pa nc reatic  graft (r ight).  
Arterial Supply 
The blood supply of the pancreas is provided by the celiac trunk and superior mesenteric arteries 
[1046]. The DL of the pancreas receives its blood supply from the superior pancreaticoduodenal 
artery, a branch of the gastroduodenal artery. The SL is supplied by the splenic artery; and the 
inferior CL and bridge of tissue supplied by the pancreaticoduodenal artery branch of the SMA. 
 
Venous Drainage 
The portal vein receives blood from stomach, pancreas, intestine, and spleen. On its way from the 
root of the mesentery to the liver, the portal vein penetrates the pancreas at an acute angle so that 
it lies caudally on the ventral surface and rostrally on the dorsal surface of the pancreas passing 
through the ring of pancreatic tissue [1043]. The portal vein has two branches that drain into it, the 
splenic vein and the superior mesenteric vein. The splenic vein drains the body and tail of the 
pancreas, is usually embedded within pancreatic tissue. The superior mesenteric vein passes through 
the portal ring receiving the inferior pancreaticoduodenal vein – draining the duodenal lobe. The 
inferior mesenteric vein usually flows into the superior mesenteric vein – a distinct anatomical 
variant compared to human pancreatic venous drainage [1043]. The gastroduodenal vein empties 
into the superior mesenteric vein immediately before its junction with the splenic vein, and receives 
drainage from the superior pancreaticoduodenal vein that also anastomoses with the inferior  
pancreaticoduodenal vein. 
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Ductal  System and Histology 
The pancreatic duct is composed of two separate ducts draining the body and tail – anatomising to 
form the common pancreatic duct prior to the pancreatic sphincter, though several anatomic 
variations exist [1043]. Histologically pancreatic islet cells are relatively indistinct, but functionally 
similar to humans . 
Pancreas Dissection and Benching 
Upon provision of the internal thoracic and intra-abdominal organs the aorta was immediately 
identified and clamped distal to the superior mesenteric artery origin. Lumbar vessels were clipped 
and the aorta cut 5-10 cm proximal to the origin of the celiac trunk. After the prescribed warm 
ischaemia time the proximal aorta was then cannulated and cold preservation solution infused into 
the pancreas via the aorta and through the celiac trunk and superior mesenteric artery. At this point 
ice was placed in the vicinity of pancreas to facilitate rapid cooling. The pancreas was then dissected 
out en block and placed on a tray of ice and preservation solution. The distal splenic artery and vein, 
the left gastric artery and vein, the distal gastroduodenal artery and vein, the hepatic artery and 
vein, components of the superior mesenteric artery (distal to branches supplying the pancreas), as 
well as lumbar arteries from the dorsal aortic wall and the aorta itself distal to the superior 
mesenteric artery origin, were then tied with silk ligatures and washout continued with cold 
preservation solution until clear solution emerged from the portal vein. Any leaks from aberrant 
arterial vessels were identified, clipped and tied with appropriate size silk ligatures.  
The final graft composition was based on the extent of dissection and two methodologies were 
employed to produce a segmental porcine pancreatic graft or a whole organ.  
Segmental Allograft 
The final graft was composed of the splenic and duodenal lobes of the pancreas – supplied by the 
celiac trunk +/- the superior mesenteric artery segments of the aorta. Venous drainage was 
composed of the splenic, gastroduodenal, and superior mesenteric veins draining into the portal 
vein. The small bowel and attached duodenal pancreatic tissue, and tissue composing the lower the 
half of the pancreatic 'portal ring' surrounding the portal vein was carefully isolated and removed. 
No further attempt was made to manipulate the pancreatic ductal system. The graft was then placed 
in an organ transfer bag with approximately 200ml of preservation solution and the bag placed on 
ice for transport back to the laboratory.  A photograph of a segmental porcine pancreatic graft can 
be seen in Figure 40. 
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Fi gure 40  Benc hed segmenta l porcine pa nc reatic  gra ft.  
  
Whole  Organ Graft 
The whole organ allograft comprised the entire porcine pancreas - involving the splenic, duodenal, 
connecting lobe and tissue surrounding the portal vein (see Figure 39). A section of small bowel from 
just distal to the gastric pylorus up to the equivalent of D3 was preserved. The aorta was tied distal 
to the origin of the SMA to preserve the arterial supply to the inferior portions of the pancreas. The 
splenic vessels were tied at the splenic hilum. The vessels and ducts to/from the liver were tied at 
the portahepatis.  
Pancreatic Bench Work  
Once returned to the laboratory further dissection of the graft, and preparation for machine 
perfusion was performed. All bench work was undertaken with the graft placed on an ice/UW 
mixture. Aberrant and earlier missed vessels were located and tied. The pancreas graft was weighed 
using electronic scales. The proximal aortic segment was cannulated with a perfusion cannula used 
for attachment to the RM3 arterial tubing. The portal and mesenteric venous vessels were left open 
ended for venous effluent drainage. In whole organ grafts an enterotomy was performed and a foley 
(14-F) catheter inserted and secured by purse string suture into the small bowel to collect pancreatic 
and small bowel secretions. A benched porcine pancreatic graft can be seen in Figure 41. 
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Fi gure 41  Benc hed whole porcine pa ncrea tic  graft.  
 
2.1.3.3 Attachment of  the Benched Grafts to the Perfusion Cassette 
Only one organ was run on the RM3 at any one time. Once the RM3 machine has been prepared and 
the cassette primed the opposite arterial tubing from the bubble trap was clamped shut. To attach 
the organ the circuit flow was reduced (using the Stroke Volume knob on the RM3 base unit) and the 
cannulated arterial segment of the dissected graft was slowly filled with perfusate and de-bubbled. 
The cannulated artery was then connected to the unclamped arterial tubing of the cassette and the 
flow then altered using the stroke volume knob to reach the desired initial flow and/or pressure 
readings. 
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Application of Rapid Sampling Microdialysis in Organ Viability Assessment During 
Preservation: A Comparison of SCS vs. HMP 
3.1 Objectives  
 
Microdialysis is a minimally invasive technique that allows the interstitial composition of a target 
tissue to be sampled, followed by ex vivo analysis, providing an accurate method of monitoring 
tissue biochemistry and metabolism over time.  
Imperial College London has successfully developed a novel online rsMD analyser capable of 
measuring the concentration of markers of tissue ischaemia at 30 second intervals. To date no such 
system has been used to directly characterise and compare the effects of SCS and HMP on renal 
biochemical activity and the ischaemic injury sustained during preservation in real time. If capable of 
accurately monitoring tissue ischaemia during organ preservation, rsMD may have a promising 
future role in graft viability assessment. 
Objectives were two-fold: 1) to assess the feasibility of using rsMD to monitor changes in glycolytic 
metabolites in the renal cortex and medulla during SCS and HMP in a porcine model; 2) to compare 
the effects of SCS and HMP on renal cellular metabolism and ischemia during the preservation 
period. 
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3.2 Methods  
An experimental porcine DCD model was employed to determine the feasibility of using the rsMD 
system for tissue viability assessment during ex vivo hypothermic preservation.  This was 
conducted in collaboration with Prof Boutelle's team in the Department of Bioengineering at 
Imperial College London who designed and built the in-house rsMD system.  
3.2.1 Organ Procurement 
Twenty-two DCD (Maastricht Type 2 equivalent)  kidneys were retrieved from 11 adult pigs (70-
100 kg), terminated at a local abattoir by stunning and exsanguination. Organs were retrieved by 
laparotomy and rapid en-bloc dissection of both kidneys. as per the shorter ischaemia protocol 
detailed in Section 3.1.3.1. After a median ischaemia time (WIT) of 15 minutes (range: 11-20 
minutes) organs were cold flushed with University of Wisconsin (UW) solution (Viaspan, Bristol 
Myers Squibb, UK) at low pressure (100 cm H2 0), until the venous effluent was clear. Organs were 
then stored in the flushing solution and transported on ice to the laboratory.  
3.2.2 Organ Preservation 
Kidneys underwent either a further 24 hours of SCS or 10 hours of HMP. Ten kidneys underwent 
24 hours of SCS (n=10, mean temperature 3.5 oC) in the original flushing solution, while twelve 
underwent 10 hours of HMP (n=10, mean temperature 7.8 oC) on a Waters Medical Systems RM3 
perfusion machine. Mean cold ischaemia time (CIT) prior to start of in-lab preservation (24 hours 
of SCS or 10 hours of HMP) and microdialysis monitoring was 254 minutes (range: 160-380 
minutes). Target systolic perfusion pressure was 40 mmHg during the first 4 hours of HMP, which 
was adjusted hourly. After 4 hours no further changes to the perfusion system were made. 
Perfusion dynamics were monitored throughout.  
UW solution (Viaspan) was used as the HMP perfusate in these experiments. This solution was 
originally developed by Belzer and colleagues as a HMP solution, and despite experimental work 
that has shown it is as effective as the machine preservation solution (MPS) variant [1047], at 
present only the Belzer MPS variant is FDA approved for clinical HMP use. The same solution was 
chosen for both preservation modalities to observe and determine differences in renal tissue 
biochemistry between SCS and HMP, and not influenced by differences in perfusate composition.  
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Following SCS or HMP preservation support was stopped abruptly and each kidney was allowed to 
warm passively for 2 hours to detect changes in lactate concentrations as tissue temperature 
increased and ischaemic cellular injury accumulated. This was a massive challenge for the kidneys, 
to test their reaction to the rewarming injury and the potential affect of each preservation 
method on the “reaction” of the kidney to the challenge. The protocol for this experiment is 
summarised in Figure 42.  
HMP kidneys experienced approximately 14 hours of total CIT (~4 hours SCS for transport and 10 
hours for HMP), while SCS kidneys underwent 28 hours of total CIT (~4 hours for transport and 24 
hours of SCS). These time periods were chosen to mimic extreme clinic settings.  
 
Fi gure 42  Di agram of the exper i mental protocol detail ing the s equential phases.  
 
3.2.3 Rapid Sampling Microdialysis 
RsMD assessment of tissue metabolism was conducted in collaboration with the Department of 
Bioengineering, Imperial College London using an custom made system.   
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Two microdialysis probes (MAB11.35.4, Microbiotech, Stockholm, Sweden) were inserted into each 
kidney, one tunnelled superficially into the parenchyma of the lateral cortex and one placed deeper 
perpendicularly into the medulla (see Figure 43).  
 
Figure 43 Mic rodialysis monitori ng in porcine ki dneys . Comparis on of si ze of a microdialysis 
probe to  a green hypodermic  needl e (top l eft), a nd a  ki dney undergoi ng moni tori ng wi th probes 
in c or tex and medullary regions (top ri ght). Two ki dneys  undergoing H MP and microdialysis 
(bottom). 
 
A fine tubular dual lumen microdialysis probe, with a semi-permeable membrane tip is introduced 
into the tissue of interest. A physiological isotonic solution is pumped through the probe inlet 
tubing at a constant flow rate, past the semi-permeable membrane tip, creating a concentration 
gradient across the membrane. Low molecular weight compounds diffuse across the membrane, 
down their concentration gradients, while larger molecules such as proteins or those bound to 
proteins are excluded by the inherent pore size of the membrane. The dialysate is sampled at the 
outlet port and analysed for compounds of interest. 
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Cortical probes were analysed in real-time; for the medulla, the liquid stream was collected in 
storage tubing and ‘played back’ afterwards to recreate the real time. In addition perfusate samples 
taken during 10 hours of HMP (0, 3, 6, 10 hours) were analysed for levels of lactate and glucose by 
using the rsMD system. 
Extensive changes were made to the rsMD system currently used to monitor brain injury [907], 
bowel ischemia [912] and free flap surgery [915], to make it suitable for monitoring a pair of kidneys 
(see Figure 44). The probe inlet tubing was connected to a syringe pump (CMA 400 pump, CMA 
Microdialysis, Stockholm, Sweden) and perfused with T1 physiological solution (2.3 millimolar [mM] 
calcium chloride, 147 mM sodium chloride, 4 mM potassium chloride) at a rate of 2 μL/min. This 
flow rate was chosen to minimise the delay in the dialysate reaching the analyser whilst maximising 
the recovery of the probe; slower flow rates would have resulted in an increased recovery but would 
have increased the lag time. The outlet tubing of the probe was connected to the 200 nanolitres (nL) 
sample loop of a custom-made 6-port internal loop valve (Valco Instruments, Schenkon, 
Switzerland). A high-pressure liquid chromatography pump (Rheos 2000, Flux Instruments, Basel, 
Switzerland) pumped a filtered analysis buffer (0.1 mM sodium citrate, 150 mM sodium chloride, 1.0 
mM ethylenediaminetetraacetic acid, 1.5mM ferrocene monocarboxylic acid, filtered through 100 
nm, then 20 nm anodisc membranes) at 100 μL/min into an analysis loop within the valve. The outlet 
tubing of two probes was connected to two separate sample loops of the valve, either side of the 
analysis loop, allowing two kidneys to be monitored simultaneously. Every 30 seconds a 200 nL 
dialysis sample was automatically injected into the analysis flow stream, alternating between each 
kidney. On some occasions the valve switching frequency was reduced to every 150 seconds. The 
stream accelerates the dialysate through an enzyme reactor containing lactate oxidase (LOx) and 
horseradish peroxidase (HRP) (Genzyme Diagnostics, Kent, UK). The LOx recognises the analyte, 
producing hydrogen peroxide, which reacts with the HRP. The HRP is regenerated by oxidation of the 
ferrocene mediator species, producing ferrocinium ions, which are detected at the downstream 
electrode (BASi, West Lafayette, IN) by reduction. Due to the small sample size, the current 
produced is directly proportional to the concentration of lactate in the sample, even above the free 
solution Km of the lactate oxidase enzyme (0.7 mM). Data was collected using a PowerLab data 
acquisition unit (8/30, ADInstruments, New South Wales, Australia) and LabChart software 
(ADInstruments, New South Wales, Australia) running on a Macbook Pro portable computer (Apple 
Computers, Cupertino, CA). 
The recorded current peaks were separated in Matlab (R2011b, MathWorks, US), to produce results 
for each kidney individually, and were converted into concentrations based on calibrations (using 
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different concentrations of lactate) carried out before, during, and after each experiment. The 
results were adjusted to correct for the transit time between the microdialysis probe and th e 
analysis system. 
 
 
Figure 44  A. A mi crodialysis probe is ins er ted into the cor tex of ea ch ki dney. The probe outl ets 
are connec ted to the flow inj ec tion valve of the rs MD s ys tem, ei ther si de of the a nalysis l oop, 
using low-volume FEP tubing, repres ented here by dotted bl ue lines . Ever y 30  s  a  200  nL 
dial ysa te sa mpl e is inj ec ted into the a nal ysis flow s trea m, al terna ti ng between ea ch ki dney, 
provi ding real -ti me da ta  fr om two ki dneys  si mul ta neousl y. B. The dialysa te sa mpl e flows 
through an enzyme reac tor  whic h contai ns two cons ec uti ve me mbra nes , the firs t loaded wi th 
lac ta te oxidas e a nd the s ec ond wi th hors era dish peroxidas e to a  glassy carbon el ec trode hel d a t 
0  V. The reac ti on is media ted by fer roc ene monocarboxyla te. C. The current is rec orded as 
pea ks , alterna ting between eac h ki dney.  The pea k hei ght is  proporti onal  to the la c ta te 
c onc entra ti on in the dialysa te s a mpl e. Abbrevia tions : rs MD: rapi d sa mpling microdialysis , nl : 
na nol itre, V: vol t.  
 
3.2.4 Storage and delayed analysis of on-line microdialysis 
The second microdialysis probe was placed into the medulla of each kidney. The probe inlet tubing 
was connected to a syringe pump and perfused with T1 solution at a flow rate of 1 μL/min. The 
outlet of the probe was connected to a length of coiled storage tubing (fine bore polyethylene 
tubing, 0.4 mm inner diameter, 12 m for SCS experiments and 6 m for HMP) primed with T1 solution. 
This lower flow rate was chosen to increase the probe recovery and to reduce the length of storage 
tubing required. Usually this would increase the time delay between the probe and the assay 
however this was not an issue in this case as the samples were analysed later. At the end of the 
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kidney monitoring experiment, during which one probe for each kidney was assayed online, the 
stored dialysate from the second probe was then pumped into the on-line assay, effectively ‘playing 
back’ the online liquid stream collected during the experiment.  To do this the end of the coiled 
tubing that had been connected to the probe was detached and connected to a syringe pump and 
perfused with T1 solution at a flow rate of 2 μL/min, while the other end of the coiled tubings were 
connected to two separate sample loops of the valve, either side of the analysis loop, as before, 
allowing the data to be analysed with temporal resolution. The dialysate was analysed as described 
above for the online assay. Differences in flow rate and delay were accounted for to compare these 
results to the online results (see Figure 45).  
In an experiment to compare online and offline methods, two probes were placed in the same 
region of the medulla; one probe was analysed online and one offline, as described above. The 
levels obtained by the two methods were coincident. The mean difference between the two 
probes was 24.7 ± 62.5 µM, compared to a mean difference of 269 ± 66.7 µM comparing two 
probes in two different regions (the cortex and medulla), both analysed using the online method 
(data not shown). 
 
 
Figure 45 Sc hema tic c omparis on of the online and s tored a nal ysis methods . Onli ne a nalysis was 
ca rri ed out a t 2  µL/mi n, givi ng 60  meas urements i n 1 hour . Stored sa mpl es  were coll ec ted a t 1 
µL/mi n a nd a nalys ed a t 2  µL/mi n, giving 30  measurements  i n 1  hour . Abbreviati ons : µL: 
mi c rolitre. 
 
3.2.5 Perfusate analysis 
Perfusate samples were taken at the start of HMP and then at 3, 6 and 10 hours. The samples 
were stored at -80 °C and were analysed at a later date. The rsMD system was re-configured and 
was set up in the same way as the system used to monitor brain injury patients. Each sample was 
manually injected into the system until 6 peaks were obtained for each of glucose and lactate.  
220 
 
3.2.6 Statistical Analysis 
For intra-preservation group comparisons, tests were done using the Wilcoxon Signed Rank Test 
(two-tail), while the Mann Whitney U-Test (two-tail), was used for inter-preservation group 
comparisons. Significance was taken to be p<0.05. Perfusion dynamics are represented as means +/ - 
SD. Lactate levels are represented as median and interquartile range, and graphically using box plots 
showing the median and interquartile range, with whiskers showing the 10th and 90th percentiles. For 
the initial 40 minutes of warming, the data was compared to an assumed linear increase, using area 
under the curve analysis. A one-sample t-test (two-tail) was used to test whether the data was 
significantly different from a linear increase. 
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3.3 Results  
3.3.1 HMP Dynamics 
Ten kidneys underwent 24 hours of SCS and a further twelve underwent 10 hours of HMP. Ten 
kidneys underwent 24 hours of SCS and a further twelve underwent 10 hours of HMP. Perfusion 
parameters were similar between HMP kidneys with systolic pressures of 36 ± 8.5 mmHg, flow rates 
of 27.7 ± 6.1 ml/min/100g, PFIs of 0.75 ± 0.27 ml/min/100g/mmHg, and resistances of 0.39 ±0.16 
mmHg/ml/min by the end of perfusion, with a trend of improving perfusion metrics  and based on 
clinical protocols, were considered indicative of kidneys suitable for transplantation [841] (Figure 
46). 
3.3.2 Microdialysis 
Overall medullary lactate levels were greater than cortical levels throughout preservation and 
passive warming. RsMD data from two kidneys that underwent HMP was excluded from analysis due 
to technical problems. 
3.3.2.1 Preservation 
SCS – Cortex  and Medulla 
SCS cortical lactate levels declined from 114 (84-164) to 65 (41-118) µM (p=0.002, n=10) between 
the 15-30 minutes interval and the 1-1.5 hour interval. Levels remained low and stable for the 
remainder of the 24 hours (63 [60-151] µM at 23.5-24 hour interval, Figure 47a). In contrast, 
however, medullary lactate levels were stable and consistent throughout monitoring (Figure 49), 
with significantly greater levels throughout the preservation period in all cases and at all time 
intervals compared to the cortex (median cortical levels at 15-30 minutes, 1-1.5 hours, 9.5-10 hours 
and 23.5-24 hours: 114 (84-164)  µM, 65 (41-118)  µM, 68 (53-102) µM, 63 (60-151) µM, compared 
to medullary levels: 600 (480-826) µM p=0.004, 478 (421-712) µM (p=0.002), 474 (361-568) μM 
p=0.002, 374 (343-624) µM p=0.004 respectively , n=10). 
HMP – Cortex and Medulla 
During HMP, cortical lactate levels were stable for the initial 1.5 hours of perfusion (98 [76-104] µM 
at 15-30 minutes and 124 [76-179] µM at 1-1.5 hours, p=0.322, n=10). Between the 1-1.5 hours and 
9.5-10 hour intervals, median levels increased to 230 (201-291) µM (p=0.002, n=10, Figure 47b). 
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Similar to the SCS data, HMP medullary lactate levels were greater than cortical levels (median levels 
at 15-30 minutes, 1-1.5 hours, and 9.5-10 hours: 98 [76-104] µM, 124 [76-179]  µM, 230 [201-291]  
µM in the cortex compared to 425 [149-645] µM p=0.027, 315 [167-447] µM p=0.009, 551 [369-877] 
µM p=0.004 in the medulla, n=10, Figure 49). 
SCS vs. HMP 
There were no significant differences in cortical lactate levels during the first 1.5 hours of SCS and 
HMP preservation. By the 9.5-10 hour interval, the median cortical lactate concentration in HMP 
kidneys was significantly higher than in those preserved by SCS (HMP 230 [201-291] µM vs. SCS 68 
[53-102] µM, p<0.001, n=10, Figure 48). In the medulla, there was no significant difference in lactate 
levels between the two methods during the entire preservation period (n=10,  Figure 48). 
3.3.2.2 Warming  
Cortical lactate profiles for SCS kidneys undergoing 2 hours of passive warming showed a significant 
increase in lactate, detected between the end of 24 hours (65 [59-169] µM) and after 1 hour of 
warming (121 [103-216] µM, p=0.004, n=9), with no further increase by 2 hours (133 [104-225] µM, 
p=0.652). Maximum lactate levels were detected within the first hour of warming (median 11 [9-15] 
minutes after warming onset, Figure 50), which then decreased to stable levels, although still higher 
than pre-warming levels, within 1 hour.  
Similarly there was a significant increase in cortical lactate levels between the end of HMP (241 [206-
276] µM) and after 2 hours of warming (470 [320-586] µM, p=002, n=10). In contrast to SCS, 
however, the time to maximum detected lactate in HMP kidneys was significantly longer (median 
120 [112-120] minutes after warming onset, p<0.001 vs. time to peak in SCS group, Figure 50).  
Overall there was a significant increase in cortical lactate after warming in both groups, with the 
increase in the HMP group significantly greater than the SCS group (SCS median increase 56 [49-62] 
µM vs. HMP 143 [88-353] µM p=0.006, Figure 51). 
Medullary data indicated a significant increase in lactate during 2 hours of warming in both groups 
(median values before and after warming, SCS: 381 [359-652] µM to 667 [617-738] µM, p=0.008, 
n=9; HMP: 517 [375-850] µM to 926 [738-1137] µMp=0.002, n=10) with a similar increase in both 
groups (median values SCS: 248 [93-357] µM, HMP: 241 [168-297] µM, p=0.968,Figure 51). Similarly, 
the median time to maximum detected medullary lactate levels was 120 [100-120] minutes in SCS 
and 98 [90-120] minutes in HMP kidneys (p=0.357). 
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Specific area under the curve analysis of the lactate profiles during the initial 40 minutes of warming 
(Figure 52) demonstrated no significant difference compared to a linear increase model in both 
cortical and medullary regions of HMP kidneys. Cortical lactate levels in SCS kidneys however, 
demonstrated a significant difference, compared to a linear increase, in a positive direction, 
corresponding to the lactate spike seen in this preservation group, while medullary levels also 
showed a significant difference from a linear increase but in a negative direction, indicating that 
levels decreased during this period, before increasing.  
The mean increase in temperature in both SCS and HMP kidneys during 2 hours of w arming was 
similar in both groups (median values: SCS 13.2 [11.6-13.3] oC vs. HMP 11.1 [10.1-11.4] oC, p=0.625). 
The final median temperature after 2 hours of warming in the SCS group was 17.1 (15.7-17.2) oC and 
17.9 (17.5-18.7) oC in the HMP group (p=0.312).  
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Figure 46  Per fusion dyna mics over  10  hours  of HMP for  12 kidneys . Per fusi on c hara c teristics 
were indica ti ve of organ viabili ty, wi th i mproving flow ra tes  and per fusion flow i ndic es . (Mean 
+/- s tandard devia tion).  Ta rget s ys tolic  per fusion press ure was 40  mmHg during the firs t 4  hours 
of HMP, whic h was  adj us ted hourl y. After  4  hours  no fur ther  c hanges  to the perfusion s ys tem 
were ma de. Abbrevi a tions: HMP: hypothermi c ma chine per fusion.  
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Figure 47  Dialysa te c or tical  lac ta te profil es for  kidneys  undergoing A. 24  hours of c old s tora ge 
(n=10). B. 10  hours  of HMP (n=10). Eac h line repres ents  real -ti me da ta  of an i ndi vidual ki dney 
wi th a  point every minute (5  mi nutes  in a  few cas es  - 2  SCS, 2  HMP, for  s ec tion fr om 2  hours  to 
end) s moothed wi th a  Savi ts ky-Gola y 21 -poi nt fi l ter  to mi ni mis e the effec t of a ny a nomal ous 
resul ts . I ns et: Media n lac ta te conc entra tions of SCS kidneys a t 4  ti me intervals (15 -30 minutes , 
1 -1 .5  hours , 9 .5 -10  hours , a nd 23.5-24  hours ) during 24 hours of pres erva tion and of HMP 
ki dneys a t 3  ti me intervals (15-30  mi nutes , 1 -1 .5  hours and 9 .5 -10 hours) during 10  hours  of 
pres erva tion. Sha ded regions  indica te the da ta wi ndow a vera ged to give the da ta  pres ented in 
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the box plots . Boxplots  show media n l evels a nd i nterquartil e ra nge. Whiskers i ndic a te 10
th
 a nd 
90
th
 perc entiles . Si gnifica nc e: * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001, NS = not 
si gni ficant. For SCS, p=0.002 for  15 -30 minutes  vs . 1 -1 .5 hours, p=0.770 for 1-1 .5  hours  vs . 9 .5 -
10  hours  a nd p=0.098 for  9 .5 -10  hours  vs . 23 .5 -24  hours . For  HMP, p=0.322 for  15 -30 minutes 
vs . 1 -1 .5  hours a nd p=0.002 for 1 -1 .5 hours vs. 9 .5 -10 hours. Abbreviations: µM: mi c romolar.  
 
 
 
Figure 48  Media n dialysa te c or tical  lac ta te l evels  in SCS a nd HMP ki dneys  during 24  hours  of SCS 
(n=10) a nd 10  hours  of HMP (n=10). Lac ta te l evels  were si milar  during the firs t 1 .5  hours  of 
pres erva tion, media n values  a t 1 -1 .5  hours : HMP 124 (76 -179) µM vs . SCS 65  (41-118) µM. At 
the 9 .5-10 hours  interval lac ta te l evels were significa ntl y higher  in HMP kidneys vs . SCS ki dneys 
(230  [201 -291] µM vs . 68  [53-102] µM, p<0.001). Boxpl ots  show media n l evels  a nd i nterquartil e 
ra nge. Whis kers  indica te 10
th
 and 90
th
 perc entiles . Signi ficanc e: * p<0.05, ** p<0.01, *** 
p<0.001, **** p<0.0001, NS = not si gni ficant. For SCS, p=0.002 for  15 -30  mi nutes vs . 1-1 .5 
hours , p=0.770 for  1 -1 .5 hours  vs . 9 .5 -10 hours and p=0.098 for 9 .5 -10 hours vs. 23 .5 -24 hours . 
For HMP, p=0.322 for  15-30 mi nutes vs . 1 -1 .5 hours and p=0.002 for 1-1 .5 hours vs . 9 .5-10 
hours . For  SCS vs . HMP, p=0.393 a t 15 -30  minutes , p=0.075 a t 1 -1 .5  hours  a nd p<0.001 a t 9 .5-10 
hours . Abbreviations: µM: mi c romolar.  
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Figure 49  Median dialysa te medullary lac ta te l evels i n SCS a nd HMP kidneys during 24 hours  of 
SCS (n=10) a nd 10 hours of HMP (n=10).  For  ki dneys  s tored usi ng SCS, lac ta te l evels  remained 
s ta bl e fr om ons et (478  [421-713] µM, 474 [361 -568] µM a nd 374 [343 -624] µM a t 1 .5 hours , 10 
hours , and 24 hours res pec tivel y). During HMP, lac ta te l evels remai ned s ta bl e for the i ni tial 1 .5 
hours , and then i ncreas ed between the 1 -1 .5 hours  and 9 .5 -10 hours i ntervals (315 [167 -447] 
µM a t 1 .5  hours  to 551 [369 -877] µM a t 10 hours). C omparing SCS to HMP, lac ta te l evels were 
si milar  throughout pres erva ti on. Boxpl ots  show media n l evels  and interquartil e ra nge. Whis kers 
indica te 10
th
 and 90
th
 perc entiles . Signi ficanc e: * p<0.05, ** p<0.01, *** p<0.001, **** 
p<0.0001, NS = not si gni fica nt. For  SCS, p=0.193 for 15 -10 mi nutes  vs . 1 -1 .5 hours , p=0.625 for 
1 -1 .5  hours vs . 9 .5 -10  hours a nd p=0.359 for  9 .5-10  hours  vs . 23 .5 -24 hours. For HMP, p=0.105 
for  15 -30  mi nutes vs . 1 -1 .5  hours  a nd p=0.014 for 1 -1 .5  hours vs . 9 .5-10  hours. For  SCS vs . HMP, 
p= 0 .315  a t 15 -30  minutes , p=0.089 a t 1 -1 .5 hours a nd p=0.353 a t 9 .5 -10 hours. Abbrevia tions : 
µM: mi c romolar. 
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Figure 50  Dialysa te cor tical  lac ta te profiles  for  ki dneys  undergoi ng 2  hours  of passive wa rming 
to a mbi ent tempera tu re a fter pres erva tion. Eac h line repres ents  real -ti me da ta of a n indivi dual 
ki dney wi th a  point every minute, s moothed wi th a Sa vits ky -Gola y 21 -poi nt fi lter to mini mis e 
the effec t of any a nomalous  resul ts . A. 24  hours  of SCS (n=9), B. 10  hours  of HMP (n=10 ). I ns et: 
media n readi ngs for lac ta te c onc entra tions a t 3 ti me intervals (30  minutes  before wa rming, 
a fter  1  hour  warmi ng, a fter  2  hours  wa rming) during 2  hours  of passive warmi ng. Shaded 
regi ons i ndica te the da ta  window avera ged to give the da ta  pres ented  in the box  plots . Boxplots 
s how media n l evels a nd i nterquartil e range. Whis kers  indica te 10
th
 a nd 90
th
 perc entil es . 
Signi ficanc e: * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001, NS = not si gnifica nt. For  SCS, 
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p=0.004 for  before vs . a fter 1 hour wa rming a nd p=0.652 for 1 hour vs . 2 hours  a fter  wa rming. 
For HMP, p=0.275 for  before vs . a fter 1 hour wa rming a nd p=0.002 for 1 hour  vs . 2  hours  after 
wa rmi ng. Abbreviations: µL: mi c rolitre.  
 
Figure 51  A. Comparis on of c or ti cal  lac ta te i nc reas e i n the two groups . The increas e i n the HMP 
group is signi ficantl y grea ter tha n the SCS group (media n val ues : HMP 143 [88 -352] µM vs . SCS 
56  [49-62] µM, p=0.006). B. Comparison of medullary la c ta te i ncreas e, whic h is  si milar  between 
both groups (media n val ues : HMP 241 [168 -297] µM, vs . SCS 248 [93 -357] µM, p=0.968). 
Boxplots s how media n l evels a nd i nterquartil e ra nge. Whis kers i ndica te 10
th
 a nd 90
th
 
perc entiles . Si gnifica nc e: * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001, NS = not si gnifica nt. 
Abbrevi a tions: µM: mi c romolar.  
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Figure 52  Area under  c urve anal ysis of lac ta te profiles  during warmi ng, compa red to a l i near 
increas e model  during the i ni tial 40  mi nutes  of wa rming. No si gni fica nt c hanges  in lac ta te l evels 
in HMP kidneys during this period were detec ted. Cor tical  lac ta te l evels  i n SCS ki dneys 
demons tra ted a  signific ant i ncreas e, corres ponding to the lac ta te s pike s een in this pres erva ti on 
group, while medullary l evels dec reas ed slightl y during this  period. Si gnifica nc e: * p<0.05, ** 
p<0.01, *** p<0.001, **** p<0.0001, NS = not sig ni ficant. HMP c or tex p=0.071, SCS c or tex 
p<0.001, HMP medul la p=0.387, SCS medulla p=0.004. Abbreviations: µM: mi c romolar.  
 
 
Figure 53 Perfusa te lac ta te (green) a nd gluc os e (red) conc entra tions  duri ng 10 hours  of HMP for 
two ki dneys . The da rker  a nd li ghter  c ol ours i ndi ca te the two kidneys . Lac ta te increas es  during 
HMP, whil e gl uc os e pea ks a fter  s everal  hours a nd declines  until  the end of per fusi on.  
Abbrevi a tions: mM: mi l l imolar .  
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3.4 Discuss ion 
We have used rsMD to identify the differing effects on renal energy metabolism brought about by 
SCS and HMP, both during hypothermic preservation and subsequent warming. Both modalities 
show contrasting effects, and these differences may help elucidate the reported clinical 
superiority of HMP, that is observed to afford metabolic resilience on the renal parenchyma to 
warm ischaemia after initial cold preservation. 
Associations between DGF and increased risk of graft loss [41], acute rejection [50], longer 
hospital stay and high costs [51] mean there is an emerging need for better viability testing prior 
to transplantation to identify and potentially reduce the risk of poor outcome, especially with the 
increasing use of organs from ECD and DCD donors. The period of preservation between retrieval 
and transplant provides a unique opportunity to assess organ viability,  particularly when 
preservation utilises HMP [841]. 
Lactate, as an end-product of anaerobic glycolysis, formed by the conversion of pyruvate by 
lactate dehydrogenase, is a key marker of tissue hypoxia, ischaemia and cell stress, which is 
potentially reversible. 
3.4.1 Lactate and The Kidney 
The physiology of lactate in the kidney, however, is complex [1048]. Under normal physiological 
conditions the kidney plays a key role in removing lactate from the systemic circulation by uptake 
and metabolism, as well as in using lactate as a metabolite for gluconeogenesis [1049,1050]. The 
fate of lactate in the kidney differs between the cortex and medulla. The medulla is the primary 
site for local production of lactate from glucose, while the cortex uses lactate as both an oxidative 
energy substrate, and to form glucose for local and systemic use. Such an intricate recycling 
system is likely to be a way of providing the medulla and cortex with energy for their complex 
tasks [1051].  
Use of perfusate lactate as a biomarker of ischaemic tissue injury in HMP preserved kidneys has 
been investigated and associations between higher levels of perfusate lactate and risk of DGF 
have been found [847,1052]. Similarly perfusate lactate dehydrogenase (the enzyme responsible 
for the inter-conversion between lactate and pyruvate) has been evaluated in a number of studies 
and shown to be associated with primary and delayed function, as wel l as with graft failure [870]. 
Lower perfusate lactate in HMP has been taken as an indicator of better organ viability, as judged 
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by improved microvascular perfusion and post-transplant function [1052,1053]. Measuring 
perfusate lactate, however, provides no indication as to the anatomical source in the perfused 
organ and thus is a sensitive but not site-specific indicator of tissue metabolism. RsMD allows 
quantification of local levels of lactate within the interstitium of the renal parenchyma – both the 
cortex and the medulla - the two principle and distinct metabolic regions of the kidney. 
3.4.2 Cortical Metabolic Profiles During SCS and HMP  
It was initially theorised that tissue lactate in HMP preserved kidneys would be lower than in SCS, 
as a result of the washout effect in HMP, with levels in SCS preservation predicted to rise 
progressively as lactate accumulation occurs during cold ischaemia - interestingly the reverse was 
found. Cortical lactate remained consistently low and stable for the duration of SCS, while levels 
in HMP kidneys increased progressively. The stable, low lactate levels seen during 24 hours of SCS 
have not been reported previously [916,923]. 
HMP differs from SCS in two key respects. Firstly, in HMP there is a sustained pulsatile perfusion, 
which allows buffering of intra- and extra-cellular acidosis, and removal of metabolic products. 
Secondly, SCS kidneys were typically stored at a lower temperature (4.6 °C lower on average). The 
protocols for this study were designed to mimic clinical practice as closely as possible to ensure its 
translational potential of the data generated. Clinically, the temperature at which HMP is 
performed is between 4-8 oC, while SCS temperatures are lower at 2-4 oC[1054,1055]. In our 
study, these differences were maintained. Hence, in SCS, local glycolytic activity may have been 
limited due to: 1) a finite local supply of glucose and ATP precursors. 2) the inhibitory effect of 
acidosis on glycolytic enzymes and therefore glycolysis rates. 3) the lower temperatures during 
storage, slowing cellular function and therefore reducing both the demand for energy and energy 
metabolism rates. During HMP, oxygen delivery via oxygen dissolved in the UW solution is much 
lower than with haemoperfusion, but even after 18 hours of perfusion remains above 100mmHg, 
however, tissue VO2 is also reduced to the extent that the delivery would be theoretically 
sufficient for basal metabolic requirements [722].   
Lactate metabolism is however complex in the kidney. Further explanation for the increasing 
lactate levels seen during HMP is that direct perfusion provides the possibility for the removal of 
local metabolic products from one part of the kidney for redistribution to other parts of the 
kidney, as the perfusate is recycled. This may re-establish local transport and redistribution of 
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glucose and lactate between the cortex and medulla, which would facilitate low levels of energy 
and glucose production in the cortex and further glycolysis in the medulla.  
Analysis of the perfusate demonstrates that perfusate lactate levels increase over the duration of 
HMP, while glucose levels increase in the first 3 hours of perfusion and then decrease over the 
remaining preservation period. Figure 53 shows data from perfusate analysis of two HMP kidneys. 
The increasing levels of glucose in the perfusate suggest that local production of glucose through 
cortical gluconeogenesis is occurring [1056,1057] as UW solution does not inherently contain 
glucose. This glucose can be transported to the medulla by the perfusion medium, enabling 
further glycolysis to occur, leading to the increasing lactate levels seen in both the tissue and the 
perfusate.  
This explanation is supported by the higher lactate levels seen in the medulla, compared to the 
cortex. The ability of HMP to re-establish glucose-lactate recycling, as well as to deliver low levels 
of oxygen and nutrients in the perfusate, may be sufficient to facilitate resumption of inherent 
physiological function to a certain degree. In contrast, SCS stored organs receive no perfusion, 
which may explain the difference in metabolic profiles seen between these two modalities. 
3.4.3 Cortical Metabolic Profiles During Warming after SCS and HMP 
The 2 hours of warming after cold preservation was designed to test the reaction of the kidney 
parenchyma to an extreme challenge and the effect to this reaction of SCS vs. HMP. During 
warming, increasing lactate levels likely represent further, more deleterious cell damage and 
death, as the type of ischaemia changes from hypothermic to sub-normothermic. The initial spike 
in lactate levels in SCS, observed in the first 30 minutes of warming, was likely a result of a surge 
in the limited metabolic activity and in anaerobic glycolysis, with the sudden increase in 
temperature. The subsequent decrease to lower stable levels representing remaining surviving 
cortical cells with minimal anaerobic potential. HMP profiles, however, do not show any initial 
surge in cortical lactate. Instead they show a gradual increase over the 2 hours, potentially due to 
an increased basal anaerobic glycolytic ability - as without continued machine circulation any 
contribution from medullary sources is negligible. The progressive cortical lactate increase in HMP 
kidneys may thus represent similar cell damage as in SCS kidneys but protracted over a longer 
time interval, possibly indicating a better “ability” of HMP kidneys to tolerate the warming insult. 
3.4.4 Metabolic Profiles in the Medulla 
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The medulla can be considered to be a physiologically distinct organ to the cortex with respect to 
function and metabolic activity [549,1056,1057]. A similar trend was seen in medullary lactate 
profiles during preservation by both HMP and SCS, with no observable diff erences between the 
two modalities. Furthermore similarities in SCS and HMP kidneys' medullary profiles during 
warming suggest any real effect of HMP may dominate in cortical regions of the kidneys.  
3.4.5 Microdialysis Studies of Renal Metabolism 
Investigating energy metabolism in renal SCS, Keller et al. [916] used conventional microdialysis 
(off-line with samples analysed every 30 minutes)  in a porcine autotransplant model and showed 
an initial decrease in cortical lactate during a relatively short CIT of approximately 2 hours. The 
decrease was expected as microdialysis monitoring commenced prior to retrieval and flushing, 
and represents decreased metabolism secondary to flushing and cold storage.  
In their later study [923] using longer CIT (24 hours), in an ex vivo porcine renal preservation 
model, they showed an overall increasing trend in cortical lactate levels during 24 hours of SCS, in 
stark contrast to our findings. Furthermore in the same experiment kidneys undergoing 24 hours 
of warming (at 37oC - without any preceding hypothermia) lactate levels peaked after several 
hours and remained high. In contrast in our experiments warming lactate profiles (in SCS kidneys) 
demonstrated a rapid peak (within 15-30mins) followed by a quick decline to a stable nadir. In our 
protocol warm ischaemia exposure was at a lower temperature (21oC) and post a period of 
hypothermic preservation so a direct comparison cannot be made accurately. However given the 
different protocols, differences in lactate profiles could be attributed to the period of SCS in our 
experiments. 
Microdialysis monitoring during in situ clamping of renal arteries to instigate ischaemia [1058], 
vascular thrombosis [917], and DGF [1059] in porcine models demonstrates a build up of cortical 
lactate and depletion of glucose. This is an expected phenomenon in ischaemic settings, which 
can be explained by the switch to anaerobic production of lactate, with glucose consumption. 
Fonouni et al. [922] recently investigated differing CIT duration on renal energy metabol ism 
during anastomosis and reperfusion in a porcine autotransplant model. They observed a similar 
lactate rise and peak in the initial period during the anastomosis, after 24 hours of SCS, followed 
by a decline until vascular reperfusion. These findings correlate with our data, however due to the 
superior temporal resolution of our rsMD system we were more accurately able to determine the 
duration and level of the warming peaks. In the same study, kidneys with a shorter SCS CIT of 6 
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hours showed a progressive increase in lactate in the same period, and interestingly this profile 
resembles the warming profile for HMP kidneys in our study. It is possible to surmise that these 
less compromised (6 hours SCS) kidneys are of a similar viability as the HMP kidneys in our study  
possibly due to the effect of HMP preservation on the renal parenchyma. 
In a novel study Baicu et al. [1060] combined microdialysis with renal HMP preservation to 
determine the efficacy of perfusate supplementation, in restoring depleted energy 
intermediaries, but failed to quantify perfusate or tissue lactate levels. The authors concluded 
that measuring interstitial chemical changes by microdialysis may provide a better means of 
assessing organ viability than by renal effluent analysis alone.  
3.4.6 Limitations of this Study 
There are some inherent limitations in this work. UW was used as both the SCS solution and HMP 
perfusate in these experiments. Despite UW solution being initially designed by Belzer and 
Southard to be a HMP perfusate, the UW Belzer MPS variant is the predominate perfusate used in 
conventional renal HMP. The predominate difference between UW and Belzer MPS is  the 
electrochemical composition with an inversion of the sodium / potassium content; UW being an 
intra-cellular solution and Belzer MPS extra-cellular [705]. The theoretical  benefits of using one 
solution is that differences in their composition should not affect any observed differences 
between preservation modalities. A limitation is that the use of one solution in the protocol does 
not truly replicate clinical practice, however recent experimental evidence from a canine kidney 
auto-transplant model suggests equity in effect and outcomes in kidney HMP preservation using 
either solution - UW or UW Belzer MPS[1047].  
The Waters Medical Systems RM3 organ perfusion unit was used in these experiments with a 
normal hypothermic perfusion temperature between 4-8oC. As indicated in Section 1.7.2.9 
MACHINE PERFUSION DEVICES the Organ Recovery Systems Lifeport immerses the organ in cold 
preservation solution in addition to perfusion thus maintaining organ temperature lower than 
with the RM3. The rsMD lactate profiles observed in these experiments are specific to kidney 
HMP using the RM3 and may be different with other devices.  
Comparatively different cold ischaemia times were used in SCS and HMP. There were several 
reasons. Twenty-four hours of SCS was chosen in this experimental setting to represent an 
elongation of the normally accepted duration of SCS in clinical practice [705]. The ten hours of 
HMP was chosen to match clinical scenarios with the rational that; the benefits of HMP are likely 
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to be experienced after 4-5 hours of HMP [1061] with minimal benefit after 10 hours; the average 
time for HMP in the UK is approximately 10 hours [831]. Furthermore more than 10 hours of HMP 
in the current model was not feasible due to logistical constraints. Such differences in cold 
preservation time however would potentially only impact rsMD data from the 2 hours post 
preservation warming period and not that during hypothermic preservation, in particular the 1st 
10 hours. Acknowledging this limitation an additional experiment using two kidneys was 
performed comparing 10 vs. 24 hours of SCS on subsequent warming lactate profiles to 
investigate the effect of the different cold storage time. In these kidneys a similar warming profile 
(with a lactate surge within 15-30 minutes followed by a decline to a stable nadir) was seen for 
both durations of CIT (data not shown). 
 rsMD monitoring was started only once the organs were back at the laboratory, and so there is 
no data for the critical time period that includes animal donor death, recovery warm ischaemia, 
organ flushing, and the first few hours of cold storage transportation.  
The 2 hour post preservation warming period was included to test the viability of the kidneys post 
preservation. This period was chosen to exert a challenge on the kidneys in an experimental 
setting and may only partly reflect the clinical period of anastomosis formation. This is because 
the 'anastomosis' takes on average less than an hour, and many transplant surgeons attempt to 
limit the temperature increase by applying ice-slush or cold external rinse. 
Finally in these experiments it was not possible to observe tissue lactate concentrations after the 
period of ambient warming, which would require either a porcine auto-transplant model or use of 
ex vivo isolated reperfusion to simulate the initial period of after reperfusion after 
revascularisation.  
3.4.7 rsMD in Context and Future Work 
Continuous online microdialysis has provided an important insight into the chemical processes 
active during the ex vivo phase of a donor kidney during SCS and HMP, offering, for the first time, 
a possible biochemical explanation regarding the protective role of HMP for kidneys. Further 
studies would need to be conducted to confirm this. Determining the potential of this technology 
in assessing allografts prior to transplantation requires an assessment of organ function in grafts 
with variable degrees of initial ischaemic injury, to correlate lactate profiles with functional 
outcome. This was not feasible using the current model. However the ability to monitor real -time 
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cellular metabolism in an organ prior to transplantation has the potential to provide unique and 
vital information on graft function post-transplantation.   
The next step is to use rsMD in a porcine kidney auto-transplant, or an ex vivo isolated 
reperfusion model, and to monitor multiple chemical markers of anaerobic metabolism (e.g. 
glucose, pyruvate, citrate and adenosine tri-phosphate) and kidney function in real-time. 
Furthermore rsMD monitoring will enable assessment of organ viability in experimental model 
testing strategies to improve preservation or ameliorate reperfusion related tissue damage. 
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Addressive Targeting of Anti-thrombin Agents to Graft Vasculature during HMP: Preconditioning 
Organs to Ameliorate Post Transplant Micro-vascular Thrombosis 
4.1 Objectives   
 
Combining the use of addressive anti-thrombin agents with the emergence of HMP as an 
increasingly effective tool in organ preservation allows a strategy to potentially pre-condition the 
graft endothelial and vasculature prior to transplantation. Our hypothesis is pre-treating a renal graft 
with Thrombalexin using HMP as a delivery tool will enable effective vasculature tethering, forming 
an anticoagulant 'coat' that would potentially diminish pro-coagulant processes by inhibiting 
thrombin activity, and improve organ perfusion. 
Ex-vivo organ perfusion models have been developed for investigating novel interventions that can 
ameliorate organ injury and improve viability. These models incorporate ex-vivo organ reperfusion 
models of porcine kidneys, as well as a direct pre-clinical model using human kidney grafts not 
suitable for clinical transplantation and subsequently donated for research. These organ perfusion 
models were used in a series of experiments investigating the feasibility and effect of using HMP for 
pre-conditioning kidney grafts with Thrombalexin. 
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4.2 Methodology 
4.2.1 Experimental Groups   
The aim of these experiments was to evaluate the potential of ex-vivo organ pre-treatment with 
Thrombalexin in ameliorating microvascular thrombosis and macro and micro vascular perfusion 
deficits using a normothermic ex-vivo renal haemo-reperfusion (NHRP) circuit with minimally anti-
coagulated autologous whole porcine blood. Four experiments were conducted. Experiment 1 tested 
an early variant of TLN (designated 'PTL006'), while Experiments 2-4 tested the current TLN 
construct. Experiment 4 involved use of human kidney grafts allocated for use in this research. 
Endothelial tethering of these proteins in porcine and human kidneys was evaluated using a 
specifically modified fluorescent labelled 'tail'. Details of the experimental groups and the protocols 
used is summarised in Figure 54.  
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Organ  
Procurement 
                         Hypothermic Perfusion 
Normothermic 
Reperfusion 
 
Graft 
retrieval, 
flush, 
and SCS 
transport 
  
 
HMP   
Stabilization: 
 
4 hours 
  
 
HMP Organ Pre-conditioning with 
TLN/PTL006:  
 
1.5 hours  
(Washout-1,Treatment, Washout-2) 
 
 
NHRP 
Challenge:  
 
6 hours 
UW Solution 
or Marshall 's 
Citrate 
Based on clinical 
protocols [841] 
Experimental Porcine Groups   
Experiment 1:  
 
 
 
 
NHRP challenge 
with porcine 
(autologous) 
blood 
CG1: n=7, control  
(Unmodified perfusate) 
Vs PTG1:n=7, TLN 
(PTL006)  
(2.1µM in 
perfusate) 
Experiment 2: 
CG2: n=8, control  
(Unmodified perfusate) 
 
Vs PTG2: n=8, TLN  
(2.1 µM in 
perfusate) 
 
Experiment 3: 
TCG3: n=4,  
Tail-only control  
(4.2µM Tail-only  
Proteins in perfusate) 
 
Vs PTG3: n=4, TLN  
(4.2µM in 
perfusate) 
 
 
Experimental Pre-clinical Group  
Experiment 4: Human kidneys Porcine blood -  
pro-coagulant 
 xenogenic 
stimulus 
CG4: n=1, control   
(Unmodified perfusate) 
 
Vs PTG4: n=1, TLN  
(4.2µM in 
perfusate) 
 
Figure 54 Schema tic  s umma ry of experi mental protoc ols  for  TLN tes ti ng in porcine and human 
rena l  grafts. CG: Control Group, PTG: Protein Tes t Group, UW: Uni versity of Wisc onsin Solution.  
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4.2.2 Organ Retrieval and Hypothermic Machine Perfusion 
Kidneys were retrieved from landrace pigs terminated at a local abattoir by stunning and 
exsanguination. This model of sacrifice was akin to substantial head injury and also DCD as animals 
were only accessed once cardiac death had occurred. Organs were retrieved as per the shorter 
ischaemia protocol detailed in Section 3.1.3.1. Access was achieved through a midline incision, 
Kidneys were retrieved via en-block dissection, flushed with preservation solution (500-1000ml at 
100cm H20) and packed on ice for transport to the laboratory. Paired kidneys were matched 
between treatment and control groups. All kidneys were perfused initially on a Waters Medical 
Systems RM3 device for 4 hours of HMP stabilization with preservation solution (500ml) according to 
clinical protocols [841] with a target systolic pressure of 40mmHg. Kidney weight pre- and post- HMP 
was recorded. Perfusion dynamics were recorded throughout.  
 
Approval was granted for research use of human kidney grafts initially retrieved but subsequently 
not used for transplantation by a National Research Ethics Committee (IRAS code: 84202) and NHS 
Blood and Transplant (the national regulator of organ transplantation in the United Kingdom). One 
pair organs were used in this study as part of a direct pre-clinical model in experiment 4, and 
underwent identical perfusion protocols as porcine kidneys. 
 
4.2.3 Cytotopic Peptides  
The TLN molecule is a conjugate peptide of the direct thrombin inhibitor  [D-Phe-L-Pro-L-Arg-L-Pro-
Gly-Gly-Gly-L-Asp-Gly-L-Asp-L-Phe-L-Glu-L-Glu-L-Ile–L-Pro-L-Glu-L-Glu-L-Tyr-L-Leu-Gly-Gly-L-Cys-
amide] and the cytotopic tail APT3146  [(N-alpha, N-epsilon Bis-myristoyl Lys-Ser-Ser-Lys-Seryl-Pro-
Lys-Lys-Asp-Asp-Lys-Lys-Pro-Gly-Asp- (S- 2-pyridyldithio) Cys] [1062].  
 
The peptide had a mass of 4649 Daltons as determined by time-of-flight mass spectrometry and was 
prepared by reaction of the two components in aqueous solution followed by further purification 
[1063].  
 
A fluorescently labelled-version, lacking anticoagulant activity (FAM-PTL), was used to study 
localisation of TLN within the kidney.  
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The component peptides were prepared using solid phase synthesis by Cambridge Research 
Biochemicals, Billingham, UK and the conjugate also synthesized at scale by Almac Sciences, 
Craigavon, UK. 
 
4.2.4 TLN Organ Pre-Treatment 
After HMP stabilization kidneys underwent preconditioning with TLN. This consisted of three 30 
minutes perfusion episodes:  
 
1) Washout-1: 30 minutes HMP with 300mls of fresh perfusate to limit the amount of remaining 
donor blood in the organ and perfusate from the initial 4 hours of HMP;  
 
2) Treatment: perfusion with 400ml of TLN spiked perfusate (Protein Test Groups 1-4; PTG1-4); or 
either un-modified perfusate (Control Groups 1, 2 and 4; CG1, CG2, CG4) or perfusate with Tail -only 
proteins (Tail Control Group 4, TCG4); and  
 
3) Washout-2: 30 minutes HMP with 300ml of fresh perfusate to facilitate removal of non-adherent 
TLN from the organ vasculature. A diagram summarising this protocol can been seen in Figure 55. 
 
The same flow driven perfusion parameters during HMP were used. HTK was used as a treatment 
medium in Experiment 1, and lab made glutathione-free University of Wisconsin solution in 
Experiments 2-4 (as glutathione content of UW solution has theoretical deleterious effects on TLN 
activity). Between each perfusion episode kidneys were removed and kept on ice in UW solution. 
 
 
4.2.5 Normothermic Haemo-reperfusion 
Kidneys underwent 6 hours of normothermic reperfusion using minimally anti-coagulated whole 
blood (WB) perfusate (10,000U/L Heparin); 600mls, 3:1 ratio WB:0.9% saline. RM3 units were setup 
to facilitate normothermic perfusion (see Figure 56). Once the perfusate was 39˚C kidneys were 
connected to the RM3 arterial tubing. Flow driven perfusion setting were maintained initially as per 
during HMP and then set to between 50-70mmHg and maintained equal between kidney pairs. 
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Human grafts were perfused with porcine whole blood to increase the likelihood of a pro-
coagulopathic reaction. 
 
 
Figure 55  Diagra m of TLN tes ting protoc ol . Three disti nc t phas es : HMP, TLN trea tment a nd 
Normothermi c  reper fusion.  
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Figure 56  Photogra ph of normothermic  ha emoreper fusion reper fusion circ ui ts  usi ng modi fi ed 
Wa ters  Medi cal RM3 per fusion devic e.  
 
4.2.6 Orthogonal Polarization Spectral Imaging 
OPS imaging technology was invented by Cytometrics, Inc. (Philadelphia, PA, USA) while developing 
a videomicroscope to take high contrast images of blood in the microcirculation using reflected light 
[1064]. The principle of OPS is based on cross-polarisation of reflected light. As can be seen in Figure 
57 light is linearly polarized in one plane by an emitter and projected through a beam splitter onto 
the target tissue. The majority of the reflected light retains its polarization and thus is unable to pass 
through to the analyser (orthogonal polarizer)  and form the image. However light that penetrates 
the tissue deeper undergoes multiple scattering events and becomes depolarized. This depolarised 
'scattered' light is reflected back which passes through the analyser and back-illuminates the 
absorbing foreground material. A wavelength of 548nm (green light) is used for the emitted light 
which is the optimal wavelength for absorption by oxy- and deoxy-hemoglobin in RBCs, enabling 
blood vessels of the microcirculation to be visualized.  
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Figure 57 Sc hema tic of the or thogonal polari za ti on spec tral i ma gi ng a ppa ra tus (a) built into a 
si mpl e ha nd-hel d devic e tha t ca n be us ed to ass ess  the renal  microcircula ti on (b). Ada pted fr om 
Spronk et a l . [1065]. 
 
Studies of the human microcirculation using OPS imaging in various pathological states have shown a 
wide spectrum of different clinical applications with evident impact on the diagnosis, treatment or 
assessment of prognosis.  
OPS has been validated in various pathologies in animal models [1066,575,1067,1068,574] and also 
partly in humans [1069,1070]. OPS has also been used to investigate changes in microcirculation in 
clinical transplantation settings specifically the kidney [572], pancreas [573] and liver [576,1071]. 
Assessment of the microcirculation demonstrated dysfunctional perfusion resembling 'no reflow' 
with hypoperfusion in kidney, pancreas and liver allografts that experienced delayed function 
[572,573,1071].  
Imaging of the renal microcirculation in this experiment was assessed using a hand held OPS imaging 
system (Cytoscan TM, Cytometrics Inc., Philadelphia, Pa., USA), whereby the kidney capsule was 
removed and probed applied to the kidney. Images were recorded for ≥2 areas at 6 hours of NHRP in 
4 pairs of kidneys. Linearly polarized light at a wavelength of 548 nm (absorption spectrum of 
haemoglobin[Hg]) is able to penetrate tissue up to a depth of approximately 200–500 µm [1072]. 
Erythrocytes (containing Hg) are visualized as dark areas, while the surrounding tissue lacking Hg 
appears lighter in contrast. 
Analysis and quantification of microdynamic parameters was performed offline by frame-to-frame 
analysis of the recorded images using a computer-assisted image analysis system (CapiScope, 
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KKTechnology, United Kingdom). Analysis included a quantitative assessment of capillary diameters 
(D), functional capillary density (FCD) and RBC velocity (RBCv). In each sample diagnostic fields 
(region of interest) each measuring 782x782 µm (0.611 mm2) of interest that were isolated and 
analysed. FCD was defined as the ratio of area of RBC perfused capillaries per area of observation 
(mm2), directly reflecting the state of nutritive tissue perfusion[1073]. vRBC (µm/s) was measured in 
the midpoint of ten capillaries that crossed a designated grid within the ROI by means of frame -to-
frame analysis (Modification of De Backer's score)[1074]. Individual volumetric capillary blood flow 
(CBF; pl/s) was calculated from RBCv and D metrics according to the formula vCBF = ∏(D/2) x vRBC . 
To evaluate changes in overall capillary perfusion, a perfusion index (PI) was calculated from using 
the FCD and CBF metrics (PI = FCD x CBF, pl/s/mm2). The degree of homogeneity (heterogeneity 
index, HI) in CBF was assessed by expressing the standard deviation (SD) relative to the difference 
between the maximum and minimum of the CBF (obtained from all observations from 1 experiment 
at the time point). 
 
4.2.7 Rapid Sampling Microdialysis 
RsMD was instituted in these experiments in line with the methodology described in Section 3.2.3 
Rapid Sampling Microdialysis. In brief microdialysis probes (MAB11.35.4, Microbiotech, Stockholm, 
Sweden) were inserted superficially into the parenchyma of the lateral cortex at the start of NRHP. 
These were connected to an in-house built rapid-sampling microdialysis analyser. Every 30 seconds a 
200 nL dialysis sample was automatically injected into the analysis flow stream, alternating between 
each kidney. The stream accelerates the dialysate through an enzyme reactor containing LOx and 
HRP (Genzyme Diagnostics, Kent, UK). The LOx recognises the analyte, producing hydrogen peroxide, 
which reacts with the HRP. The HRP is regenerated by oxidation of the ferrocene mediator species, 
producing ferrocinium ions, which are detected at the downstream electrode (BASi, West Lafayette, 
IN) by reduction. Due to the small sample size, the current produced is directly proportional to the 
concentration of lactate in the sample even above the free solution Km of the lactate oxidase 
enzyme (0.7 mM). Data was collected using a PowerLab data acquisition unit (8/30, ADInstruments, 
New South Wales, Australia) and LabChart software (ADInstruments, New South Wales, Australia) 
running on a Macbook Pro portable computer (Apple Computers, Cupertino, CA). Lactate levels were 
analysed in real-time to reveal information on interstitial lactate concentration during the 6 hours of 
reperfusion, as an indication of tissue viability and metabolism. 
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4.2.8 Clotting Assays 
Perfusate samples were taken during the pre-conditioning Treatment and Washout-2 phases. 
Samples were analysed using a simple clotting assay using citrated plasma and calcium chloride with 
time to visual formation of fibrin in glass test tubes at normothermic temperatures reflecting relative 
concentrations of TLN in perfusate samples. Blood perfusate samples were taken at 0 minutes, 20 
minutes, 1 hour, 3 hour and 6 hours of NHRP and collected into citrate blood collection tubes. Tubes 
were centrifuged at 3000rpm for 4 minutes, and the plasma stored at -80oC. Plasma was analysed 
for levels of fibrin degradation products (INNOVANCE® D-Dimer Siemens Healthcare Diagnostics), 
fibrinogen and Prothrombin Factor 1+2 (Quadratech Diagnositics Ltd, UK) using commercially 
available kits. 
 
4.2.9 Histology 
Wedge biopsies were taken for histopathological analysis after 6 hours of NHRP and fixed in 10% 
formaldehyde or snap frozen with liquid nitrogen and stored at -80°C. Tissue blocks were processed 
in paraffin wax blocks by routine, automated, procedures. Sections were cut at 4 µm and stained 
with 1) hematoxylin and eosin (H&E) to assess morphology), 2) periodic acid-Schiff (PAS) reagent and 
counterstained with hematoxylin to assess tubular brush border. 
Immuno-histochemistry was conducted on frozen sections. Sections were incubated with primary 
antibody to fibrin(ogen) (No. 350, American Diagnostica Inc) that reacts with the human fibrin(ogen) 
Beta -chain only, reacting with fragments X & Y, but not D & E, (therefore with fibrin monomer) for 1 
hour at 37°C, washed, and then incubated with a biotinylated secondary antibody for 1 hour at 37°C. 
After the sections were washed, the streptavidin– horseradish peroxidase conjugate was applied, 
and the sections were stained with diaminobenzidine. For each run, a negative control was 
processed by deleting the primary antibody and applying an isotype-specific control antibody 
(Zymed). 
Samples were evaluated for morphology and overall structure using light microscopy. Variables 
specifically assessed were endothelial detachment, presence of tubular debris/tubular intratubular 
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cell detachment, tubular dilatation, and peritubular vessel congestion. Slides were blinded for the 
assessor and variables scored using a scale of 0 - 4 according to the degree of changes seen in 
each field of view at 10x magnification, where: 0 denoted normal cells with normal no 
abnormalities; 1: changes affecting 25% of the sample; 2: changes affecting 25-50%; 3: changes 
affecting 50-25%; and 4: changes affecting >75% of  the sample. Peritubular congestion was 
assessed in slides from paired kidneys separately and comparatively ranked with slide 
demonstrating more congestion graded 1, the other 0. Three fields of view were analysed in each 
slide for each of these changes. 
 
4.2.10 TLN Adherence 
Two porcine kidneys underwent the complete experimental protocol but were treated with a TLN-
tail derivatised at the N-terminus with a FAM fluorescent derivative (FAM-PTL) to histologically 
demonstrate tethering and adherence to the porcine kidney microvasculature. One human graft 
underwent the HMP and Pre-conditioning phases of the experimental protocol, and was treated 
with FAM-PTL to demonstrate similar tethering and microvasculature localisation in a human graft.  
 
4.2.11 Statistics 
Values are represented as mean and standard deviation. Continuous variables were plotted as levels 
versus time curves for each kidney and the mean area under the curve calculated. Continuous 
variables from paired contra-lateral kidneys were evaluated using the paired students T-test or non-
parametric Wilcoxon signed rank test as appropriate. Repeated measures were analysed for 
differences using ANOVA for repeated with measures with Bonferroni correction for post-hoc tests 
as required. Data and statistical analysis was performed using Microsoft® Excel Software (Reading, 
UK). A p value of ≤ 0.05 was considered significant. 
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4.3 Results  
4.3.1 Kidney Characteristics 
A total of thirty-eight  porcine kidneys and two human kidney grafts were utilised in this project. 
Porcine kidneys experienced a retrieval WIT of 15 minutes (Range: 10-20), CIT until perfusion of 298 
minutes (Range: 219-480), and had  a mean graft weight of 233g (Range:107-330). Table 6 
summarizes porcine kidney characteristics in the experimental groups. 
Kidney 
 Characteristics 
Warm Ischaemia Time  
(minutes) 
Cold Ischaemia Time 
Before HMP (minutes) 
Weight Pre-HMP (g) 
Overall for All 
Kidneys (n=36) 
15  ( 10-20) 298  ( 219-480) 233 (107-330) 
       
Experiment 1  CG1 PTG1 CG1 PTG1 CG1 PTG1 
 
13.6 (2.4) 12.8 (2.6) 345 (80.6) 348 (80.9) 175.1 (229-
116) 
185.7 (258-
107) 
Experiment 2  CG2 PTG2 CG2 PTG2 CG2 PTG2 
 
16 (2) 16 (2) 334 (76) 334 (76) 253 (188-330) 237 (197-315) 
Experiment 3 TCG3 PTG3 TCG3 PTG3 TCG3 PTG3 
 15.5 (0.6) 15.5 (0.6) 247 (16) 247 (16) 257 (249-295) 251 (240-290) 
Ta bl e 6 . Porcine kidney c haracter istic s.  
 
4.3.2 Hypothermic Machine Perfusion Stabilization 
Perfusion characteristics and weight gain in kidneys during initial HMP stabilization were not 
significantly different between the Protein Treated Groups (PTG1,PTG2,PTG3) and the Controls 
Groups (CG1, CG2, TCG3), and are summarised in Table 7 and Table 8. 
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HMP Stabilization  
Perfusion Dynamics 
Systolic Pressure 
(mmHg) 
Perfusate Flow Rate 
(ml/min/100g) 
Perfusion Flow Index 
(ml/min/100g/mmHg) 
Experiment 1 CG1 PTG1 CG1 PTG1 CG1 PTG1 
 
46.2 ± 9.4 43.5 ± 6.3 21.4 ± 6.7 23.4 ± 8.2 0.55 ± 0.22 0.52 ± 0.17 
Experiment 2 CG2 PTG2 CG2 PTG2 CG2 PTG2 
 
38.7 ± 3.8 38.3 ± 3.8 16.2 ± 6.2 16 ± 5.8 0.42 ± 0.08 0.39 ± 0.12 
Experiment 3 TCG3 PTG3 TCG3 PTG3 TCG3 PTG3 
 
36.8 ± 2.7 36.8 ± 1 12.7 ± 3.8 13.6 ± 4.2 0.38 ± 0.08 0.37 ± 0.13 
Ta bl e 7 . HMP per fusion dyna mics in Treatment a nd Control Groups in Experiments  1 -3  
 
 
 Percent Weight Change 
Post HMP (%) 
Percent Weight Change 
Post NHRP (%) 
Experiment 1 CG1 PTG1 CG1 PTG1 
 
42.5  ±  
12.6 
42.8  ±  
12.9 
10.9 ± 7.8 11.9 ± 9.4 
Experiment 2 CG2 PTG2 CG2 PTG2 
 
20.6 ± 7.8 21.8 ± 7.2 9.8 ± 7.9 14.2 ± 14.8 
Experiment 3 TCG3 PTG3 TCG3 PTG3 
 14.8 ± 5.5 14 ± 5.5 19 ± 10 27.8 ± 4.4 
Ta bl e 8 . Perc ent wei ght c hange dur ing HMP a nd NHRP  
 
4.3.3 TLN Delivery and Adherence 
4.3.3.1 Perfusate Analysis 
Perfusate samples taken during organ preconditioning from TLN treated kidneys (PTG1, PTG2 and 
PTG3 Groups) were assessed via a clotting assay. Results are expressed as a multiple of the clotting 
time for a control sample of unmodified perfusate, and are shown in Figure 58. A higher clotting 
ratio indicates a greater concentration of TLN present in the sample. Experiment 1 demonstrated a 
significant decrease in the clotting time ratio between 0 minutes of TLN treatment (2.19 ± 0.17)  and 
15 minutes (1.89 ± 0.12, p=0.001) which remained stable at the end of treatment (1.92 ±0.11). 
Furthermore clotting times did not significantly increase between the start and end of the washout 
phases (1.15 ± 0.04 vs. 1.26 ± 0.1). Experiment 2 and 3 also demonstrated a similar trend with 
decreasing clotting time ratios during TLN treatment, but with these differences not reach 
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significance. In Experiment 2 there was also significant increase in clotting time ratios between the 
start and end of the washout phase, with clotting time ratios in the washout samples were 
significantly lower than those at 30 minutes of TLN treatment. While in Experiment 3 clotting time 
ratios did not increase during the washout phase, and remained stable.  
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Figure 58  Perfusa te Clotti ng Anal ysis. Clotti ng ti mes  are express ed as  mul tipl e of the cl otting 
ti me for a c ontrol sa mpl e of unal tered per fusa te (repres ented by the blue line). The larger  the 
value the grea ter the conc entra tion of TLN. pres ent.  Experi ment 1 : ANOVA p=0.001, 0  mins 
(2 .19  ± 0 .17) vs . 15  mi ns  (1 .89  ± 0 .12) p=0.001, 30mins  (1 .92  ±0.11) vs . s tar t washout (1 .15  ± 
0 .04)p<0.001, s tar t vs . end of was hout (1 .26  ± 0 .1) NS, 30mi ns  vs . end of was hout p<0.001. 
Experi ment 2 : ANOVA p=0.001, Cl otting ti me ra ti os  tre nded lower  during trea tment: 0  mi ns  (2 .0 
± 0 .09), 15 mi ns  (1 .97 ± 0 .11), 30mi ns (1 .89  ±0.14), p>0.05  for all  trea tment c omparison. Star t of 
was hout (1 .15  ± 0 .02) vs . end of washout (1 .46  ± 0 .06  ) p=0.001 a nd 30mi ns  vs . both s tar t of 
was hout a nd end of was h out p=0.001, p=0.002 res pec ti vel y. Experi ment 3 :  ANOVA p=0.004, 
Clotti ng ti me ra ti os trended lower duri ng trea tment: 0  mins  (1 .72 ± 0 .06), 15 mins (1 .5 ± 0 .02), 
30mi ns (1 .51 ±0.02), p>0.05  for  all  trea tment compa risons . Star t of washout (1 .12  ± 0 .03) vs . 
end of washout (1 .15 ± 0 .01 ) p=0.7 a nd 30mi ns  vs . both s tar t of was hout a nd end of was hout 
p=0.06, p=0.08  respec tively.  
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256 
 
4.2.3.2 Fluorescent Labelled PTL 
Treatment with FAM-PTL histologically demonstrated tethering and adherence to the porcine kidney 
microvasculature after treatment, with continued adherence after 6 hours of NHRP challenge ( Figure 
59).  
 
Porcine Kidney Treatment with FAM-PTL 
 
Standard Treatment Protocol: 30 Minutes Washout, 30 Minutes Treatment with 
FAM-PTL, 30 Minutes Washout followed by 6 hours of NHRP 
 
 
A) Prior to Treatment 
 
B) Post-Treatment with  
2µM FAM-PTL 
 
C) After 6 hours of NHRP 
 
Translational Treatment Protocol: FAM-PTL added to HMP Perfusate at 4 hours 
with continued perfusion for 1 hour, 30 minute washout, followed by 6 hours of 
NHRP 
 
D) Prior to Treatment 
 
 
E) Post-Treatment with  
2µM FAM-PTL 
 
F) After 6 hours of NHRP 
 
 Kidney microstructure        FAM-PTL Proteins 
Figure 59 His tology of bi opsies  under  UV li ght ta ken fr om a  porcine kidney during experi mental 
trea tment wi th fl uoresc ent la bell ed (FAM -PTL) tail  mol ec ul es . Prior  to trea tment (A); after 
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trea tment demons tra ting pres enc e of the proteins  a dherent to the ki dney mi crovas cula ture (B); 
a nd wi th c onti nued adherenc e a fter  6  hours  of normothermic  reper fusion wi th bl ood (C). A 2nd 
porcine kidney underwent a sli ghtl y modi fi ed trea tment protoc ol tha t was desi gned to as 
clinic ally tra nsla tional  as  possi bl e, where by the protei ns  a re si mply a dded to the per fusa te 
during HMP, ra ther tha n requiri ng removal  of the ki dney a nd per fusi on wi th '  protein spi ked' 
s oluti on. No proteins were pres ent adherent to the mi crovascula ture prior t o inj ec tion of the 
FAM-PTL i nto circ ula ting HMP per fusa te (D); wi th FAM -PTL pres ent 1 hour a fter  addi tion (E), 
a nd a l so a fter  subsequent 6  hours of normothermic  reperfusion (F).  
 
 
Human Kidney Treatment with FAM-PTL 
 
Standard Treatment Protocol: 30 Minutes Washout, 30 Minutes Treatment with 
FAM-PTL, and 30 Minutes Washout 
 
 
A) Prior to Treatment 
 
B) Post-Treatment with  
2µM FAM-PTL 
 
C) After 30 minutes     
Washout 
 
 Kidney microstructure      FAM-PTL Proteins 
 
 
Figure 60  Histology of bi opsi es  under  UV li ght taken fr om a  huma n ki dney as par t of experi ment 
5 . Pri or  to trea tment wi th fl uoresc ent la bell ed (FAM -PTL) tail  mol ec ul es (A); a fter  trea tment 
wi th FAM-PTL demons tra ting pres enc e of the proteins  adherent to the kidney mic rovasc ula ture 
(B); a nd wi th c ontinued adherenc e a fter  the fur ther  30 mi nutes  of Washout -2 per fusion (C).  
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4.3.4 Normothermic Haemoreperfusion 
4.3.4.1 Vascular Perfusion Dynamics  
Protein Treated kidney groups demonstrated superior blood flow and PFI compared to the Control 
Group kidneys (Figure 61 for a summary of NHRP perfusion data). Renal blood flow rates were on 
average 26.4%, 33.7%, and 45% higher, and PFIs 28.9%, 32.1%, and 44.4% greater in protein treated 
PTG1, PTG2 and PTG3 kidneys compared to controls. Weight gain was not different between Treated 
and Non-treated groups (Table 8). Systolic perfusion pressures were similar between groups in each 
experiment during NHRP: CG1: 70.7 ± 17.9 mmHg vs. PTG1: 71.7 ± 9.2 mmHg; CG2: 48 ± 18.5 mmHg 
vs. PTG2: 49.5 ± 18.27 mmHg; TCG3: 50.5 ± 3.5 mmHg vs. PTG3: 49.5 ± 0.63 mmHg;  p=0.349, 
p=0.316, p=0.777 respectively. 
 
Figure 61 . NHRP renal per fusi on dyna mics i n experi ments 1 -3 . Protei n Tes t Group ki dneys 
demons tra ted higher renal blood flow ra tes  (PTG1: 30 .6  ± 6 .8 , PTG2: 26 .7 ± 9 .9 , PTG3: 25 .9 ± 8 .6  
ml /mi n/100g) tha n control kidneys (CG1: 23 .1 ± 3 .7 , CG2: 20 .4 ± 7 .7 , TCG3: 17 .9 ± 6 .2 
ml /mi n/100g; p=0.02, p=0.022, p=0.009 respec tivel y), as  well as higher per fusion flow indic es 
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PTG1: 0 .43  ± 0 .12, PTG2: 0 .53  ± 0 .23, PTG3: 0 .49  ± 0 .1 6  ml /mi n/100g/mmHg) vs . c ontrol 
ki dneys (CG1: 0 .32  ± 0 .1 , CG2: 0 .43  ± 0 .23,TCG3: 0 .34  ± 0 .12  ml /mi n/100g/mmHg; p=0.0494, 
p=0.031, p=0.009 respec tivel y) during six  hours of NHRP c hall enge. Two -tail ed paired t-tes t. 
*=s i gni ficant differenc e vs. c orrespondin g c ontrol group. 
 
4.3.4.2 Orthogonal Polarisation Spectral  Imaging  
In Experiment 2 OPS data was recorded and analysed for 4 pairs of kidneys after 6 hours NHRP to 
assess the microdynamics of the kidney microvasculature (Figure 62). FCD was similar between 
treated and non treated kidneys however TLN treated kidneys had 44% larger diameter capillaries, 
50% faster RBCv, 3.5 times greater CBFs and PIs compared to the non-treated control kidneys ( 
Figure 63).  
 
Figure 62  OPS I ma gi ng: Exa mpl e of pos t-ca pture fra me a nalysis (LEFT) and a kidney undergoing 
OPS a s sessment (RI GHT).  
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Figure 63 . OPS mic rocirc ula tory per fusi on dyna mics i n ki dneys a t 6  hours of NHRP. Func ti onal 
ca pillary densi ty (FCD ) was  si milar between trea ted a nd non trea ted ki dneys  (CG2: 19 .3  ± 3 .1  % 
vs . PTG2: 20 .5  ± 2 .0  %, p=0.4). TLN trea ted kidneys  rec orded vess el  dia meters  were larger  (CG2: 
7 .44  ± 0 .81  µM vs . PTG2: 10 .77 ± 1 .23 µM, p=0.052), a nd RBC vel oci ty (CG2: 272.1  ± 26 .3 µM/ s 
vs . PTG2: 403.2  ± 31 .2  µM/s , p=0.011), calc ula ted CBF (CG2: 13 .2  ± 3 .65  µM3/s  vs . PTG2: 41 .9  ± 
14 .5  µM3/s, p=0.032), and the PI  (CG2: 2 .77   ± 0 .98  pl /s /mm
2
 vs . PTG2: 9 .05  ± 2 .48  pl /s /mm
2
, 
p=0.021) hi gher  compared to c ontrol  ki dneys. The HI  c alcula ti on re veal ed si milar  l evels  of 
homogenous per fusion wi thin the a reas sa mpl ed wi thin eac h ki dney (CG2: 3 .21 ± 0 .18  AU vs . 
PTG2: 3 .27  ± 0 .21  AU, p=0.79). Two-tailed paired t-tes t. *=si gnifica nt di fferenc e vs . c ontrol 
group. 
 
 
4.3.4.3 Rapid Sampl ing Microdialysis  
Data of cortical micro-dialysis levels were recorded for four pairs of kidneys during Experiment 2 
during the HMP stabilization phase, and NHRP. Data from two pairs during HMP and one during 
NRHP were excluded due to background signal interference in two, and technical problems in one, 
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during recording that prohibited accurate analysis. During HMP cortical microdialysis lactate 
concentrations were similar between the non-treated control and treated kidneys (CG2: 0.128 ± 
0.006 mM/min vs. PTG2: 0.137 ± 0.04 mM/min, p=0.78). In NHRP cortical lactate levels were higher 
in non-treated vs. treated kidneys (CG2: 3.28 ± 1.04 mM/min vs. PTG2: 1.67 ± 0.28 mM/min, 
p=0.072), with the difference approaching significance (Figure 64). 
 
 
 
Figure 64 rs MD: Sca tter  dia gra m of rs MD rea dings  meas ured fr om 
one kidney during HMP a nd NHRP (Top). NHRP c or tical lac ta te c onc entra ti ons trended higher in 
non-trea ted vs . trea ted kidneys during (CG2: 3 .28  ± 1 .04  mM/mi n vs . PTG2: 1 .67  ± 0 .28 
mM/mi n, p=0.072, bottom l eft). Photograph of kidney undergoi ng microdialysis  moni tori ng by 
i ns er tion of probes  into c ortex  a nd di agram of mi crodialysis c atheter  tip (bottom r ight).  
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4.3.4.4 Haemoreperfusion Clotting Analysis  
Clotting data is summarised in Table 9. Higher levels of D-Dimers (average AUC) were observed over 
the 6 hours of perfusion in the Experiment 1 control group, CG1(14.5 ± 7.9 mg/L ) vs. the treated 
kidneys, PTG1 (9.5 ± 5.1 mg/L, p=0.051) with this difference at significance. No other differences 
were observed in clotting parameters between treated and non-treated kidneys in the Experiments 
2 and 3. 
NHRP Perfusate  
Clotting Analysis 
 
D-dimers (mg/L) Fibrinogen (µg/L) 
Prothrombin Fragment 1+2  
(mg/L ) 
Experiment 1 CG1* PTG1 CG1 PTG1 CG1 PTG1 
 
14.5 ± 7.9 9.5 ± 5.1  
0.385 ± 
0.06  
0.373 ± 
0.21 
0.006 ± 
0.003  
0.007 ± 0.002  
Experiment 2 CG2 PTG2 CG2 PTG2 CG2 PTG2 
 
5.63 ± 2.2  
11.2 ± 
11.06  
1.08 ± 0.19  1.2 ± 0.24 
0.005 ± 
0.001  
0.009 ± 0.002  
Experiment 3 TCG3 PTG3 TCG3 PTG3 TCG3 PTG3 
 
6.18 ± 9.6  6.4 ± 7  0.78 ± 0.07  0.79 ± 0.33  
0.002 ± 
0.001  
0.001 ± 0.002  
 
Ta bl e 9 . NHRP blood per fusa te clotti ng a nalysis  for  Experi ments  1 -3 . * Hi gher  l evels  of D-di mers 
were obs erved in c ontrol CG1 (14.5 ± 7 .9  mg/L ) vs . the trea ted kidneys , PTG1 (9 .5  ± 5 .1  mg/L, 
p=0.051). Two-ta iled paired t-tes t. 
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4.3.4.5 Histology 
Light microscopy histological assessment of biopsy samples between Control (CG1-2, TCG3) and 
Treatment (PTG1-3) Groups showed no significant differences in endothelial detachment, tubular 
debris/epithelial detachment, tubular Dilatation, and peritubular congestion, all p-values > 0.5 (Table 
10, Figure 65). 
 
Endothelial  
detachment 
Tubular 
Debris Tubular Dilatation 
Peritubular 
 Congestion 
Experiment 1 CG1 PTG1 CG1 PTG1 CG1 PTG1 CG1 PTG1 
 
1.4 
±0.24 
1.27 
±0.19 
4 ± 0 4 ± 0 4 ± 0 4 ± 0 
0.6 ± 
0.24 
0.4 ± 
0.24 
Experiment 2 CG2 PTG2 CG2 PTG2 CG2 PTG2 CG2 PTG2 
 
1.08 
±0.08 
1.08 
±0.08 
3.5  ± 
0.5 
3.5  ± 
0.5 
3.5  ± 
0.5 
3.5  ± 
0.5 
0.6 ± 
0.24 
0.5 ± 
0.29 
Experiment 3 TCG3 PTG3 TCG3 PTG3 TCG3 PTG3 TCG3 PTG3 
 
1.13 
±0.13 
1 ± 0 
3  ± 
0.58 
3  ± 
0.58 
3.25  ± 
0.25 
3  ± 
0.24 
0.5 ± 
0.29 
0.5 ± 
0.29 
Ta bl e 10 . His tology sc ores  of biopsi es taken a fter 6  hours  of NHRP ass essing endothelial 
detac hment, tubular debris /epi thelial  detac hment, tubular  Dila ta tion, and peri tubular 
c onges tion. No significa nt differenc es  were s een between trea ted a nd non -trea ted kidneys , wi th 
si milar degrees of reper fusion induc ed vasc ular a nd tubular da ma ge a nd mi cro -vasc ular 
c onges ti on. Two -ta iled Wilcoxon signed rank tes t.  
 
Immuno-histochemistry for fibrin(ogen) was conducted in biopsies from kidneys in CG1 and PTG1 
groups and demonstrated a generalised fibrin(ogen) deposition in interstitial tissues and peritubular 
capillaries. There was a generalised deposition of fibrin in all biopsies examined with no difference 
between treated and non-treated kidney grafts (see Figure 66). 
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Figure 65   Photomicrogra phs of l i ght microsc opy of Protein Trea ted vs . Control kidneys after  6 
hours  of NHRP. H&E s taini ng, x20. A: PTG1 ki dney, B: CG1 ki dney, C: PTG2 ki dney, D: CG2 
ki dney. Showi ng s imilar  degrees of tubular debr is, dilata tion, a nd per itubula r c on gestion. 
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Figure 66 I mmuno-histoc hemis try for  fibri n(ogen) in Protei n Trea ted a nd Control  ki dneys a fter  6 
hours  of NHRP. A a nd B: Protein trea ted (PTG1) kidney, C a nd D: Control (CG1) kidney. There is 
generalised i ntra vasc ular  an d inters ti tial fi bri n deposi ti on to a  si milar degree i n both groups  of 
ki dneys . 
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4.3.4.6 Pre -clinical Experimentation with Human Kidney Grafts  
A pair of DCD kidney grafts were used in a pre-clinical model in Experiment 4. CIT was 78 hours 
(4680 minutes) until start of the experiment. Table 11 summarizes kidney characteristics, perfusion 
dynamics, perfusate clotting results and microdialysis cortical lactate levels in these kidneys. During 
HMP stabilization perfusion characteristics were superior in the CG4 control kidney vs. the PTG4 
kidney. 
Kidney  
Characteristics 
Warm Ischaemia Time (minutes) 
Cold Ischaemia Time 
Before HMP (minutes) 
Weight Pre-HMP (g) 
Experiment 4 CG4 PTG4 CG4 PTG4 CG4 PTG4 
 
NA NA 78 hours 78 hours 210 230 
    
HMP Stabilization 
Perfusion  
Dynamics 
Systolic Pressure (mmHg) 
Flow Rate 
(ml/min/100g) 
Perfusion Flow Index 
(ml/min/100g/mmHg) 
Experiment 4 CG4 PTG4 CG4 PTG4 CG4 PTG4 
 
37.8  49.5  18.2  10.2  0.48  0.2  
   
  
Weight Changes 
Percent Weight Change 
Post HMP (%) 
Percent Weight Change 
Post NHRP (%) 
  
Experiment 4 CG4 PTG4 CG4 PTG4   
 
14.3 15.6 1.2 -0.8   
   
  
RSMD [Lactate] HMP [Lactate] mM NHRP  [Lactate] mM 
 
 
 
Experiment 4 CG4 PTG4 CG4 PTG4   
 
0.17 0.28 6.997 4.442   
    
Perfusate  
Analysis 
Ddimers (mg/L) Fibrinogen (µg/L) 
 
Pro-thrombin Fragment 
1+2 (mg/L ) 
Experiment 4 CG4 PTG4 CG4 PTG4 CG4 PTG4 
 4.74 1.89 3.7 1.2 NA NA 
Ta bl e 11 . Human ki dney gra ft cha rac teris tics, HMP dyna mics , wei ght c ha nges , rs MD l evels 
dur i ng NHRP, a nd NHRP blood per fusate c l otting data .  
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Figure 67  NHRP per fusion dyna mi cs in a trea ted a nd non -trea ted human kidney pair . Renal 
bl ood fl ow: PTG4: 70 .8  ml/min/100g vs . CG4: 60 .7  ml /mi n/100g, PFI : PTG4: 0 .97 
ml /mi n/100g/mmHg vs . CG4: 0 .83  ml/min/100g/mmHg.  
 
Despite initially more viable perfusion dynamics HMP in the CG4 control kidney during the NHRP the 
opposite was observed.  Systolic perfusion pressures were similar (CG4: 73.2 mmHg vs. PTG4: 72.9 
mmHg) but TLN treated kidneys demonstrated superior perfusion with 16.6% higher renal blood 
flow and 16.8% higher perfusion indices as seen in Figure 67. Micro-dialysis lactate concentrations 
were lower in the control kidney during HMP prior to treatment but were subsequently 36% lower in 
the treated PTG4 kidney during NRHP. D-Dimer and fibrinogen levels were 2.5-3x higher over the 6 
hours of perfusion in the control CG4 group. There was insufficient sample for PF1.2 testing. Percent 
weight change was not different after HMP stabilization nor after the NHRP challenge between the 
non-treated and treated kidney.  Light microscopy demonstrated a similar degree of reperfusion 
injury in the treated and non-treated graft (see Figure 68). A human DCD kidney was also treated 
with FAM-PTL. FAM-PTL was observed in biopsies after the 30-minutes of  treatment, after then still 
present after the washout phase (Figure 60).  
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Figure 68  Photomicrogra phs  of l i ght microsc opy of Protei n Trea ted vs . Control  human ki dneys 
a fter 6  hours  of NHRP. H&E s tai ning, x20. A: PTG4 ki dney, B: CG4 kid ney. Showi ng si milar 
degrees  of tubul ar  debris, dilatation, a nd per itubular c ongestion.  
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4.4 Discuss ion 
ECD and DCD donor kidneys are more susceptible to microcirculatory failure during reperfusion, with 
increased risk of subsequent DGF. The increasing use of these organs to expand the donor pool 
means any approach that could ameliorate micro-vascular dysfunction and improve organ perfusion 
at the reperfusion stage is in high clinical demand.  
Thrombalexin and its variants are a novel series of membrane localising 'cytotopic' anti-coagulant 
constructs that have proven efficacy in improving graft function in murine kidney transplantation 
models[940]. This is the first study of preconditioning large animal organs with addressive cytotopic 
anti-coagulant agents using HMP as a delivery vehicle, and further assessing the benefits of this pre-
treatment using  a NHRP challenge. Using a series of translational porcine ex-vivo renal perfusion 
and haemo-reperfusion models we demonstrated HMP can be used to deliver TLN into the 
vasculature of  a kidney graft, and facilitates cytotopic tethering and adherence; improving macro 
and micro-vascular organ tissue perfusion, with biochemical evidence of less thrombophili a during 
NHRP challenge. These significant advances in pre-conditioning the graft, in particular the 
microvasculature endothelium, are derived from the TLN cytotopic agent, that localises to 
endothelial cells and presents a Hirulog based direct thrombin inhibitor moiety within the 
intravascular space, conferring local thrombin inhibition and both anti -coagulant, and potentially 
anti-inflammatory effects. Inhibition of thrombin reduces fibrin(ogen) activation and cross linked 
fibrin generation, and in parallel decreased inflammatory responses mediated by PAR receptor 
activation. 
IR injury sustained during organ transplantation is a complex interplay between endogenous 
coagulative and inflammatory processes, with endothelial and tissue damage characterised by 
microcirculatory failure and the 'no re-flow' phenomenon [348,1075]. The clinical effect of this injury 
is DGF, which increases the risk of later immunologic rejection [1076]. Improving microvasculature 
perfusion improves organ function. 
With the increasing use of ECD and DCD organs to address the growing need of patients on 
transplant waiting lists, the impact of IR injury is seen by the higher rates of DGF in these more 
susceptible organs and reluctance of their use by surgeons [1077,1078]. However use of the 
DCD/ECD cohort could expand the donor pool by 40% [11]. Interventions that can improve organ 
viability, and improve function in the perioperative period during which IR injury is most dominant 
are the key to better utilization of these donor organs[12].  
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HMP is recommended for use in ECD and DCD donor allograft preservation and clinically such 
preserved organs encounter less DGF after transplantation [891,946,1079]. HMP is also used as a 
tool for allograft viability assessment using a variety of perfusion dynamic calculations and perfusate 
biomarkers to aid identification of potentially unsuitable allografts [1061,1080–1082]. As of yet HMP 
is has not been widely utilized in organ preconditioning using pharmacological agents. Several 
reports have described augmenting traditional HMP preservation solutions with agents to reduce IR 
injury (e.g. N-acetylcysteine, L-arginine, nitroglycerin, prostaglandin E1, paparavine) and improve 
perfusion dynamics [1083–1087]. Use of HMP to delivery pharmacological agents to pre-condition 
allografts against specific injury after transplantation has not been widely attempted. HMP however 
would be an ideal tool to deliver addressive therapeutics, and precondition the organ vasculature 
before transplantation.  
4.4.1 TLN Delivery 
HMP successfully delivered TLN into the kidney vasculature, with tethering and adherence. The 
decrease in clotting time ratios using the simple plasma-CaCl based clotting assay in samples from 
Experiment 1 taken as treatment progressed demonstrates the removal of TLN (specifically the 
PTL006 early variant) from the perfusate and sequestration onto the vasculature, while at the same 
time demonstrating functionality of the HLL anti-coagulant moieties. Similar trends were seen 
Experiment 2 and 3 demonstrating removal of TLN from the perfusate however the significance was 
limited. In Experiment 2 and 3 TLN was used to treat kidneys as opposed to the earlier TLN variant 
PTL006 in Experiment 1, with the primary difference between the two molecules the mechanism of 
the tethering peptide. Experiment 3  utilised a higher concentration of TLN vs. Experiment 2, despite 
this increase in amount of TLN clotting times were similar in both Experiment 2 and 3. The 
manufacturing process for TLN used in these experiments is laboratory based compared to 
pharmaceutical quality production, thus the potential for inconsistencies in batch qualities exist 
despite through care. Furthermore Experiment 3 only utilised 4 kidneys in each arm limiting 
statistical potential.  
Cytotopic protein adherence in these experiments however was then confirmed using the FAM-PTL 
analogue. This qualitatively demonstrated the presence of the TLN after treatment, with continued 
adherence to the kidney microvasculature and ultra-structure after 6 hours of NHRP challenge when 
using the perfusion protocols in these experiments. Use of a directly translational protocol to deliver 
FAM-PTL in porcine organs demonstrated similar adherence, further emphasising the potential for 
translational application of this large animal ex-vivo organ perfusion work. 
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4.4.2 NHRP Challenge 
Isolated organ reperfusion circuits using autologous blood have developed as ex -vivo methods to 
experimentally assess organ viability in large animal models without the need for live auto-
transplantation [1088]. Any extra-corporeal organ haemoperfusion work requires anti-coagulation to 
inhibit clotting during blood procurement, storage and also development of clots within the 
perfusion circuit and graft being perfused. In general heparin or sodium citrate is used to ensure 
adequate ant-coagulation, with these agents used alone or in combination; some studies using high 
doses of heparin alone (15,000-25,000U/L)[1089,1090]; lower doses of heparin (5,000-10,000U/L) 
but with added citrate (18-50ml/U)[1088]; while others also advocate in addition a continuous 
heparin infusion (3,000U/L/hr) into the circuit[722].  
The normothermic haemoreperfusion phase of the protocol used minimally heparinised (10,000U/L) 
autologous whole porcine blood. The aim of the NHRP phase of the protocol was to induce a 
haemodynamic and pro-coagulant insult and damage the kidney to determine the effect of the 
presence of the TLN proteins tethered to the kidney endothelium. The dose of heparin was chosen 
to ensure adequate retrieval and storage of the blood until the NHRP phase, but balanced so as to 
not completely abolish any coagulatory potential. This was successful as demonstrated by the 
detection of D-Dimers levels during reperfusion, indicating fibrin deposition and subsequent 
fibrinolysis; with histological evidence of tubular and endothelial damage, and a generalised and 
diffuse pattern of fibrin(ogen) deposition, which is characteristic of IR injury[312].  
4.4.3 Normothermic Macrovascular Perfusion Dynamics  
These experiments confirmed that TLN anchored to endothelium can also inhibit activation of 
clotting. Both macro-vascular and micro-vascular perfusion metrics (renal blood flow, PFI) were 
persistently superior in TLN treated kidneys compared to the non-treated and Tail-only protein 
treated controls. Macro-vascular PFI is a useful calculation as it incorporate both renal flow rates and 
systolic pressure but corrects for differences in kidney mass. In these experiments observed renal 
blood flow rates and PFIs were between 25-45% superior in the TLN treated kidneys vs. controls. 
Relative flow rates during ex-vivo NHRP can be considered indicators of relative organ viability 
[1091,1092].     
Ameliorating the microcirculatory perfusion dysfunction that is seen in renal IR injury in both 
experimental and clinical settings has been shown to be important and beneficial in improving initial 
graft function after transplantation, and limiting DGF [249,317,563,1093,1094].  
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4.4.4 Haemoperfusate Clotting Activity 
Immediately after transplantation there is systemic activation of the coagulatory system[665]. The 
interlace between coagulation and inflammation renders the ischaemically damaged endothelium 
vulnerable to reperfusion mediated damage, and subsequent microcirculatory failure. This provokes 
further ischaemia and tissue injury manifested as DGF, with a higher risk of immunologic rejection 
[1076]. 
TLN is a DTI and anchored to endothelium can mitigate local thrombin action. Because thrombin has 
both coagulatory and inflammatory effects (via PAR-1-4) thrombin inhibition can ameliorate both 
these sequelae [672,314].  
Direct thrombin inhibitors reduce IR injury during systemic administration in various animal IR 
models (e.g. kidney, lung, heart and brain) [423–425,1095] by reducing the pro-inflammatory effects 
of thrombin [426–428]. Recently in a porcine model of kidney auto-transplantation intervention with 
a DTI (melagatran) by either adding it to the UW during SCS for 24 hours, or in conjunction with 
systemic administration to the animal prior to nephrectomy improved allograft function, and 
survival after subsequent re-transplantation [672].  
4.4.5 Normothermic Microvascular Perfusion Dynamics  
In our study OPS of the microcirculation demonstrated better perfusion in TLN treated kidneys 
during the NHRP challenge. The improved calculated microvascular PI (pl/s/mm2) in these kidneys 
stemmed from larger diameter cortical capillaries, and faster blood flow through these vessels.  
The presence of larger calibre vessels can be due to relative vessel dilation [1096,1097] - secondary 
to potentially less thrombin action at the endothelial cell surface, and less generation of local 
vasoconstrictors[274,1098] (e.g. endothelin) or alternatively more release of nitric oxide (NO). 
However the TLN HLL anti-coagulant moiety is an analogue of Hirulog, and Hirulog has actually be 
shown to inhibit NO bioavailability in endothelial cells[1099,1100].  
Alternatively the larger capillaries could be due to less fibrin formation and aggregation of cellular 
blood components at the endothelial surfaces, rendering better transit through vessels. OPS 
microcirculatory analysis routinely underestimates vessel diameter due to presence of undetectable 
endothelial-leucocyte interactions at the glycocalyx that narrow the vessel lumen reducing the 
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diameter of the channel available for the passage of blood[572]. The larger observed diameter in 
these vessels may relate to a relative inhibition of dynamic leucocyte aggregation at the endothelial 
due to less thrombin mediated inflammatory activation via PAR receptors, and diminished fibrin 
generation. Fibrin it-self is known to be a potent pro-inflammatory mediator[1101].  
These changes correlated with reduced levels of clotting activity during NHRP challenge in TLN 
treated kidneys, with lower DDimer levels indicating less fibrinolysis and thus indirectly less 
intravascular fibrin formation. The lack of statistical difference in DDimer levels in the 2nd and 3rd 
experiments points to 1) the traumatic nature of the animal sacrifice used in this uncontrolled DCD 
model (where a cytokine surge from stunning may render blood more pro-coagulant); and 2) 
DDimers levels may be a useful indicator of the effects of TLN treatment in a closed haemo-
reperfusion circuit, but may not be the best marker as they are an indirect measure of thrombin 
activity.    
Faster RBC velocity could be attributed to the relatively lower intravascular clotting activity and less 
obstruction to flow in capillaries. Maintaining equal systolic perfusion pressures between control 
and TLN treated kidneys during NHRP dictates that any observed differences in renal perfusion blood 
flow dynamics (blood flow rates, PFI) are due to inherent differences in the kidney vasculature and 
effect of the presence of the addressive anti-coagulant proteins. The similar changes in weight in 
kidneys during HMP and NHRP further indicates that perfusion differences between treated and 
non-treated grafts are not due to tissue oedema limiting blood flow. 
4.4.6 Rapid sampling Microdialysis 
The effect of improved perfusion seen in treated kidneys is further demonstrated by the trend of 
lower concentrations of detected rsMD cortical lactate. Lactate as the end product of anaerobic 
glycolysis is one of several surrogate markers of tissue ischaemia, and tissue  lactate measured by 
microdialysis has been demonstrated to be raised in allograft hypoperfusion associated with 
ischaemia and thrombosis [917,1059].  
During reperfusion the oxygen debt is not immediately remediated, and mitochondrial damage 
limits effective ATP production and so anaerobic pathways remain active. The lower levels of tissue 
lactate detected via rsMD in TLN treated kidneys in this model likely reflects the better overall tissue 
perfusion, both in relative oxygen delivery, and potentially as well as washout of toxic 
metabolites[1102,1103]. The higher variability seen in the control group reflects the variation in 
graft damage sustained during sacrifice and retrieval, and is an inherent component of a 
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uncontrolled DCD model and may be a reason for the lack of statistical significance. Furthermore 
rsMD analysis was available only for 4 pairs of kidneys due to technical difficulties with the rsMD 
system itself. Finally localisation of the probes to the cortex was done visually without image guided 
confirmation introducing the slight possibility of placement of part of the rsMD probe in an alternate 
region of the kidney parenchyma - such as the medulla (which has different metabolic profiles to the 
cortex [1104]). 
4.4.7 Addressive Anti-coagulant Therapy  
There have been several reports of attempts to use addressive-type targeting of anti-coagulants in 
experimental models of systemic IR injury (sepsis) as well as xenotransplantation where coagulation 
is a dominant pathology. These data complement those obtained in other model systems illustrating 
the benefits of localised anticoagulation. 
Early work by colleagues Chen et al. in developing the HLL moiety of TLN generated transgenic mice 
expressing hirudin and TFPI tethered to the endothelium by fragments of CD4 and P-selectin [1105]. 
During LPS induced sepsis in these transgenic mice expression of hirudin or TFPI inhibited 
widespread intravascular thrombosis and consumptive coagulopathy associated with severe 
endotoxaemia, but with limited risk of bleeding. Intravascular thrombosis and coagulation is an 
identified reliable marker of early acute humoral rejection, and a xenograft model is extremely pro-
thrombogenic with widespread fibrin deposition[312]. In a series of experiments these colleagues 
used hearts from these transgenic mice and transplanted them into rats in a xenograft model, with 
both endothelial TFPI and hirudin expressing allografts surviving for more than 100 days (vs. 3 days 
in controls) and rendered completely resistant to acute humoral xeno-rejection[1106]. These reports 
demonstrate the feasibility and benefit of targeting anticoagulants to graft endothelial cells and 
inhibiting coagulation, especially in so using an extremely pro-thrombotic model of acute humoral 
rejection, but also highlighting the potential for use of such therapy in modulating IR related 
coagulation events. 
Ding et al. synthesized a TM based fusion protein by linking the extracellular domain of mouse TM to 
an antibody for PECAM-1 [937]. TM is a potent endogenous anti-coagulant normally present on the 
vasculature endothelium, but presence and activity is reduced during IR mediated endothelial injury. 
The TM fusion proteins localised to inflamed PECAM-1 expressing endothelial in the pulmonary 
vasculature in a murine lung IR model and inhibited fibrin deposition and leucocyte infiltration, 
suppressing NFκB activation, preserving pulmonary function and blood oxygenation, without 
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haemorrhage. Similarly Crikis et al. reported that using transgenic mice expressing human 
endothelial TM, cardiac graft survival in a model of acute vascular rejection was longer than wild 
type mice[1107]. In the same study these transgenic mice demonstrated a reduced inflammatory 
response in stasis-induced thrombosis and a mouse-to-rat xenograft model, with reduced HMGB1 
levels in LPS induced endoxtaemia. Thus targeting anti-coagulants to the endothelium mediates both 
anti-coagulatory and anti-inflammatory effects in several models of IR injury, however transgenic 
therapeutics are complex and with limited scope for current application to clinical practice.  
Targeting and delivering localising thrombin inhibitors into an organ prior to transplantation is 
simple,  and potentially safer in terms of anti-coagulant side-effects and more effective than 
systemic treatment of the recipient where there is no guarantee of success [611,650–655]. 
Furthermore the use of localised DTIs introduces the potential for anti-inflammatory effects of these 
agents in modulating IR responses at the site of injury (the graft vasculature), with DTIs having 
recently demonstrated benefit on organ function in an experimental porcine renal transplant model 
[672]. 
4.4.8 Pre-clinical Human Kidney Model 
Use of appropriate pre-clinical models is a pre-requisite to the development of protocols for clinical 
introduction. The data obtained from TLN pre-conditioned human kidneys correlated with our 
findings in the porcine models. These experiments utilized porcine blood during the NHRP challenge 
phase, thereby presenting a pro-coagulant and pro-inflammatory xenogenic stimulus to the organs. 
In this context xenogenic models are useful because of the prominent coagulopathy that develops 
[1092,1108]  as evidenced by the progressive increase in fibrin degradation products during NHRP in 
the control kidneys.  
Histological evidence demonstrated HMP can successfully deliver TLN into human grafts with 
tethering to the renal microvasculature. During normothermic reperfusion the superior perfusion 
with less intravascular coagulation, and lower cortical lactate in the treated kidney correlated with 
the porcine models.  
The pre-clinical model using human kidneys not used for research utilized porcine blood during the 
NHRP challenge and presented a pro-coagulant and pro-inflammatory xenogenic stimulus to the 
organs. This discordant model is different to the conventional ex-vivo xenogenic perfusion models 
frequently described in the literature [1092,1108]. The conventional approach entails perfusing a 
porcine graft with human blood, where apart from the potential ABO blood group incompatibility 
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(pigs have only two blood groups A and O), Gal carbohydrate residues on porcine endothelium 
readily and aggressively cross-react with preformed antibodies in human blood, instigating acute 
humeral xenograft rejection[1109]. The model described in these experiments involves human 
endothelium interacting with porcine whole blood. Apart from basic incompatibilities between 
blood groups porcine blood has not been shown to contain high concentrations of antibodies to 
other endothelial glycocalyx components [1110,1111]. The human-to-pig reaction in our model is 
thus theoretically less pro-coagulant compared to a pig-to-human xeno-reaction, but none-the-less 
means it is more pro-coagulant and pro-inflammatory than would be with use of cross matched 
whole human blood.  Importantly, experimentally it is a suitable test of effect of the presence of the 
TLN in the pre-treated graft.  
4.4.9 Mechanism of Effect 
The definitive mechanism of TLN in this model still requires further elucidation. The likely effect of 
TLN is through inhibiting thrombin action and the associated coagulatory, and potentially 
inflammatory sequelae associated with normal thrombin function. However the localisation of TLN  
to the endothelium also introduces the possibility of interaction with the glycocalyx and other 
membrane associated proteins. Cytotopic painting of the endothelium with TLN can be considered a 
potential example of 'immunocamouflage' where by the cell membrane surface is modified by non-
immunologic molecules creating a barrier[1112]. This camouflage could then prevent direct 
interactions between plasma and cellular components of the blood and the endothelium, limiting IR 
inflammation and coagulation. Thus there are several limitations to our work that require 
mentioning. The aim of this study was on establishing efficacy in a large animal pre-clinical model of 
using HMP to deliver TLN into renal grafts, pre-conditioning the endothelial, and observe the 
subsequent effects on macrovascular and micro vascular tissue perfusion. This study did not look at 
the endothelial membrane and glycocalyx interactions with TLN, nor on endothelial activation 
though it is likely that localisation of these proteins to the endothelial in an IR setting modulates 
activity of these cells during reperfusion. Further work is being directed to investigate the 
interactions at the endothelial surface.  
The other caveat to be applied to interpreting this work is that the histological outcomes did not 
reveal remarkable differences in the treated grafts, and this is likely due to the experimental time 
frame employed. Despite use of isolated organ reperfusion circuits as well established initial 
alternatives to in-vivo experimentation the relatively short duration of ex-vivo reperfusion is not a 
sufficient timescale for development of histological changes that can be seen in-vivo during 
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transplantation [1113] with the predominant effects of reperfusion in this model on cellular and 
molecular processes within the graft. Extending experimentation and reperfusion time to 24 hours 
and longer would allow further development of histological sequale.  Ongoing research would thus 
ideally would involve large animal porcine auto-transplantation and incorporate aspects of the ex-
vivo experiments including OPS during the initial 4-6 hours, and rsMD during preservation and then 
reperfusion and during the 1st 24-48 hours post operatively. Such experiments would provide 
further translational evidence for a clinical and functional effect of the changes in circulation and 
organ perfusion seen in these ex-vivo experiments. However this type of experiment was beyond the 
scope of the initial objectives of these experiments.  
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4.4.10 Organ Pre-Treatment in Context and Future Work 
The addressive approach suggest here using HMP to deliver TLN is novel and ideal. An allograft 
would theoretically undergo HMP for several hours as part of a transplant centre's clinical protocol, 
then TLN would be added to the perfusate, preconditioning the endothelial with tethering of the 
proteins. The allograft would ultimately be transplanted with the thrombin inhibiting anti-coagulants 
localised to the allograft vasculature, limiting the need for systemic anti -coagulation (with associated 
bleeding risks) and be potentially more effective. The DTI effects of the TLN would inhibit both the 
pro-coagulant and pro-inflammatory actions of thrombin - ameliorating IR responses, and improve 
post-operative allograft perfusion and theoretically function. For the first time the feasibility has 
successfully been demonstrated of pre-conditioning kidney grafts with addressive thrombin 
inhibiting therapeutics using HMP, in ex-vivo porcine and pre-clinical human kidney perfusion 
models, and that the presence of these agents improves organ perfusion. There is a high potential 
for application of this addressive technique to clinical practice, not solely for kidney transplantation, 
but for also for other organs, for example pre-conditioning marginal pancreatic allografts which are 
very susceptible to reperfusion injury and allograft thrombosis.  
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Development of Adenocaine as a Novel Hypothermic Machine Perfusion Preservation Solution  
5.1 Objectives   
 
Adenocaine as a composite of adenosine, lidocaine, and magnesium has been demonstrated in 
cardiac models to afford better protection than conventional preservation solutions possessing 
membrane voltage stabilisation, vasodilatory, anti-inflammatory and anti-coagulant properties, as 
well as been shown to preserve high-energy phosphates during ischaemia (5,9,77–79). With the 
increasing use of ECD and DCD donor organs being used to expand donor pools interventions to 
optimise kidney viability are in much clinical need, and the cytoprotective properties of Adenocaine 
may prove beneficial in kidney transplantation. 
Adenocaine Machine Preservation Solution (AL-MPS) is a variant of Adenocaine specifically modified 
to facilitate HMP of abdominal organs. The objective of this study was test the benefits of AL-MPS 
compared to University of Wisconsin (UW) solution (Belzer MPS, the gold standard machine 
preservation solution) for HMP kidney preservation using a series of large animal ex-vivo porcine 
kidney perfusion and reperfusion models.  
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5.2 Methods  
5.2.1 Experimental Protocol 
Twenty porcine kidneys were used in this study. In the laboratory one kidney of each pair underwent 
HMP with either AL-MPS (AL, n=10) or UW (Belzer MPS) (UW, n=10) solution for 10 hours on a 
Waters Medical Systems RM3 perfusion machine (TM). Kidneys then underwent viability assessment 
for 2 hours using an oxygenated normothermic reperfusion (NMR) circuit with Kreb Henseleit Buffer 
(KHB) solution. The protocol for this experiment is summarised in Figure 69. Ten hours of HMP was 
chosen as a suitably duration period to that used in recent clinical trials comparing SCS to HMP (ref). 
Longer cold perfusion overnight (i.e. 24 hours) was not logistically possible with current RM3 
perfusion systems. 
5.2.2 Preparation of Solutions 
AL-MPS was prepared in- laboratory and refrigerated for 24 hours before each experiment. The AL-
MPS solution was composed of a KHB base with 4mM adenosine; 0.5mM lidocaine, 0.26mM 
calcium, 16 mM Magnesium, and 4% BSA. Commercially available UW solution was used as the 
control perfusate. 
5.2.3 Graft Retrieval 
Porcine kidneys were obtained from adult landrace pigs after sacrifice at a local abattoir. Local 
guidelines were adhered to. Organs were retrieved as per the longer ischaemia protocol detailed in 
Section 3.1.3.1. Kidneys were flushed at a pressure of 100cmH20 with 500ml of either AL-MPS or UW 
depending on the assigned experimental group. At the laboratory grafts were further benched for 
HMP and the renal artery cannulated for perfusion.   
5.2.4 Hypothermic Machine Perfusion 
Kidneys were perfused hypothermically (5-7˚C) on two commercially available Waters Medical RM3 
perfusion units for 10 hours. 1L of preservation solution was used in either circuit. Perfusion was 
based on clinical protocols[1114] with a target systolic perfusion pressure of 40mmHg by 15 minutes 
of perfusion. Volume driven flow was then adjusted at 1, 2 and 3 hours of HMP to maintain a target 
systolic pressure of 40-45mmHg, and then left to take its course. 
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5.2.5 Reperfusion Circuit 
The first four pairs of kidneys in these experiments only underwent HMP. In the following six pairs a 
normothermic reperfusion assessment of viability was introduced after the initial period of cold 
HMP. After 10 hours of HMP 6 kidney pairs were then connected to a NMR circuit to assess organ 
viability. Reperfusion with KHB was performed after a 20 minute re-warming period at room 
temperature to mimic the implantation of the kidney into the recipient. The Waters Medical RM3 
units were modified to facilitate normothermic reperfusion by in line incorporation of an automated 
temperature controlled water pump (Grant) with the target temperature set to 39oC. The circuit 
was primed with 1L of KHB (BRAND) supplemented with 2g glucose, 1.8mg H2CO3, 10g/L (1%) BSA, 
spiked with 1000mmol/L creatinine, and oxygenated by bubbling a mixture of 95% O2 / 5% CO2 gas 
mixture through RM3 cassette arterial reservoir. The ureter was cannulated to allow collection of 
urine. Urine volume was replaced with fresh KHB. Reperfusion was maintained for 2 hours. Initially 
systolic perfusion pressure was set to 40 mmHg and gradually increased to 50 mmHg within the first 
10 minutes and then maintained between 45-50mmHg.  
 
Figure 69 Dia gra m of experi mental  protoc ol for  tes ti ng of novel  AL s ol ution vs . UW s oluti on 
dur i ng HMP. 
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Outcome Measures  
Real-time perfusion dynamics (perfusion pressures, flow rates, and resistances) were recorded 
throughout HMP and reperfusion. Kidneys were weighed pre-HMP, post-HMP, and post-
Reperfusion, to quantify oedematous change. During reperfusion urine output was collected and 
measured. Perfusate was iso-volumetrically replaced with the amount of urine lost, using KHB with 
1% BSA. Urine samples were collected at 1 and 2 hours, and reperfusate samples collected at 5mins, 
1hour and 2 hours of reperfusion. All reperfusate and urine samples were centrifuged for 3 min at 
3500rpm and the supernatant stored at -80 degrees for later analysis. Samples were analysed for 
electrolytes, creatinine, lactate dehydrogenase (LDH). Blood gas analysis was performed real-time on 
arterial and venous reperfusate samples at 30mins, 1 hour and 2 hours of reperfusion and allowed 
calculation of oxygen consumption. 
5.2.6 Rapid sampling microdialysis 
RsMD was instituted in these experiments in line with the methodology described in Project 1. In 
brief microdialysis probes (MAB11.35.4, Microbiotech, Stockholm, Sweden) were inserted 
superficially into the parenchyma of the lateral cortex at the start of HMP. These were connect to an 
in-house built rapid-sampling microdialysis analyser. Every 30 seconds a 200 nL dialysis sample was 
automatically injected into the analysis flow stream, alternating between each kidney. The stream 
accelerates the dialysate through an enzyme reactor containing LOx and HRP (Genzyme Diagnostics, 
Kent, UK). The LOx recognises the analyte, producing hydrogen peroxide, which reacts with the HRP. 
The HRP is regenerated by oxidation of the ferrocene mediator species, producing ferrocinium ions, 
which are detected at the downstream electrode (BASi, West Lafayette, IN) by reduction. Due to the 
small sample size, the current produced is directly proportional to the concentration of lactate in the 
sample even above the free solution Km of the lactate oxidase enzyme (0.7 mM). Data was collected 
using a PowerLab data acquisition unit (8/30, ADInstruments, New South Wales, Australia) and 
LabChart software (ADInstruments, New South Wales, Australia) running on a Macbook Pro portable 
computer (Apple Computers, Cupertino, CA). Lactate levels were analysed in real-time to reveal 
information on interstitial lactate concentration during the 10 hours of HMP, and then 2 hours of 
normothermic reperfusion. 
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5.2.7 Histological Analysis 
Needle core biopsies were taken pre-HMP, post-HMP, and wedge biopsies after 2 hours of 
normothermic reperfusion, fixed in 4% formalin, dehydrated, and embedded in paraffin wax. 4 µm 
sections were cut and stained with hematoxylin and eosin, (periodic acid-Schiff) for light microscopy 
evaluation. 
Tubular dilation, epithelial flattening, epithelial shredding, tubular debris, vacuolation, condensed 
tubular nuclei, and glomerular shrinkage were each scored over three fields using a semi-
quantitative scale (0 normal; 1 mild (0-25% affected); 2 moderate (25-50% affected); 3 severe (>50% 
affected). 
5.2.8 Analytical methods 
During HMP and reperfusion, recorded flow rates were adjusted for kidney weight to calculate flow 
rate per 100g (ml/min/100g). PFI (ml/min/100g/mmHg) values which incorporate flow rate and 
pressure per 100g of tissue were calculated for each kidney.  
During reperfusion creatinine clearance was calculated to determine GFR per gram of tissue as 
(urinary creatinine × urinary volume/reperfusate creatinine). Fractional excretion of sodium was 
calculated  as (urinary sodium × urinary flow)/(GFR × reperfusate sodium)×100)/g. Urinary LDH/GFR 
ratio per gram of tissue was similarly calculated. Oxygen consumption was calculated as (difference 
between arterial and venous partial pressure of oxygen) × flow rate/100g of tissue.  
5.2.9 Statistical Methods 
Values are represented as mean and standard deviation. Continuous variables were plotted as levels 
versus time curves for each kidney and the mean area under the curve calculated. Continuous 
variables from paired contra-lateral kidneys were evaluated using the paired students T-test or non-
parametric Wilcoxon signed rank test when distribution assumptions were not met.  Histology scores 
were compared using the Wilcoxon signed rank test. Data and statistical analysis was performed 
using Microsoft® Excel Software (Reading, UK). All tests were 2-tailed and a p value of ≤ 0.05 was 
considered significant. 
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5.3 Results  
5.3.1 Adaptation of AL Cardioplegia for kidney Machine Perfusion 
A pilot experiment utilized un-modified AL as the HMP perfusate for perfusion of a single porcine 
kidney (WIT:15 minutes, SCS CIT 135 minutes). Perfusion failure occurred after 2 hours due to 
massive oedema (77% weight gain), and poor perfusion dynamics: perfusion pressure >100mmHg, 
flow rate: 3ml/min/100g, resistance: 8.8 mmHg/ml. The perfusate composition was adjusted with 
addition of 4% BSA to prevent oedema, and facilitate machine perfusion, this final solution was 
designated AL-MPS. 
5.3.2 Kidney Characteristics 
Ten pairs of porcine kidneys were used in these experiments (AL group n=10, UW group n=10). 
Kidney characteristics were similar between experimental groups. WIT was identical for both AL and 
UW kidneys (WIT: 34.6 ±14.5 minutes) while SCS CIT in AL kidneys was 270.4 ±22.5 minutes, and 264 
±18.8 minutes in UW kidneys, p=0.356. Average kidney weight was 308.4g±107.5 in AL group, and 
316g ±109.8 in UW group (p=0.816).  
5.3.3 Hypothermic Machine Perfusion 
Perfusion dynamics during HMP are shown in Figure 70. After the initial 3 hour stabilization phase 
perfusion where systolic pressures were maintained at 40mmHg pressures remained stable in AL 
perfused kidneys (Systolic pressure during 3-10h of AL HMP: 39.6 ±4.1mmHg) but decreased in UW 
kidneys (UW=35.7 ± 4.6 mmHg, p=0.022). HMP perfusate flow rates in AL kidneys were 20% higher 
compared to UW kidneys (Flow rates: AL=21.5 ±7.7; UW=17.9 ± 7.7 ml/min/100g, p=0.011). The PFI 
during the initial stabilization phase was 25% greater in AL kidneys vs. UW kidneys (0-3h of HMP: 
AL=0.50± 0.2, UW=0.40 ± 0.17; p=0.033), but equalised during the remainder of HMP (3-10h of HMP: 
AL=0.55 ± 0.2, UW=0.54 ± 0.23 ml/min/100g/mmHg; p=0.817) with an increase in PFI in UW group to 
the levels seen with AL. Resistance was not different during HMP (AL=0.59 ±0.29, UW=0.63 ±0.27 
mmHg/ml/min; p=0.462).  
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Figure 70 Per fusion dyna mi cs duri ng HMP wi th AL a nd UW sol utions for 5  hours . Sys tolic 
per fus ion pressure a nd flow rates (top), resistance (mi ddle) and per fusion flow i ndex  (bottom).  
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5.3.4 Normothermic Reperfusion 
5.3.4.1 Reperfusion  Dynamics  
After 10 hours of HMP kidneys underwent viability assessment on a isolated normothermic 
reperfusion circuit. Reperfusion dynamics were similar in both AL and UW perfused kidneys (Systolic 
pressure: AL=46.1 3.2, UW=46.2 2.2 mmHg, p=0.856; Reperfusion flow rate: AL=44.7±10.4, 
UW=50.5±17.4 ml/min/100g, p=0.319; Resistance:  AL=0.21±0.04, UW=0.17±0.11 mmHg/ml/min, 
p=0.305; PFI: AL=0.97±0.23, UW=1.1±0.37 ml/min/100g/mmHg, p=0.317). Reperfusion dynamics are 
depicted in Figure 71 and Figure 72.  
 
5.3.4.2 Weight Change 
There was a 38.8±8.2% significant increase in graft weight after AL HMP vs. 18.9 ±8.6% with UW 
HMP (p=0.002). While weight increase after RP trended lower in the AL group (9.7 ±7.9%) vs. the UW 
group (21.9 ±10.7%, p=0.113). Weight changes are represented in Figure 73. 
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Figure 71 Reper fusi on Dyna mics  in AL a nd UW kidneys . Sys tolic pressure (top) and renal flow 
ra tes (bottom). There were no di fferenc es  in reperfusion dyna mics  between the two groups  of 
ki dneys . 
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Figure 72 Reper fusi on Dyna mics i n AL a nd UW kidneys . Resis ta nc e (top) a nd per fusion flow 
index (bottom). There were no differenc es  in reperfusion dyna mics  between the two groups  of 
ki dneys . 
 
 
 
 
 
 
 
 
0
0.2
0.4
0.6
0.8
1
0 60 120
m
m
H
g/
m
l/
m
in
 
Resistance (mmHg/ml/min) during NMR 
 
AL
UW
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
0 60 120
m
l/
m
in
/1
00
g/
m
m
H
g 
PFI (ml/min/100g/mmHg) during NMR 
 
AL
UW
292 
 
 
 
 
Figure 73  Perc ent wei ght cha nge in AL and UW kidneys  a fter  HMP and NMR.  There was a 
38 .8±8.2% signi ficant i nc reas e i n gra ft wei ght a fter  AL HMP vs . 18 .9  ±8 .6% wi th UW HMP 
(p=0.002). Whil e wei ght i ncreas e a fter  RP trended l ower  in the AL group (9 .7  ±7 .9%) vs . the UW 
group (21.9  ±10.7%, p=0.113).  
 
5.3.4.3 Urine output/GFR 
Urine output trended higher at 60 and 120 minutes of RP in UW perfused kidneys (Urine output 
60mins: AL= 0.79±0.67, UW=1.26±1.3 ml/hour/g, p=0.41; Urine output 120 minutes: AL= 1.10±0.74, 
UW=1.25±1.51 ml/hour/g, p=0.748). Despite significantly lower reperfusate creatinine 
concentrations at the end of RP in AL perfused kidneys (AL=413.2 ± 103, UW=512.9±75.5 mmol/L, 
p=0.026) overall creatinine clearance was not different between the preservation solutions (AL= 
0.016 ± 0.01, UW = 0.018 ± 0.01 ml/min/g, p=0.73). Fractional sodium excretion per gram of tissue 
was not different (AL=0.3±0.18, UW=0.27±0.11 AU, p=0.748), and assessment of tubular damage via 
urinary LDH/GFR ratio indicated similar levels of ischaemic injury (AL=0.29±0.4, UW=0.28±0.09 
IU/ml/min/g). Functional assessment of graft viability is depicted in Figure 74. 
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5.3.4.4 Oxygen consumption  
Overall oxygen consumption was comparable between AL and UW perfused kidneys during 
reperfusion (AL=3.46±2.5, UW=3.09±1.7 kPa/ml/min/g, p=0.58) and is shown in Figure 74. 
Furthermore the buffering capacity of AL kidneys was superior to UW kidneys with preservation of 
higher levels of reperfusate bicarbonate during 2h of reperfusion (AL=17.1±3.3, UW=12.1±4.3 
mmol/L, p=0.02, see Figure 74).  
 
Figure 74  Func ti onal  a nd bi oc hemical  ass ess ment of AL and HMP gra ft via bility during NMR. 
Uri ne output, c rea ti nine cl eara nc e, frac ti onal exc reti on of s odium, uri nary LDH/GFR ra tio, 
oxygen c ons umption a nd per fusate bi carbonate l evels.  
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5.3.4.5 Rapid sampl ing microdialysis 
Cortical tissue lactate concentrations were quantified using rsMD in kidneys during both 10 hours of 
HMP and 2 hours of reperfusion (Figure 75). During HMP cortical lactate levels were comparable 
between AL and UW perfused kidneys (AL= 0.154 ±0.096, UW= 0.144±0.038 mM/min, p=0.851). 
During reperfusion cortical lactate levels trended lower in AL kidneys vs. UW kidneys (AL= 
0.66±0.306, UW= 0.887±0.534 mM/min, p=0.33). Lactate levels were also quantified in the 
reperfusate using blood gas analysis and were significantly lower in the AL vs. UW group 
(AL=3.1±0.4, UW=4.1±1.0 mmol/L, p=0.04) during reperfusion. 
 
 
Figure 75  Rs MD for tissue lac ta te during HMP a nd NMR in AL and UW ki dneys . Exa mpl e sca tter 
dia gra m of rs MD rea dings  meas ured from one ki dney during HMP a nd NMR (Top). Avera ge 
c or tic al tissue lac ta te during HMP a nd NMR in AL and UW kidneys (bottom l eft). Per fusa te 
l a c tate c oncentrations during NMR (bottom r ight).   
 
 
0
0.25
0.5
0.75
1
1.25
1.5
HMP NMR
m
M
/m
in
Average cortical microdialysis lactate 
concentration during 10 hours of HMP 
and 2 hours of NMR (mM/min) 
AL
UW
0.0
1.0
2.0
3.0
4.0
5.0
6.0
m
m
o
l/
L
Perfusate lactate (mmol/L) during NMR
AL
UW
0
200
400
600
800
1000
1200
1400
1600
1800
0
50
100
150
200
250
300
350
400
0 100 200 300 400 500 600 700 [L
ac
ta
te
 m
M
] 
d
u
ri
n
g 
re
p
e
rf
u
si
o
n
[L
ac
ta
te
 m
M
] 
d
u
ri
n
g 
H
M
P
 
Minutes of Perfusion
Example of detected lactate levels via rapid sampling microdialysis (rsMD) during 
10 hours HMP and 2 hours Reperfusion from one porcine kidney allograft 
HMP Reperfusion
295 
 
5.3.4.6 Histology 
There were no significant differences in core biopsies between AL and UW kidneys in pre-HMP and 
Post-HMP samples. After NMR all kidneys exhibited evidence of reperfusion induced tubular damage 
with a significantly greater degree of tubular dilation in UW vs. AL kidneys (p=0.003), see Figure 76. 
There were no other significant differences (see Table 12 ).   
 
Parameter Tubular Debris  Tubular Dilation Nuclear Fragmentation 
Group AL UW AL UW AL UW 
Score 2.4 ± 0.5 2.6 ± 0.5 2.1 ± 0.6* 3.1 ± 0.7 1.2 ± 0.5 1.2 ± 0.2 
 
Ta bl e 12  His tology sc ores  of biopsi es  ta ken a fter  2  hours  of NMR  ass essing tubular  debris, 
tubular  Dilata ti on, a nd nucl ear  fra gmenta ti on. There was a  signi ficantl y grea ter degree of 
tubul a r dilation i n UW vs . AL ki dneys (p=0.003). There were no other  s ignificant differenc es. 
 
 
Figure 76   Photomicrographs  of l i ght microsc opy of AL vs . UW per fus ed kidneys  a fter  2  hours  of 
NMR. H&E s taining, x20. A: AL ki dney, B: UW ki dney. Showi ng grea ter degree of tubular 
di l atation in UW kidneys.  
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5.4 Discuss ion 
Increasing use of DCD and ECD has led to a resurgence of methods to improve allograft viability and 
function. Interest has focussed on the further potential of HMP which has shown benefit compared 
to SCS in terms of graft survival and DGF[946].  
The preservation solution used in clinical practice for renal HMP was first developed 40 years ago, 
and is the gold standard solution, but may not be the most effective solution for marginal allografts. 
Ischemia reperfusion injury is believed to contribute to graft function dysfunction and new methods 
of protection are required to expand with the increasing use of marginal kidneys secondary to organ 
shortages [1115]. Adenocaine MPS (AL-MPS) is a HMP solution based on the cardioplegia 
Adenocaine containing adenosine and lidocaine as the primary effector agents in the solution. 
The present study was the first using a AL-MPS solution [1116]  in a DCD porcine kidney HMP model. 
We report that Al-MPS solution showed significantly improved flow rates and flow indicies 
compared to UW during a period of 10 hours of HMP, and significantly lower perfusate lactate levels 
during 2 hours warm reperfusion.  In all other areas, modified AL solution showed equivalency 
compared to UW in hypothermic perfusion dynamics, normothermic functional viability assessment, 
and histological injury. 
5.4.1 Potential Benefits of AL-MPS in Renal HMP 
In addition both adenosine and lidocaine have been demonstrated to exert protective effects on 
kidney physiology against IR injury. Through A1 adenosine receptors adenosine has been shown to 
lower renal oxygen consumption by reducing GFR through selective afferent arteriolar 
vasoconstriction, thus decreasing filtration workload during IR injury while cellular energetics are 
reconstituted and repaired[965]. This effect may be a mechanism of 'acute renal success' where in 
an ischaemic setting reduced formation of ultrafiltrate will decrease tubular workload and thus 
oxygen consumption, and aid recovery from the initial ischaemic insult[1117]. Conversely via A2 
receptors adenosine facilitates an increase in medullary blood flow and oxygenation while at the 
same time lowering medullar transport activity [955] through NO generation[970,971].  
While lidocaine is a local anaesthetic agent, it is also used as an anti-arrhythmic drug [983] and has 
been used in cardiac resuscitation[984,985] possessing negative chronotropic, inotropic effects, and 
vasodilatory effects[986]. Independent of its inhibition of voltage sensitive fast opening sodium 
channels lidocaine has also been suggested to exert anti -inflammatory effects by 1) inhibiting 
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leucocyte endothelial interaction [987]; 2) inhibiting release inflammatory cytokines and chemokines 
from endothelial cells [988]; 3) inhibiting production of superoxide anion ROS by XO[989,990]; 4) 
reducing ROS damage by scavenging hydroxyl free radical species [991]; and 5) by inhibiting 
sodium/calcium exchange reducing cellular calcium accumulation during ischemia [992–994]. 
The inclusion of magnesium in AL is based upon its effects as a natural calcium antagonist on 
membrane stabilisation and preventing ischaemic cytoplasmic calcium overload[1017], as well as 
facilitating ATP production[1013], and observed anti-inflammatory properties in IR settings[1018]. 
At a concentration of 5.8mM the potassium content of AL-MPS is normokalaemic and less than that 
of UW (25mM). High potassium concentrations above 10mM promote ionic imbalances[951], 
depolarise endothelial cells rendering them into an activated pro-inflammatory state[1020], and 
cause vasoconstriction during preservation[951,1021]. 
5.4.2 Comparison of AL-MPS to UW Solution during HMP 
In this experiment AL-MPS was compared to UW, the gold standard perfusate for machine organ 
perfusion. UW does not contain adenosine, nor lidocaine, however UW does contain adenine a 
component and pre-cursor of adenosine, included in UW as an energy metabolite precursor. 
Adenine has not been shown to exert pharmacological effects as adenosine. 
Overall during HMP flow rates were higher during perfusion with AL-MPS, suggesting more effective 
perfusion. A mechanistic effect of lidocaine's vasodilatory properties may be a factor in these 
differences[1118]. However differences may further stem from the relative viscosity of UW 
compared to AL-MPS. UW contains hydroxy-ethyl-start a pentose starch that acts as the primary 
osmotic agent in UW and which renders it viscous. AL-MPS however relies on an albumin 
supplement at isotonic levels (4%) as an oncotic agent.  
The resistance values calculated by the perfusion machine however showed no difference between 
HMP solutions, and this in part can be attributed to its calculation using the mean perfusion 
pressure. The systolic pressure as an indication of potential barotrauma in our experience is the 
preferred value to be monitored. We utilised the systolic pressure, the flow rate, and weight of 
individual kidneys to calculate the PFI as a measure of effective organ perfusion. The PFI is thus a 
more informative metric than the Resistance Index.  
With AL-MPS PFI levels remained within viable parameters (>0.4)[876] for the duration of perfusion, 
and during initial perfusion (0-3 hours) was superior to perfusion with UW. It is suggested a 
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minimum perfusion time of 4 hours is required before perfusion dynamics have stabilised sufficiently 
to allow there use in predicting organ function after transplantation [1061]. With AL-MPS perfusion 
stabilises within the 1st 60 minutes, compared to 4 hours with UW potentially allowing earlier use of 
perfusion dynamics for viability assessment to guide and plan recipient management.  
Higher interstitial oedema after HMP with AL-MPS reflects the absence of HES, a potent oncotic 
present in UW. Greater than 25% weight gain in renal allografts with HMP has been suggested to 
predicate to poorer graft outcome[1114]. It is interesting that increased tissue water was found in 
the isolated heart perfused with AL cardioplegia but this affect functional recovery, as AL was shown 
to be superior in left ventricular performance than high potassium solutions [1119]. Similarly the 
association is however is not absolute[659] and the reliance on individual parameters  is less 
sensitive in assessing viability than with combined indices such as perfusion dynamics[832]. During 
reperfusion, for example, the interstitial oedema was lower in AL perfused kidneys compared the 
UW solution .  
The normokalaemic nature of AL-MPS compared has been attributed as one of the key factors in the 
benefits seen in cardiac preservation and subsequent re-animation. However note must be 
considered in drawing parallels to kidney preservation as cardiac preservation CIT is shorter (up to 4 
hours clinically) and may not be ideal in situations with longer CIT as a relatively low potassium 
content may result in intracellular potassium depletion. The potassium content of AL-MPS however 
is in line with newer preservation solutions such as Polysol which have shown promise in 
experimental models[880].  
5.4.3 NMR Viability Assessment  
Isolated kidney reperfusion models have been used to determine renal preservation injury in a 
number of settings particularly for comparing preservation solutions[581,751,761,1120]. Functional 
assessment of kidney grafts during reperfusion demonstrated similar viability profiles in AL-MPS and 
UW perfused kidneys. Adenosine, through A1 and A2 receptors modulates renal arteriolar 
glomerular and medullary blood flow, limiting glomerular filtrate formation and reducing oxygen 
demand. This effect was not seen in these experiments; urine output trended lower with AL-MPS but 
not significantly, with creatinine clearance, fractional sodium excretion, oxygen consumption, and 
LDH/GFR ratio comparable to UW. Adenosine receptor activation produces both and immediate and 
delayed receptor mediated effect [968], suggesting preservation with adenosine in the hypothermic 
state would mediate a degree of benefit during subsequent reperfusion. However AL-MPS contained 
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a 4mM adenosine concentration which may be an insufficient level to exert a protracted effect in an 
ex-vivo reperfusion model.  
In addition to using the LDH/GFR ratio for assessing tubular damage as proposed by Kehrer et al. 
[1121], ischaemic injury was further characterised using rsMD for cortical tissue lactate. The real-
time nature of the rsMD system ensured dynamic changes during HMP and reperfusion were 
characterised. This high resolution technique demonstrated non-significant differences between 
cortical lactate profiles in both preservation solutions. 
The trend of lower lactate in modified AL pumped kidneys suggests potentially less ischaemic 
damage during reperfusion, correlating with the trend of increased O2 consumption in these 
kidneys. 
An alternative explanation of these trends is suggested by the data presented in Chapter 3. and 
relates to the intrinsic lactate metabolism inherent in the renal cortex. In contrast to traditional 
thought higher lactate may actually represent more viable cells able to undergo anaerobic 
metabolism during reperfusion when the oxidative enzymes are still undergoing repair and oxygen 
consumption and aerobic metabolism is not efficient. In the same sense a lower lactate signifies less 
cells able to undergo metabolism in the cortex. The limitation in significance in this data pronounces 
further experimentation will be required to clarify these trends, which should then be correlated to 
functional differences during reperfusion.  
 
AL-MPS kidneys demonstrated a resilience to development of acidosis during reperfusion, 
maintaining higher perfusate bicarbonate levels than UW kidneys. This effect may in part be 
mediated by A1 receptors within the proximal convoluted tubules, activation of which as well as 
modulating filtrate formation is known to increase tubular bicarbonate reabsorption[1122,1123]. 
5.4.4 Adenosine and Lidocaine in Preservation Solutions 
Lidocaine has been evaluated as a cytoprotective supplement to conventional SCS solutions with a 
degree of success by Erkasap et al. They added 0.081mmol/L of lidocaine to Euro-Collins solution, 
and investigated the effect of this composite solution to unmodified Euro-Collins in a series of 
experiments using canine kidneys. The effectiveness of 48 hours of SCS preservation with these 
solutions was compared by assessing organ viability using an isolated normothermic reperfusion 
circuit. Reperfusate flow rates, GFR, urine output, and fractional sodium excretion levels were all 
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found to be significantly higher; with markers of tubular damage (urinary LDH/GFR ratio), and lipid 
peroxidation (malondialdehyde tissue levels) significantly lower, after Euro-Collins/lidocaine 
preservation. A potential mechanism for these observations is based on lidocaine's ROS scavenging 
properties[1002]. This will be active during HMP, and so potentially limit lipid peroxidation and cell 
damage during reperfusion; hence promote better functional metrics. Acknowledging Euro-Collins 
solution was not used in our study, despite using a 7-fold higher concentration of lidocaine in AL-
MPS than Erkasap et al. used such differences in functional reperfusion dynamics were not seen. 
These differences may stem from the fact that in the AL-MPS experiments grafts came from a DCD 
animal model with WIT more than 30 minutes, and thus considerably longer ischaemic injury, 
compared to Erkasap et al. where canine kidneys were retrieved under anaesthesia with minimal 
reported WIT before flushing.   
Lopez-Neblina et al. developed a SCS preservation solution, Human Biosystems (HBS) composed of 
macro molecules, high-energy substrates, precursors, and co-factors, with a mixture of anti-
proteolytic amino acids, antioxidants, and anti-inflammatory compounds[1124]. HBS contained 
adenosine as an energy substrate, and lidocaine as a membrane stabilizer, exact concentrations of 
each not reported. They compared effectiveness of HBS to UW solution and HTK in renal SCS 
preservation using a murine kidney transplant model. HBS preserved kidneys better, with improved 
allograft function and survival at 7 days. The specific role of both adenosine and lidocaine in 
improving allograft preservation cannot be determined considering the presence of other 
substances active to limit IR injury. However this study further highlights the theoretical benefits of 
adenosine and lidocaine in abdominal organ preservation, and supports their potential use.  
5.4.5 Limitations 
This study had several limitations. Despite widespread use of isolated organ perfusion models, they 
provide only a limited, acute and early assessment of organ function after preservation. A more 
direct translational approach would entail use of a porcine auto-transplant model. An optimal 
middle ground is use of an isolated haemo-reperfusion circuit which provides a more physiological 
challenge to the organ, and which can be maintained for several hours; use of which clinically has 
been demonstrated to predict allograft function. DCD porcine kidneys were used with a length WIT 
but with only a relatively short (4 hours) CIT prior to the start of HMP, determination of the effects 
of modified AL HMP on kidney function and metabolism using grafts exposed to longer lengths of 
initial SCS would allow further elucidation on the potential for use of AL MPS.  
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Adenosine and lidocaine concentration levels used in AL-MPS were in-line with levels in cardioplegic 
Adenocaine and chosen as a starting reference point. Both these agents have dose related effects 
and so higher concentrations of each in AL-MPS require evaluation. The AL solution in modified-
Krebs Henseleit and 16 mM MgsO4 was refrigerated for 24 hours before the experiment and, while it 
was visually checked for precipitates, future studies should include a full quantitative particulate 
analysis prior to kidney perfusion.  
During NMR standard methods of determining renal function and creatinine clearance were utilised, 
and included ml for ml replacement of fluid filtered by the graft (urine) with stock KHB solution to 
ensure an equal and constant volume of fluid in the perfusion circuit. Despite being widely used and 
described in the literature [1125] this methodology however introduces an unavoidable and 
potential inaccuracy in the calculation of creatinine clearance due to the fluid movements.  
The PFI calculation utilised pre-HMP weight. With significant changes in weight during HMP a 
recalculation of PFI using dynamic weights as perfusion progresses would be ideal to demonstrate 
dynamic perfusion metrics. This was not logistically possible  however to measure kidney weight 
every hour.    
5.4.6 Future Development of AL-MPS 
The University of Wisconsin solution (Belzer MPS) has been the gold standard HMP solution for the 
past 40 years. Clinical studies have shown HMP with UW vs. SCS is beneficial for graft function and 
patient survival, however this benefit is less dominant with marginal allografts. With the increasing 
demand for kidney transplantation, and more dependence on marginal allografts, novel solutions 
that can ameliorate IR injury are needed. In our study cold machine perfusion with AL-MPS was 
superior to UW for the initial 4 hours of HMP and may allow earlier viability assessment. 
Furthermore AL-MPS HMP preservation demonstrated equivalency to UW in functional organ 
assessment during normothermic reperfusion. Dose related effects of the adenosine and lidocaine 
may be reason differences in organ viability between AL-MPS and UW were not observed.  AL-MPS is 
the initial attempt introducing a successful cardiac preservation solution into the setting of renal 
HMP, and our results are promising allowing further refinement of the AL-MPS composition.  
  
302 
 
 
  
303 
 
CHAPTER 6:   
CAN POST ISCHAEMIC RECONDITIONING 
BY HMP RECOVER KIDNEYS FROM 
EXTREME COLD ISCHAEMIA? 
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Can Post Ischaemic Reconditioning by HMP Recover Kidneys from Extreme Cold Ischaemia? 
6.1 Objectives  
Hypothermic preservation has formed the mainstay for organ maintenance in transplantation, with 
SCS constituting the commonest and simplest method. Prolonged static storage is associated with 
deleterious graft outcomes, especially in marginal allografts. HMP preservation however has been 
shown to be beneficial for marginal organs promoting a washout of blood and equilibration with the 
perfusate medium; delivering oxygen and nutrients and removing toxic metabolites.  
The use HMP to evaluate the effect of extreme CIT on parameters measured during machine 
perfusion was investigated. Furthermore, it aimed to establish whether HMP is able to reverse the 
effect of prolonged CIT and restore renal function. 
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6.2 Methods  
6.2.1 Experimental Protocol 
Eight porcine kidneys were used in this study. After retrieval one kidney of each pair underwent SCS 
for either 4 hours (SCS4, n=4) or 52 hours (SCS52, n=4). All kidneys after SCS underwent 10 hours of 
HMP reconditioning on a Waters Medical Systems RM3 device with UW solution. Heterogeneous 
clinical HMP pump times have been reported in the literature with averages varying between 
10[831] to 31[838] hours. Thus 10 hours of HMP was considered to be a reasonable starting point 
for reconditioning in this extreme CIT model to allow for stabilization of HMP parameters for viability 
interpretation. After HMP kidneys underwent viability assessment for 2 hours using an oxygenated 
NMR circuit with KHB solution. The protocol for this experiment is summarised in Figure 77.  
6.2.2 Graft Retrieval 
Porcine kidneys were obtained from adult landrace pigs after sacrifice at a local abattoir. Local 
guidelines were adhered to. Organs were retrieved as per the longer ischaemia protocol detailed in 
Section 3.1.3.1. Kidneys experienced 45 minutes of in-situ warm ischemia prior to retrieval, benching 
and flushing. Kidneys were flushed at a pressure of 100cmH20 with 1L of Eurocollins solution 
(Soltran, Baxter, Compton, UK). At the laboratory grafts were further benched for HMP and the renal 
artery cannulated for perfusion.   
6.2.3 Hypothermic Machine Perfusion 
Kidneys were perfused hypothermically (5-7˚C) on two commercially available Waters Medical RM3 
perfusion units for 10 hours. 1L of preservation solution was used in either circuit. Perfusion was 
based on clinical protocols[1114] with a target systolic perfusion pressure of 40mmHg by 15 minutes 
of perfusion. Volume driven flow was then adjusted at 1, 2 and 3 hours of HMP to maintain a target 
systolic pressure of 40-45mmHg, and then left to take its course. 
 
6.2.4 Reperfusion Circuit 
After 10 hours of HMP kidneys were connected to a NMR circuit to assess organ viability. 
Reperfusion with KHB was performed after a 20 minute re-warming period at room temperature to 
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mimic the implantation of the kidney into the recipient. The Waters Medical RM3 units were 
modified to facilitate normothermic reperfusion by in line incorporation of an automated 
temperature controlled water pump (Grant) with the target temperature set to 39oC. The circuit was 
primed with 1L of KHB supplemented with 2g glucose, 1.8mg H2CO3, 10g/L (1%) BSA and oxygenated 
by bubbling a mixture of 95% O2 / 5% CO2 gas mixture through RM3 cassette arterial reservoir. The 
ureter was cannulated to allow collection of urine. Urine volume was replaced with fresh KHB. 
Reperfusion was maintained for 2 hours. Initially systolic perfusion pressure was set to 40 mmHg and 
gradually increased to 55 mmHg within the first 10 minutes and then maintained between 55-
60mmHg.  
Outcome Measures  
Real-time perfusion dynamics (perfusion pressures, flow rates, and resistances) were recorde d 
throughout HMP and reperfusion. Kidneys were weighed pre-HMP, post-HMP, and post-
Reperfusion, to quantify oedematous change. During reperfusion urine output was measured and  
iso-volumetrically replaced using KHB with 1% BSA. Blood gas analysis was performed real-time on 
arterial and venous reperfusate samples at 30mins, 1 hour and 2 hours of reperfusion and allowed 
calculation of oxygen consumption. 
 
Figure 77  Dia gra m of experi mental protocol  inves ti ga ting potential for  hypother mic 
rec ondi tioning a fter  an lengthy c old storage per iod.  
 
Retrieval – Flush with 
Soltran and transport 
to lab
Static Cold Storage 
4 hours : n=4 (SCS4)
52 hours : n=4 (SCS52)
Hypothermic Machine 
Perfusion  – 10 hours
UW solution
NMR – Reperfusion 
Circuit (2 hours) for all 
kidneys
Dissection, flushing and transport
Hypothermic Machine 
Perfusion (10 hours)
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6.2.5 Analytical methods 
During HMP and reperfusion, recorded flow rates were adjusted for kidney weight to calculate flow 
rate per 100g (ml/min/100g). PFI (ml/min/100g/mmHg) values which incorporate flow rate and 
pressure per 100g of tissue were calculated for each kidney. Oxygen consumption was calculated as 
(difference between arterial and venous partial pressure of oxygen) × flow rate/100g of tissue.  
6.2.6 Rapid sampling microdialysis 
RsMD was instituted in these experiments in line with the methodology described in Project 1. In 
brief microdialysis probes (MAB11.35.4, Microbiotech, Stockholm, Sweden) were inserted 
superficially into the parenchyma of the lateral cortex at the start of HMP. These were connect to an 
in-house built rapid-sampling microdialysis analyser. Every 30 seconds a 200 nL dialysis sample was 
automatically injected into the analysis flow stream, alternating between each kidney. The stream 
accelerates the dialysate through an enzyme reactor containing LOx and HRP (Genzyme Diagnostics, 
Kent, UK). The LOx recognises the analyte, producing hydrogen peroxide, which reacts with the HRP. 
The HRP is regenerated by oxidation of the ferrocene mediator species, producing ferrocinium ions, 
which are detected at the downstream electrode (BASi, West Lafayette, IN) by reduction. Due to the 
small sample size, the current produced is directly proportional to the concentration of lactate in the 
sample even above the free solution Km of the lactate oxidase enzyme (0.7 mM). Data was collected 
using a PowerLab data acquisition unit (8/30, ADInstruments, New South Wales, Australia) and 
LabChart software (ADInstruments, New South Wales, Australia) running on a Macbook Pro portable 
computer (Apple Computers, Cupertino, CA). Lactate levels were analysed in real-time to reveal 
information on interstitial lactate concentration during the 10 hours of HMP, and then 2 hours of 
normothermic reperfusion. 
6.2.7 Histological Analysis 
Needle core biopsies were taken pre-HMP, post-HMP, and wedge biopsies after 2 hours of 
normothermic reperfusion, fixed in 4% formalin, dehydrated, and embedded in paraffin wax. 4 µm 
sections were cut and stained with hematoxylin and eosin, (periodic acid-Schiff) for light microscopy 
evaluation. Tubular damage was scored for: tubular dilation, tubular debris, and nuclear 
fragmentation of tubular cells. were each scored over three fields using a semi-quantitative scale: 0 
(normal); 1 (0-25% affected); 2 (25-50% affected); 3 (50%-75% affected) and 4 (>75% affected).  
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6.2.8 Statistical Methods 
Values are represented as mean and standard deviation. Continuous variables were plotted as levels 
versus time curves for each kidney and the mean area under the curve calculated. Continuous 
variables from paired contra-lateral kidneys were evaluated using the paired students T-test or non-
parametric Wilcoxon signed rank test when distribution assumptions were not met.  Histology scores 
were compared using the Wilcoxon signed rank test. Data and statisti cal analysis was performed 
using Microsoft® Excel Software (Reading, UK). All tests were 2-tailed and a p value of ≤ 0.05 was 
considered significant. 
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6.3 Results  
6.3.1 Hypothermic Machine Perfusion 
6.3.1.1 Perfusion Dynamics 
Perfusion dynamics during HMP are shown in Figure 78. There were no significant differences in 
overall perfusion dynamics during HMP between SCS4 and SCS52 kidneys. However the perfusion 
time necessary to reach viable perfusion parameters (measured resistance <0.5 mmHg/ml/min, and 
calculated PFI >0.4 ml/min/100g/mmHg) was significantly less in SCS52 (Resistance: 165±90 minutes, 
PFI: 120±85 minutes) than SCS4 kidneys (Resistance: 450±180 minutes, PFI: 330±180 minutes; 
p=0.008, p=0.027 respectively). 
6.3.2 Normothermic Reperfusion 
6.3.2.1 Reperfusion Dynamics  
After 2 hours of NMR reperfusion dynamics were not significantly different between SCS4 and SCS52 
kidneys (see Figure 79). (Systolic pressure: SCS4=55.7 1.3, SCS52=58.1 0.7 mmHg, p=0.080; 
Reperfusion flow rate: SCS4=69.6±19.64, SCS52=73.2±31.6 ml/min/100g, p=0.853; Resistance:  
SCS4=0.11±0.02, SCS52=0.19±0.14 mmHg/ml/min, p=0.305; PFI: SCS4=1.25±0.36, SCS52=1.26±0.53 
ml/min/100g/mmHg, p=0.976).  
6.3.2.2 Functional Assessment  
Urine output during NMR was significantly higher in SCS4 kidneys (See Figure 80). (Urine output 
60mins: SCS4= 0.71±0.21, SCS52=0.27±0.06 ml/hour/g, p=0.034; Urine output 120 minutes: SCS4= 
1.03±0.19, SCS52=0.32±0.17 ml/hour/g, p<0.001). Total oxygen consumption during NMR was 
similar between kidneys (SCS4: 6.1 ± 5.6, SCS52: 5.7 ± 2.5 kPa/min/ml/g, p=0.894). 
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Figure 78  Hypothermic  mac hine per fusi on dyna mics  i n SCS4  a nd SCS52 kidneys . There were no 
s i gnific ant di fferences i n HMP per fusion parameters between ki dneys.  
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Figure 79  Normothermi c reper fusion dyna mi cs in SCS4 a nd SCS52 ki dneys. Th ere were no 
s i gnific ant di fferences i n NMR reper fusion pa rameters between ki dneys.  
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Figure 80  Func ti onal ass ess ment in SCS4  and SCS52 ki dneys . Uri ne output duri ng NMR was 
si gni ficantl y higher  in SCS4  ki dneys . Urine output 60mi ns : SCS4= 0 .71±0.21, SCS52=0.27±0.06 
ml /hour/g, p=0.034; Uri ne output 120 mi nutes : SCS4= 1 .03±0.19, SCS52=0.32±0.17 ml /hour/g, 
p<0.001). Tota l oxygen c onsumption during NMR wa s  similar  between SCS4  a nd SCS52 kidneys.  
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6.3.2.3 Rapid sampl ing microdialysis 
Real time cortical tissue lactate concentrations were quantified using rsMD in kidneys during HMP 
(SCS4:n=4, SCS52:n=2) and NMR (SCS4:n=2, SCS52:n=2, Figure 81).  During HMP cortical 
microdialysis lactate concentration trended higher between 1.5 and 10 hours in SCS4 and SCS52 
kidneys, with overall lactate levels higher in SCS4 vs. SCS52 kidneys, though these differences  were 
not significant (p=0.288, p=0.507, p=0.248 respectively). 
 During NMR detected lactate trended 2 fold higher in SCS4 kidneys (SCS4: 1.07 ±0.41 mM/min, 
SCS52: 0.50 ± 0.01 mM/min; p=0.285). and lactate increased between the start and end of NMR in 
both SCS4 (Start: 0.59 ± 0.23 mM ; End: 1.94 ± 1.04 mM, p=0.255) and SCS52 (Start: 0.2 ± 0.04 mM ; 
End: 1.06 ± 0.44 mM, p=0.241) kidneys by 3.3 and 5.4 times respectively (p=0.432).  Cortical lactate 
correlated with perfusate lactate which also trended higher in SCS4 kidneys (SCS4: 3.7 ± 0.39, SCS52: 
3.0 ± 0.69 mmol/L, p=0.055) with the difference bordering significance. 
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Figure 81  Rs MD for  tissue lac ta te duri ng HMP and NMR in SCS4  a nd SCS52 kidneys . Exa mpl e 
sca tter  dia gra m of rs MD rea dings  measured from one ki dney duri ng HMP a nd NMR (Top). 
Avera ge c or tical  tissue la c ta te during a t 1 .5  hours  a nd 10  hours  of HMP in SCS4  a nd SCS52 
ki dneys  (bottom l eft). Avera ge c or ti cal tiss ue lac ta te duri ng the NMR i n SCS4  and SCS52 ki dneys 
a t s ta r t (1st 20mins) a nd end (l ast 20 mi nut es ; bottom r ight).    
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6.3.2.4 Graft Weight Change 
Kidney weight in the SCS4 group remained unchanged between flushing and the end of cold storage, 
while SCS52 kidneys lost weight (-17.1 %, p=0.012) after 52 hours of cold storage. Weight change 
after HMP (SCS4: 43.1 ±28.1%; SCS52: 46.3 ± 5.2%, p=0.826) and NMR (SCS4: 8.1 ±16.2%; SCS52: 
13.4 ± 10.6%, p=0.092) was not different between both groups of kidneys (see Figure 82). 
 
Fi gure 82  Percent wei ght c hange in SCS4 a nd SCS52 ki dneys during HMP a nd NMR.  
 
6.3.2.5 Histology 
There were no significant differences in core biopsies between SCS4 and SCS52 kidneys in pre -HMP 
and Post-HMP samples. After NMR all kidneys exhibited evidence of reperfusion induced tubular 
damage as measured by tubular debris, tubular dilation, and fragmented nuclei, however there were 
no significant differences between SCS4 and SCS52 kidneys, see Table 13 and Figure 83.   
 
Parameter Tubular Debris Tubular Dilation Nuclear Fragmentation 
Group SCS4 SCS52 SCS4 SCS52 SCS4 SCS52 
Score 3.5 ± 0.58 4.0 ± 0 2.3 ± 0.5 2.7 ± 0.6 2.1 ± 0.2 2.3 ± 0.3 
Ta bl e 13   His tology sc ores  of biopsi es  ta ken a fter  2  hours  of NMR ass essing tubular  debris, 
tubular  Dila ta tion, a nd nucl ea r  fra gmenta ti on. There was  no si gni ficant di fferenc e i n the degree 
of tubul a r da mage i n SCS4 a nd SCS52 kidneys.  
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Figure 83  Photomic rographs  of l i ght mi crosc opy of SCS4  vs . SCS52 kidneys  a fter  2  hours  of NMR. 
H&E s tai ning, x20. A: SCS4  ki dney, B: SCS52 kidney. Showing si milar degrees of reper fusi on 
i nj ury. 
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6.4 Discuss ion 
HMP reconditioning of kidneys after cold storage offers the possibility of re-vitalising allograft 
viability and measuring metrics for viability assessment, especially in 'marginal' organs[1126]. 
Characterising the potential for HMP reconditioning in DCD grafts exposed to long durations of cold 
storage is of particular interest for the successful expansion of the donor pool.  
6.4.1 Effect of Long SCS on Post-Ischaemic HMP Dynamics 
We have shown that HMP after an period of extreme SCS CIT in DCD porcine kidneys yields  
perfusion parameters indicative of suitable organ viability for transplantation[841], but with no 
demonstrated benefit on kidney function during isolated reperfusion. 
Measured renal resistance and calculated PFI during HMP are used by clinicians as measures of renal 
viability[841] and resistance has been shown to be an independent risk factor for primary non-
function[1127]. Perfusion dynamics are used by some centres to determine organ discard[856], 
though conservative advocates suggest such parameters to be used as only one of several factors in 
determining organ transplantability[1061,1127]. Furthermore resistance during HMP has been 
shown to correlate with the post-transplant reperfusion renal resistivity index[862].  
Overall HMP perfusion dynamics were similar in kidneys previously exposed to relatively short SCS of 
4 hours and extreme SCS of 52 hours. Furthermore if clinical HMP viability criteria[841] (Resistance 
and PFI levels) were applied SCS52 kidneys attainted levels of accepted viability significantly earlier 
during HMP compared to SCS4 kidneys with shorter cold ischaemic injury.  
Lower HMP flow rates, high resistance, and low PFI values are associated with poorer graft 
outcomes. In this experiment the severely injured kidneys grafts perfused as well and achieved 
'viability' quicker as those with limited injury. After extreme SCS there was a l oss in kidney weight 
compared to weight recorded post flushing at retrieval. Similar weight loss is reported after 
extended SCS of kidney allografts by other groups[832,1128]. The weight reduction arises from 
recovery from 'flush' induced oedema at retrieval, suggested to stem from malfunction of the Na+K+ 
pump, cellular swelling, and dehydration of the renal parenchyma during SCS[1129]. The SCS4 
kidneys with limited SCS time did not experience a reduction in mass. The reduced oedema in SCS52 
kidneys facilitated better perfusion during HMP with less tissue osmotic pressure resisting pulsatile 
flow. The SCS4 kidneys required several more hours of HMP to achieve optimal perfusion, 
potentially explaining the equity between these kidneys in HMP dynamics. The benefit conferred on 
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SCS52 kidneys however was only evident until HMP equilibration in both SCS4 and SCS52 was 
achieved producing a similar degree of weight gain after HMP. 
6.4.2 Effect of Post-Ischaemic HMP after Extreme Length of SCS on Viability  
Despite SCS4 and SCS52 kidneys also perfusing with equity during NMR, and with comparable 
oxygen consumption, the SCS52 kidneys demonstrated significantly depressed renal function with 
lower urine production.  Ten hours of HMP was not sufficient to ameliorate the level of extreme SCS 
ischaemic injury sustained by these kidneys, and oxygenation during HMP may be a potential factor.  
Conventional HMP utilizes one of several commercially available perfusion machines. Two machines 
widely used are the Waters Medical Systems RM3 and the Organ Recovery Systems Lifeport. HMP in 
routine clinical practice at present does not incorporate active oxygenation of the perfusate. Recent 
experimental evidence has suggested that oxygenation may be potentially beneficial and restore 
cellular energy stores and improve allograft function during reperfusion[1130] though this may be 
limited to specific donor types[1131]. The RM3 unit used in our laboratory allows for passive 
oxygenation  while the Lifeport provides no option for active or passive oxygenation. In our study 
passive oxygenation with room air on a RM3 was used during HMP as in clinical practice, this 
provides a perfusate oxygen pressure of approximately 24 kPa (180 mmHg) [805] which is 
theoretically sufficient for tissue needs at 4-7˚C [722,730] sustaining kidney metabolism. Active 
oxygenation delivering a higher partial pressure of oxygen may however afford further benefit in 
kidneys that have sustained severe ischaemic stress, such as those in the SCS52 group.  
Furthermore pulsatility during HMP has been shown to mediate protective effects on the 
vasculature endothelial, with pulsatile perfusion limiting pro-inflammatory cytokine expression with 
reduced tissue expression of ICAM-1 [1132], and reduced TLR-4 mRNA levels[812]. It is now known 
that endothelial gene expression is strongly influenced by vascular shear stress[822]. During organ 
retrieval and SCS the cessation of vasculature flow promotes a pro-inflammatory and pro-
coagulatory phenotype, which could worsen IR responses after transplantation[263]. Flow mediated 
endothelial dysfunction is linked to decreased expression of the mechanosensitive transcription 
factor Kruppel-like-factor 2 (KLF-2), which normally suppresses inflammatory signals and cytokine 
production[261].  HMP has been shown to restore levels of KLF-2 compared to SCS during 
reperfusion[823]. Because the NMR model utilized acellular KHB the full benefits of HMP mediated 
endothelial protection against IR injury may not have been fully appreciated without the added 
stress of the cellular and plasma components evident in a normothermic haemoreperfusion model. 
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rsMD observed a trend of higher cortical tissue lactate both during HMP and NMR in the SCS4 
kidneys exposed to a shorter period of SCS. Lactate is the terminal product of anaerobic glycolysis; 
the primary source of ATP production during ischaemia[1133].  The kidney itself however is also an 
endogenous source of lactate during physiological aerobic conditions[1051]. Despite neither 
difference reaching significance an explanation for this trend may lie in SCS4 kidneys being 
intrinsically more viable due to the shorter SCS CIT. Cortical cells were able to undergo anaerobic 
glycolysis to either augment low grade aerobic energy production during passively oxygenated HMP, 
or simply maintain physiological lactate production.  
This greater viability can be extrapolated to explain the higher lactate during NMR in the SCS4 
kidneys, when lower levels would be expected vs. SCS52 kidneys, where full provision of oxygen 
would abort the need for anaerobic metabolism. In fact during IR a degree of anaerobic metabolism 
is necessary as the mitochondrial pathways required for aerobic ATP production are repaired[1134]. 
Though raised tissue lactate is indicative of allograft thrombosis and tissue ischaemia, this 
correlation is accurate in a transplantation[1059] or isolated haemoreperfusion model, where 
microcirculatory dysfunction can affect tissue perfusion and oxygen delivery. In this experiment with 
KHB such microcirculatory failure is absent, and augmented cortical lactate production suggests 
improved cortical cell viability.   
However the sustained production of cortical lactate by the SCS52 kidneys during NMR in a 
comparable trend to the SCS4 kidneys further suggests a degree of viability in the renal parenchyma 
of these kidneys which was not expected. This may be related to the initial finding of reduced post-
ischaemic graft weight before HMP in those kidneys. A longer CIT that allows greater equilibration 
between the solution and the organ parenchyma may facilitate better preservation and buffering, 
which then allows improved HMP perfusion due to less graft oedema. Thus though shorter lengths 
of CIT are invariably more desirable and less damaging than longer CITs, a longer CIT may confer a 
better SCS preservation effect from the solution. The longer term effect of this better equilibration 
however on renal function is unknown but the possibility that kidneys initially considered to be 
extremely marginal due to lengthy cold ischaemia may actually be useable after a period of post-
ischaemic HMP deserves further thought and investigation. 
6.4.3 Mechanisms of Effect of Post-Ischaemic HMP 
Koetting et al.[800] demonstrated the benefit of 90 min of hypothermic reconditioning by 
oxygenated HMP compared to non-oxygenated HMP to recover organs after prolonged (18 hours) 
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SCS ischemic injury. No comparison was reported on HMP perfusion dynamics, but oxygenation 
produced substantial 3-fold higher clearances of creatinine and urea, and less apoptotic caspase-3 
activity during organ viability assessment on an isolated reperfusion circuit. The authors concluded 
that continuous oxygenation during HMP effectively ameliorated energetic breakdown and 
deterioration of mitochondrial redox balance. The same group in another study using a porcine renal 
autotransplantation model demonstrated that a short period (2 hours) of reconditioning after 
prolonged (21 hours) SCS proved as effective as continuous HMP for the whole storage time [812]. 
Active oxygenation was provided in both continuous HMP and 2 hours of post-ischaemic 
reconditioning HMP, and equally improved urea and creatinine clearance, as well as tubular 
function, with lower expression of TLR-4, lower HMGB-1 release. A short period of HMP even after 
extended SCS can also normalise expression of KLF-2 reducing the pro-inflammatory endothelial 
phenotype[823]. Furthermore a period post-ischaemic reconditioning of even 1 hour duration is as 
effective as 4 hours, after 18 hours of SCS, with improved creatinine clearance, tubular reabsorpti on, 
and renal flow on an isolated reperfusion circuit[1025]. Additionally the use of pulsatile flow in HMP 
appears to be the important factor in HMP vs. non-pulsatile flow to ensure benefits of HMP are 
realized compared to SCS[801,823].  
6.4.4 Limitations 
There are several potential caveats to the interpretation of this study. The HMP dynamics and 
effects on HMP on kidney viability in the SCS4 group was considered in this  model to reflect ideal 
kidneys with minimal CIT injury, and a suitable control for kidneys exposed to prolonged SCS prior to 
HMP, with the objective to determine the differences between kidneys exposed to different 
durations of CIT.  The next evolution of these experiments will investigate the benefit of a period of 
HMP or not after exposure to extreme SCS CIT.   
The significance of differences observed in the experimental groups may have been limited by the 
use of four pairs of kidneys for experimentation. Furthermore due to technical problems with the 
rsMD apparatus data was not available for all kidneys during both HMP and NMR (data available for 
6 kidneys during HMP, and 4 during NMR).  
During NMR renal urine output was measured however calculation of glomerular filtration by 
biochemical analysis of the perfusate and urine would provide a greater assessment of glomerular 
and tubular function, this resource however was not available during these experiments.  
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NMR using acellular KHB is useful for acute determination of renal function and viability, however 
isolated haemoreperfusion would provide a more physiological assessment and challenge in kidney 
grafts. 
rsMD of tissue biomarkers concentrated on lactate as a marker of ischaemic injury, however 
detection of other glycolytic molecules such as glucose, pyruvate and ATP would provide a greater 
assessment of tissue metabolism. Finally HMP was only passively oxygenated as per clinical practice 
with the RM3 unit. There is however a potential benefit of actively oxygenated HMP after extreme 
SCS on renal viability which is another avenue of investigation.  
6.4.5 Future Considerations 
As post-ischaemic HMP reconditioning emerges as a viable technique for revitalising marginal 
allografts[1135] consideration must be made as to the length of SCS from which the allograft is being 
recovered.  In our study porcine kidneys exposed to extreme CIT demonstrated HMP dynamics 
suggestive of viability with equity to minimally injured grafts. However this period of HMP 
reconditioning did not confer a functional advantage during isolated reperfusion. It will be important 
for future practitioners of this technique to be aware that graft weight loss during SCS, and hence 
resolution of flush induced oedema may affect perfusion dynamics during HMP. Nescessitating any 
subsequent viability assessment incorporating these parameters to be reconsidered. Furthermore 
despite the clinical success with conventional HMP, in its present form utilising passive oxygenation 
HMP may not be able to functionally recover grafts exposed to extreme SCS, suggesting that HMP 
interventions utilising active oxygenation of the perfusate may be better positioned to provide 
benefit in such organs. 
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Development of Pancreatic Machine Perfusion Models 
7.1 Objectives  
The objectives of this project were to develop a series of protocols for whole organ pancreas HMP as 
well as experimental normothermic reperfusion to allow assessment of organ viability and function. 
The overall goal of developing these models is to provide a superior more dynamic method of 
preservation, as a tool to allow assessment of pancreatic viability, and also a delivery mechanism for 
pharmacological intervention to optimise pancreatic integrity and viability. For example overall no 
strategy has yet been identified to be an effective measure in minimizing the incidence of early 
vascular thrombosis of a pancreatic graft[698]. An ideal option would be for a locally delivered 
addressive anti-coagulant which would curb graft thrombus formation without the worrisome risks 
associated with systemic anti-coagulation. This would also be a logical approach if indeed a local 
hypercoaguable state is induced in the pancreatic bed through IR injury, and an addressive an ti-
coagulant could be delivered using HMP. 
In development of pancreatic perfusion models initially a comparison was made to determine a 
suitable pancreatic HMP perfusion pressure compared to a renal model of HMP using porcine grafts 
(Phase 1). This pressure was then used in a series of models to compare the effect of a period of 
post-ischaemic HMP after 24 hours of SCS to only SCS preservation in porcine pancreases, with 
viability determined using a normothermic reperfusion model  (Phase 2). Finally the protocols 
developed in the porcine models were applied to a series of human pancreases to determine their 
applicability to clinical grafts (Phase 3). These human pancreases were grafts considered unsuitable 
for clinical transplantation and that had subsequently been donated for research through NHS Blood 
and Transplant.  
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7.2 Methods  
7.2.1 Phase 1: Comparison of Renal and Pancreatic HMP Perfusion 
Porcine pancreases and kidneys were retrieved from pigs using the shorter ischaemia protocol as 
described in Section 3.1.3.1. Briefly 9 kidneys were retrieved, flushed, placed on ice, and returned to 
the laboratory. There they underwent 5 hours of HMP on a Waters Medical Systems RM3 perfusion 
machine using University of Wisconsin (UW) solution as the circulating perfusate for 5 hours at 
40mmHg (40 Systolic Group, 40SG, n=9). Seven porcine pancreases were similarly retrieved flushed 
with UW solution, placed on ice and transported to the laboratory. Four of these pancreases were 
based on a segmental pancreatic graft with  perfusion via the celiac axis (splenic artery)through an 
aortic segment,  outflow via the splenic and portal veins, and perfused on an RM3 with Belzer UW 
for 5 hours with a target systolic pressure of 30mmHg (30 Systolic Group, 30SG, n=4). The remaining 
three pancreases where based on whole organ grafts and similarly perfused on an RM3 for 5 hours 
with Belzer UW with a target perfusion pressure of <20mmHg (<20 Systolic Group, 20SG,  n=3). 
Perfusion consisted of a priming phase (2h) followed by stable perfusion(3h). Perfusion dynamics, 
graft weight gain were recorded, and the PFI calculated for each organ. Belzer UW used for 
pancreatic HMP was modified by the addition of 60mmol/L of mannitol. 
7.2.2 Phase 2: Short Post-ischaemic Pancreatic HMP vs. Pancreatic SCS 
Porcine pancreases were retrieved from pigs using the shorter ischaemia protocol as described in 
Section 3.1.3.1.  Briefly 6 porcine pancreases were retrieved, flushed, placed on ice, and returned to 
the laboratory. There pancreases underwent 24 hours of SCS. After SCS 3 pancreases (SCS group, 
n=3) underwent  viability assessment on an isolated autologous NMR circuit. The remaining three 
pancreases (SCS-HMP group, n=3) underwent 5 hours of HMP at low pressure (<20mmHg) with 
Belzer UW (see Figure 85) and then underwent 2 hours of viability assessment via NMR.  The 
protocol for this experiment is shown in Figure 84.  
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Figure 84  Diagra m of experi mental  porcine pancrea tic  per fusi on protoc ol  c ompari ng HMP to 
SCS. HMP consis ted of a  pri ming phas e (2h) followed by  s ta bl e per fusion(3h). NMR was 
c onduc ted a t a  sys tolic  pressure of 30mmHg. Per fusion dyna mi cs , graft weight gain were 
rec orded, a nd the PFI  was c alculated for ea c h organ.  
 
 
Fi gure 85  Whole porcine pa nc reatic  graft undergoing HMP (left) a nd NMR (r i ght).  
 
Belzer UW used for pancreatic HMP was modified by the addition of 60mmol/L of mannitol. NMR 
perfusate involved a whole blood saline mixture (3:1), with 21mmol NaH2CO3, and oxygenated with 
a 95% O2 / 5%CO2 gas mixture.  
Endocrine functionality was assessed by addition of 25mmol/l of glucose to the reperfusate at 30 
minutes of NMR. Perfusate samples were collected during reperfusion, centrifuged at 3000rpm, and 
the supernatant stored at -80˚C. Samples were analysed at a later date for levels of glucose, insulin, 
c-peptide and amylase via the Chemical Pathology Department of Imperial College Healthcare NHS 
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328 
 
Trust using routinely used assays. Exocrine functionality was assessed by cannulating the duodenum 
with a large bore foley catheter to collect pancreatic exocrine and bowel secretions.  
Core biopsies were taken after SCS and HMP, and wedge biopsies after NMR. Biopsies were fixed in 
4% formalin, dehydrated, and embedded in paraffin wax. 4 µm sections were cut and stained with 
hematoxylin and eosin for light microscopy evaluation. to assess for degree of reperfusion injury 
noting for degree of tissue necrosis and oedema. 
7.2.3 Phase 3: Application of experimental pancreatic HMP protocols to human grafts 
Human pancreases used in development of a direct pre-clinical model were obtained through NHS 
Blood and Transplant. These organs were considered to be unsuitable for clinical transplantation and 
that had subsequently been donated for research through NHS Blood and Transplant. Three human 
pancreatic grafts were used. Pancreases underwent a similar protocol consisting of 5h of HMP at low 
pressure (<20mmHg) and then 2h of NMR at 40mmHg. Perfusion was through a reconstructed Y-
graft via the splenic and superior mesenteric arteries (see Figure 86). Perfusion dynamics, graft 
weight gain were recorded, and the PFI was calculated for each organ.  
 
Figure 86 Huma n pa ncrea tic gra ft undergoing HMP a nd NMR. Perfusion is via rec ons truc ted Y 
gra ft. HMP (l eft) a nd NMR (r ight).  
 
NMR utilised a KHB based solution as the reperfusate and included supplementation with 21mmol 
NaH2CO3, and oxygenated with a 95% O2 5%CO2 gas mixture.  
Endocrine functionality was assessed by addition of 25mmol/l of glucose to the reperfusate at 30 
minutes of NMR. Perfusate samples were collected during reperfusion, centrifuged at 3000rpm, and 
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the supernatant stored at -80˚C. Samples were analysed at a later date for levels of glucose, insulin, 
c-peptide and amylase via the Chemical Pathology Department of Imperial College Healthcare NHS 
Trust using routinely used assays. Exocrine functionality was assessed by cannulating the duodenum 
with a large bore foley catheter to collect pancreatic exocrine and bowel secretions.  
Core biopsies were taken after SCS and HMP, and wedge biopsies after NMR. Biopsies were fixed in 
4% formalin, dehydrated, and embedded in paraffin wax. 4 µm sections were cut and stained with 
hematoxylin and eosin for light microscopy evaluation to qualitatively assess for reperfusion injury 
noting for degree of tissue necrosis and oedema. 
7.2.4 Rapid sampling microdialysis 
The rsMD system was used to sample and quantify levels of tissue lactate in pancreases during both 
HMP and NMR this was instituted in line with the methodology described in Project 1. In brief 
microdialysis probes (MAB11.35.4, Microbiotech, Stockholm, Sweden) were inserted superficially 
into the ventral section of the pancreatic tail at the start of HMP. These were connect to an in-house 
built rapid-sampling microdialysis analyser. Every 30 seconds a 200 nL dialysis sample was 
automatically injected into the analysis flow stream, alternating between probes in two pancreases. 
The stream accelerates the dialysate through an enzyme reactor containing LOx and HRP (Genzyme 
Diagnostics, Kent, UK). The LOx recognises the analyte, producing hydrogen peroxide, which reacts 
with the HRP. The HRP is regenerated by oxidation of the ferrocene mediator species, producing 
ferrocinium ions, which are detected at the downstream electrode (BASi, West Lafayette, IN) by 
reduction. Due to the small sample size, the current produced is directly proportional to the 
concentration of lactate in the sample even above the free solution Km of the lactate oxidase 
enzyme (0.7 mM). Data was collected using a PowerLab data acquisition unit (8/30, ADInstruments, 
New South Wales, Australia) and LabChart software (ADInstruments, New South Wales, Australia) 
running on a Macbook Pro portable computer (Apple Computers, Cupertino, CA). Lactate levels were 
analysed in real-time to reveal information on interstitial lactate concentration after the 24 hours of 
SCS, during 5 hours of HMP, and then 2 hours of NMR. 
7.2.5 Statistical Analysis 
Values are represented as mean and standard deviation. Continuous variables were plotted as levels 
versus time curves for each organ and the mean area under the curve calculated. Where continuous 
variables were compared significance was assessed using a student's T-test or the non-parametric 
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equivalent when distribution assumptions were not met. In a comparison of more than 2 groups one 
way ANOVA with Bonferroni correction post-test was utilised. Data and statistical analysis was 
performed using Microsoft® Excel Software (Reading, UK). All tests were 2-tailed and a p value of ≤ 
0.05 was considered significant. 
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7.3 Results  
7.3.1 Examination of Kidney and Pancreas Machine Perfusion Dynamics 
7.3.1.1 Organ Characteristics  
40SG kidneys experienced 18.3 ±9.7 minutes of WIT, and 12.5 ±9.7 hours of CIT (range: 3.4-26 hours) 
prior to HMP. 30SG pancreases experienced 38.7 ±11.1 minutes of WIT, and 4.0 (±2.0) hours of CIT 
(range: 3-7 hours) prior to HMP, and all 20SG pancreases experienced equal WIT of 30 minutes and 
CIT of 26.2 ± 0.3 hours.  
WIT in 40SG was significantly shorter than in 30SG pancreases (p=0.003), but not 20SG pancreases 
(p=0.082). All pancreases experienced statistically similar WITs (p=0.239).  CIT was significantly 
longer in 20SG pancreases compared to 30SG pancreases (p=0.002) and 40SG kidneys (p=0.016), 
which also had similar CITs. 
7.3.1.2 Hypothermic Machine Perfusion  
Systolic pressures were different between all three perfusion groups ( SG40: 40.5 ± 2.6 mmHg; SG30: 
30.5 ±5.1 mmHg; SG20: 16.5 ± 5.4 mmHg; ANOVA p<0.001, p<0.001 for all comparisons).  
Overall flow rates were similar in 40SG kidneys 32.6 ± 7.6 ml/min/100g and 30SG pancreases 26.5 ± 
2.1 ml/min/100g,  and lower in 20SG pancreases 12.9 ± 0.5 ml/min/100g compared to SG40 kidneys 
(p=0.002), but not SG30 pancreases.  
Despite differing perfusion pressures and flow rate the PFI were similar between all three groups 
SG40: 0.81 ± 0.2 ml/min/100g/mmHg; SG30: 0.91 ± 0.21 ml/min/100g/mmHg; SG20: 0.83 ± 0.23 
ml/min/100g/mmHg; ANOVA p=0.67) implying a similar ratio between pressure and flow dynamics. 
Perfusion dynamics are shown for all three groups in  Figure 87, and average perfusion dynamics 
during HMP in  Figure 88. 
Weight gain was highest (95.2 ± 37.5%) in 30SG pancreases compared to  SG40 kidneys (36.8 ± 13 %, 
p=0.002) and 20SG Pancreases (21.5 ± 8.7%, p=0.004), but not statistically different between SG40 
kidneys and SG20 pancreases (p=0.410), see Figure 89. 
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Figure 87  Per fusion dyna mics  c omparing renal  HMP to Pa nc rea tic  HMP. Kidneys  were per fus ed 
a t a  higher pressure (Target: 40mmHg) compa red to pa ncreas es  (30mmHg and 20mmHg). Flow 
ra tes  a nd PFI were s imilar between a l l  three per fusion groups.  
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Figure 88  Avera ge flow ra tes  a nd PFI  duri ng HMP of kidneys per fus ed a t 40 mmHg s ys tolic 
press ure, and both pa ncreas es per fus ed a t 30mmHg s ys tolic and 20mmHg s ys tolic press ure. 
Flow ra tes were si gni ficantl y l ess in the 20 Sys tolic  Group pancreas es  vs. the 40 Sys tolic  Group 
ki dneys  (p=0.002).  
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Figure 89  Perc ent wei ght c hange during HMP i n kidneys  and pa nc reas es . 40 Sys tolic  Group 
ki dneys a nd 20 Sys tolic group pa nc reas es , ha d si gnifica ntly pos t HMP wei ght i ncreas es vs . 30 
Sys tol ic group pancreases (p=0.002, p=0.004 respectively).  
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7.3.2 Short Post-ischaemic Pancreatic Machine Perfusion  
WIT were the same (30 minutes) and CIT similar (26.8 ±0.35 hours vs. 26.2 ± 0.26 hours, p=0.23) in 
the SCS Group and SCS-HMP Group pancreases.  
7.3.2.1 Hypothermic Machine Perfusion  
During 5 hours of HMP at low pressure of 16.5 ± 3.5 mmHg, flow rates were stable at an average of 
19.4 ± 10.1 ml/min/100g. Calculated PFI increased from 0.99 ± 0.61 ml/min/100g/mmHg after 15 
minutes of perfusion to 1.35 ± 0.9 ml/min/100g/mmHg by 3 hours remaining stable until end of 
HMP (1.3 ± 0.83 ml/min/100g/mmHg at 5 hours). Machine measured resistance remained low 
throughout HMP at 0.15 ±0.04 mmHg/ml/min. Weight change after HMP was 19.4 ± 7.1 %. Perfusion 
dynamics and weight change are shown in Figure 90 and Figure 91 respectively. 
 
Figure 90  HMP perfusion dyna mics  in SCS -HMP pa nc reas es . Stabl e perfusion was  ac hi eved a t 
l ow pres sures . 
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Fi gure 91  Wei ght c hange during HMP in SCS -HMP pa ncreases .  
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7.3.2.1 Normothermic Reperfusion 
Reperfusion Dynamics 
One SCS pancreas did not perfuse during NMR, with limited venous portal outflow and observable 
mass oedema. This experiment was stopped and data excluded from all analysis. Reperfusion 
dynamics in SCS and SCS-HMP pancreases shown in Figure 92 and Figure 93. 
SCS pancreases were perfused at a higher pressure to SCS-HMP pancreases (SCS: 39.8 ±0.3 mmHg vs. 
SCS-HMP pancreases at 29.3 ± 2.1 mmHg, p=0.011).  
Average flow rates and PFIs trended higher in SCS pancreases (Flow: 48.8 ± 12.6 ml/min/100g, PFI: 
1.23 ± 0.33 ml/min/100g/mmHg) vs. SCS-HMP pancreases (Flow: 30.8 ± 23.7 ml/min/100g, PFI: 1.06 
± 0.85 ml/min/100g/mmHg), but these differences were not significant (Flow: p=0.35,PFI: p=0.776). 
Resistances also trended higher in SCS-HMP pancreases but not significantly (p=0.34). 
PFI during reperfusion tended to increase by 12 ± 21.2% in SCS-HMP between 15 minutes and the 
end of NMR in SCS-HMP pancreases, but decrease by 32.5 ± 19.5% in the SCS only pancreases.  
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Figure 92 Normothermi c reper fusi on dyna mics of SCS-HMP pa ncreas es . Reper fusi on 
demons tra ted s table fl ow rates a nd PFI.  
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Figure 93  Normothermic  reper fusion dyna mics  of SCS pa ncreas es . Reper fusion demons tra ted 
dec l i ning per fusion pa rameter s during NMR. 
Functional Assessment 
After 30 minutes of NMR glucose was added to the NMR circuit to stimulate insulin secretion (see 
Figure 94). In both groups insulin was detected at 15 minutes, prior to active beta cell islet 
stimulation. Analysis indicated the presence of variable amount of glucose in the reperfusate blood 
(SCS Group: 4.7 ±0.4 mmol/L; SCS-HMP Group: 8.4 ± 2.4 mmol/L) prior to addition of 25mmol/L of 
glucose. Detected insulin levels in SCS-HMP pancreases remained stable during NMR (26.2 ± 28.9 
uM/ml at 15 minutes, and 24.2 ± 23.5 uM/ml at 2 hours), while levels decreased from a peak at 15 
minutes (17.3 ±15.4 uM/ml) to a trough at 2 hours (0.7 ± 0.7 uM/ml). Average insulin levels in SCS 
pancreases was 7.6 ± 3.5 uM/ml and in SCS-HMP pancreases 27.4 ± 25.7 uM/ml (p=0.373). Amylase 
levels were unable to be determined due to interference with the assay by haemolysis of 
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reperfusate blood samples. There were no exocrine of duodenal secretions from any porcine 
pancreases during reperfusion. 
 
 
Figure 94  Ins ulin a nd Gl uc os e l evels  duri ng func ti onal  ass ess ment of SCS a nd SCS -HMP 
pa nc reases.  
Rapid sampling Microdialysis 
During HMP pancreatic tissue lactate was detected via rsMD in all SCS-HMP pancreases. Detected 
lactate levels remained stable for the duration of HMP (1-1.5hours: 0.157 0.06 ± mM/min; 4.5-5 
hours: 0.146 ± 0.08 mM/min,  p=0.756). During NMR there was a progressive rise in tissue lactate in 
pancreases in both groups, with levels trending higher in SCS only pancreases (1.05 ± 0.51 mM/min) 
vs. SCS-HMP pancreases (0.71 ± 0.46 mM/min, p=0.44). rsMD lactate levels in pancreases during 
HMP and NMR are shown in Figure 95. 
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Figure 95  Rs MD for  tissue la c ta te during HMP a nd NMR i n SCS-HMP pancreas es , a nd during NMR 
in SCS pa nc reas es . Exa mpl e sca tter  dia gra m of rs MD rea dings  meas ured fr om one SCS -HMP 
pancreas  (top). Avera ge tiss ue la c ta te duri ng a t 1 .5  hours  and 5 hours of HMP in SCS -HMP 
pancreas es  (bottom l eft). Avera ge tissue lac ta te duri ng NMR i n SCS-HMP and SCS pa nc reas es 
(bottom r i ght).   
 
Histology 
Core biopsies were of limited histological value in determining post-SCS injury in both SCS and SCS-
HMP groups. The majority of samples however demonstrated intact pancreatic cells with intact 
nuclei, considered normal and potentially indicative of viability. However a number of biopsies from 
both SCS and SCS-HMP pancreases demonstrated focal areas of necrosis and detachment of cells 
from the underlying connective tissue. After HMP there was no observable change compared to pre-
HMP core specimens. 
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Wedge biopsies taken after reperfusion in both SCS and SCS-HMP pancreases demonstrated severe 
tissue injury, ranging from focal necrosis ranging encompassing 40% of specimens to 90% with 
extensive tissue disruption (see Figure 96). Despite these findings some areas of these specimens 
showed no evidence of necrosis, with intact acini and islet highlighting the variable and 
heterogeneous level of injury sustained. 
 
Figure 96  Photomicrogra phs of l i ght mic ros copy of a n SCS pa nc reas a fter  2  hours of NMR. H&E 
s ta i ning, x10. Demonstrating a rea s of severe nec rosis but also a reas of i nta ct pancreas.  
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7.3.3 Application of Experimental Pancreatic HMP Protocols to Human Grafts: 
Of three human grafts used in the development of the pre-clinical pancreatic perfusion model, one 
was successfully perfused using the experimental HMP protocol, but during failed to perfuse during 
reperfusion with KHB, developing massive oedema with limited venous outflow. This pancreas was 
excluded from all analysis. 
WITs were the similar for all human grafts, and based on normal clinical retrieval times in the UK. In 
the remaining two grafts  (HP1, HP2) CIT was 26.8 and 56 hours respectively (Average: 28.7 ± 30.5 
hours).  
7.3.3.1 Hypothermic Machine Perfusion  
Pancreases were perfused at low pressures of 15.8 ± 0.8 mmHg with a flow rate of 6.8 ± 5.8 
ml/min/100g, resistance of 0.4 ± 0.2 mmHg/ml/min and PFI of  0.44 ± 0.34 ml/min/100g/mmHg (see 
Figure 97). 
Comparing the two pancreases directly perfusion was superior in pancreas HP1 vs. HP2 (HP1= 10.9 ± 
1.9 ml/min/100g, HP2= 2.6 ± 0.4 ml/min/100g; measured resistance: HP1= 0.24 ± 0.04 
mmHg/ml/min, HP2= 0.56 ± 0.06 mmHg/ml/min; and calculated PFIs: HP1= 0.69 ± 0.1 
ml/min/100g/mmHg, HP2= 0.18 ± 0.03 ml/min/100g/mmHg). 
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Figure 97 Perfusion dyna mics  a nd wei ght cha nge i n huma n gra fts  duri ng 5  hours  of l ow press ure 
HMP. 
 
7.3.3.2 Normothermic Machine Perfusion 
During NMR pancreases were perfused at a systolic pressure of 37.3 ± 5.7 mmHg, with a flow rate 
flow rate of 42.7 ± 11 ml/min/100g, resistance of 0.17 ± 0.15 mmHg/ml/min and PFI of  1.18 ± 0.47 
ml/min/100g/mmHg (see Figure 98). 
Comparing NMR perfusion dynamics of the two pancreases directly it was evident that, in contrast 
to HMP dynamics, perfusion was better in HP2 despite a lower perfusion pressure (HP1: 40 ± 2.8 
mmHg vs. HP2: 32 mmHg; flow rate: HP1= 32.2 ± 3.5 ml/min/100g, HP2= 49.8 ± 3.1 ml/min/100g; 
measured resistance: HP1= 0.29 ± 0.07 mmHg/ml/min, HP2= 0.07 ± 0.03 mmHg/ml/min; and 
calculated PFIs: HP1= 0.81 ± 0.14 ml/min/100g/mmHg, HP2= 1.56 ± 0.1 ml/min/100g/mmHg). The 
average perfusate amylase measured during NMR was 3475 ± 1068 U/L. HP1 NMR amylase was 
4229.9 U/L, while HP2 amylase was lower at 2719.2 U/L.  
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Figure 98  Reper fusion dyna mics  in huma n gra fts  duri ng 2  hours  of NMR, demons tra ti ng s tabl e 
reper fus ion pa rameters.  
 
7.3.3.3 Functional Assessment 
After 30 minutes of NMR glucose was added to the NMR circuit to stimulate insulin secretion. In HP2 
insulin was detected at 15 minutes (16.8 uU/ml) but none during the remainder of NMR. In contrast 
in HP1 insulin was detected at 15 minutes (70.4 uM/ml), peaked at 75 minutes (199.2 uM/ml) before 
decreasing to the end of perfusion (120mins: 73 uM/ml). Exocrine and duodenal secretions were 
produced by both pancreases (1 hour: 176 ± 106 ml/hr; 2 hour: 113 ± 19 ml/hr), see Figure 99. 
Secretions were analysed for amylase (HP1: 1 hour=2116 U/L/g, 2 hour=3327 U/L/g; HP2: 
1hour=1497 U/L/g, 2 hour=1410 U/L/g) and insulin (HP1: 1 hour=1.61 uM/ml/g, 2 hour=0.89 
uM/ml/g; HP2: 1hour=4.2 uM/ml/g, 2 hour=3.5 uM/ml/) demonstrating both endocrine viability and 
confirming exocrine functionality. 
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Fi gure 99  Vol ume of exoc r ine s ec retions dur ing NMR.  
 
7.3.3.4  Histology 
Core biopsies taken after SCS and before HMP demonstrated normal pancreatic structures and cells 
with intact nuclei, with similar observations after HMP. After reperfusion there were focal scattered 
areas of central necrosis (10% of tissue) and universally at the periphery of the specimens, however 
there was overall good preservation of the cellular architecture (see Figure 100).  
 
Figure 100   Photomi crogra phs  of l i ght mic ros copy of a n huma n pancreas . After 5 hours  of HMP 
a nd then 2 hours of NMR. H& E s taining, x10. Demons tra ti ng focal areas of c entral necrosis but 
a l s o a rea s of intact c ellular a rchitec ture.  
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7.4 Discuss ion 
7.4.1 Comparison of Renal and Pancreatic HMP Perfusion 
Pancreatic graft preservation by machine organ perfusion has been attempted experimentally by a 
number of groups over the past four decades. In canine models HMP was shown to be potentially 
feasible, but complex and with no benefit on graft preservation and function after experimental 
allotransplantation. However the increasing use of ECD and DCD donor organs to expand donor 
pools in recent years has renewed interest in HMP as potential preservation modality for these 
organs as HMP in renal setting has shown to provide a functional and survival advantage to allografts 
compared to simple SCS.  
The majority of research in machine organ perfusion has remained focussed on renal perfusion. In 
developing a model of pancreatic perfusion it is necessary to delineate the important differences 
and characteristics of the pancreas compared to the kidney.  
Physiologically the kidney is a high flow organ [896], while the pancreas is not[1136]. Tersigni et al. 
observed that graft oedema is detrimental for the pancreas, and despite lowering perfusion 
pressures (ranging from 5 to 20 mmHg) to reduce barotrauma was unable to ameliorate oedema 
during HMP[1028]. An antomical cause for this occurance is potentially the lack of a organ capsule 
unlike the kidney, presence of which could limit fluid accumulation.  Modification of their 
cryoprecipitated plasma perfusate with human albumin however allowed perfusion at a higher 
25mmHg pressure with minimal oedema. The canine pancreas however has a distinct anatomy 
compared to the porcine pancreas, which is relatively  more complicated[1029,1043]. In the UK it is 
logistically preferable to use porcine models for experimental organ preservation.  
This project demonstrated that using Belzer UW supplemented with mannitol it is feasible  to 
hypothermically perfuse at a low pressures (<20mmHg) a porcine pancreas for 5 hours. Using this 
protocol produced significantly lower flow rates but similar PFI profiles as use of higher pressures 
(30mmHg), but without detrimental oedema. Furthermore such PFI profiles and low oedema were 
comparable to a high flow, high pressure model of renal perfusion.  
The flow rates observed in this model were lower than those seen in historical attempts at 
pancreatic HMP. The University of Wisconsin group perfused kidneys at a series of pressures ranging 
from 5 to 25 mmHg, which produced flow rates of 10-40 mls/min[1028]. While Brynger et al.'s 
perfusion of pancreases at 50mmHg produced high flow rates of 90ml/min[1030]. The differences 
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may be explained by several reasons: 1) use of perfusates of differing viscosity will generate 
different flow rates through an graft, 2) in this project flow rate was calculated per 100g of 
pancreatic tissue, while in the described reports only observed flow was reported. 
It has been suggested that both perfusion pressure and the nature of the perfusate are key to 
achieving successful organ perfusion[1137], as these results have demonstrated. Belzer UW has a 
composition similar to Belzer MPS the only commercially HMP preservation solution[878]. It was 
initially designed as both a SCS and a HMP solution by Belzer and Southard at the University  of 
Wisconsin, however with the specific development of Belzer MPS for HMP, Belzer UW remained only 
in use for SCS organ preservation[722]. Belzer UW is the preservation solution of choice for 
pancreatic SCS [682,768], but is theoretically suitable for pancreatic HMP. Belzer UW was compared 
to Belzer MPS for HMP in canine kidneys with Belzer UW conferring a survival and functional 
advantage after auto-transplantation in compromised allografts[1138]. Belzer UW may be preferable 
to Belzer MPS for pancreatic HMP as the pancreas is more susceptible to ischaemic stress than the 
kidney. Furthermore the omission of glucose from the perfusate may further limit unnecessary 
stimulation of insulin secreting islet cells during preservation. The addition of mannitol (a 
polysaccharide and potent impermeant) to the perfusate in this project intended to further limit 
cellular oedema in the pancreatic graft.  
Mannitol is used in numerous organ preservation solutions, including HTK and UW solution, and has 
also has been used in clinical practice as osmotic diuretic. Its use however in has been associated 
with osmotic nephrosis and vacuolization in proximal tubules of kidneys with the development of 
acute kidney injury [1139]. Vacuolization in proximal tubular cells as a histologic entity has been 
documented with other compounds, including those used in preservation solutions (e.g. HES and 
sucrose) [1140]. No evidence of vacuolization was found during microscopy of pancreases 
undergoing HMP.   
7.4.2 Short Post-ischaemic Pancreatic HMP vs. Pancreatic SCS 
A short period of post-ischaemic HMP has been shown to confer a functional benefit in experimental 
porcine renal transplant models[1141]. Experimental studies of long duration (≥24 hours) of HMP in 
pancreatic allografts has not demonstrated a benefit compared to SCS preservation[1137]. However 
the feasibility and benefits of a short period of post-ischaemic HMP in the pancreas after 24 hours of 
SCS has not been investigated.  
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The viability of pancreases preserved via 24 hours of SCS was compared to pancreases that 
underwent 24 hours of SCS and then a short 5 hour period of HMP. Using the low pressure protocol 
with modified Belzer UW 5 hours of HMP in porcine pancreases demonstrated stable perfusion 
characteristics, and limited weight change of approximately 20%. Islet and tissue oedema has been 
reported in experimental perfusion of porcine pancreases and is an expected  occurance in grafts 
post HMP [1032]. Despite the oedema encountered during HMP however there was no evidence of 
tissue or islet cell oedema seen at microscopy.    
The NMR circuit then allowed a short duration of ex-vivo viability assessment using perfusion 
metrics, insulin release, and histology[1033].  
During NMR pancreatic blood flow rates were overall higher in SCS only, compared to SCS -HMP 
pancreases. However blood flow decreased during perfusion in the SCS only preserved grafts, while 
it remained stable in SCS-HMP pancreases. Suggesting a stability in endothelial resistance and 
integrity in SCS-HMP pancreases but potentially progressive microvascular disruption in the SCS 
pancreases and severe dysfunction. 
Administration of glucose to stimulate insulin secretion is the most sensitive test for determining 
functional viability of the preserved pancreatic grafts[1028].  
The NMR circuit employed was a closed loop circuit, as such the blood perfusate would act as a sink 
for insulin secreted by the graft. Insulin levels in SCS pancreases peaked at 15 minutes, prior to 
administration of glucose, and despite a higher presence of glucose insulin levels decreased for the 
remainder of NMR. It is likely that this decrease reflects both a decline in insulin secretion by islet 
beta cells and also degradation of circulating insulin by insulin degrading enzymes (IDE) known to be 
present within blood plasma of the perfusate [1142,1143]. In the SCS-HMP pancreases however 
insulin levels peaked by 15 minutes and remained relatively stable for the duration of NMR, and that 
despite the likely presence of IDE in the blood perfusate plasma insulin levels remained stable due to 
a persistent and stable secretion by islet cells. 
Florak et al used a canine allotransplant model when they compared SCS to HMP preservation of 
pancreatic allografts, thus assessing graft viability by determining the endocrine capacity of the 
pancreas by the ability of the pancreaticoduodenal  segments to maintain a previously 
pancreatectomized dog[1137].  
However experimental normothermic models of isolated pancreatic perfusion have used insulin 
levels to gauge organ viability. Bartel et al. demonstrated that longer cold ischaemic injury sustained 
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by the porcine pancreas the greater the deterioration in normothermic perfusion dynamics, as well 
as the decline in insulin release in response to a glucose load during viability assessment on the 
isolated haemoperfusion circuit [1035]. Interestingly 3-6 hours of CIT did not affect normothermic 
reperfusion parameters, nor endocrine viability, however SCS CIT of 24 hours or greater produced 
severe pancreatic dysfunction. In our model pancreases with 24 hours of SCS only had deteriorating 
perfusion during NMR, and poor insulin secretion. In contrast pancreases that had also been 
subjected to 5 hours of HMP had lower, but stable perfusion characteristics during NMR and 
sustained insulin release, suggesting better viability.  
In the porcine pancreases there was no evidence of exocrine or duodenal segment secretions during 
NMR. The porcine pancreas is a very fragile organ compared to the native human pancreas, in both 
cases (SCS and SCS-HMP) 24 hours of CIT may have been extreme and the damage sustained 
unrecoverable. Barthel et al. document that less CIT damage is required for exocrine and duodenal 
segment functional failure than with the endocrine failure [1035]. 
rsMD for lactate during HMP of pancreases demonstrated stable levels throughout perfusion. While 
tissue lactate was higher during NMR of SCS only pancreases compared to those having been 
subjected to HMP after cold storage. The pancreas is not an endogenous source of physiological 
lactate like the liver or kidney[1051]. Thus lactate will solely originate from glycolytic metabolism 
during ischaemic stress, which is the most likely source of the low levels of lactate detected during 
HMP. During NMR higher levels of lactate were detected in SCS only vs. SCS-HMP preserved 
pancreases suggesting cells of SCS only pancreases were unable to effectively restart aerobic 
metabolism, relying on glycolytic energy production to a greater degree than the SCS-HMP grafts. 
Histological assessment of the pancreatic grafts in this project after NMR showed a similar degree of 
severe pancreatic necrosis in both SCS and SCS-HMP grafts. As suggested from the model by Barthel 
et al. 24 hours of SCS may induce irreversible damage in pancreatic grafts upon reperfusion[1035]. 
Interestingly this damage was evident in all pancreases despite SCS-HMP pancreases demonstrating 
better functional viability.  
7.4.3 Application of experimental pancreatic HMP protocols to human grafts  
Use of porcine models are a crucial step in the translational application of experimental protocols 
into the clinical arena[1144]. Porcine organs in particular are of a similar anatomical and 
physiological construct to those in the human[1136]. Low pressure perfusion protocols with 
modified Belzer UW solution have been demonstrated to successfully perfuse porcine pancreases 
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with minimal weight gain, however the feasibility of HMP in human pancreases needs to be 
demonstrated. In the development of novel organ perfusion and preservation technologies the gap 
between porcine work and clinical application is routinely bridged by experimentation using human 
grafts that are retrieved but not used for clinical transplantation and instead donated for 
research[1145]. 
Recent developments in the UK national system of organ retrieval for transplantation has led to the 
formation of the National Organ Retrieval Service under the aegis of NHS Blood and Transplant (the 
national overseeing body), with regional centralisation of this service. Furthermore responsibility of 
consent for deceased donor donation has been placed with the donor coordinators. Despite efforts 
to place all organs donated some retrieved grafts are unable to be used for conventional clinical 
therapies due to physiological status of the organs which places them outside of the suitable criteria 
for transplantation. Relatives to the donor of such organs however often feel that donation for 
research can maximise the benefit from the sad events that led to the stage requiring such decisions 
to be made[1146]. In the UK a national process and framework under NHS Blood and Transplant is in 
place for organs that are retrieved but subsequently declined for clinical transplantation to be used 
for ethically and nationally approved research projects. 
Pancreatic grafts not used for clinical transplantation, obtained through NHS Blood and Transplant 
were used in this project to determine the feasibility of applying perfusion protocols developed the 
translational porcine model to human pancreases. Recently early attempts to apply normothermic 
perfusion preservation to human pancreases was described with limited success[1147]. There are no 
reports in the literature of applying HMP to human pancreases, with the aim of preservation, nor 
then using isolated whole organ haemoreperfusion to assess graft viability [1148]. This project has 
successfully shown for the first time that using human pancreas HMP is feasible at low pressures for 
5 hours producing stable perfusion dynamics with minimal oedema. 
Functional assessment during NMR indicated that similar to results seen in the porcine model 
human pancreases produce insulin in response to a glucose load - despite extreme cold ischaemia 
prior to HMP and subsequent NMR assessment. 
Furthermore unlike the porcine model, human pancreases produced exocrine and duodenal 
secretions during NMR, despite longer CITs than in the porcine grafts. Analysis of the exocrine 
secretions revealed secretion of both amylase, and insulin[1149] which has been shown to indicate 
graft exocrine and endocrine functionality respectively in experimental settings [1028,1035].  
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Histologically despite longer SCS CIT prior to HMP and NMR in the human models than in the porcine 
pancreases there was qualitatively less focal necrosis and better preservation of the tissue. This 
further demonstrates that despite the anatomical and physiological similarities between human and 
porcine pancreases[1043], they are more susceptible to ischaemic injury[1150], and even in light of 
promising initial data in the porcine model, application of these HMP techniques to unused human 
grafts is necessary. 
 
7.4.4 The Next Step for Pancreatic MP 
There has been a renewed interest in applying the success of HMP enjoyed in renal preservation to 
the pancreas. Historically experimental attempts at pancreatic HMP in animal models have been 
complex with limited scope and merit compared to simpler SCS methods[1028,1137]. The 
predominate problem of the pancreas is that it is physiologically a 'low flow' organ, with a delicate 
vasculature that is easily damaged with deleterious oedema a result[1150]. We have shown that 
using current commercially available technology a low pressure perfusion protocol using modified 
Belzer UW solution is capable of perfusing a porcine pancreas for 5 hours with stable perfusion 
dynamics and minimal oedematous weight change. Comparing viability of porcine pancreases that 
underwent SCS only or SCS and HMP demonstrated potentially better endocrine viability and 
functionality in the HMP subjected grafts. 
Further more for the first time a HMP protocol has successfully been applied to human pancreatic 
grafts, with isolated ex-vivo viability assessment demonstrating both endocrine and exocrine graft 
functionality despite prior exposure to an extreme period of cold ischaemia.  
The development of these perfusion models and demonstration of their feasible applicability in 
human grafts is key to exploring further strategies to allow 1) better preservation of pancreases, 2) 
assessment of graft viability, and 3) use of HMP as method of organ pre-conditioning and delivery of 
pharmacological agents into grafts to optimize viability. Such strategies will be useful in the context 
of using ECD and DCD donor pancreases to further expand the donor pool by allowing selection and 
usage of suitably viable grafts, and minimising unnecessary discard. 
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Chapter 8: 
Conclusions 
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This thesis focussed on the development of number of pre-clinical translational ex-vivo strategies in 
assessing and optimising organ viability during dynamic HMP and normothermic reperfusion of 
kidney and pancreas grafts.  
In recent years efforts to expand donor pools has necessitated use of ECD and DCD kidneys and 
pancreases. Use of such organs is set to grow to address the growing demand by patients on 
transplant lists. The inherent nature of the donors of these organs renders these grafts at higher risk 
of post-transplant complications particularly of thrombosis, delayed-function, non-function, 
subsequent rejection and longer-term graft-failure, with the mechanism of damage through IR 
injury. IR is characterised by endothelial injury, and the development of pro-inflammatory and pro-
coagulant milieu within the transplanted organ leading to micro-vascular dysfunction, reduced tissue 
perfusion and organ failure. To enable effective use of these organs in clinical transplantation 
advances in organ preservation need to focus on techniques to both assess and optimise organ 
viability prior to transplantation.     
Five project themes were prevalent in this research: 1) use of real-time rsMD for tissue viability 
assessment during SCS and HMP preservation; 2) pre-conditioning organs by targeting novel 
localising anti-coagulants to the endothelium of kidneys in an addressive strategy to prevent 
microvascular dysfunction; 3) developing a new HMP preservation solution from a novel 
adenosine/lidocaine based cardioplegia; 4) exploring the potential for a period of post-ischaemic 
HMP to recover porcine kidneys after extreme length of SCS; and 5) developing an experimental 
model of HMP for pancreases.  
The majority of work was conducted using large animal porcine kidney and pancreas grafts. However 
permission and ethical approval was obtained for use of nationally retrieved but subsequently 
unused human kidney and pancreatic grafts for applying and testing several of these strategies in a 
pre-clinical human model. 
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8.1  
Application of Rapid Sampling Microdialysis in Organ Viability Assessment  
During Preservation: A Comparison of SCS vs. HMP 
 
This study characterises for the first time in real time metabolic differences between SCS and HMP 
preserved allograft which can help elucidate why HMP is clinically superior to SCS allowing 
development of interventions to augment these benefits. HMP enables ongoing anaerobic 
metabolism, but may also facilitate a resumption of normal kidney physiological processes by 
recycling substrates between cortico-medullary beds and energy production. Furthermore this data 
provides the baseline ischaemic profile for porcine kidneys whilst demonstrating the technique of 
rsMD as a tool for organ viability assessment during preservation, enabling further use of this 
technology in experimental ex-vivo strategies to optimise organ viability. 
The recent developments in normothermic machine perfusion organ preservation is an area where 
real-time assessment of tissue biochemistry will be most useful. Furthermore downscaling of the size 
of component in the rsMD system to be more portable and with probes that allow a larger region of 
tissue to be sampled will enable this technology to be more applicable to the clinical arena. Newer 
technologies for organ preservation must be matched by progress in organ viability assessment and 
that of the tissue itself and rsMD is one such novel technique that could provide this.  
 
8.2  
Addressive Targeting of Anti-thrombin Agents to Graft Vasculature during HMP: 
Preconditioning Organs to Ameliorate Post Transplant Micro-vascular Thrombosis 
 
The interventional potential of using HMP for pre-conditioning the endothelium of organs during 
preservation with localising anticoagulants has been successfully demonstrated for the first time. 
Such pre-conditioning ameliorates the deterioration in macro- and micro-vascular perfusion 
dynamics seen in an ex-vivo haemo-reperfusion model, with less clotting activity and metabolic 
evidence of superior tissue perfusion.  There is high potential for further development of this 
translational strategy to deliver targeted and locally-active anti-coagulants directly within allografts 
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where they are needed, decrease the development of microvascular thrombophilia and perfusion 
deficits, while avoiding systemic anticoagulation and its associated risks.  
Such a therapy will be of most interest in the pancreas which is an organ very prone to thrombosis. 
As newer organ preservation techniques emerge, in particular machine perfusion for organs 
normally preserved predominantly by SCS, such as the pancreas the potential to pharmacologically 
manipulate the graft to optimise viability and prevent potential complications related to reperfusion 
injury will more fully be recognised. Targeting key processes only now appreciated to be involved in 
reperfusion such as the serine proteases will be feasible and beneficial.  
 
8.3  
Development of Adenocaine as a Novel Hypothermic 
Machine Perfusion Preservation Solution 
 
UW solution is the gold standard HMP solution in use, however its composition, developed 40 years 
ago in an era where the majority of allografts were from SCD and DBD donors may not be the 
optimal HMP perfusate for ECD and DCD kidneys. AL is a novel cardioplegia and cardiac preservation 
solution that has recently demonstrated superiority in cardiac surgery models compared to 
conventional solutions. This solution may offer benefits in renal preservation, in particular HMP. 
Using a modified version of AL solution renal HMP is feasible and produces a more rapid stabilisation 
of perfusion dynamics to viable levels, with higher flow rates and PFI compared to the gold standard 
UW, potentially allowing earlier viability assessment and categorisation. NMR viability assessment 
demonstrated similar renal function and viability profiles between AL and UW perfused kidneys. 
Development of AL as an alternative HMP solution to UW is a step towards maximising the benefits 
of HMP for marginal grafts. By improving both organ viability and its assessment there is potential 
for cost-savings in relation to current techniques, while potentially expanding donor pools. Further 
refinement and modfication of ALs components will aim to achieve the success seen in cardiac 
preservation with both the kidney, and other abdominal organs that are also very susceptible to 
ischaemic injury and the subsequent damage during reperfusion - in particular the pancreas.    
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8.4  
Can Post Ischaemic Reconditioning by HMP Recover Kidneys 
from Extreme Cold Ischaemia? 
 
Post-ischaemic HMP reconditioning has the potential for benefit in the use of ECD and DCD organs 
for transplantation. Kidneys with exposure to an extremely prolonged period of SCS for 52 hours 
demonstrated similar perfusion and viability dynamics during post-ischaemic HMP as less injured 
kidneys with only 4 hours of SCS. This observation is attributed to detected graft weight loss after 
prolonged SCS, which may facilitate better HMP perfusion dynamics and thus incorrectly suggesting 
suitable viability. Such a phenomenon deserves recognition by clinicians utilising HMP to reduce the 
risk of inadvertent use of unsuitable grafts for transplantation. Despite clinical success with 
conventional HMP, in its present form however utilising passive oxygenation HMP may not be able 
to recover grafts exposed to extreme SCS, suggesting that HMP interventions utilising active 
oxygenation of the perfusate may be better to provide benefit in such organs. The ability to salvage 
grafts exposed to prolonged ischaemia, by application of a period of 'revitalization' via oxygenated 
HMP has the potential to improve logistical access and organizational constraints in the use of 
marginal and DCD donor kidneys, and allow a much needed and welcomed expansion of the donor 
pool to meet the increasing demands for grafts on national waiting lists throughout the world.  
 
8.5  
Development of Pancreatic Machine Perfusion Models 
 
HMP is in routine clinical use for kidney preservation but historical technical difficulties have limited 
the expansion of HMP into pancreatic preservation. With the increasing use of ECD donor allografts 
HMP may be of benefit in pancreatic preservation al lowing opportunities to improve and assess 
viability. This project has successfully established a pre-clinical model of pancreatic HMP using 
porcine grafts. HMP at low pressures is feasible in the pancreas, with stable perfusion dynamics and 
minimal oedema. Importantly these protocols were applied to a series of human pancreatic grafts 
demonstrating the key translational potential of this perfusion strategy. These ex-vivo perfusion 
models will allow further development of strategies to improve graft preservation by 1) optimising 
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the HMP perfusate, 2) determining the appropriate viability assessment criteria, and 3) allowing for 
and testing various pharmacological interventions, for example use of TLN in prevention of 
pancreatic graft thrombosis, the Achilles heel of pancreas transplantation. The era of machine organ 
preservation started approximately 100 years ago with Lindberg and Carrel, and now a century on 
the interest in the novel and potentially revolutionary possibility of ex-vivo preservation and 
assessment of organ function prior to transplantation is becoming a reality. Despite this challenges 
await in the development and application of these techniques to the clinical arena, never the less 
the potential benefits envisioned out weigh the current obstacles and dynamic machine perfusion of 
the pancreas is likely only a few years away.  
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